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ABSTRACT 
Alzheimer’s disease (AD) is increasing in prevalence due to increasing lifespan and 
altered lifestyle. It is the fourth major cause of death in Western countries, resulting in 
significant economic and social impact (Von Strauss, et al., 1999; Goate, 1997).  There 
are no blood biomarkers currently accepted for the diagnosis of AD, and the 
identification of suitable biomarkers would eventually reduce the necessity for 
invasive, expensive and slow diagnostic procedures, as well as facilitate prognostic 
studies.  An AD blood test would decrease the need for delaying diagnosis due to 
ambivalent presentation, and allow therapeutic intervention to commence at an 
earlier and more functional stage for the sufferer, thereby maximising the benefits of 
treatment.  It is also feasible that a blood biomarker would be of use in the 
development of therapeutic treatments, which are currently inadequate. 
Numerous studies have suggested that hyperinsulinemia and type II diabetes (DM2) 
significantly increase the risk of developing Alzheimer’s disease (AD).  Therefore, much 
research interest has been aimed recently toward determining the putative common 
mechanisms of these conditions.  One enzyme which has been implicated in both AD 
and DM2 is insulin degrading enzyme (IDE).  This project focuses largely on the 
characterisation of plasma IDE expression and catalytic activity, to help determine 
potential role/s of IDE in the development of AD, and the suitability of IDE as an AD 
biomarker.  Evidence is also provided to support the concept that IDE impairments 
may be the common factor that links AD, hyperinsulinemia and DM2. 
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CHAPTER 1 - Literature review/introduction. 
AD Introduction 
Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder, and is the most 
common form of dementia, accounting for between 50% and 80% of all dementia 
cases (Alzheimer’s disease facts and figures (2012)).  Clinical symptoms include 
increasing memory loss and cognitive functioning, ultimately leading to severe 
disability and death.  The prevalence of AD is rising globally, and the prevalence and 
incidence increases with age (Von Strauss, et al., 1999; Gascόn-Bayarri et al., 2007).  In 
Australia, the number of individuals with dementia is currently around 266,000, and is 
expected to exceed 940,000 by 2050 (Deloitte Access Economics, 2011).  In the United 
States of America (USA), AD has been found to be the sixth highest cause of death 
(Alzheimer’s disease facts and figures (2012)) and results in significant economic and 
social impact, yet research funding to date has been grossly inadequate. 
One of the key hallmarks of AD pathology is the development of senile plaques in 
various regions of the brain, of which the core component is a 4kDa peptide termed 
beta-amyloid or A-beta (Aβ).  It is widely believed that the initiation of AD pathology is 
triggered by abnormal increases in the steady-state levels of Aβ in the brain, as 
described by the “amyloid cascade hypothesis” (Hardy & Higgins, 1992). 
AD can be classified according to the age of onset, with the majority of cases occurring 
after the age of 65 years (around 95%).  This type of AD is termed “late-onset AD” 
(LOAD), whereas AD with an onset occurring prior to 65 years of age is termed “early-
onset AD” (EOAD).   While most EOAD cases are known to be caused by mutations in 
one of three genes, the aetiology of LOAD is less clear. The accumulation of Aβ in 
EOAD appears to be due primarily to increased production of Aβ peptides, or a 
proportionate increase in the production of the longer, more amyloidogenic Aβ1-42 
peptide (Hardy, 1997), however evidence suggests that faulty Aβ clearance 
mechanisms may also be implicated in the development of LOAD (Selkoe, 2001).  At 
present, the most significant known genetic risk factor for LOAD is possession of the 
Apolipoprotein E epsilon 4 allele (APOE ε4).   
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Numerous studies have found an association between Type 2 diabetes (DM2) and AD; 
however the mechanisms that are common to these two diseases, and mechanisms of 
DM2 that cause an increased risk of AD are not well understood.  One enzyme which is 
believed to have a role in both diseases is insulin-degrading enzyme (IDE):  this enzyme 
can degrade Aβ therefore it is believed to play a major part in the clearance of Aβ.  This 
chapter will explain the processes and key features of AD pathology, specifically 
focusing on recent literature and encompassing IDE-related Aβ clearance mechanisms 
as well as factors that link type-2 diabetes and LOAD. 
 
1.1  AD symptoms and characteristics 
1.1.1  Clinical Characteristics of AD 
Clinically, individuals with AD present with amnestic memory deficits and usually one 
or more other symptoms such as aphasia (language impairment), agnosia (impaired 
ability to recognise objects, people, sounds, shapes or smells) or impairment of 
executive functioning (Cummings & Cole, 2002).  These symptoms progressively 
worsen, leading to functional and behavioural difficulties in daily life activities and 
eventually severe disability and death.  There are also a number of neuropsychiatric 
symptoms that are regularly seen in AD such as depression, anxiety, psychosis and 
hallucinations, among others (Cummings, 2001).  In advanced AD, apraxia (inability to 
perform voluntary movements) also becomes apparent and the patient can be prone 
to secondary infection, which is the usual cause of death (McKhann, et al., 1984).  On 
average, the life expectancy after diagnosis of AD is approximately 3-10 years (Zanetti, 
et al., 2009), and this is highly influenced by the age at which a person is diagnosed – 
for example, newly diagnosed patients in their 60s or 70s will live an average of 7-10 
years, whereas a person diagnosed in their 90s is expected to have a life expectancy of 
around 3 years. 
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1.1.2  Macroscopic Characteristics 
At a macroscopic level, severe atrophy occurs in the amygdala, the entorhinal cortex 
(EC) and the hippocampus, with the latter being one of the earliest affected brain 
regions (Duyckaerts, et al., 2009; Scahill, et al., 2002). These areas have essential roles 
in memory formation, spatial awareness, and emotional reaction, which are functions 
that are affected in the early AD stages.  This atrophy appears to result from the 
degeneration of neurons and other cells, leading to loss of volume in the inferior 
temporal and superior and middle frontal gyri (Duyckaerts, et al., 2009).  The rate of 
the atrophy also appears to be accelerated in individuals with one or more APOE ε4 
alleles, in a dose-dependent manner (Chen et al., 2007, Agnosta, et al., 2009). 
 
1.1.3  Pathological Characteristics 
At a microscopic level, the primary pathological features of AD include extracellular 
deposits of amyloid called senile plaques (SP) and intracellular neurofibrillary tangles 
(NFT) that appear in cortical and limbic areas of the brain, and the number and 
distribution of these lesions increase as the disease progresses.  As mentioned earlier, 
the main components of amyloid are aggregates of Aβ peptides. Another pathological 
feature frequently found in AD is cerebral amyloid angiopathy (CAA), sometimes called 
congophilic angiopathy (Glenner & Wong, 1984).  This is characterised by the 
deposition of Aβ aggregates in the cerebrovascular walls in a regional pattern which is 
similar to the deposition of SP, leading to vascular damage (Thal et al., 2008).  Aβ 
deposition in the vasculature indicates peripherally circulating Aβ may influence AD 
pathogenesis. 
There are other pathological features commonly seen in AD, including granulovacuolar 
degeneration (GVD) which involves intraneuronal double-membraned bodies that 
appear to be related to autophagic mechanisms (Funk, et al., 2011).  GVD is not only 
found in AD, but in other neurodegenerative disorders as well. Another feature, hirano 
bodies (HB) - actin-related aggregates - are also found in neurons in AD, however are 
also considered to be common in normal ageing as well (Gibson & Tomlinson, 1977).  
4 
 
These disturbances cause neuronal dysfunction and synaptic loss, leading to brain 
atrophy and cognitive impairment. 
1.1.3.1  Neurofibrillary Tangles (NFT)  
Like HB, NFT are not just found in AD, but can be found in some specific regions of the 
brain in healthy ageing. NFT are also found in some other brain degenerative 
conditions (Nelson, et al., 2012; Bouras, et al., 1994).  It has been shown that the 
number of NFT correlates with the level of cognitive impairment in AD (McKee et al., 
1991).  It is widely believed that the processes leading to SP deposition may cause the 
subsequent formation of NFT which leads to neuronal death (Hardy & Allsop, 1991; 
Yamaguchi, et al., 2001).  NFT are insoluble aggregates that build up following the 
hyperphosphorylation of tau protein. Tau is normally associated with microtubule 
stability related to cytoskeletal structure, as well as the formation of axons and 
dendrites.   
1.1.3.2  Senile Plaques (SP) 
First recognised over 100 years ago by Alois Alzheimer  (Stelzmann, et al., 1995), the 
main component of SP is insoluble, fibrillar beta-amyloid (Aβ) which forms its core 
(Glenner & Wong, 1984), and plaques are often bordered by activated microglia and 
abnormal neurites (Zubenko, 2007).  Plaques do contain other components, including 
ApoE (Barger, et al. 2008; Sheng, et al., 1996), IDE (Bernstein, et al., 1999) alpha1 
antichymotrypsin, alpha2 macroglobulin, interleukin 6, complement proteins C1Q, C3, 
and C4, amongst others (Liao, et al., 2004).  SP form extracellularly and are often found 
in close proximity to neurons containing NFT (Masters, et al., 1985).   
The deposition of Aβ fibrils and SP in specific regions of the brain appears to precede 
the onset of neuronal loss and synaptic dysfunction (Glenner & Wong, 1984; Masters, 
et al., 1985). As Aβ is the major component of SP, and abnormal accumulation of this 
peptide is thought to initiate the pathogenic cascade of processes seen in AD (Hardy & 
Selkoe, 2002), the regulation of Aβ concentration and factors that may accelerate its 
aggregation are believed to be of vital importance. 
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1.2  Beta Amyloid (Aβ) - A Key Molecule 
The Aβ molecule is a 39-43 amino acid 4kDa peptide, which is synthesised and 
detectable throughout the body under normal physiological circumstances, however 
its role is unclear (Masters et al., 1985; Haass et al., 1992; Seubert et al., 1992).  It is a 
breakdown product of a larger protein (see below), and is normally cleared quickly, 
however during pathological processes such as AD, there appears to be an imbalance 
between its production, and its degradation and/or clearance (Savage, et al., 1998; 
Selkoe, 2001).  This leads to the accumulation of Aβ, and as it is highly fibrillogenic, 
aggregation and deposition of amyloid fibrils occur in the brain in the form of SP as 
well as diffuse aggregates (Hardy & Selkoe, 2002; Suzuki et al., 1994).  
 
1.2.1  Early onset and Late onset AD 
AD is broadly divided into two main subtypes, referred to as early-onset AD (EOAD) 
and late-onset AD (LOAD).  EOAD, in which the onset of symptoms occurs before the 
age of 65 years, is caused by autosomal dominant mutations in either the presenilin 1 
(PS1), presenilin 2 (PS2) or the amyloid precursor protein (APP) genes, and is often also 
termed early-onset familial AD (EOFAD) (Goate, et al., 1991; Sherrington, et al., 1995; 
Levy-Lahad, et al., 1995).  There is also a very small subgroup of sporadic EOAD.  EOAD, 
however, only accounts for around 5% of AD cases, with LOAD accounting for the 
majority of cases (Cummings & Cole, 2002). However, some AD cases exhibit 
Mendelian inheritance in which no mutations in any of the recognised genes exist, 
indicating the involvement of genes which are yet to be identified (Goate, 1997).   
A greater understanding of AD has come from studies of EOAD. The discoveries of the 
many APP, PS1 and PS2 genetic mutations that lead to AD highlight the central role of 
Aβ in AD, as Aβ peptide is a proteolytic product of APP, and the presenilins are 
proteins involved in the last proteolytic process that cleaves Aβ from the parent 
molecule. In EOAD, genetic mutations in PS1, PS2 and APP have been demonstrated to 
cause the disease mostly via increased production of Aβ (Selkoe, 2001; Verdile, et al., 
2004; Hardy, 1997), and depending on the site of the APP mutation, can also alter Aβ’s 
affinity for fibrillogenesis (Walsh & Selkoe, 2007).  The increased understanding of Aβ 
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properties associated with identifying these mutations initiated one of the most widely 
accepted hypotheses amongst AD researchers, “the amyloid cascade hypothesis” 
(Hardy & Allsop, 1991).  The hypothesis contends that AD pathology is initiated by 
increased levels of Aβ, which leads to Aβ accumulation and aggregation, as well as a 
cascade of other events including NFT formation, oxidative stress, mitochondrial 
dysfunction (reviewed in Lin & Beal, 2006), inflammatory responses and vascular 
damage, culminating in neuronal loss (Hardy & Higgins, 1992).  There is substantial and 
growing evidence which supports this hypothesis, however it remains controversial 
due to a number of discrepancies (Hardy & Selkoe, 2002; Selkoe, 2011; Karran, et al., 
2011).  As yet, it has not been either proved or disproved, but regardless, Aβ is widely 
believed to be central in the pathogenesis of AD.  In the case of LOAD, which comprises 
approximately 95% of AD cases, it appears that the accumulation of Aβ may be largely 
due to defective clearance and/or degradation mechanisms rather than 
overproduction (Selkoe, 2001).  As such, proteins which are directly involved in Aβ 
degradation and clearance mechanisms are being studied to characterise AD 
neuropathology better, as well as to identify potential AD biomarkers.   
 
1.2.2  Amyloid Precursor Protein (APP) 
Through multi-step proteolytic processing, Aβ is generated from its parent molecule, 
the amyloid precursor protein (APP).  Aβ is synthesised via sequential cleavage of APP 
(see Figure 1), a transmembrane protein which is ubiquitously expressed (Kinoshita et 
al., 2003; Haass et al., 1992).  This process involves two enzymatic proteases, β-
secretase (also referred to as “BACE”) and γ-secretase.  APP is initially cleaved by BACE 
extracellularly, and the remaining membrane bound portion (termed “C99”) is then 
cleaved within the membrane by γ-secretase to liberate Aβ (LaFerla et al., 2007).  
Because γ-secretase does not have sequence specificity, the intra-membrane cleavage 
site at the C-terminus can vary, producing Aβ peptides that range from 38-43 residues 
long (Wolfe et al., 1999).  The two main Aβ peptides in the human brain are 40 and 42 
amino acids long, of which Aβ1-40 (Aβ40) is the principal species in normal physiology 
(Seubert, et al., 1992; Haass, et al., 1992).  Aβ42 appears to be the most conducive to 
self-association and fibrillogenesis (Jarrett, et al., 1993; Burdick, et al., 1992; Snyder, et 
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al., 1994), and has also been found to be more neurotoxic than the shorter species 
(Davis & Van Nostrand, 1996).  APP can also be cleaved by α-secretase which cleaves 
within the Aβ sequence,at position 16, thus precluding the formation of the full length 
Aβ peptide.  
 
Figure 1.1  Representation of the generation of Aβ. 
1. Cleavage of membrane-bound APP extracellularly by β-secretase (BACE). 
2. Cleavage of remaining C99 portion of APP within the plasma membrane by γ-
secretase. 
3. Liberation of Aβ into the extracellular milieu.  The remaining portion of APP (AICD) 
is released into the cytosol (intracellular space). 
 
It should be noted that while Aβ is shown in Figure 1 to be released extracellularly, and 
this was originally the accepted location for its generation, further studies have shown 
that it can also be produced intracellularly (Wertkin, et al., 1993; reviewed in La Ferla, 
et al., 2007).  There is also now considerable evidence that Aβ can accumulate 
intracellularly as well as extracellularly in the human brain (Gouras, et al., 2000; 
Martin, et al., 1995; Cabrejo, et al., 2006) and that this precedes plaque formation 
(Gyure, et al., 2001; Knobloch, et al., 2007).  This indicates that intracellular 
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accumulation of Aβ is an early event in AD pathogenesis and may be an upstream 
event to extracellular accumulation. 
As well as intracellular accumulation, recent evidence suggests that Aβ accumulates 
within the mitochondria early in AD, and this appears to be due to its importation into 
the mitochondria from the cytosol (Manczak, et al., 2006; Reddy, et al., 2008; reviewed 
in Chen & Yan, 2010; Leal, et al., 2013).  Increased mitochondrial Aβ (mitAβ) has 
recently been associated with the severity of both mitochondrial dysfunction and 
cognitive function in transgenic mouse models of AD (Dragicevic, et al., 2010; 
Caspersen, et al., 2005).  Furthermore, the distribution of mitAβ in AD brains is similar 
to the distribution of AD pathology.  Therefore the regulation of mitAβ as well as 
intracellular Aβ is crucial in preserving normal mitochondrial function and disruption of 
mitochondrial function may be an initiating factor in the development of AD. 
 
1.2.3  Aβ Toxicity in AD 
Monomers of Aβ self-associate to form oligomers, and subsequently fibrils, that 
appear to be associated with the level of toxicity and degree of neurodegeneration 
(Roher, et al., 1996; Pike, et al., 1991).  These Aβ fibrils then aggregate into SP.  
Originally, it was thought that the neurotoxicity of Aβ could be primarily attributed to 
the insoluble amyloid fibrils present in SP, however further research has suggested 
that plaques are relatively inert, and it is more likely to be soluble, pre-fibrillar small Aβ 
oligomers which cause neuronal injury (Stine, et al., 2003; Walsh & Selkoe, 2007; Pike, 
et al., 1993; McLean, et al., 1999; Lue, et al., 1999).  Aβ has been demonstrated to 
have neurotrophic properties in vitro, which are dependent on low peptide 
concentration, and reduced length of exposure time (Pike, et al., 1991; Yankner, et al., 
1990; Pike, et al., 1993).  Similarly, oligomer and fibril formation, and the respective 
neurotoxicity of these aggregates, have been shown to be isoform-dependent, 
concentration-dependent and time-dependent, as well as dependent on certain metal 
ions such as Zn2+  or Cu2+  (Stine, et al., 2003; Hartley, et al., 1999).  In addition, studies 
have uncovered an apparent intermediate between oligomers and mature fibrils, 
termed “protofibrils” which appear to be similar to oligomers regarding formation and 
neurotoxicity (Dahlgren, et al., 2002; Hartley, et al., 1999; Walsh, et al., 1997; Stine, et 
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al., 2003).  Oligomers of Aβ have also been found to inhibit long-term potentiation 
(LTP), which is associated with memory formation (Walsh, et al., 2005; Wang, et al., 
2002).  Therefore, the accumulation of Aβ, and in particular the Aβ42 isoform, may 
instigate the self-association of this peptide into soluble, pre-fibrillar forms, initiating 
the neurotoxicity that precedes plaque formation. 
One mechanism which is believed to be partly responsible for the accumulation and 
aggregation of cerebral Aβ is the impairment of its degradation or clearance from the 
CNS. 
 
1.3  Aetiology of LOAD 
The aetiology of LOAD is complex and not completely understood.  The major risk 
factor for AD is age. There have been a number of other risk factors reported, such as a 
family history of AD, which have also been shown to be significant (van Duijn, et al., 
1994; Lindsay, et al., 2002).  Other risk factors include female gender, low education 
level, head trauma, late maternal age and depression, among others, however the 
results of some studies have been conflicting (Launer, et al., 1999; Lindsay, et al., 2002; 
van Duijn, et al., 1994; van Duijn, 1996).  
The major genetic risk factor to date appears to be possession of one or more ε4 allele 
of the APOE gene, as mentioned previously (Goate, 1997; Corder, et al., 1993; 
Strittmatter, et al.,1993(a); Rebeck, et al., 1993).  However, around 50% of LOAD cases 
do not carry the APOEε4 genotype and this indicates that other factors are involved in 
the aetiology of LOAD (Corder, et al., 1993).  Genetic studies have uncovered several 
other genes which appear to have some influence on the risk of LOAD, although not as 
great an influence as the APOE gene.  It is highly probable that environmental and 
lifestyle factors also influence the risk of sporadic AD, and probably interact with 
relevant genetic factors (Roher, et al., 2009).    
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1.4  Diagnostic Techniques 
There are currently two diagnostic standards used for AD, the National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease 
and Related Disorders Association (NINCDS-ADRDA) Alzheimer’s criteria, and criteria 
outlined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text 
Revision (DSM-IV-TR®) (American Psychiatric Association, 2000).  These two standards 
are similar in nature.  There are also several imaging techniques in use, which can 
complement these diagnostic standards. 
NINCDS-ADRDA criteria categorises patients into one of four categories; “definite”, 
“probable”, “possible” or “unlikely” Alzheimer’s disease.  A diagnosis of “definite” AD 
requires histopathologic confirmation, via an autopsy or brain biopsy.  For a diagnosis 
of “probable” AD, there must be impairment in at least two of the eight cognitive 
domains: “memory, language, perceptual skills, attention, constructive abilities, 
orientation, problem solving and functional abilities” (McKhann, et al., 1984).  A 
diagnosis of “possible” or “unlikely” AD indicates that there is dementia present with 
features that are atypical of AD, yet which cannot be explained by any other diseases 
that may cause dementia. 
Similarly, the current DSM-IV-TR® diagnostic procedure involves initially ascertaining 
the presence of dementia, by the confirmation of memory impairment, accompanied 
by at least one other symptom such as aphasia, apraxia, agnosia and/or impairment of 
executive functioning.  The severity of these deficits must be sufficient to impair 
functionality of daily living (DSM-IV-TR®, American Psychiatric Association, 2000), and 
are evaluated using assessment tools such as the Mini-Mental State Exam (MMSE).  
The DSM-IV-TR® states that onset of the disease should be gradual, and that the 
decline in impairment must be progressive and distinguishable from the decline that 
occurs in the normal ageing process.  Essentially, the diagnosis of Alzheimer’s disease 
can only be made once all other causes of dementia and disorders with similar 
symptoms have been excluded, and consideration must be given to potentially 
confounding factors such as ethnicity, culture and educational history, all of which may 
have an effect on the outcome of the evaluation.   
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1.4.1  Imaging Techniques and Biopsy 
Cerebral computerised tomography (CT) and/or magnetic resonance imaging (MRI) can 
also be used to confirm specific macroscopic changes that are characteristic of AD such 
as atrophy, particularly of the hippocampus, and to eliminate any other pathological 
cause of dementia which is not of the Alzheimer type.  Less commonly, functional 
imaging techniques such as MRI, positron-emission tomography (PET) or single photon 
emission computed tomography (SPECT) have been used to assist in differential 
diagnosis.  Although not part of the standard diagnostic screening, these imaging 
techniques have been shown to be very useful for differentiation of AD, and 
suggestions have been made for revision of the NINCDS-ADRDA to include them in the 
criteria, along with CSF biomarkers such as Aβ and tau which have also shown promise 
(Dubois et al., 2007; Visser, et al., 2009).  In the last ten years advances have been 
made with the discovery of amyloid-imaging agents such as “Pittsburgh Compound-B” 
(PiB) which are used in conjunction with PET imaging (Klunk, et al., 2004).  PiB-PET 
allows quantification of amyloid deposition in the brains of living individuals.  The 
deposition of Aβ amyloid (as well as synaptic loss and neuronal death) occurs for many 
years before symptoms manifest, therefore the PiB-PET imaging technique can also 
identify patients with no symptoms, yet who are likely to develop AD - people at a pre-
clinical stage (Okello, et al., 2009; Pike, et al., 2007).  Microscopic analysis from a 
biopsy may also reveal pathological hallmarks of AD such as SP and NFT, and similarly 
can help exclude or confirm a diagnosis of AD (DSM-IV-TR®, 2000).  However these 
techniques are costly and invasive, require an expert clinician or surgeon, and in the 
case of biopsy, there are considerable risks.  Due to these factors, their usefulness in a 
clinical setting is limited. 
As mentioned above, by the time AD symptoms appear, considerable synaptic and 
neuronal loss has occurred.  For the foreseeable future, potential treatments are at 
best likely to stop or slow the pathogenesis of the disease, not reverse it.  To maximise 
the effect of potential future treatments, early pre-clinical diagnosis is necessary.  Thus 
it is clear that current standard diagnostic techniques for AD are insufficient, as they do 
not identify the disease at an early stage, and are definitive only after autopsy 
examination.  Therefore, the identification of AD pre-clinical biomarkers would 
improve diagnostic efficacy.  
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While Aβ would seem to be an obvious candidate as a biomarker for AD, research 
findings have been inconclusive concerning its validity, and it is probable that a 
combination of biomarkers may be necessary for accurate diagnostics.   While the 
mutations responsible for EOAD appear to alter Aβ concentration via increased 
production, particularly of the Aβ42 peptide (Hardy, 1997), increasing evidence 
suggests that impaired clearance of this peptide may be responsible for the majority of 
sporadic AD cases (Selkoe, 2001).  As such, proteins or other biological substances that 
directly affect the regulation of Aβ levels via clearance mechanisms may have value as 
possible biomarkers. 
 
1.4.2  AD Biomarkers  
To date, there is no universally accepted biomarker or set of biomarkers, that has the 
level of specificity or sensitivity required for definitive diagnosis of AD (DSM-IV-TR®, 
2000; Consensus Report of the Working Group on: “Molecular and Biochemical 
Markers of Alzheimer’s Disease”, 1998).  Although studies on CSF biomarkers such as 
Aβ and tau have shown potential for differentiating between AD, mild cognitive 
impairment (MCI), subjective memory complainers (SMC) and healthy controls 
(Blennow, 2004; Visser, et al., 2009; Wallin et al., 2006; Herukka et al., 2007), the 
invasiveness of CSF collection and high costs of imaging make these techniques 
impractical for routine use in clinical practice.  Current diagnostic techniques are 
largely based on a clinician’s subjective judgement, the quality of which may vary 
based on their experience.  Knopman et al., 2001, states that the two diagnostic 
standards described above have good reliability, with a sensitivity of 81% on average, 
but a specificity of only 70%, on average.  These figures are based on thirteen studies 
which examined the accuracy of clinical diagnostic tools for AD.  It is likely, however, 
that these figures are not likely to be representative of accuracy in the early stages of 
the disease (Frank et al., 2003), and as previously stated, the only way to confirm the 
diagnosis of Alzheimer’s at present, is by autopsy examination. 
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1.4.3  MCI 
Potential Alzheimer’s patients in the very early stages of the disease may be diagnosed 
with MCI (Frank et al., 2003).  MCI is characterised by memory loss and other cognitive 
impairment, without meeting the neuropathologic criteria for dementia (Petersen et 
al., 1999).  When memory loss is the primary symptom, it is termed “amnestic” MCI, 
and is considered to be a particular risk factor for AD.  It has been shown that at least 
50% of MCI patients do progress to dementia (Schmidtke & Hermeneit, 2008; 
Gauthier, et al., 2006), however some MCI patients either go on to develop disorders 
other than AD, show no progression of impairment, or even recover, so the ability to 
differentiate between these cases is of particular diagnostic importance. 
 
1.4.4  SMC 
Individuals with SMC have also been found to have an increased risk for developing 
dementia in a number of studies (Obrien, et al., 1992; Geerlings, et al., 1999; Schmand, 
et al., 1996).  In a recent study, SMC individuals were found to have significantly lower 
scores on tests for cognitive impairment, such as the MMSE, compared with controls.  
In addition, the APOE ε4 allele was found to be over-represented in this cohort, in a 
dose-dependent manner (Laws, et al., 2002).  This may indicate that individuals with 
subjective memory complaints could be at a higher risk for developing AD, similar to 
MCI patients. 
 
1.4.5  The need for better AD biomarkers 
One of the problems with current diagnostics is the inability to identify individuals 
before or during the early stages of neurodegeneration that lead to clinical dementia.  
As mentioned earlier, it would be of enormous benefit to identify one or more 
biomarkers to assist AD diagnosis at the earliest possible stages, and preferably prior 
to the onset of the irreversible symptoms.  This would allow treatment to commence 
at a more functional stage for the patient and slow or delay the progression of 
symptoms (Borroni, et al., 2006).  Quality of life could be maximised for sufferers and 
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their families, and economic benefits regarding healthcare would be significant 
(Brookmeyer et al., 1998).  Recently, recommendations were made by the National 
Institute of Ageing (NIH) and Alzheimer’s Association for the revision of current 
diagnostic criteria (Jack, et al., 2011).  The recommendations from these working 
groups were in part to include scientifically validated biomarkers of AD in the 
standards that may detect AD at a preclinical stage, namely CSF levels of Aβ, total tau 
(T-tau) and phosphorylated tau (P-tau), increased brain amyloid load and reduced 
fluorodeoxyglucose uptake determined by positron-emission topography (PET) 
imaging (pattern-specific), and brain atrophy determined by structural magnetic 
resonance imaging (MRI).  Searching for blood biomarkers as well as any biomarkers 
that can detect AD at the earliest possible stage is therefore of great importance and 
many potential biomarkers are currently in the process of being validated (Hampel, et 
al. 2010). 
1.4.5.2  The “Ideal Biomarker for AD” 
The Working Group on Molecular and Biochemical Markers of Alzheimer’s Disease 
(The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and 
the National Institute on Ageing Working Group, 1998) has suggested that the “ideal 
biomarker” for AD should possess a number of features.  Firstly it should be related to 
a pathological feature of AD, and be validated in confirmed AD cases.  It should be 
sensitive enough to allow early diagnosis and to differentiate it from other dementias.  
In addition, the “ideal biomarker” should be reliable, biomarker screening should be 
inexpensive and simple, and should involve relatively non-invasive testing.  The 
detection of biomarkers in easily accessible biological fluids is therefore an area of 
intense interest.  Although CSF is likely to be the most accurate biological fluid for 
reflecting pathophysiological changes, as it is in direct contact with the brain (Blennow, 
2004), techniques such as lumbar puncture for the analysis of CSF, are highly invasive, 
uncomfortable for the patient and often expensive, requiring an expert clinician to 
perform the procedure.  Therefore, identification of one or more peripheral blood 
biomarkers would be highly useful for diagnostic, prognostic and therapeutic purposes. 
A variety of different blood biomarkers could potentially be used together to improve 
the precision of the screening process.  For example, studies have recently been 
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focusing on the analysis of protein expression patterns in plasma or serum, with 
positive results (Doecke, et al., 2012; Soares, et al., 2012; O’Bryant, et al., 2010; Ray et 
al. 2007).  In addition, the Aβ42/Aβ40 ratio has been shown in plasma to be potentially a 
promising biomarker for identifying persons at risk of developing MCI or AD (Okereke, 
et al., 2009; Graff-Radford et al., 2007).  However, there is some controversy regarding 
the usefulness of plasma Aβ as a reliable, pre-clinical biomarker (Rissman, et al., 2012).  
The identification of additional biomarkers that could be used in conjunction with, or 
instead of the above potential biomarkers, would be highly beneficial.   Regardless, Aβ 
and/or proteins that interact with it may be the most useful due to their key roles in 
AD pathology.  The use of Aβ as a biomarker is discussed in detail below. 
 
1.4.6  Aβ as a Biomarker for AD Diagnosis 
1.4.6.1  Aβ and PET Imaging 
Fibrillar amyloid deposits in the brain of living persons can be visualised by PET, using 
amyloid-imaging agents such as [18F]1,1-dicyano-2-[6-(dimethylamino)-2-
naphthalenyl]-propene, more commonly known as  18F-DDNP, and N-methyl-[11C]2-(4'-
methylaminophenyl)-6-hydroxybenzothiazole, known as PiB (Klunk, et al., 2004; 
Nordberg, 2004).  While PiB only detects amyloid burden (Ikonomovic, et al., 2008), 
18F-DDNP is believed to detect both amyloid and NFT (Shin, et al., 2008).  Studies have 
demonstrated that AD patients in the early stages can be differentiated from healthy 
controls by PiB-PET imaging and an inverse correlation has been shown between PiB 
retention and glucose metabolism in the brain (Klunk, et al., 2004).   
1.4.6.2  Aβ in CSF 
Currently, the most promising biomarkers for the diagnosis of early AD appear to be 
CSF levels of Aβ42 together with total tau (t-Tau) and hyperphosphorylated tau (tau 
phosphorylated at residue 181, P-tau181P), which are clearly linked to the different 
pathological hallmarks of AD.  This combination of biomarkers has been shown to be 
able to differentiate AD from normal ageing and other diagnoses (Blennow, 2004), as 
well as identifying which individuals are likely to convert from SMC or MCI to AD 
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(Mattson, et al., 2009; Diniz, et al., 2008; Visser, et al., 2009).  Nevertheless again, the 
value of CSF biomarkers is limited clinically as a routine diagnostic test for AD, as the 
collection of CSF is highly invasive and side effects are common (Williams, et al., 2008).  
Blood would be preferential for the identification of potential biomarkers as it is 
inexpensive and simple to collect, and is not particularly invasive. 
1.4.6.3  Aβ in Plasma 
A number of studies have focused on the detection of Aβ as a biomarker in blood, yet 
with inconsistent results (Graff-Radford, et al., 2007; Fukumoto, et al., 2003).  
Although plasma levels of Aβ have been shown to be increased in familial types of AD 
(Scheuner, et al., 1996), this trend is less clear in sporadic forms, with considerable 
overlap between controls and AD cases.  In addition it appears that levels of plasma Aβ 
increase with age, which may lend a confounding factor (Mayeux, et al., 1999).  
Overall, it appears that plasma Aβ is elevated prior to amyloid deposition, though after 
some deposition occurs there is a concomitant, progressive reduction in plasma levels 
(Kawarabayashi, et al., 2001; Kuo, et al., 2000; Schupf, et al., 2008).  This suggests that 
peripheral Aβ may be a source for cerebral accumulation of the peptide, it may also 
mean that less cerebral Aβ is reaching the circulation.  Longitudinal studies support the 
theory that elevated plasma Aβ is a risk factor for AD (Mayeux, et al., 1999; Mayeux, et 
al., 2003).  The pattern of plasma Aβ levels over time may explain why various cross-
sectional studies have found such a broad overlap between controls and sporadic 
cases (Fukumoto, et al., 2003; Vanderstichele, et al., 2000).  It has also been shown 
that Aβ can pass from CSF to plasma and vice versa through the blood-brain barrier 
(BBB), however there is no correlation between Aβ levels in these biological fluids, 
indicating contributions from both CNS and peripheral tissues (Le Bastard, et al., 2009; 
Mehta, et al., 2000; GhersiEgea, et al., 1996). 
Several studies have investigated the plasma Aβ42/Aβ40 ratio as a possible indicator of 
AD risk.  In general, it appears that a low Aβ42/Aβ40 ratio may be associated with 
increased risk of AD and/or MCI (Graff-Radford, et al., 2007; Abdullah, et al., 2007; Van 
Oijen, et al., 2006; and reviewed by Koyama, et al., 2012).  Interestingly, it may be an 
increase of the Aβ40 species relative to Aβ42 that causes this decrease, as some studies 
have not found a change in Aβ42 levels (Van Oijen, et al., 2006; Abdullah, et al., 2007).  
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However, a recent meta-analysis showed that there was no change in Aβ40 levels, 
while there was a slight reduction in Aβ42 levels, albeit non-significant (Song, et al., 
2011).  Furthermore, in longitudinal studies it was shown that baseline levels of Aβ and 
the Aβ42/Aβ40 ratio were marginally higher in AD patients but again these results were 
non-significant.  Another study found that the Aβ42/Aβ40 ratio was not affected by 
APOE genotype, contrary to individual concentrations of plasma Aβ40 and Aβ42 
(Blennow, et al., 2009).  This may indicate that the Aβ42/Aβ40 ratio in plasma could be 
more beneficial as a biomarker than individual Aβ42 and Aβ40 levels, or could be used in 
conjunction with other biomarkers.  In accordance with a number of other studies, 
findings from the AIBL study (see Chapter 2, Materials and Methods for details) have 
found lower levels of plasma Aβ42, and thus a decrease in the Aβ42/Aβ40 ratio in AD 
patients when compared with healthy controls (HC) (Lui, et al., 2010).  In addition, it 
was found that the levels of Aβ42 as well as the Aβ42/Aβ40 ratio were negatively 
correlated with brain Aβ load.  These results are consistent with findings from the AIBL 
follow-up at 18 months, which also showed a reduction of Aβ42 in MCI individuals and 
healthy controls who converted to MCI during this period (Rembach, et al., 2013).  This 
suggests that although plasma Aβ may have limited usefulness as a single biomarker 
for AD, it may have some clinical value for early detection of AD when used in 
conjunction with other biomarkers. 
Although the current literature on plasma levels of Aβ is inconsistent, this 
inconsistency may also be due to methodological difficulties and different techniques.  
Results from the AIBL study acknowledged differences in results when using different 
commercial kits to measure Aβ levels, as well as various confounding covariates (Lui, et 
al., 2010; Rembach, et al., 2013).  ELISA-based methods may fail to detect Aβ which is 
bound to other proteins or differentiate between Aβ oligomers and free Aβ, resulting 
in only a portion of the total peptide being measured (Portelius, et al., 2008; Kuo, et 
al., 1999; Abdullah, et al., 2007).  In a study by Xia, et al. (2009), using a specially 
designed ELISA for the purpose of detecting Aβ oligomers, they found that oligomeric 
and monomeric levels of Aβ were strongly associated.  In a study by James & Mamo 
(2005), they demonstrated that the presence of lipids with Aβ in vitro can alter the 
predominant form of Aβ, and sequester it, rendering it unavailable for detection by 
commonly used methods.  In addition, it has been shown that in gel-based techniques, 
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denaturing conditions can liberate these oligomers or bound proteins, increasing total 
levels of measurable Aβ (Portelius, et al., 2008).  Various other methodological factors 
have also been demonstrated to confound results (Vanderstichele, et al., 2000), 
indicating a need for a methodological standard for measurement of this protein (and 
likely other proteins) in plasma.  It is more than likely that one blood protein marker 
will not be sufficient to diagnose pre-clinical AD, with adequate specificity and 
sensitivity.  There are many plasma proteins that are being investigated for their 
potential as a biomarker.  The following will be a discussion on those that are directly 
related to my project, ApoE, insulin and IDE. 
 
1.5  Apolipoprotein E 
Apolipoprotein E (ApoE) is a 34 kDa, 299-residue polymorphic protein that has been 
strongly implicated in the pathogenesis of AD (Sheng, et al., 1996; Mahley, et al., 2006; 
Strittmatter, et al., 1993(a); Corder, et al., 1993).  The APOE gene on chromosome 19 
that encodes ApoE has three alleles, ε2, ε3 and ε4.  The three ApoE protein isoforms 
differ by substitutions at residues 112 and 158, with ApoE2 containing cysteine at 
these positions, ApoE4 containing arginine at both positions, and ApoE3 having an 
arginine substitution at only residue 158 (Bentley, et al., 2002).  To date, ε4 is still the 
major genetic risk factor for LOAD, being significantly overrepresented in LOAD cases 
compared with controls (Kaur & Balgir, 2006; Saunders, et al., 1993; Strittmatter, et al., 
1993(a)).  Generally, the ε3 variant of APOE appears to be the “wild-type” allele, with a 
frequency of 60-70% in the general population, while the ε4 variant has a frequency of 
only 15-20% (Mahley, et al., 2006).  The ε2 allele seems to have some protective effect 
against AD, however in the general population, its frequency is only 5-10%. 
 
1.5.1  Association of APOE genotype with AD 
A number of studies have investigated the association of APOE genotype with AD. 
Most have found that the ε4 allele is significantly associated with an increased risk for 
developing AD, in a dose-dependent manner (Kaur & Balgir, 2006; Corder, et al., 1993; 
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Saunders, et al., 1993).  Corder, et al. (1993) found that the risk for AD increased from 
20% for individuals without an ε4 allele, to 47% in individuals with one ε4 allele, and to 
91% in individuals homozygous for the ε4 allele. 
Not only is the risk for developing AD increased by the ε4 allele, but also the age of 
disease onset has been shown to be significantly decreased in a dose-dependent 
manner (Corder, et al., 1993).  Hence, ε4/ε4 homozygotes have been found to develop 
AD earlier than their heterozygotic ε4/ε3 and ε4/ε2 counterparts.  For individuals 
without an ε4 allele, Corder, et al. (1993) found the mean age of onset was 84.3 years, 
while the ages of AD onset for ε4 heterozygotes and ε4 homozygotes were 75.5 years 
and 68.4 years, respectively.  In addition, the ε4 allele has been associated with 
accelerated brain atrophy rates, in both cognitively normal individuals and AD patients, 
also in a dose-dependent manner (Chen, et al., 2007; Agnosta, et al., 2009).  Rebeck, et 
al. (1993) also showed that ε4/ε4 AD patients had significantly greater amyloid plaque 
deposition when compared with ε3/ε3 AD patients. 
 
1.5.2  Functions of ApoE 
The ApoE protein is a normal component of certain lipoproteins, and as such has 
functional roles in lipid (including cholesterol and lipid soluble vitamins) transport and 
clearance in the body (Mahley, 1988), and in the brain it plays a role in neuronal 
growth, maintenance and repair (Ignatius, et al., 1986; Cedazo-Mínguez, 2007).  ApoE 
functions as a ligand in receptor-mediated endocytosis of lipoprotein particles. In 
plasma, ApoE proteins are found on lipoproteins in association with other 
apolipoproteins, whereas in the brain ApoE and two other apolipoproteins, ApoJ and 
ApoA-1, are predominantly found in high density lipoprotein (HDL)–like particles (Kim, 
et al., 2009)  
ApoE is generated predominantly in the liver and brain, but also in much smaller 
amounts in most other tissues (Bentley, et al., 2002).  The isoforms of ApoE have 
different affinities for the blood lipoproteins, with ApoE2 and ApoE3 showing 
preferential affinity for HDL while ApoE4 binds preferentially to VLDL (Weisgraber & 
Mahley, 1996). 
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1.5.3  APOE and AD 
While the APOE ε4 genotype has been confirmed as a risk factor for AD, the 
mechanism of pathogenesis is less clear.  The ApoE protein has been localised within 
both SP and NFT, indicating a direct interaction with components of these lesions 
(Sheng, et al., 1996; Namba, et al., 1991).   Many other pathogenic changes observed 
in AD have also been associated with ApoE, including NFT formation, oxidative stress, 
and dysfunction of lipid regulation, synaptic plasticity and cholinergic function 
(reviewed by Cedazo-Mínguez, 2007), indicating how important ApoE may be in AD 
pathogenesis.   
Abnormal cholesterol and lipid metabolism has been associated with the pathogenesis 
of AD, with high total plasma cholesterol suggested as a risk factor (Roher, et al., 1999; 
Notkola, et al., 1998), however some studies have shown a decrease in cholesterol and 
lipid levels in AD patients compared with controls (Siest, et al., 2000).  In addition, it 
has been reported that AD patients have higher serum levels of the detrimental LDL 
cholesterol, and lower levels of the beneficial HDL cholesterol than control cases 
(Roher, et al., 1999; Kuo, et al., 1998).  Kuo, et al., (1998) also demonstrated a positive 
correlation between total and LDL cholesterol levels, and cerebral levels of Aβ42, 
independent of APOE genotype.  It is feasible that either low levels or dysfunction of 
the ApoE protein may contribute to AD pathology independently of the ε4 allele, 
possibly due to abnormal lipid transport or metabolism. 
Due to the discovery of ApoE in amyloid plaques and CAA, studies were carried out to 
ascertain whether ApoE could bind Aβ directly, and it was found that ApoE can bind to, 
and facilitate the fibrillogenesis of Aβ in an isoform-dependent fashion, suggesting a 
role as a “pathological chaperone” (Strittmatter, et al., 1993(b); Wisniewski & 
Frangione, 1992, p237; Wisniewski, et al., 1994; LaDu, et al., 1994).  The differences in 
amino acids between ApoE2, ApoE3 and ApoE4 appear to differentially affect the 
binding interactions within the protein, as well as to other molecules such as Aβ (LaDu, 
et al., 1994; LaDu, et al., 1995), and there was in vitro evidence that ApoE4 could bind 
Aβ peptides more avidly than the other two isoforms, potentially explaining why 
ApoE4 increases AD risk.  
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However, the association of ApoE with lipids is also a determinant of its binding affinity 
toward Aβ (Tokuda, et al., 2000).  Not only does the binding affinity increase following 
lipidation, it also changes the isoform-specific differences (LaDu, et al., 1995). It was 
then found that the efficiency of complex formation between lipidated ApoE and Aβ 
follows the order of ApoE2 > ApoE3 >> ApoE4 (Tokuda et al., 2000). 
Since the binding efficiency of ApoE isoforms to Aβ correlates inversely with the risk of 
developing AD, it was then hypothesised that ApoE2 and ApoE3 may enhance the 
clearance of Aβ, compared to ApoE4 (Hone, et al., 2003; Yang, et al., 1999). To 
complicate the story further, later studies have since also found in AD-model 
transgenic mouse studies that a complete lack of ApoE results in no deposition of true 
plaques and much less Aβ deposition overall, which would not be expected if ApoE’s 
major interaction with Aβ was to facilitate clearance.  Other in vivo studies that 
involved crossing AD-model mice with ApoE knock-in mice demonstrated a clear 
isoform-dependent (E4>E3>E2) effect on Aβ accumulation (Bales et al., 2009; Kim et 
al., 2009).  Due to such apparently conflicting results, it is still not clear whether 
increasing or decreasing brain ApoE levels would be therapeutic against AD 
development.  
The ApoE isoforms also appear to have different neurotrophic properties, with E3 
facilitating, and E4 inhibiting neurite outgrowth, respectively (Nathan, et al., 1994).  
Studies have shown that ApoE, and in particular E4, may exacerbate the neurotoxicity 
of Aβ (Manelli, et al., 2007), and may also be directly toxic to neurons when not 
associated with lipids (Cedazo-Mínguez, et al., 2001).  Overall, ApoE appears to be 
intimately involved with many of the pathogenic mechanisms which are characteristic 
of AD.  
 
1.5.4  ApoE in plasma 
As with Aβ, there has been contention regarding the levels of ApoE in plasma.  
Although it has been demonstrated that APOE genotype has an effect on serum levels 
of the ApoE protein, with ε4 carriers having the lowest levels and ε2 carriers the 
highest, it has been suggested that APOE genotype and protein levels may affect AD 
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risk independently (Schiele, et al., 2000; Siest, et al., 2000).  Indeed, there does not 
appear to be consistency between reports on AD diagnosis and plasma ApoE protein 
levels.  Studies have found both increased levels (Taddei, et al., 1997) and decreased 
levels (Siest, et al., 2000), and some have found no difference (Scacchi, et al., 1999; 
Slooter, et al., 1998).  Preliminary studies of the AIBL cohort have been promising, with 
total plasma ApoE levels being able to differentiate SMC and MCI patients from either 
HC or AD patients, with the lowest levels occurring in APOE ε4 homozygotes and the 
highest in healthy controls (Martins, 2009).  Moreover, plasma ApoE4 levels have also 
been measured, and could differentiate between AD patients, MCI patients and 
controls, with AD patients once again having the lowest levels (AD<MCI<HC).  In 
addition, as previously mentioned, there was an inverse correlation between ApoE4 
levels and Aβ42 levels in the plasma regardless of disease status.  These results indicate 
that plasma levels of total ApoE and ApoE4 may be good candidates as early diagnostic 
biomarkers, particularly together with other blood biomarkers.  However, it should be 
taken into account that some independent factors may alter levels of plasma ApoE, 
such as geographical location (Schiele, et al., 2000), levels of the cholesterol 
transporter ABCA1 (Hirsch-Reinshagen, et al., 2009), and other biological factors such 
as age, gender and body mass index (BMI) and possibly certain medications (Vincent-
Viry, et al., 1998).  In addition, methodological differences may have contributed to the 
inconsistencies in previous literature.  Similar to the data for plasma Aβ, 
standardisation of methodological procedures for the measurement of ApoE in plasma 
would be highly beneficial. It has also been demonstrated that expression levels of 
ApoE correlate with the formation of SP and levels change with disease progression 
(Barger, et al., 2008; Kuo, et al., 2000). 
 
1.6  Aβ Degradation and Clearance 
The removal of Aβ from the CNS may occur via several mechanisms.  Firstly, according 
to the well-characterised “peripheral sink hypothesis”, cerebral Aβ has been shown to 
be transported across the blood brain barrier (BBB) and into the peripheral circulation, 
facilitated by the LDL receptor-related protein-1 (LRP-1) (Shibata, et al., 2000; 
DeMattos, et al., 2001).  This efflux appears to be isoform-dependent, with studies 
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showing a slower rate of clearance across the BBB of Aβ42 in comparison to Aβ40 (Bell, 
et al., 2007).  Once in the periphery, Aβ-binding agents may bind to the peptide and 
prevent its return to the CNS (Sagare, et al., 2007; Takata, et al., 2007).  However, free 
peripheral Aβ may enter the CNS due to the BBB’s bi-directional nature, assisted by the 
receptor for advanced glycation end products (RAGE) (Deane, et al., 2003).  It is 
therefore probable that the degradation and/or binding of Aβ to other agents in the 
periphery could be of importance to its accumulation in the brain. 
Another mechanism for cerebral Aβ clearance is by transport through perivascular 
drainage pathways into the CSF, and subsequently into the peripheral circulation via 
the blood-CSF barrier (Zlokovic, et al., 2005; Preston, et al., 2003).  Failure of 
components of this mechanism may have a role in both vascular and parenchymal 
deposits of Aβ, and may be related to the development of CAA. 
The elimination of Aβ from the CNS can also potentially occur via proteolytic 
degradation.  A number of proteases have been shown to degrade Aβ including insulin-
degrading enzyme (IDE), neprilysin (NEP), endothelin-converting enzyme (ECE), 
angiotensin-converting enzyme (ACE), the uPA/tPA-plasmin system, cathepsin D, 
gelatinase A, gelatinase B, matrix metalloendopeptidase-9, coagulation factor Xia, 
antibody light chain c23.5 and hk14, and α2-macroglobulin complexes (Wang, et al., 
2006; Miners, et al., 2008a).  Of these, IDE has attracted considerable interest as a 
primary regulator of Aβ levels, and accumulating evidence suggests that it may have a 
role in AD pathology via this interaction with Aβ. 
 
1.6.1  Insulin-Degrading Enzyme 
Insulin-Degrading Enzyme (IDE) (EC 3.4.24.56, formerly known as EC 3.4.22.11), also 
known as insulysin, insulin protease and insulinase, is a 110 kDa 
thiolmetalloendopeptidase which consists of 1019 amino acid residues (Selkoe, 2001; 
Affholter, et al., 1988).  The high degree of evolutionary conservation in both exonic 
and intronic sequences of IDE suggests an important role in cellular function (Qiu & 
Folstein, 2006).  It is a multi-functional protein, with some of its identified roles being 
1) regulation of peripheral insulin levels, 2) processing of antigenic proteins destined 
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for the major histocompatibility complex (MHC) (Parmentier, et al., 2010), 3) 
regulating cellular proteasome activity (Bennett, et al., 2000(b)) and 4) playing a role in 
cell survival and differentiation (Tundo, et al., 2012; Kayalar & Wong, 1989).  It was 
also reported by Li and associates (2006) that IDE was a receptor for the varicella-
zoster virus, however this has since been found to be controversial (Carpenter, et al., 
2010).  Other important functions for IDE include regulation of steroid-related 
signalling (Kupfer, et al., 1994), and also notably being responsible for the clearance of 
amyloidogenic peptides (Farris, et al., 2003; and reviewed in Authier, et al., 1996(a)). 
IDE is expressed in almost all tissues of the body, including the brain, where it is highly 
expressed in cerebral neurons (Bernstein, et al., 1999; Kuo, et al., 1993). Studies have 
also shown that it is produced and secreted by microglial cells in association with 
exosomes (Tamboli, et al., 2010; Qiu, et al., 1997) as well as astrocytes (Jiang, et al., 
2008).  IDE has been detected in most peripheral tissues, including the lung, skeletal 
muscle, skin, breast, testes and several blood cell types, as well as the liver and kidney 
which are believed to be the primary organs responsible for the clearance of 
peripheral Aβ (Kuo, et al., 1993; Hone, et al., 2003).  In addition, its presence has been 
reported in endothelial and smooth muscle cells, and pericytes within cerebral 
microvessels; areas of Aβ deposition in cerebral amyloid angiopathy (CAA), which often 
co-exists with AD (Morelli, et al., 2004; Gao, et al., 2004).  Interestingly, it has also 
been detected in AD senile plaques, indicating a role for IDE in plaque pathology 
(Bernstein, et al., 1999). 
At a subcellular level, IDE is mainly located in the cytosol (Akiyama, et al., 1988; 
Authier, et al., 1996(b)), however it has also been localised to peroxisomes (Kuo, et al., 
1994), endosomes (Hamel, et al., 1991), exosomes (Bulloj, et al., 2010), rough 
endoplasmic reticulum (RER) (Qiu, et al., 1998), plasma membranes (Seta & Roth, et 
al., 1997; Goldfine, et al., 1984) and recently, lipid rafts associated with the plasma 
membrane (Bulloj, et al., 2008).  In addition, it has been detected within proteasome 
complexes (Bennett, et al., 2000(b)), and has also been found secreted into the CSF 
(Qiu, et al., 1998).  A longer, mitochondrial isoform of IDE has also been confirmed in 
vitro, this mitochondrial isoform is generated from an alternative translation start site 
41 amino acids upstream of the first Met of cytosolic IDE, and the additional amino 
acid sequence forms a mitochondrial targeting sequence (Leissring, et al., 2004).  This 
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isoform has been shown to exist in the human brain and recently has been 
demonstrated to regulate mitAβ (Leal, et al., 2013).  It is highly likely that IDE found in 
different subcellular locations of IDE controls different pools of Aβ; where 
mitochondrial IDE regulates mitAβ, cytosolic IDE regulates intracellular Aβ, and 
membrane-bound IDE most likely degrades extracellular Aβ. 
Most of the expressed IDE has been reported to be the 110kDa isoform, with the 
membrane-bound isoform having a molecular weight of 115kDa (Vekrellis, et al., 
2000).   However, some older studies have reported other molecular weights including 
80kDa (Burghen, et al., 1972), 150-160kDa (Kolb & Standl, 1980), 135kDa (Yokono et 
al., 1981), 170kDa and 60kDa (Camberos, et al., 2001).  While these discrepancies may 
be due to methodological differences or analyses of different tissues and species, it is 
possible that multiple forms exist.  A truncated isoform of IDE has also been identified 
which has been reported in the National Centre for Biotechnology Information (NCBI) 
database (Reference sequence NP_001159418.1, 
http://www.ncbi.nlm.nih.gov/protein/NP_001159418.1).  This form is identical to the 
464 amino acid residues on the C-terminal end of the full-length protein.  This may 
correspond to the 60kDa protein reported.  However, this isoform is unlikely to be 
active in degrading Aβ as it does not contain the catalytic site required for catabolism.  
In agreement with this, it has been shown experimentally that the C-terminal half of 
IDE is not catalytically active (Li, et al., 2006).  The molecular weights stated in the 
UniProtKB database (http://www.uniprot.org/uniprot/P14735) for the full-length and 
the truncated IDE isoforms are 117.968kDa and 54.240kDa, respectively.  At the 
commencement of this project, there were no published results of IDE in blood or 
plasma so it was unknown what isoforms may be present in this biofluid.  However, a 
paper published very recently is, to our knowledge, the first to detail IDE activity in 
human serum in AD and MCI patients (Liu, et al., 2012(a)).  The results of this study 
suggest that AD and MCI have lower IDE activity levels when compared with healthy 
controls (n = 216).  However, only 8.7% of this cohort were MCI individuals (n = 19), 
and 7.4% were AD patients (n = 16), therefore this study may not have sufficient power 
to form a solid conclusion. 
Farris and colleagues (2005) identified an alternative full-length human isoform of IDE 
which was generated as a result of alternative splicing, which they termed “15b-IDE”.  
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This isoform was similar to the canonical isoform (termed “15a-IDE”) with the 
exception of exon 15, and was shown to exist in both the cytosol and in the 
mitochondria of human brain and liver.  The 15b-IDE isoform was demonstrated to 
have an impaired ability to degrade insulin and Aβ, when compared with 15a-IDE, and 
it was also found that both isoforms could exist intracellularly as either homodimers or 
heterodimers.  Hence, an increase in the ratio of 15b-IDE:15a-IDE isoforms could 
potentially have a negative effect on Aβ and/or insulin degradation. 
1.6.1.1  Structure and Function of IDE 
IDE was first discovered around 60 years ago due to its ability to degrade the insulin B 
chain (Mirsky & Broh-Kahn, 1949), and has since been found to cleave a variety of 
other substrates, including amylin (Bennett, et al., 2000(a)), β-endorphin (Safavi, et al., 
2006), insulin-like growth factors I and II (IGF-I and IGF-II) (Roth, et al., 1984), glucagon 
(Duckworth & Kitabchi, 1974), atrial natriuretic peptide (ANP) (Müller, et al., 1991), 
transforming growth factor-alpha (TGF-α) (Garcia, et al., 1989), bradykinin, kallidin 
(Malito, et al., 2008), somatostatin (Ciaccio, et al., 2009) and the APP intracellular 
domain (AICD), which is cleaved from APP during Aβ processing by γ-secretase 
(Edbauer, et al., 2002; Venugopal, et al., 2007).  However, AD researchers suddenly 
developed significant interest in this enzyme when it was discovered that IDE was also 
found to degrade Aβ (Kurochkin & Goto, 1994; Qiu, et al., 1998; McDermott & Gibson, 
1997; Chesneau, et al., 2000) (Figure 1.2).  Although IDE is known to bind and degrade 
a wide range of substrates, it has a preferential affinity for insulin (Qiu, et al., 1998; 
Duckworth, 1988; Edbauer, et al., 2002).  However, unlike most enzymes which 
recognise substrates via sequence specificity, IDE appears to have conformational 
specificity for its substrates, many of which share a similar secondary structure – can 
form beta strands, and have a tendency toward amyloidogenesis (Kurochkin, 1998; 
Kurochkin, 2001; Bennett, et al., 2000(a)).  It is therefore possible that it may have a 
primary function in the prevention of amyloid formation and deposition by degrading 
potentially amyloidogenic peptides. 
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IDE can be divided into two subunits, the N-terminal half and the C-terminal half (IDE-
N and IDE-C, respectively) of approximately 55 kDa each, which are joined by a loop 
comprised of 28 amino acids (Shen, et al., 2006).  These subunits interact with each 
other to form a triangular crypt which engulfs and binds its substrates to the internal 
catalytic site before hydrolysing them at specific residues, favouring smaller substrates 
which are less than 6kDa with few positively-charged residues at the C-terminus 
(Duckworth, et al., 1998; Shen, et al., 2006).  IDE can also be divided further into four 
domains, with domains 1 (AA 43-285) and 2 (AA 286-515) comprising IDE-N, and 
domains 3 (AA 542-768) and 4 (769-1016) comprising IDE-C (Shen, et al., 2006).  The 
active catalytic site of IDE is located in domain 1, and residues His108, Glu111, His112 
and Glu189, which associate with a zinc ion, have been demonstrated to be crucial for 
normal activity of the enzyme (Shen, et al., 2006; Perlman & Rosner, 1994; Song, et al., 
2005). 
IDE displays allosteric kinetic properties with evidence suggesting that the enzyme 
usually exists in a closed conformation, but shifts to an open conformation when 
activated.   This has been shown to occur by each half rotating away from each other.  
One proposed mechanism responsible for this appears to be a disruption in hydrogen 
bonding at the IDE-N and IDE-C interface; it has been confirmed that mutations in this 
region which dislocate this interface between domains 1 and 4, promote the open 
conformation and hence substantially increase the catalytic activity of the enzyme 
(Shen, et al., 2006; Im, et al., 2007).  It has also been demonstrated that the open 
conformation can be initiated by the binding of nucleotide polyphosphate anion 
regulators such as ATP, to a cationic distal exosite located primarily in domain 4, within 
the catalytic chamber (Shen, et al., 2006; Im, et al., 2007; Noinaj, et al., 2011).    
Although ATP was first reported to be an inhibitor, the regulation of IDE by nucleotide 
Figure 1.2  The IDE protein in complex with an 
Aβ peptide.  (Shen, et al., 2006) 
 
The N-terminal domain of IDE is green, and C-
terminal domain is red.   The Aβ peptide (blue) is 
shown within the degradation chamber of the 
IDE protein. 
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polyphosphates appears to be concentration-dependent, and at physiological 
concentrations ATP activates the enzyme to increase hydrolysis of small peptide 
substrates (Camberos & Cresto, 2007; Song, et al., 2004).  It is possible that other 
anions may also regulate IDE in this way (Noinaj, et al., 2011 (b)).  IDE’s ability to be 
activated selectively through the polyphosphate cationic exosite could be useful in 
developing drug targets for this mechanism, and synthetic compounds have been 
identified which can activate the enzyme nearly 7-fold in this manner (Cabrol, et al., 
2009).   
In addition to the active site in domain 1, a distal site which binds peptide substrates 
has been identified in domain 2, also within the catalytic cavity.  The binding of small 
peptides to this site is also thought to be involved in allosteric kinetics and activation. 
This is supported by studies of mutations in this region which have been found to 
eradicate these properties (Noinaj, et al., 2011 (a)).  However, the distal site appears to 
be a distinct site from the anion-binding site, as activation of IDE by the small peptide 
bradykinin was largely unaffected by an excess of either ATP or triphosphate (Song, et 
al., 2004).  Larger IDE substrates such as insulin and Aβ have been demonstrated to 
bind to this distal site via their N-terminus, while simultaneously binding to the active 
site, inducing a change in substrate conformation toward β-strands.  This mechanism 
has been proposed as a way of positioning larger substrates for cleavage via the active 
site, and in addition may also indicate a means of locking IDE in the closed 
conformation due to electrostatic charges (Leissring, et al., 2010).  Smaller substrates 
less than 12 amino-acids in length are unable to bind to both sites simultaneously, 
however may act as heterotropic activators if they have a stronger affinity for the 
distal site than the active site, as in the case of bradykinin (Amato, et al., 2009; Song, et 
al., 2003; Noinaj, et al., 2011 (a)).  Binding to both the active site and distal site 
simultaneously by larger peptides such as insulin, has been shown to eliminate both 
allosteric behaviour and activation by ATP and small peptide substrates, possibly by 
either physical blocking of the cationic binding site/s and/or steric hindrance.  
Experimental evidence suggests that via peptide binding to this site, IDE can be 
selectively activated toward particular substrates; for example dynorphin B-9 increases 
the rate of Aβ1-40 degradation but inhibits insulin degradation (Song, et al., 2003).  
Similarly, somatostatin, has been shown to positively regulate the degradation of Aβ 
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by IDE (Tundo, et al., 2012; Ciaccio, et al., 2009), and interestingly, reduced levels of 
somatostatin have been implicated both in the pathology of AD, and also as part of 
normal ageing (Ciaccio, et al., 2009; Gavilán, et al., 2007).  This feature of selective 
activation by small peptides could offer a potential target for Aβ-reducing therapies for 
AD. 
As well as activation by small peptides and phosphates, IDE activity has also been 
found to be regulated by calcium, manganese, magnesium and zinc ions (Duckworth, 
et al., 1990; Ebrahim, et al., 1991) with zinc being essential for its function.  It was 
demonstrated recently that a single exposure of lead can impair IDE activity in vitro, 
and increase the intracellular accumulation of Aβ (Behl, et al., 2009).  One theory that 
was put forward to explain this mechanism involved lead replacing the zinc ion at the 
catalytic site, being a bivalent cation itself.  Physiological levels of these cations, 
therefore, are likely to be influential in regulating IDE catalytic activity. 
IDE also requires free thiol groups for its proteolytic activity and this seems to be 
related to its cysteine residues.  Studies have shown that alkylation, oxidation, 
nitrosylation or glutathionylation may modify cysteine-related thiols and cause 
complete or partial inhibition of the enzyme (Neant-Fery, et al., 2008; Shinall, et al., 
2005; Malito, et al., 2008; Cordes, et al., 2011).  While alkylation of thiols is 
irreversible, nitrosylation and glutathionylation appear to be reversible modifications.  
Oxidation may inhibit IDE directly, or indirectly via oxidised glutathione.  These effects 
could therefore provide another mechanism for IDE dysfunction in AD. 
The aggregation status of IDE is also important in regulating its function, and IDE has 
been found to exist normally as a mixture of monomers, dimers and tetramers in 
equilibrium, with dimers and tetramers being the dominant species (Song, et al., 2003; 
Song, et al., 2004).   The dimer is reportedly the most active form.  Evidence suggests 
that ATP shifts the aggregation status of IDE towards the monomeric form, and 
increases its affinity for degrading smaller peptides such as bradykinin and dynorphin 
B-9, without effect on larger peptides like insulin and Aβ (Song, et al., 2004).  In 
addition, the monomeric variant of IDE does not appear to be activated by small 
peptides or ATP, and displays classic Michaelis-Menten kinetics rather than allosteric, 
indicating that the association of two or more subunits has a cooperative effect (Song, 
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et al., 2010).  Thus the balance of these species is important in the overall function and 
enzymatic activity of IDE. 
As mentioned previously, IDE appears to have many roles in human physiology, as well 
as disease pathology, one of them being its association with the development of type 2 
diabetes, otherwise known as diabetes mellitus type 2 (DM2) (Furukawa, et al., 2008; 
Karamohamed, et al., 2003; Kwak, et al., 2008).  Numerous studies have also found an 
association between DM2 and AD (Ott, et al., 1996; Ott, et al., 1999; Muller, et al., 
2007).  However, the putative mechanisms which may be common to both DM2 and 
AD, or mechanisms for DM2 increasing risk of AD have yet to be elucidated.  This link 
between DM2 and AD will be discussed in more detail below. 
 
1.7  Type 2 Diabetes, Insulin Resistance Syndrome and AD 
One of the precursors to DM2 is the insulin resistance syndrome (also called 
“Metabolic Syndrome” or “Syndrome X”), which has also been implicated in the 
development of AD.  Characteristics associated with DM2 and insulin resistance 
syndrome include insulin resistance, high peripheral levels of insulin 
(hyperinsulinemia), hyperglycaemia and impaired glucose tolerance, obesity, 
hypertension, and abnormal peripheral lipid and cholesterol concentrations, among 
others (Kuusisto, et al., 1997; Chang, 2008; Wehr, et al., 2006; and reviewed by Craft, 
2006 and Mielke & Lyketsos, 2006).  Accumulating evidence suggests that in particular, 
insulin resistance, hyperinsulinemia and DM2 are significant risk factors for AD (Ott, et 
al., 1996; Ott, et al., 1999; Kuusisto, et al., 1997; Muller, et al., 2007). 
Cross-sectional studies have demonstrated that DM2 is considerably over-represented 
in AD patients in comparison with non-AD controls (Kuusisto, et al., 1997; Ott, et al., 
1996; Stewart & Liolitsa, 1999).  In addition, it has been shown in numerous large, 
population-based longitudinal studies that DM2 may significantly increase the risk of 
AD (Peila, et al., 2002; Ott, et al., 1999; Leibson, et al., 1997; Xu, et al., 2004; 
Arvanitakis, et al., 2004).  However, some studies have not found an association 
between DM2 and risk of AD, or the results may have demonstrated a trend but were 
non-significant (Luchsinger, et al., 2001; MacKnight, et al., 2002; Hassing, et al., 2002). 
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A study by Peila et al. (2002) found that AD patients with co-morbid diabetes had an 
increase in the prevalence of SP, NFT and CAA, and especially in carriers of the APOE ε4 
allele.  In addition, both AD and DM2 have an increased prevalence with age (von 
Strauss, et al., 1999; Davidson, 1979).  This may suggest that a common pathological 
mechanism related to ageing may be implicated in both DM2 and AD. 
Pathological similarities exist between DM2 and AD; cytotoxic amyloid is deposited in 
both conditions.  While fibrillar Aβ is deposited in particular brain regions in AD 
(Glenner & Wong, 1984), most DM2 patients have similar amyloid deposits in the islets 
of Langerhans in the pancreas, composed of fibrillar islet amyloid polypeptide (IAPP), 
also known as amylin (Cooper, et al., 1987; Westermark, et al., 1987).  Studies have 
shown that amylin may aggregate intracellularly in the β-cells prior to cell loss, and 
subsequently form extracellular deposits after the death of cells (O’Brien, et al., 1995; 
O’Brien, et al., 1994).  It is possible that AD pathology follows the same pattern.  In 
fact, several studies have shown that Aβ is produced intracellularly and over-
production or reduced clearance may be significant in AD pathology (Wertkin, et al., 
1993; and reviewed by Gouras, et al., 2010).  Interestingly, islet amylin deposits 
contain ApoE akin to Aβ deposits, indicating a role for ApoE in amyloid formation in 
both conditions (Wisniewski & Frangione, 1992).  Further evidence linking DM2 to AD 
comes from a study by Janson et al. (2004), which found that AD patients are more 
likely to have islet amyloid deposits than non-AD controls.  The same study found that 
non-AD DM2 patients are not more likely to develop SP, although when diffuse or 
neuritic plaques were present, they correlated with the duration of DM2.  The results 
are different to what has been found in other studies, as their data support the 
hypothesis that patients with Alzheimer disease are more vulnerable to DM2 (not the 
other way around). The results need to be replicated in other studies, using a larger 
cohort. 
DM2 patients have been shown to be more susceptible to cognitive impairment, and 
to have lower MMSE scores than controls (van den Berg, et al., 2005; Grodstein, et al., 
2001; Sinclair, et al., 2000; Arvanitakis, et al., 2004).  Interestingly, it has been reported 
that medications that promote the secretion of insulin further increase the risk for AD 
in diabetics (Luchsinger, et al., 2001; Ott, et al., 1999; Ott, et al., 1996).  It is possible, 
therefore, that the link between DM2 and AD may be related to insulin. 
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1.7.1  Insulin and AD 
Insulin, well known for its role in regulating peripheral glucose levels, is principally 
produced and secreted by β-cells in the pancreas, and insulin secretion occurs in 
normal physiology in response to elevated plasma glucose (Martini, 1998).  It is also 
known that insulin plays an important role in the CNS, gaining access from the 
periphery by receptor-mediated transport across the BBB (Banks, et al., 1997).  It has 
been shown that insulin plays a role in long-term potentiation (LTP), a process which 
underlies memory formation (Craft, 2006).  In addition, animal studies have 
demonstrated that neurons can generate insulin, and insulin receptors have been 
found in key areas of the brain involved with AD pathology and cognitive function 
(Devaskar, et al., 1994; Schechter, et al., 1988; Craft & Watson, 2004).  Due to the role 
of insulin in glucose regulation, it is likely that insulin abnormalities impair cerebral 
glucose metabolism, a characteristic which has been demonstrated in both AD and 
MCI brains (De Santi, et al., 2001).  Elevation of peripheral insulin levels has also been 
shown to increase insulin concentration in the CNS (Wallum, et al., 1987).  However, it 
has been shown that insulin levels in the brain are actually lower in AD patients (Craft, 
et al., 1998) and evidence suggests this can be caused by the presence of 
hyperinsulinemia-related insulin resistance in the periphery, causing a reduction in 
brain insulin uptake through the blood-brain barrier (Baura, et al., 1996; Craft, et al., 
1998; Kaiyala, et al., 2000).  In addition, insulin resistance in the CNS may be associated 
with impairment of several molecules involved in the insulin signalling cascade (Talbot, 
et al., 2012). Conversely, hyperinsulinemia could also inhibit Aβ degradation in the 
periphery itself through competitive inhibition of IDE, leading to Aβ accumulation both 
peripherally and then in the CNS by migration across the BBB. 
1.7.1.1  Hyperinsulinemia 
Hyperinsulinemia, referring to high peripheral levels of insulin, is an early feature of 
DM2 in many individuals, occurring well prior to altered glucose metabolism (Weyer, 
et al., 2000).  Chronic hyperinsulinemia leads to, correlates with, and therefore is used 
as a measure of insulin resistance.  It is also used as a predictor of DM2 (Laakso, 1993; 
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Lundgren, et al., 1990; Weyer, et al., 2000).  Research suggests that hyperinsulinemia 
is also a significant risk factor for AD (Luchsinger, et al., 2004), and in contrast to the 
findings that brain insulin levels decrease in AD as mentioned above, numerous studies 
have demonstrated elevated serum insulin levels in AD subjects in comparison with 
controls (Kuusisto, et al., 1997; Weyer, et al., 2000; Muller, et al., 2007; Carantoni, et 
al., 2000; Fujisawa, et al., 1991).  This association has been demonstrated in non-
diabetic individuals too, suggesting that this feature of DM2 may be more relevant to 
AD risk than just DM2 itself (Luchsinger, et al, 2004; Stolk, et al., 1997).  In support of 
this, other evidence suggests that AD severity also correlates with plasma insulin levels 
(Craft, et al., 1998). 
Two studies have shown that hyperinsulinemia is a significant risk factor in AD patients 
who do not possess the APOE ε4 allele, indicating that these factors may affect risk 
independently (Kuusisto, et al., 1997; Craft, et al., 1999).  Moreover, Craft et al. (1998) 
found that AD subjects with only one APOE ε4 allele or no ε4 alleles had higher plasma 
insulin levels than ε4/ε4 homozygotes.  Craft et al. (2003) later found that memory 
facilitation occurred with peripheral insulin infusions at a similar dose for normal 
adults and APOE ε4/ε4 homozygotes with AD, however AD patients with one or less ε4 
alleles required much higher doses for the same effect.  These results may indicate 
that those who are not ε4/ε4 homozygotes may have reduced sensitivity to insulin.  
Another large study found no association between diabetes and AD risk overall, 
however when stratified for APOE ε4 genotype, this study found an association only in 
APOE ε4 negative individuals (Akomolafe, et al., 2006).  These results indicate that 
insulin metabolism dysfunction may be a relevant pathological mechanism for the 
approximate 50% of AD patients who do not possess the ε4 allele, in respect to AD risk. 
It may indicate that for those individuals with APOE ε4 alleles, the supposed metabolic 
deficiencies caused by the ApoE4 protein are sufficient to increase AD risk, whereas in 
non-APOE ε4 individuals, AD may develop after long-term insulin resistance and 
associated effects.  
1.7.1.2  Insulin and Cognition 
Accumulating evidence suggests that insulin is involved in a number of key roles in 
cognition and memory. In support of this, insulin has been shown to play a part in 
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regulating cerebral levels of neurotransmitters which are involved in memory and 
cognition, such as dopamine, acetylcholine and norepinephrine (Craft & Watson, 
2004). In vivo studies have shown memory facilitation in rats after insulin was directly 
applied to the brain (Park, et al., 2000) and after intravenous insulin infusion in 
humans (Craft, et al., 2003).  The administration of insulin via nasal pathways has the 
effect of elevating levels in the CNS without raising peripheral levels, and several 
studies have also demonstrated improvements in memory and cognitive function after 
such treatment both in diabetic mice, and in early AD and MCI patients (Craft, et al., 
2012; Francis, et al., 2008; Reger, et al., 2006; Reger, et al., 2008(a); Reger, et al., 2008 
(b)).  Interestingly, in the study by Reger et al. (2008(a)), memory facilitation only 
occurred in APOE ε4 negative subjects while memory was impaired in ε4 carriers.  It is 
possible that this outcome was dose-related as it is in contrast to previous reports 
(Craft, et al., 2003).   
Conversely, DM2 and elevated plasma insulin has also been associated with impaired 
cognition and memory (Stolk, et al., 1997; Vanhanen, et al., 1998; Marfaing-Jallat, et 
al., 1995).  The discrepancy in these results may be due to the fact that insulin-induced 
memory facilitation is attenuated at higher (and lower) doses, indicating an optimum 
level is required for cognitive improvement (Craft, et al., 2003; Reger, et al., 2008 (a)).  
In addition, APOE genotype-related differences in insulin sensitivity may have affected 
this result.  The study by Stolk et al. (1997) excluded diabetics and dementia patients 
from the analysis, which may have skewed the results, and significant results were only 
obtained for females.  Similarly, Vanhanen’s study (1998) was only on elderly glucose 
intolerant individuals.  Much more likely, however, is that acute hyperinsulinemia may 
facilitate memory and cognition, while chronic hyperinsulinemia appears to produce 
deleterious effects.  
1.7.1.3  Insulin and Aβ 
Insulin has been demonstrated to regulate Aβ levels, both in the CNS and peripherally, 
although the mechanisms that control Aβ levels are unclear.  An in vivo study on 
healthy adults found that Aβ levels in the CSF were elevated after intravenous insulin 
infusion (Watson, et al., 2003).  In vitro studies have found that insulin stimulates Aβ 
production via upregulation of APP trafficking and increased secretion of Aβ into the 
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extracellular milieu (Gasparini, et al., 2001).  The same study showed that insulin also 
increased extracellular levels of Aβ by impairing its degradation by IDE.  This has been 
supported by other studies that have found that hyperinsulinemia has an inhibitory 
effect on Aβ degradation (Qiu, et al., 1998; Kulstad, et al., 2006).  Moreover, it has 
been recently demonstrated that AD patients respond differently to insulin when 
compared to healthy controls (Kulstad, et al., 2006).  While levels of plasma Aβ 
dropped in normal adults after receiving a peripheral insulin infusion at optimal levels, 
the AD patients consistently showed an increase in Aβ levels in a dose-dependent 
manner.  This indicates that AD patients may have impaired insulin clearance which 
could be attributable to IDE dysfunction or a reduction in levels of IDE, which then 
leads to accumulation of Aβ. 
1.7.1.4  Hypercholesterolemia, Insulin and IDE 
There are other sources of evidence which link insulin and IDE with Aβ regulation.  
Hypercholesterolemia has been associated with AD, MCI and increased levels of Aβ in 
some studies (Pappolla, et al., 2003; Kivipelto, et al., 2001), and research has shown 
that a high-fat diet in AD-model transgenic Tg2576 mice induces insulin resistance and 
subsequently impairs insulin signalling in the brain (Ho, et al., 2004).  Concomitantly, 
there is a decrease in IDE activity, and an increase in both Aβ40 and Aβ42 levels and 
brain plaque load.  The suggested role of insulin signalling in IDE regulation is 
supported by a similar study by Zhao et al. (2004).  Obesity and elevated free fatty 
acids (FFA), features related to hyperinsulinemia, have also been shown to impair 
insulin degradation via direct non-competitive inhibition of IDE (Hamel, et al., 2003; 
Eckel, et al., 2005).   
Insulin potentially affects other aspects of AD pathology.  It has been demonstrated 
that both insulin and insulin-like growth factor-1 (IGF-1) regulate the phosphorylating 
protein kinase, glycogen synthase kinase-3β (GSK-3β) to stimulate transient tau 
phosphorylation in vitro and in vivo, which may be involved in the formation of NFT 
(Engel, et al., 2006; Lesort, et al., 1999; Lesort & Johnson, 2000; Hong & Lee, 1997; Ho, 
et al., 2004).  IGF-1 not only has neurotrophic properties and a role in apoptosis, but 
also regulates levels of IDE and therefore may modulate Aβ levels, and as mentioned 
above may be involved in tau phosphorylation through regulation of GSK-3β (Sharma, 
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et al., 2008; Costantini, et al., 2006).  Interestingly, IGF-1 is also a substrate for IDE 
degradation, and low levels have been found in AD brains (Steen, et al., 2005).  In 
addition, IGF-1 signalling has an effect on GSK-3α, which has been shown to regulate 
APP processing (Phiel, et al., 2003).  Another study has shown that 
hypercholesterolemia increases production of Aβ via GSK-3α, and decreases clearance 
of Aβ due to a reduction in levels of IDE, through alterations in the IGF-1 signalling 
pathway (Sharma, et al., 2008).  This association between hypercholesterolemia and 
low IDE is supported in another study (Prasanthi, et al., 2008).  Therefore, 
hypercholesterolemia may also play an important part in the link between DM2 and 
AD.  In addition, hyperinsulinemia has been shown to promote inflammatory 
responses in the CNS, a feature associated with AD (Craft, 2005; Aisen, 1997; Fishel, et 
al., 2005).  Research has found that the degree of chronic inflammation correlates with 
both cognitive decline (Parachikova, et al., 2007) and brain atrophy (Cagnin, et al., 
2002) and therefore may exacerbate neuronal degeneration.  Increased peripheral 
insulin levels have been found to lead to increased cerebral levels of pro-inflammatory 
cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumour necrosis factor-
α (TNF-α), all of which have been reported to be elevated in AD and have been located 
in SP and their related glial cells in Alzheimer’s patients (Craft, 2005; Sokolova, et al., 
2009; Griffin, et al., 1989; Bauer, et al., 1991; Fishel, et al., 2005; Dickson, et al., 1993).  
Interestingly, anti-inflammatory cytokines have been shown to increase both IDE 
expression as well as Aβ degradation (Shimizu, et al., 2008).  Inflammation is a known 
characteristic of DM2, and there is mounting evidence that chronic inflammation is an 
important early stage of AD pathogenesis (reviewed by Bhamra & Ashton, 2012).  In 
fact, inflammation-linked proteins such as alpha-2 macroglobulin and clusterin 
(amongst others) are considered to be good potential biomarkers of early stages of AD 
(Thambisetty, et al., 2010; reviewed by Bhamra & Ashton, 2012).   Chronic activation of 
microglia in neurodegenerative disorders such as AD, Parkinson's disease (PD), 
Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) as well as inflammatory 
conditions of CNS such as multiple sclerosis (MS) results in overall upregulation of pro-
inflammatory cytokines and chemokines in the brain. As a result, many therapeutic 
strategies aim to alleviate neurodegenerative disease progression by reducing 
inflammation (Reinhart, et al., 2011; reviewed by Holmes, 2013; Cappellano, et al., 
2013; Rizzo, et al., 2013).   
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1.8  Hyperinsulinemia, IDE and AD 
Insulin resistance and hyperinsulinemia are related conditions, such that each 
condition induces the other (Craft, 2006).  Therefore it is plausible that low levels of 
plasma IDE may lead to hyperinsulinemia, which leads to insulin resistance and 
possibly the development of DM2.  In addition, IDE deficiency-induced 
hyperinsulinemia could reasonably lead to the accumulation of Aβ in the periphery, 
due to competitive inhibition.  This could potentially instigate or exacerbate AD 
pathology.  In accordance with this, it has in fact been demonstrated that 
hyperinsulinemia can increase Aβ levels in the periphery, and also in the CSF and brain 
(Fishel, et al., 2005).  Certain diets may exacerbate this problem too, if they lead to 
high peripheral lipid levels and/or chronic insulin release.   
In other studies, including studies by our group in the AIBL study, it has been shown 
that greater levels of exercise have a protective effect against AD, and also induce 
positive effects on AD-related pathological biomarkers (Brown, et al., 2012(a); Brown, 
et al., 2012(b); Liang, et al., 2010).  This may be, in part at least, associated with 
exercise-induced elevation of IDE levels, as a recent study in rats confirmed that IDE 
levels increase, causing a decrease in insulin levels, as a result of even short-term 
exercise (Kim, et al., 2011).  
It has been demonstrated that levels of IDE decline as a result of ageing, in areas of the 
brain susceptible to AD pathology (Caccamo, et al., 2005); for example IDE levels were 
found to decline in hippocampal regions, an area commonly affected by AD pathology, 
but not in the cerebellum, a region of the brain where Aβ deposits are rare.  This 
ageing-related, regional decline in IDE levels supports the concept that insulin and IDE 
levels are relevant in AD pathogenesis.  Insulin resistance and chronic 
hyperinsulinemia, as previously mentioned, can also have other effects relevant to AD, 
such as reducing insulin transport across the BBB into the CNS (Baura, et al., 1996).  
This may lead to reduced levels of insulin in the brain, attenuating the benefits of 
insulin on cognition and memory. 
If hyperinsulinemia forms the basis for the putative relationship between AD and DM2, 
IDE could be a good candidate as a plasma biomarker for AD.  Leissring and colleagues 
38 
 
(2003) examined the effect of genetic over-expression of IDE in APP transgenic mice.  
The results showed a significant decrease in both soluble and insoluble cerebral Aβ 
levels, with a concomitant prevention or reduction in formation of SP when compared 
with APP transgenic controls.  In addition, premature death was attenuated in the 
mice over-expressing IDE.  This result paralleled a previous in vitro IDE over-expression 
study, where extracellular levels of both Aβ40 and Aβ42 were also found to be 
significantly reduced (Vekrellis, et al., 2000).  In this cell culture study, the reduction of 
Aβ was inhibited by insulin incubation, highlighting the competition between insulin 
and Aβ for IDE, and its preference for insulin.  Another over-expression study on 
Chinese hamster ovary cells demonstrated a significant reduction in both extracellular 
and intracellular Aβ levels (Sudoh, et al., 2002).  Interestingly, IDE has been shown to 
degrade monomeric but not oligomeric or fibrillar Aβ, indicating that a reduction in 
monomeric Aβ may be sufficient to prevent plaque formation, and that IDE may not 
recognise/bind aggregated Aβ (Leissring, et al., 2003; Vekrellis, et al., 2000; Mukherjee, 
et al., 2000).  However, in a more recent study, it was shown that IDE is responsible for 
a significant portion of the degradation of fibrillar Aβ in monocyte-derived 
macrophages (Yamamoto, et al., 2008).  It is likely that protein chaperone-mediated 
disassembly of the fibrils may occur before the degradation by IDE.  It has also been 
suggested that monomeric and polymeric Aβ may exist in equilibrium, where reduction 
of monomers may instigate the disassembly of pre-formed fibrillar aggregates 
(Leissring, et al., 2003).  A study by Lazarov et al. (2002) supports this equilibrium 
hypothesis by demonstrating that SP formation is reversible.  If this is the case, then 
IDE may be ideal as a therapeutic target against AD. 
Further support for the concept that IDE is important in Aβ breakdown comes from in 
vivo studies which have found that levels of Aβ in the brain elevate as a response to 
deletion of the IDE gene, in transgenic knockout mouse models (Farris, et al., 2003; 
Miller, et al., 2003).  While Miller et al. (2003) found an increase of both Aβ40 and Aβ42, 
Farris and colleagues (2003) demonstrated that murine IDE knockouts not only display 
chronic elevation of Aβ levels, but also develop hyperinsulinemia and impaired glucose 
tolerance, characteristics of DM2.  In these experiments, levels of AICD were also 
found to be elevated, signifying impaired clearance.  The function of AICD is not 
precisely known, however it has been suggested that it may have a role in nuclear 
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signalling and apoptosis (Edbauer, et al., 2002; Kinoshita, et al., 2002).  In addition, 
AICD is thought to be neurotoxic and it appears to regulate GSK-3β (Kim, et al., 2003; 
Ryan & Pimplikar, 2005).  This suggests a mechanism that is separate from Aβ 
accumulation which could be involved in AD pathogenesis. 
Farris et al. (2004) demonstrated further evidence for IDE’s possible involvement in the 
development of LOAD, in a study on Goto-Kakizaki (GK) rats.  The GK rat is a well-
characterised rat model of DM2, with typical features such as hyperinsulinemia and 
postprandial hyperglycaemia, and mutations within the IDE gene (Fakhrai-Rad, et al., 
2000).  This study showed that partial IDE hypofunction was sufficient to induce 
elevations in neuronal Aβ levels; however increases in steady-state levels of Aβ did not 
occur until the age of 14 months, indicating a possible compensatory effect in the early 
stages of life.  This may reflect possible mechanisms for the development of LOAD.  In 
addition, the levels of Aβ in this study compared along with knockout and over-
expression studies appear to indicate a dose-dependent effect of IDE on Aβ, further 
supporting the importance of expression levels on Aβ homeostasis (Farris, et al., 2003).  
Overall the results indicate that impaired expression and/or activity of IDE are 
sufficient to generate symptoms of AD pathology. 
Clinical evidence supports the premise that IDE may be integral to the development 
and progression of AD.  A study by Perez et al. (2000) found that the activity level of 
IDE was significantly lower in AD brains compared with controls.  While this study did 
not measure the cerebral levels of the full length IDE protein due to detection 
difficulties, levels of a 44 kDa fragment of IDE in the cytosolic fraction were shown to 
be decreased in AD brains compared with controls.  These findings were supported by 
a larger-scale study by Cook et al. (2003), who found decreased levels of IDE protein 
and mRNA in hippocampal regions of AD brains compared with control brains.  
Interestingly, this reduction was only observed in APOE ε4 carriers, which suggests that 
the ε4 allele either directly affects IDE expression, or interacts with an independent 
process of AD pathology which leads to reduced IDE expression.  This finding of 
decreased levels of IDE in hippocampal regions was supported in a murine study, 
where homozygous triple-transgenic models of AD (Oddo, et al., 2003) showed 
significantly lower levels of IDE in the hippocampus compared with wild-type and 
hemizygous transgenic mice (Caccamo, et al., 2005).  In accordance with these 
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findings, a new transgenic mouse model of AD has been reported to demonstrate 
reduced cortical expression of IDE prior to the appearance of SP (Ferretti, et al., 2011). 
Conversely, studies have also shown that levels of IDE are increased in certain regions 
of the AD brain in comparison with controls, the enzyme can be localised to neurons 
and has also been associated with SP (Bernstein, et al., 1999).  It is possible that small 
sample size, lack of APOE ε4 stratification, and/or region-specific alterations in IDE 
levels may be causing these conflicting results.  Miners et al. (2008a) demonstrated 
that hippocampal IDE expression differs depending on the region examined; with 
CA3/4 neurons showing the highest expression and CA1 the lowest, and significantly 
lower levels being found in AD patients compared with controls in the CA2 and CA3/4 
regions.  In this study, the lowest levels were also associated with the most advanced 
AD cases.  Furthermore, slight differences were found between APOE ε4 carriers and 
non-carriers with respect to IDE expression levels; however they failed to reach 
significance. 
 
1.8.1  IDE Catalytic Activity 
It is plausible that it is a combination of decreased activity and expression levels, or 
simply impaired activity alone that leads to decreased Aβ degradation.  Although there 
have been reports of increased IDE activity in AD individuals compared with healthy 
controls in some studies (Miners, et al., 2009), numerous studies have reported 
reduced activity levels compared with healthy controls (Kim, et al., 2007; Perez, et al., 
2000; Qin & Jia, 2008; Zhao, et al., 2007; Morelli, et al., 2004).  The relatively recent 
study by Zhao and colleagues (2007) showed impairment in both IDE levels and activity 
in membrane fractions of the hippocampus in MCI patients compared with normal 
adults.  Moreover, both activity and concentration levels continued to decrease during 
the progression from MCI to AD, and were inversely correlated with cerebral Aβ42 
levels.  This supports the notion that IDE dysfunction and impairment of expression are 
present and apparent in the prodromal stages of AD.  The importance of IDE activity is 
further highlighted in the study by Morelli et al. (2004).  This study examined the levels 
and activity of IDE in cerebral microvessel fractions, in AD patients with concomitant 
CAA, compared with non-AD controls.  The results found that although expression 
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levels of IDE were markedly comparatively increased in AD/CAA patients, the activity 
levels were significantly decreased. 
One recent study on familial EOAD patients with a novel PS1 mutation found that 
accumulation of extracellular and intracellular Aβ42 was always associated with 
decreased activity levels of IDE, both in the cytosol and on the plasma membrane (Qin 
& Jia, 2008).  Moreover they discovered that elevated intracellular, but not 
extracellular Aβ42, was also associated with decreased expression levels of IDE.  This 
indicates that intra- and extracellular IDE may function in different ways.  It has 
recently been shown that cytosolic IDE has a longer half-life than membrane-bound 
IDE, which has a considerably faster turnover (Bulloj, et al., 2008).  This localisation, 
and IDE activity can be modulated by changes in membrane lipid composition, and has 
been shown to result in alterations in Aβ degradation.  This may explain a mechanism 
for an IDE-lipid interaction which impacts on IDE activity levels.  As previously 
mentioned, the novel 15b-IDE isoform (Farris, et al., 2005), could also suggest a 
mechanism for the reduced activity levels observed in AD, whether it exists 
physiologically as a homodimer or with 15a-IDE as a heterodimer.   
There are a number of other factors that may contribute to the impairment of IDE 
activity.  It has been shown that ubiquitin, a regulatory protein which has been 
suggested as having a possible role in AD and other neurodegenerative diseases, binds 
to and inhibits the activity of IDE, and this interaction was found to be modulated by 
insulin (Grasso, et al., 2008; Saric, et al., 2003) indicating it is affected via a competitive 
mechanism.  This would be likely to affect the degradation of Aβ in the same manner.  
Ubiquitin has also recently been found to be a substrate of IDE (Ralat, et al., 2011).  
Pathological mechanisms of AD such as oxidative stress or intracellular accumulation of 
Aβ could increase the levels of ubiquitin and therefore reduce IDE activity. 
IDE activity has also been found to be reduced through impaired insulin signalling due 
to diet-induced insulin resistance (Ho, et al., 2004), inhibition through elevation of 
FFA’s (Hamel, et al., 2003) and elevated glucocorticoids (Kulstad, et al., 2005; Harada, 
et al., 1996).  Interestingly, the glucocorticoid cortisol has been found to be elevated in 
the periphery of AD patients (Umegaki, et al., 2000; Hartmann, et al., 1997; Davis, 
1986).  A recent study showed that different types of fatty acids can differentially 
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affect the expression of IDE as well, with saturated palmitic acid causing down-
regulation and polyunsaturated docosahexaenoic acid (DHA) causing the opposite 
effect (Du, et al., 2010).  Interestingly, saturated dietary fatty acids such as palmitic 
acid have been shown to exacerbate AD pathology while unsaturated fatty acids such 
as DHA are considered to be protective (Morris, et al., 2003; Patil, et al., 2007; Cole & 
Frautschy, 2006).  It is possible that this may be due in part to their effects on IDE 
expression and activity. 
As previously mentioned, the activity of IDE has also been shown to be inhibited by 
cysteine-directed modifications such as alkylation, S-nitrosylation by nitric oxide (NO), 
and oxidation  or glutathionylation (Neant-Fery, et al., 2008; Cordes, et al., 2009; 
Malito, et al., 2008; Shinall, et al., 2005).  IDE activity has also been reported to be 
positively regulated by the peptide hormone somatostatin, which is known to be 
reduced in AD (Ciaccio, et al., 2009).  In addition, the important discovery that fibrillar 
Aβ binds to, and inhibits the activity of IDE, is also a very significant observation 
(Chander, et al., 2007).  One or more of these factors may contribute to the 
impairment of IDE activity and subsequent development of AD pathology.  Overall the 
results suggest a need to examine both expression levels and activity in conjunction 
with each other to gain a more complete picture of IDE-related AD pathology. 
 
1.8.2  IDE and Aβ Neurotoxicity 
Another positive effect of IDE cleavage of Aβ is the subsequent neutralization of the 
neurotoxic effects of the fragments produced.  An in vitro study by Mukherjee, et al. 
(2000) found that IDE reduced the cytotoxicity of both Aβ40 and Aβ42 in a dose-
dependent manner.  However, while only 50 ng of IDE was sufficient to almost 
completely eliminate the toxicity of Aβ40, a ten-fold increase in IDE was required to 
neutralize Aβ42 to a similar degree.  The significance of this difference is not clear, 
however may reflect the differing degrees of neurotoxicity and/or propensity to 
oligomerise, of each of the species.  In addition, this study also showed that these 
hydrolysed fragments of Aβ produced by IDE did not deposit on synthetic amyloid in 
vitro.  This further highlights a possible role for IDE in a therapeutic capacity. 
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1.8.3  ApoE and IDE 
While it is not known how the ApoE protein contributes to AD pathogenesis, it has 
been reported that ApoE is essential for, and may assist with cerebral clearance of Aβ, 
via degradation extracellularly by IDE and within microglia by IDE and its related 
protease, neprilysin (NEP) (Jiang, et al., 2008).  The capacity of ApoE in this degradative 
facilitation is determined partly by isoform, with ApoE4 demonstrating a reduced 
capability to assist this process, and ApoE2 being most efficient.  In addition, this study 
demonstrated the importance of ApoE lipidation status in the proteolytic clearance of 
Aβ, with unlipidated ApoE also demonstrating a reduced capacity for facilitation 
compared with the lipidated protein.  This finding supports similar previous reports 
that found that lipidation of ApoE is essential for effective Aβ clearance (Cole & Ard, 
2000).  Defects in the ATP-binding cassette transporter A1 (ABCA1) have been shown 
to result in abnormally lipidated ApoE, and lead to a reduction of ApoE levels in the 
CNS and plasma (Wahrle, et al., 2004; Hirsch-Reinshagen, et al., 2005).  Studies on 
ABCA1 deficiency have shown an increase in the levels of both soluble and insoluble 
Aβ in murine brains (Wahrle, et al., 2005; Koldamova, et al., 2005), that cannot be 
attributed to an increase in Aβ production (Hirsch-Reinshagen, et al., 2005).  
Therefore, another possible mechanism for the development of AD pathology may be 
related to the interaction between the ApoE and IDE proteins in the clearance of Aβ. 
Another recent study by Du and colleagues (2009) demonstrated that IDE mRNA and 
protein expression was down-regulated by ApoE4 in comparison to ApoE2 or ApoE3 in 
rat primary hippocampal neurons and PC12 cells.  The same study showed that ApoE is 
required for normal IDE expression levels as APOE knockout mice had significantly 
lower IDE levels than wild-type mice.  By culturing hippocampal primary neurons from 
these APOE knockouts and treating them with ApoE3-containing conditioned medium, 
they showed that this IDE deficit could be rescued, however treating with ApoE4 
containing medium had no effect.  These effects could be attenuated by blocking the 
N-methyl-D-aspartic acid receptor (NMDAR); in fact, by inhibiting this receptor they 
showed an increase in IDE levels and a corresponding decrease in IDE levels when this 
receptor was activated.  This indicates that the regulatory effect of ApoE isoforms on 
IDE levels is dependent on the NMDA receptor pathway. 
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Other interactions appear to occur between IDE and APOE genotype to alter IDE 
expression levels.  Studies have shown that elderly individuals carrying the ε4 allele 
have higher peripheral levels of the glucocorticoid cortisol than non-ε4 individuals 
(Peskind, et al., 2001), as do AD patients (Umegaki, et al., 2000; Hartmann, et al., 1997; 
Davis, 1986), and in a study of aged macaque monkeys, oral cortisol treatment was 
found to cause a decrease in IDE mRNA and protein levels in both the frontal cortex 
and the hippocampus (Kulstad, et al., 2005).  It has also been reported that other 
glucocorticoids interact with IDE to inhibit its capacity for insulin degradation (Harada, 
et al., 1996).  Overall this could suggest that the increased risk conferred by the ε4 
allele may be partly due to an increase in glucocorticoid levels, affecting IDE expression 
and activity. 
 
1.9  IDE Levels in Plasma 
IDE levels have been studied in regions of the brain, both in cytosolic and membrane 
fractions, as well as in brain microvessels. It has been investigated in liver, kidneys, 
erythrocytes, skeletal muscle, testes and ovaries, among other tissues, in both rodents 
and humans (Miller, et al., 2003; Duckworth, et al., 1988; Morelli, et al., 2004; 
Vekrellis, et al., 2000; Farris, et al., 2003; Duckworth, et al., 1990).  IDE has also been 
detected in extracellular biological fluids such as CSF and wound fluid (Qiu, et al., 1998; 
Shearer, et al., 1997).  It has been shown that the expression of IDE is ubiquitous (Kuo, 
et al., 1993; Weirich, et al., 2008), and evidence also exists for the presence of an 
enzyme with insulin-degrading capacity in human serum (Misbin, et al., 1981).  
However, although the activity of IDE has been examined in blood in rudimentary 
studies with respect to insulin degradation (Ionushas, et al., 1987; Ardy & Pontremoli, 
1953), and more recently IDE expression has been detected in blood and all other 
tissues examined (Su, et al., 2002), surprisingly it appears that no study at the 
commencement of this project, had examined IDE protein or activity in blood, and 
certainly not with respect to AD.  However as mentioned previously, one very recent 
study has been published on serum IDE activity but had low sample numbers in the AD 
and MCI groups (Liu, et al., 2012(a)). 
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Given the evidence associating hyperinsulinemia, elevated plasma Aβ levels and AD, it 
would be highly beneficial to examine the blood concentration and catalytic activity of 
this protease in a large cohort. 
 
1.10  Genetic Linkage and Association of IDE 
The gene for IDE is located on chromosome 10q23-q25 (Espinosa, et al., 1991; 
Affholter, et al., 1990), and in addition to functional evidence supporting IDE as a 
putative biomarker for AD, there is accumulating evidence that the region in and/or 
around IDE may be genetically associated with both AD (Kehoe, et al., 1999; Myers, et 
al., 2000; Bertram, et al., 2000; Ait-Ghezala, et al., 2002; Bian, et al., 2004; Liu, et al, 
2007; Hamshere, et al., 2007; Vepsäläinen, et al., 2007; Mueller, et al., 2007; Bjork, et 
al., 2006; Zuo & Jia, 2009; Carrasquillo, et al., 2010) and DM2 (Duggirala, et al., 1999; 
Wiltshire, et al., 2001; Karamohamed, et al., 2003; Furukawa, et al., 2008; Zeggini, et 
al., 2007).  Moreover, as with many conditions, various studies on both dizygotic and 
monozygotic twins have shown that genetic factors may account for a significant 
proportion of the risk of LOAD (Petersen, et al., 2004; Bergem, et al., 1997; Gatz, et al., 
1997).  A recent large study demonstrated an association between a novel IDE variant 
and lower plasma Aβ40 levels and a reduced risk of LOAD.  It was found that this 
variation resulted in an increase in IDE mRNA expression (Carrasquillo, et al., 2010). 
In addition, IDE has been linked to other quantitative indices (QTL) of AD, such as age 
of onset (Li, et al., 2002; Blacker, et al., 2003; Prince, et al., 2003; Dickson, et al., 2008), 
plasma Aβ levels (Ertekin-Taner, et al., 2000, Ertekin-Taner, et al., 2004), MMSE score, 
memory and cognitive function, CSF levels of tau protein, cerebral Aβ and NFT load 
(Prince, et al., 2003; McQueen, et al., 2007; Liu, et al, 2007; Blomqvist, et al., 2005; 
Mueller, et al., 2007).  Quantitative indices of DM2 such as elevated fasting plasma 
glucose levels (Meigs, et al., 2002; Karamohamed, et al., 2003), plasma insulin levels 
(Marlowe, et al., 2006; Gu, et al., 2004), and age of onset (Duggirala, et al., 1999) have 
also been associated with the region in and/or around the IDE gene.  A recent study by 
Hong and colleagues (2008) also discovered an association between human life span 
and IDE. 
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Interestingly, some studies showed genetic association with IDE only in APOE ε4 
negative individuals (Feuk, et al., 2005; Edland, et al., 2003; Zuo & Jia, 2009), 
supporting findings of insulin resistance and hyperinsulinemia in non-ε4 carriers with 
AD (Kuusisto, et al., 1997; Craft, et al., 1999), and an association between AD and DM2 
only in non-ε4 carriers (Akomolafe, et al., 2006).   This suggests that the effect of the 
APOE genotype and IDE might affect risk independently, and may be of significance for 
a subset of AD and DM2 sufferers.  In addition, this also highlights the importance of 
stratifying results by APOE genotype. 
Although many studies have reported an association between the IDE gene and AD, 
there are also studies that refute this association (Marlowe,et al.,2006; Ozturk, et al., 
2006; Nowotny, et al., 2005).  It was suggested that these discrepancies could be due 
to a number of factors including allele frequency, linkage disequilibrium and locus 
variance in different populations, subject selection bias and genotyping errors. 
Another common theme which occurs in some of these genetic analyses is that often 
the association is only seen in males (Gu, et al., 2004; Hong, et al., 2008) or the study 
only used men in their cohort (Marlowe, et al., 2006).  Of course, in addition, it is not 
possible to analyse every single nucleotide polymorphism within the limitations of a 
single study.  This may be another factor to consider when translating the data. 
Although disease-causing mutations have not yet been discovered within the coding 
region of the IDE gene, it is possible that mutations exist within the non-coding region.  
These non-coding region mutations may affect the cap, tail, polyadenylation signal, 
promoter or other regulatory sequences which may alter the gene product and/or its 
expression or function (Knight, 2003). In accordance with this, a recent meta-analysis 
of the literature found a significant positive association between the IDE 
polymorphism rs1832196 and AD risk (Zhang, et al., 2013).  This polymorphism is 
located within an intronic sequence of IDE.  Collectively, there is considerable evidence 
supporting the genetic involvement of IDE in both AD and DM2 pathology. 
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1.11  Summary and Project Hypothesis 
For the moment, the only way to ascertain a definite diagnosis of AD is via post-
mortem analysis, and current diagnostic methods are not sufficient in the early or 
prodromal stages of the disease for accurate diagnosis.  With the increasing 
prevalence and incidence of AD in the ageing population, the identification of a 
suitable biomarker, or set of biomarkers, for prognostic, diagnostic and therapeutic 
monitoring purposes is becoming all the more imperative.  In particular, a blood 
biomarker would be highly beneficial due to the invasive nature, difficulties and 
expense associated with current diagnostic procedures.  Aβ is widely believed to be 
central to the pathogenesis of AD, with increased accumulation as a product of an 
imbalance between production and clearance of this peptide.  The vast majority of AD 
cases are of the non-familial and/or late-onset variety, and increasing evidence 
suggests that impairment of Aβ clearance mechanisms may be the more important 
factor in LOAD pathogenesis, rather than increased Aβ production.  Enzymes, 
receptors and any other proteins involved in the clearance and/or degradation of Aβ 
are therefore viable biomarker candidates. 
IDE is a protease of interest, due to increasing evidence supporting its mechanistic 
involvement in the regulation of Aβ and AD pathology, and genetic studies supporting 
the existence of an AD risk locus, and AD QTL loci in the vicinity of the IDE gene on 
chromosome 10q.  In addition, IDE is associated with hyperinsulinemia and DM2, 
which have both been suggested as potential risk factors for AD.  IDE has also been 
shown to interact with the ApoE protein and can be affected by APOE genotype.  Some 
gaps in current knowledge include the quantification and activity of IDE in the blood, 
and the possible association of IDE expression and/or IDE activity levels with AD risk. 
 While numerous studies have reported associations between IDE and AD, replication 
of these results has been inconsistent, and a number of factors may have led to these 
discrepancies.  An analysis of these variables in a large population would assist in 
determining the associations between IDE and AD pathogenesis, as well as evaluate 
the potential of IDE as a functional AD biomarker. 
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Therefore, the project hypotheses are as follows: 
1. The levels and catalytic activities of IDE in human plasma differ between clinical 
classifications of AD, MCI and healthy controls. 
2. The levels and catalytic activities of IDE in human plasma are affected by APOE 
genotype. 
 
To test these hypotheses, the particular aims of this project are: 
1. To measure the levels of plasma IDE protein in a large cohort (n = 1000+). 
2. To measure the catalytic activity of plasma IDE in a large cohort. 
3. To determine if there is any relationship between IDE levels, catalytic activity, and 
other biochemical markers including Aβ, ApoE and insulin in plasma between 
AD/MCI affected individuals and healthy controls. 
4. To determine if APOE ε4 genotype impacts upon the levels or catalytic activity of 
plasma IDE. 
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Figure 1.3  Representation of various factors associated with AD or DM2 which may affect IDE function.  A number 
of physiological conditions may negatively regulate the catalytic activity (yellow), expression levels (pink), or both 
levels and activity (purple) of IDE.  Low ApoE protein, indicated in blue, regulates the ability of IDE to degrade Aβ 
independently of IDE levels or catalytic activity, and this has been shown to be modulated by the lipidation status of 
ApoE.  Individual factors or a combination of these may lead to an insufficiency of IDE to efficiently degrade Aβ and 
lead to its accumulation in the periphery and/or the brain. 
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Figure 1.4  Flowchart of how a reduction in IDE levels or activity may lead to the development of both AD and DM2.  
Reduction of IDE levels or activity cause an insufficiency in both Aβ and insulin degradation, leading to their 
accumulation in plasma.  The increased proteins/peptides then compete further for IDE, causing a positive feedback 
mechanism.  The hyperinsulinemic state is also central to both conditions.  This leads to an increase in amyloid 
deposition in the brain (Aβ) and pancreas (ProIAPP/IAPP) which subsequently develops into DM2 and/or AD. 
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CHAPTER 2 – Materials and Methods. 
2.1   Materials 
2.1.1   Antibodies 
The antibodies used in this project are summarised in Tables 2.1 and 2.2.  Figure 2.1 
illustrates the epitopes on IDE to which each antibody binds. 
 
Table 2.1  Commercial primary IDE antibodies. 
PRIMARY IDE ANTIBODIES 
Antibody Catalogue Number Supplier Host 
Immunogen 
Source 
Immunogen 
Sequence Formulation 
Ab 1(a) – 
Batch 1 
Ab 1(b) – 
Batch 2 
AB9210 
Chemicon Aust. P/L 
(now 
Merck/Millipore, VIC, 
Australia) 
Rabbit Synthetic rat AA200-250 Serum 
Ab 2 LS-C55007 
LifeSpan Biosciences, 
Inc. (Seattle, WA, 
USA) 
Goat Synthetic Human AA914-924 Purified 
Ab 3 ab28561 Abcam (Cambridge, UK) Rabbit 
Synthetic 
Human AA238-416 Purified 
Ab 4 250706 Abbiotec
™ (San 
Diego, CA, USA) Mouse 
Synthetic 
Human 
N-terminus 
(Not defined) Purified 
Ab 5 AF2496 
R&D Systems® Inc. 
(Minneapolis, MN, 
USA) 
Goat Recombinant Human AA42-1019 Purified 
Ab 6 H00003416-A01 
Abnova (Taipei, 
Taiwan) Mouse 
Synthetic 
Human AA 920-1019 Serum 
(M)Ab 7 MMS-282R  Covance (MA, USA) Mouse Human AA 1-1019 Ascites 
Ab 8 GTX111664 GeneTex Inc. (California, USA) Rabbit 
Synthetic 
Human  AA 349-585 Purified 
(M)Ab 9 5282-1  Epitomics (CA, USA) Rabbit Synthetic Human AA 50-75 
Tissue culture 
supernatant 
• (M) denotes monoclonal antibody 
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Table 2.2  Additional commercial non-IDE and secondary antibodies. 
NON-IDE ANTIBODIES 
Antibody Supplier Host Immunogen Epitope Formulation 
GTX27793 
(AL-01) (M) 
GeneTex Inc. (California, 
USA) Mouse 
Human serum 
albumin Full-length Purified 
      
SECONDARY ANTIBODIES 
Antibody Supplier Host Classes Conjugate Formulation 
P0449 Dako (VIC, Australia) Goat All HRP Purified 
AP322P Chemicon Australia Pty. Ltd. (VIC, Australia) Rabbit IgG HRP Purified 
AP326P Chemicon Australia Pty. Ltd. (VIC, Australia) Mouse IgG HRP Purified 
• (M) denotes monoclonal antibody 
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Figure 2.1  Diagram of IDE epitopes to which commercially-available antibodies bind.  Monoclonal antibodies are indicated by (M).
AA1 AA1019 
Ab 1 (200-250) Ab 2 (914-924) 
Ab 3 (238-416) 
Ab 4 (N-terminus) 
Ab 5 (42-1019) 
Ab 6 (920-1020) 
MAb 7 (1-1019) 
Ab 8 (349-595) MAb 9 (50-75) 
1) Western Immunoblotting 
2) Sandwich ELISA (Coating antibody) 
3) Fluorometric Activity Assay Sandwich ELISA (Detection antibody) 
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2.1.2   Suppliers of Reagents 
2.1.2.1 Proteins 
The fluorogenic peptide substrate (Mca-R-P-P-G-F-S-A-F-K(Dnp)-OH, also called 
Substrate V), ES005, and human recombinant IDE, 2496-ZN were purchased from 
R&D Systems, Inc. (Minneapolis, MN, USA).  Recombinant His-tagged rat IDE, 
407241, was purchased from Calbiochem/EMD Biosciences, Inc. (Merck KGaA, 
Darmstadt, Germany).  Lyophilized recombinant Aβ40 and Aβ42 was synthesized and 
purchased from W.M. Keck Foundation Biotechnology Research Laboratory (Yale 
University, New Haven, CT, USA).  The custom-synthesized blocking peptide against 
LS-C55007 primary antibody was purchased from Mimotopes Pty. Ltd. (Clayton, VIC, 
Australia).  The commercial blocking peptide (and immunogen) against antibody 
ab28561 was purchased from Abcam (Cambridge, UK). 
2.1.2.2 Other reagents 
All de-ionized ultra-pure water (MQ H2O) was obtained from the usual laboratory 
distilled water system, and filtered through the Sartorius Arium® (611DI) filtration 
system (Sartorius AG, Göttingen, Germany). 
Polyoxyethylene (20) sorbitan monolaurate (Tween-20), bovine serum albumin 
(BSA), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), Trizma 
Hydrochloride (Tris-HCl) (T-3253) and Ponceau S powder (78376) were all 
purchased from Sigma-Aldrich Pty. Ltd. (Castle Hill, NSW, Australia).   
NuPage® Novex 10% (NP0316BOX) and 4-12% (NP0336BOX) Bis-Tris 1.5mm x 15-
well pre-cast gels, NuPage® 4x lithium dodecyl sulfate (LDS) sample buffer (NP0007), 
NuPage® 10x Reducing Agent containing 500 mM dithiothreitol (DTT) (NP0009), 
NuPage® Antioxidant (NP0005), Novex® Sharp Pre-stained Protein Standard 
(LC5800), NuPage® 20x MES SDS Running Buffer (NP0002-02) and NuPage® Transfer 
Stacks – Regular Nitrocellulose (IB3010-01) were all purchased from Invitrogen™  
Australia Pty. Ltd. (Mulgrave, VIC, Australia). 
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Sodium chloride (NaCl), ethylenediaminetetraacetic acid tetra-sodium salt (EDTA), 
ethanol absolute was purchased from Merck Pty. Ltd. (Merck KGaA, Darmstadt, 
Germany).  Fraction V bovine serum albumin (10 735 086 001) was purchased from 
Roche Diagnostics Australia Pty. Ltd. (Castle Hill, NSW, Australia).  AnalaR sodium 
carbonate (Na2CO3) (10240.4H), AnalaR sodium hydrogen carbonate (NaHCO3) 
(10247.4V), and sodium dodecysulfate (SDS) were all purchased from BDH 
Chemicals Australia Ltd. (VIC, Australia).  The Thermo Scientific Micro BCA™ Protein 
Assay Kit (23235), Pierce Direct IP Kit (26148), Restore™ Western Blot Stripping 
Buffer (21059) and Gelcode Blue Stain Reagent (Coomassie stain) (24592) were all 
purchased from Thermo Fisher Scientific (Scoresby, Vic, Australia).  Glycerol 
(193996), 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) (151245) and Tris-
[hydroxymethyl]aminomethane (Tris) (152176) was purchased from MP 
Biomedicals Australia (Formerly ICN Biomedicals Inc., Seven Hills, NSW, Australia).  
Amersham ECL™ Western Blotting Detection Reagents (RPN2106), Amersham ECL™ 
Advance Western Blotting Detection Kit (RPN2135) and Amersham ECL™ Prime 
Western Blotting Detection Reagents (RPN2232) were all purchased from GE 
Healthcare Australia Pty. Ltd. (Rydalmere, NSW, Australia).  Phosphate-buffered 
saline (PBS) was purchased from Fisher Biotech International Ltd. (Wembley, WA, 
Australia).  Complete Mini Protease Inhibitor Cocktail (11836153001) was 
purchased from Roche Australia (Osborne Park, WA, Australia).  3,3’,5,5’-
Tetramethylbenzidine (TMB) Microwell Peroxidase Substrate System (50-76-00) 
was purchased from Kirkegaard and Perry Laboratories Inc. (Maryland, USA).  Block 
Ace (BUF029) was purchased from AbD Serotec (Oxford, UK). 
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2.1.3   Suppliers of Equipment 
Aβ42 solution concentration was determined using an Implen Nanophotometer 
(Version 7122, V2.0.0). 
2.1.3.1 Western Immunoblotting 
Proteins were resolved by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) using the Invitrogen™ NuPage® Electrophoresis system, 
using the XCell SureLock™ Mini-Cell Electrophoresis Blot Module and the 
Invitrogen™  iBlot® Gel Transfer Device, both purchased from Invitrogen™  Australia 
Pty. Ltd. (Mulgrave, VIC, Australia).  Bands were visualised by densitometric analysis 
using the Bio-Rad GS-800 Densitometer (Bio-Rad Laboratories Pty. Ltd., CA, USA). 
2.1.3.2 ELISA/Fluorescent and BCA Protein Assay 
IDE ELISA kit was purchased from Kamiya Biomedical Company (Seattle, USA).  96-
well microplates 655900 were purchased from Greiner Bio-One (Frickenhausen, 
Germany), U16 MaxiSorp™ Modules 469264 and black F16 MaxiSorp™ Modules 
475515 were purchased from Nunc (Rochester, NY, USA).  Microplates were 
washed using either the Bio-Rad Immunowash Microplate Washer (Model 1575) or 
the BioTek® Select Deep Well Microplate Washer (ELx405™, VT, USA).  Proteins 
were quantified using the Fluostar Optima Microplate Reader (BMG Labtech GmbH, 
Ortenberg, Germany). 
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2.2  Methods 
2.2.1  The Australian Imaging, Biomarker and Lifestyle Flagship Study 
of Ageing (AIBL) Cohort 
Plasma samples to be analysed were sourced from the Australian Imaging, 
Biomarker and Lifestyle Flagship Study of Ageing (AIBL) study 
(http://www.aibl.csiro.au/) which has been well characterised (Ellis, et al., 2009).  
Launched in November 2006, this longitudinal study includes participants recruited 
from Perth, Western Australia (40%) and Melbourne, Victoria (60%).  The primary 
aim of this study has a focus on early detection, and prevention or delay of 
Alzheimer’s disease, by research into a variety of diagnostic markers, biomarkers 
and neuroimaging techniques.  AIBL is also assessing the role of diet and exercise in 
relation to the prevention of AD. 
The AIBL cohort consists of 1112 individuals, of which 211 have AD, 133 have MCI 
and 768 are healthy controls (HC) (Figure 2.2).  Of the 768 HC participants, 396 
reported having memory complaints that did not meet the criteria for MCI or 
dementia.  Using a multidisciplinary approach, all participants underwent extensive 
clinical (including blood collection for biomarker analysis), neuropsychological and 
lifestyle assessments at baseline, and neuroimaging with PiB-PET and MRI was 
performed on approximately one quarter of the cohort.  Consenting participants 
are subsequently re-assessed at 18 month intervals until death.  The exclusion 
criteria included comorbid conditions that could affect cognitive function, including 
non-AD dementias, uncontrolled diabetes, past serious head injury, current clinical 
depression, history of stroke, and alcohol consumption exceeding two standard 
drinks per day for women, and four standard drinks per day for men. 
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768 HEALTHY CONTROLS 
133 MCI 
211 AD 
180 NINCDS-ADRDA “Probable AD” 
31 NINCDS-ADRDA “Possible AD” 
126 Amnestic 
7 Non-Amnestic 
49 Single Domain 
77 Multi Domain 
1 Single Domain 
6 Multi Domain 
396 Memory Complainers 
372 Non-Memory Complainers 
 
 
Figure 2.2  Classification of AIBL cohort subgroups at baseline by diagnosis 
(n=1112). 
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2.2.2  Sample preparation 
Blood collection details can be found in Ellis, et al., 2009.  In summary, whole blood 
from the participants was collected into three types of tubes; lithium-heparin, 
serum and EDTA (with prostaglandin E1 added at a concentration of 33.3ng/mL to 
EDTA tubes only).  The tubes were divided into aliquots and stored in liquid 
nitrogen, and after removal samples were subsequently stored at -80°C until use.  
Immediately prior to assaying, plasma samples were thawed on ice, and then 
centrifuged at 12,000 RPM for 15 minutes, and the supernatant collected.  All 
plasma samples used in this project were sourced from EDTA tubes unless 
otherwise specified.  It should be noted that separate subsets of the AIBL cohort 
were used to measure full-length IDE levels by Western immunoblotting, total IDE 
levels by ELISA, and IDE activity with very few samples in common between each 
assay. 
2.2.2.1  Methods used for the measurement of biomarkers other 
than IDE 
Testosterone, estradiol, total cholesterol, LDL/HDL cholesterol and insulin 
measurements were collected by clinical pathology services PathWest Laboratory 
Medicine WA (Perth) or Melbourne Health (Melbourne).  With the exception of 
insulin for which measurements were taken using serum samples, the remainder of 
the test measurements from the clinical pathology services were taken from blood 
plasma collected in Lithium-Heparin tubes or serum samples.  Total testosterone 
was measured using a chemiluminescent microparticle immunoassay.  Free 
testosterone was calculated from total testosterone levels and sex-hormone 
binding globulin (SHBG) levels.  Estradiol was measured using a chemiluminescent 
microparticle immunoassay.  Total cholesterol was measured using an enzymatic 
assay based on the formulation of Allain, et al., 1974 with modifications of this 
procedure by Roeschlau, et al., 1974.  HDL cholesterol was measured with an 
Accelerator Selective Detergent method.  LDL cholesterol was calculated using the 
Friedewald formula (Friedewald, et al., 1972) from HDL cholesterol, total 
cholesterol and triglyceride measurements (if triglycerides were < 4.5 mmol/L) 
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otherwise if triglycerides were ≥ 4.5mmol/L, direct measurements were taken with 
a Measured, Liquid Selective Detergent method.  Insulin levels were measured 
using a chemiluminescent microparticle immunoassay.  An in-house sandwich ELISA 
was used to measure the Aβ isoforms using EDTA-collected plasma as previously 
documented (Mehta, et al., 2000).  A commercial sandwich ELISA kit (ApoE4/Pan 
ApoE ELISA, MBL International, Woburn, USA) was used to measure the levels of 
plasma ApoE and ApoE4 using EDTA-collected plasma as previously documented 
(Gupta, et al., 2011).  DNA for the APOE genotyping was isolated from whole blood 
using a Qiamp DNA blood Midikit (Qiagen) as per manufacturer instructions.  APOE 
genotyping was performed using either APOE TaqMan® SNP Genotyping Assays 
(Life Technologies) for rs7412 (Assay ID: C____904973_10) and rs429358 (Assay ID: 
C___3084793_20), or by amplification by polymerase chain reaction with restriction 
enzyme digestion as previously detailed (Hixson & Vernier, 1990).  Brain Aβ load 
was determined by PET imaging using a radioactive imaging agent, Pittsburgh 
Compound B (PiB) as previously detailed (Pike, et al., 2007).  
 
2.2.3  Determination of plasma total protein content 
The total protein content of human plasma was obtained with the Micro BCA™ 
Protein Assay kit (Pierce, 23235).  To summarise, bovine serum albumin (BSA) 
standards were prepared with MQ H2O, in the range of 0 – 80 μg/mL from a stock 
concentration of 2.0 mg/mL.  150 μL per well of each standard dilution was loaded 
in duplicate onto a standard 96-well microplate (Greiner Bio-One).  Plasma was 
diluted to 1:100, 1:1000 and 1:2000 with MQ H2O, and 150 μL of the plasma 
dilutions were loaded in quadruplicate.  A working reagent was prepared with 25 
parts Pierce reagent MA, 24 parts reagent MB, and one (1) part reagent MC as per 
manufacturer instructions, and 150 μL was added to the wells containing the 
standards and plasma dilutions.  The plate was agitated for 30 seconds, then 
covered and incubated at 37°C for two hours.  The plate was then allowed to cool 
to room temperature and absorbance was read on a Fluostar Optima microplate 
reader (BMG Labtech GmbH, Ortenburg, Germany) at 562 nm.  A standard curve 
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was generated from the BSA standard dilutions and the plasma total protein 
concentration was interpolated from this curve. 
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2.2.4  IDE levels in human plasma by Western immunoblotting 
2.2.4.1  Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) separation of proteins 
All samples were prepared using NuPage® LDS Sample Buffer and Reducing Agent 
(Invitrogen) on 10% Bis-Tris 1.5mm 15 well pre-cast gels with MES SDS running 
buffer, unless otherwise specified.  Proteins were resolved by SDS-PAGE under 
reducing conditions.  Total protein concentration of undiluted pooled control 
plasma (PCP) was determined to be 59.503 μg/ul.  IDE as a positive control was 
prepared from purified recombinant rat IDE (rrIDE) diluted in MQ H2O to a 
concentration of 20 ng/μL using a 1 mg/mL stock solution, with the final content 
per well being 100 ng.  Plasma samples were diluted 1:7 with MQ H2O (1μL per 
well), including an internal standard of pooled human plasma (PCP) which was 
loaded onto each gel.  Total protein content after dilution was calculated to be 
59.503 μg per load for PCP.  LDS Sample Buffer and reducing agent (Invitrogen™) 
were added in the ratio of 8:3:1 (IDE standards or diluted plasma: LDS Sample 
buffer: reducing agent).  The standards and plasma samples were heated at 70°C 
for 10 minutes.  Where rat liver, human frontal cortex or zebrafish brain were used 
in optimization steps, the samples were heated for 5 mins at 95°C.  The samples, 
PCP and positive control were loaded onto NuPage® 10% Bis-Tris mini pre-cast gels, 
using the XCell SureLock™ Mini-Cell Electrophoresis Blot Module (Invitrogen™), and 
NuPage® 1x MES SDS Running Buffer (Invitrogen™) for inner and outer chambers.  
500 μL of NuPage® Antioxidant was added to the inner chamber immediately prior 
to loading samples.  Proteins were separated according to their molecular weight 
along with pre-stained molecular weight markers (in the range of 3.5 kDa to 260 
kDa; Invitrogen™) by electrophoresis, at 100 V for 1.5 to 3 hours.  The semi-dry 
transfer of proteins to nitrocellulose membranes by electrophoresis was performed 
using the iBlot® Dry Blotting System (Invitrogen™) on programme P3 for 8.5 mins. 
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2.2.4.2  LS-C55007 immunoblotting protocol 
Following electrophoretic transfer of the proteins, the nitrocellulose membranes 
were incubated with tris-buffered saline (TBS, pH 7.4) containing 3% non-fat dairy 
milk powder (NFDM) for one hour at room temperature with rocking, to block any 
non-specific binding sites.  No Tween-20 was included in the blocking buffer at this 
stage to avoid the detergent loosely binding to the membrane and displacing the 
NFDM, as this may lead to the Tween-20 being removed by subsequent washes in 
TBST and leaving spaces for non-specific binding of the antibodies.  After washing 
twice for 2 mins in TBS containing 0.05% Tween-20 (TBST), the membranes were 
then incubated with primary antibody LS-C55007 (LifeSpan Biosciences Inc.) diluted 
1:5000 in TBST at 4°C overnight (approximately 18 hours) with rocking.  Following 
the overnight incubation, the membranes were washed twice for 2 mins, then 4 
times for 3 mins each in TBST to remove unbound antibody.  The anti-goat HRP-
conjugated secondary antibody (P0449) was then diluted 1:7500 in TBST and the 
membranes were incubated for 1 hour at room temperature (RT) with rocking.  This 
was followed by washing twice for 2 mins and four times for 3 mins each in TBST to 
remove any unbound secondary antibody, then two 3 minute washes in TBS to 
remove any traces of Tween-20.  The membranes were then incubated with ECL™ 
detection reagent (for 2 mins) for optimization only, or ECL Advance/Prime 
detection reagents (GE Healthcare Australia P/L) prepared as per manufacturer’s 
instructions for 5 mins and exposed to film for up to 1.5 hours to obtain the desired 
signal intensity. 
2.2.4.3  AB9210 immunoblotting protocol 
Following electrophoresis, the membranes were incubated in TBS containing 5% 
NFDM.  Membranes were then incubated overnight with primary antibody AB9210 
diluted 1:8000 in TBST containing 0.5% NFDM at 4°C as per the LS-C55007 protocol.  
Following the overnight incubation, blots were washed three times for 10 min in 
TBST, and then incubated with HRP-conjugated anti-rabbit secondary antibody 
(AP322P) for 1 hour at RT as above.  A further three 10 min washes in TBST and two 
3 min washes in TBS followed.  Secondary antibodies were detected by incubation 
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in ECL™ detection reagent for 2 mins and exposure to film for up to 20 minutes to 
achieve desired signal intensity. 
2.2.4.4  ab28561 immunoblotting protocol 
After electrophoretic transfer or stripping (stripping protocol detailed below in 
section 2.2.4.5), the membranes were incubated in TBS containing 3% NFDM at 4°C 
overnight with rocking.  After washing twice in TBS, primary antibody ab28561 was 
diluted 1:2000 (or 1:1000 for some optimization steps) in TBST containing 0.5% 
NFDM and incubated for 2 hours at RT (rocking).  Following primary antibody 
incubation, membranes were washed as per LS-C55007 protocol and then 
incubated in HRP-conjugated anti-rabbit secondary antibody, diluted 1:5000 in TBST 
with 0.5% NFDM, for 1 hour at RT.  The membranes were then washed and 
incubated in ECL™  or ECL™ Prime detection reagent as per the LS-C55007 protocol, 
and exposed to film for up to 30 mins to achieve desired signal intensity. 
2.2.4.5  Stripping of antibodies from membrane 
Membranes were stored between cellulose acetate sheets at RT prior to stripping.  
After removing from acetate, blots were re-hydrated in TBS for 15 mins (no 
rocking), and then washed in TBS for 7 mins (with rocking for all steps from here 
on).  Blots were then washed in 20 μL of Restore™ stripping buffer for 10 minutes in 
the fumehood to remove all bound antibodies, before washing in TBS for 2 mins.  
Following this, blots were washed in TBST four times for 5 mins, and in TBS twice 
for 2 mins.  For AIBL samples, after stripping, the membranes were stained with 
Ponceau S, then destained and immunoblotted using ab28561 antibody.  
Alternatively, blots were re-stripped following immunoblotting and Coomassie 
stained. 
2.2.4.6  Ponceau S and Coomassie staining as a loading control 
The freshly stripped membranes were subsequently stained using a 0.1% (W/V) 
solution of Ponceau S in 5% acetic acid, for 5 mins, rocking.  They then were were 
rinsed in MQ H2O twice for 30 seconds to remove excess background staining.  
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After scanning, blots were then destained using one 2 min wash in hot TBS, then a 
further two washes for 2 mins in cold TBS prior to immunoblotting. 
After immunoblotting, membranes were stripped of antibodies as previously 
described in Section 2.2.4.5.  The freshly stripped membranes were then Coomassie 
stained using Pierce GelCode Blue Stain Reagent as per manufacturer instructions. 
2.2.4.7  Test of EDTA spiking on IDE levels in lithium-heparin 
collected plasma 
The approximate concentration of EDTA in the EDTA-collected tubes is 1.8 mg/mL, 
and may vary per sample, therefore non-EDTA containing plasma was assessed to 
determine if varying amounts of EDTA would affect the detectable levels of IDE via 
Western immunoblotting.  EDTA was diluted in MQ H2O to a concentration of 10 
mg/mL, then spiked into diluted lithium-heparin collected plasma to a final 
concentration of 2.0, 1.5 and 1.0 mg of EDTA per mL of (non-diluted) plasma.  A 
control sample of lithium-heparin plasma containing 0 mg of EDTA was included for 
comparison, as well as two positive controls of 50ng and 100ng of rrIDE.  Samples 
were subsequently analysed by Western blot using the LS-C55007 protocol as 
detailed above, with the exception of the washing steps after the antibodies.  The 
wash steps were twice for 2 mins, one 15 min wash and then three 5min washes.  
Two three minute TBS washes were included after the secondary antibody to 
remove the Tween-20. 
The same membrane was subsequently stripped of antibodies and re-probed using 
antibody ab28561 using the protocols described previously. 
2.2.4.8  Test of cross-reactivity of LS-C55007 (and ab28561) to 
purified BSA and HSA 
To test if antibody LS-C55007 or ab28561 detects purified BSA or HSA within the 
region of interest in the Western blot, purified BSA and HSA was diluted in MQ H2O 
to a final concentration of 30 and 60 μg per well.  This represents the lower and 
upper limits of albumin levels found in human plasma in normal physiology.   A 
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separate HSA sample equivalent to 60 μg per well was also spiked with 175.2 ng of 
purified human recombinant IDE (rhIDE) and a separate sample spiked with 8 ng 
rrIDE to determine if IDE was sequestered by albumin under denaturing and 
reducing conditions.  The spiked sample was pre-incubated for 1.5 hours at RT to 
allow time for binding.  Samples were then resolved by SDS-PAGE and 
immunoblotted using the LS-C55007 or ab28561 protocols as previously described. 
2.2.4.9  Test of cross-reactivity of ab28561 to purified BSA and 
albumin-free blocking agent 
To test if antibody ab28561 detects purified BSA or an albumin-free blocking agent 
(ECL™ Advance Blocking Agent) within the region of interest in the Western blot, 
purified BSA and ECL™ Advance were both diluted in MQ H2O to a final 
concentration of 15, 30 and 60 μg per well.  A single lane of rrIDE (7.5 ng/well) was 
added as a positive control.  All samples were resolved on a single gel and 
immunoblotted as per the previously detailed protocols with antibody ab28561. 
2.2.4.10  Pre-incubation with recombinant human IDE blocking 
test for AB9210 for specificity 
PCP was diluted in MQ H2O (59.503 μg/well), LDS Sample Buffer and Reducing 
Agent to a ratio of 6 parts diluted PCP/3 parts Sample Buffer/1 part Reducing Agent 
and four lanes of each were loaded onto a single gel (two duplicates).  Proteins 
were resolved by SDS-PAGE and electrophoretically transferred to a nitrocellulose 
membrane as previously described in Section 2.2.4.1.  The single membrane was 
then cut into two identical pieces, designated membrane A (control) and 
membrane B.  The separate membranes were then immunoblotted with IDE 
antibody AB9210 as previously described in Section 2.2.4.3, with the exception of a 
brief pre-incubation step prior to the primary antibody incubation.  This step 
involved spiking and pre-incubating the antibody solution with either 0 (membrane 
A) or 1.32 μg (membrane B) of rhIDE for 10 minutes prior to adding the respective 
membranes before incubating overnight.  The remainder of the protocol was 
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identical to previously described, using separate containers to prevent cross-
contamination. 
2.2.4.11  Pre-incubation with immunizing peptide blocking test 
for LS-C55007 for specificity 
PCP was diluted in MQ H2O as previously described (59.503 μg/well) as well as rrIDE 
(200 ng/well) and five lanes of each were loaded onto a single gel.  Proteins were 
resolved by SDS-PAGE and electrophoretically transferred to a nitrocellulose 
membrane as previously described in Section 2.2.4.1.  The single membrane was 
then cut to result in 5 identical pieces; each containing one lane of molecular 
weight marker (MWM), one lane of PCP, and one lane of rrIDE.  The separate pieces 
were designated membrane A (control), B, C, D and E.  All membranes were then 
immunoblotted with IDE antibody LS-C55007 as previously described in Section 
2.2.4.2, with the exception of a pre-incubation step prior to the primary antibody 
incubation.  This step involved spiking the antibody solution with 0 μg (A), 5 μg (B), 
10 μg (C), 15 μg (D) and 20 μg (E) of a custom-synthesized peptide matching the 
immunogen to antibody LS-C55007.  The five tubes were then incubated at RT for 
30 mins prior to incubating the membranes.  The remainder of the protocol was 
identical to previously described, using separate containers to prevent cross-
contamination. 
The test was repeated twice more using increasing amounts of blocking peptide up 
to 500 μg, to ensure validity of results. 
2.2.4.12  Pre-incubation with immunizing peptide blocking test 
for ab28561 for specificity 
PCP (59.503 μg/well) and rrIDE (25 ng/well) were diluted in MQ H2O, prepared with 
sample buffer and reducing agent prior to SDS-PAGE and stored at -80°C until use.  
Rat liver (1 μL/well) was pre-homogenized, centrifuged for 10 mins at 12,000 RPM 
and the supernatant pre-prepared in tris-tricine sample buffer (1M Tris-HCl 
containing 2% (W/V) SDS, 4% (W/V) glycine, 0.05% (W/V) phenol red).  Liver was 
then stored at -80°C until use.  Zebrafish brains (25 ng/well) were pre-homogenized 
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in PBS containing a protease inhibitor cocktail (PI), and centrifuged at 6,000 RPM 
for 10 mins at 4°C.  The supernatant was collected and the total protein content 
determined by a BCA Protein Assay. 
Samples were all heated for 70°C for 10 mins, with the exception of rat liver which 
was heated at 95°C.  Three lanes of each sample were loaded onto a single gel 
(NuPage® 4-12% Bis-Tris 1.5mm 15 well pre-cast) and resolved by SDS-PAGE for 2 
hours at 100V.  After semi-dry transfer as previously described, the membrane was 
cut into three identical pieces, each with one lane of molecular weight marker and 
one lane of each sample.  The separate pieces were designated membrane A 
(control), B and C.  All membranes were then immunoblotted with ab28561 as 
previously described, with the exception of a pre-incubation step prior to the 
primary antibody incubation.  This step involved spiking the antibody solution 
(diluted 1:1000) with 0 μg (A), 5 μg (B) and 40 μg (C) of a commercially available 
peptide matching the immunogen to antibody ab28561.  The three tubes were then 
incubated at RT for 30 mins prior to incubating the membranes.  The remainder of 
the protocol was identical to previously, using separate containers to prevent cross-
contamination. 
2.2.4.13  Pre-clearing IgG from plasma 
PCP was diluted 1:3 in PBS containing PI, and pre-cleared using the Pierce Direct IP 
kit, as per manufacturer instructions, to remove any immunoglobulins which may 
bind non-specifically to the beads. 
2.2.4.14  Pre-clearing albumin from plasma 
To clear some of the albumin from the PCP, the Pierce Direct IP kit was used as per 
manufacturer instructions.  Briefly, 20 μL of a 50% agarose bead slurry was added 
to a spin column and equilibriated with a coupling buffer.  10 μg of purified anti-
albumin antibody GTX27793 was then covalently bound to the beads for 2 hours.  
After washing with tris buffer, the pre-cleared (see above) PCP sample was diluted 
to a volume of 300 μL in PBS containing PI and added to the column.  The column 
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was then sealed and incubated overnight on a rotating mixer at 4°C.  The column 
was centrifuged and the flow-through collected. 
2.2.4.15  Preparation of Aβ42  
To prepare a stock solution of purified Aβ42 from lyophilized stock, 100 μL of 
hexafluoroisopropanol (HFIP) was added per 1mg of lyophilized peptide into a tube, 
and allowed to sit open for 15 mins in the fumehood to assist with solubilization.  
After removing the HFIP by vacuum, and sitting for a further 10 mins, 1 mL of MQ 
H2O was added to the tube, vortexed and allowed to sit a further 5 mins.  The 
solution was then centrifuged for 10 mins at 10,000 RPM and the supernatant 
transferred into a low protein-binding tube.  The concentration was subsequently 
determined using an Implen Nanophotometer at a wavelength of 214nm. 
Purified Aβ was subsequently incubated with rhIDE (9ug Aβ to 100ng rhIDE) 
overnight at 4°C with end-over-end mixing, then resolved by SDS-PAGE and probed 
with an IDE antibody (LS-C55007 or ab28561) as previously described.  This was to 
determine if IDE and Aβ denaturant-resistant binding occurs, leading to a shift in 
molecular weight.  Purified Aβ was also used as an IDE inhibitor for the fluorometric 
activity assay as detailed in Section 2.2.6.3. 
2.2.4.16  Immunoprecipitation of IDE from plasma 
To assist with determining the band/s of interest on Western blot, PCP and pre-
cleared/albumin-depleted PCP (AD-PCP), as well as rrIDE and rhIDE were used in an 
immunoprecipitation (IP) procedure for enrichment of the target protein (IDE).  
rhIDE was also spiked with Aβ42 and included in the immunoprecipitation 
experiment, to determine if IDE-Aβ binding was resistant to the 
immunoprecipitation method and subsequently denaturing and reducing 
conditions, leading to an increased molecular weight determined by Western 
blotting.  All dilutions and washes were done using TBS containing a protease 
inhibitor cocktail (TBS/PI).  IDE antibody 250706 or AF2496 was diluted 1:120 in 
TBS/PI (per tube) and bound to Protein G-coupled Magnetic Sepharose beads (20% 
slurry) as per manufacturer instructions, using the Classic Protocol.  4-8 μL each of 
73 
 
PCP and AD-PCP, and 100 ng of rrIDE was diluted to 500 μL with TBS/PI, and 
incubated in separate tubes with the antibody-bound beads for 1 hour with end-
over-end mixing.  The supernatant was then discarded and after washing the beads, 
the proteins were eluted from the beads by adding NuPage® LDS sample buffer and 
reducing agent, and then heating the tubes for 5 mins at 95°C.  The supernatant 
was then separated from the beads and the samples stored at -80°C until resolved 
by SDS-PAGE. 
2.2.4.17  Western Blotting image analysis and quantitation 
Films were scanned using a Bio-Rad GS-800 Calibrated Densitometer, and Quantity 
One software (version 4.5.1).  Images were acquired using high-resolution settings 
of 36.3 x 36.3 microns.  Quantity One software was used to measure the density of 
the scanned IDE bands, and the data was then exported to Microsoft® Excel 2007 for 
normalization to adjust for gel to gel variation using the internal control sample 
included on every gel.  Background density for each band was determined 
separately by measuring an area close to the band that did not contain any protein; 
and was then removed from the density of the band.  Duplicates having a 
coefficient of variation of < 15% were omitted from the analysis.  The data was 
analysed using IBM® Statistical Package for the Social Sciences (SPSS®) Version 
19.0.0 (Section 2.2.6). 
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2.2.5  IDE levels in human plasma by enzyme-linked immunosorbent 
assay (ELISA) 
All loading volumes are 100 μL per well and all wells were loaded in duplicate unless 
otherwise stated. 
2.2.5.1  Kamiya IDE ELISA commercial kit 
To determine if the Kamiya IDE ELISA commercial kit would be suitable for 
measuring IDE in plasma samples, IDE standards were prepared as per 
manufacturer instructions to concentrations of 0.78 to 50 ng/mL, and human 
plasma samples were applied neat and diluted from 1:1 up to 1:1000 using the 
buffer supplied with the kit.  The remainder of the protocol was performed as per 
manufacturer instructions and absorbance was measured using a Bio-Rad Fluostar 
Optima microplate reader at a wavelength of 450nm. 
2.2.5.2  Indirect In-house ELISA for IDE 
To test if various antibodies would be suitable for use in an indirect in-house ELISA, 
a screening test was performed using various commercially-available monoclonal 
(MMS-282R and 5282-1) and polyclonal (GTX111664, AB9210, 250706, H00003416-
A01, LS-C55007 and ab28561) IDE antibodies (see Section 2.1.1 for antibody 
details).  96-well Nunc Maxisorp microplates (modules) were coated with purified 
rrIDE standards at concentrations of 78.12 to 5000 ng/mL, diluted in 50 mM 
carbonate/bicarbonate buffer (pH 8.6).  PCP was coated neat (undiluted) and at 
several dilutions of 1:1 up to 1:20 in the same buffer.  All samples were applied in 
duplicate.  The plates were incubated O/N at 4°C with shaking.  Following the O/N 
incubation, plates were washed with a microplate washer four times in PBS (pH 7.4) 
and then incubated in a PBS solution containing 2% bovine serum albumin (BSA) to 
block any unbound sites on the plate (200 μL per well), for 1.5 hours at 4°C with 
shaking.  No Tween-20 was included in the blocking buffer at this stage to avoid the 
detergent loosely binding to the plate and displacing the BSA, as this may lead to 
the Tween-20 being removed by subsequent washes with PBS containing 0.05% 
Tween-20 (PBST) and leaving spaces for non-specific binding of the antibodies.  The 
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plates were then loaded with the primary antibody diluted 1:1000 in PBST 
containing 1% BSA (1% BSA/PBST), and incubated for either 2 hours at RT or 4°C 
O/N with shaking.  Washing was then performed four times with PBST to remove 
any unbound antibodies.  The HRP-conjugated anti-rabbit (AP322P), anti-goat 
(P0449) or anti-mouse (AP326P) secondary antibodies were then diluted 1:10000 in 
1% BSA/PBST, loaded onto the respective plates, and incubated for 2 hours at 4°C 
with shaking.  After washing another four times with PBST, 3,3′,5,5′-
tetramethylbenzidine (TMB) was prepared as per manufacturer instructions and 
applied to each well while protecting from light.  The substrate was incubated for 
30 minutes in darkness and the reaction stopped with the addition of 1M 
phosphoric acid (H3PO4).  The absorbance was then quantified using a microplate 
reader at a wavelength of 450nm to determine optical density. 
2.2.5.3  Sandwich ELISA for IDE 
96-well Nunc Maxisorp microplates (modules) were coated with an inactive domain 
IDE antibody (ab28561) at 2.5 μg/mL diluted in 50 mM carbonate/bicarbonate 
buffer (pH 9.6, or 8.6 for some optimisations).  The plates were then incubated O/N 
(18 hours) at 4°C with shaking.  Following the O/N incubation, the plates were 
washed four times with PBS (pH 7.4) to remove unbound antibodies, on a 
microplate washer.  After washing, wells were incubated (200 μL per well) with 3% 
BSA/PBS for 1 hour at RT with shaking, to block any unbound sites on the plate.  No 
Tween-20 was included in the washing or blocking buffer prior to this stage to avoid 
the detergent loosely binding to the plate and displacing the BSA, as this may lead 
to the Tween-20 being removed by subsequent washes with PBST and leaving 
spaces for non-specific binding of the antibodies.  IDE protein standards were then 
prepared from rrIDE, serially diluted to concentrations of 50 to 16000 ng/mL, and 
plasma samples were each diluted 1:2 in PBST (pH 7.4).  For some optimisations 1% 
BSA was added to the diluent.  An internal standard of human plasma (PCP) was 
also included (1:2).  IDE standard and plasma samples were loaded in each well in 
duplicate, and the plates were incubated for 1 hour at RT with shaking.  Following 
this incubation, the plates were further incubated O/N (18 hours) at 4°C with 
shaking.  After the O/N incubation, any unbound protein was removed by washing 
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four times with a microplate washer.  The detection antibody LS-C55007 (or 
H00003416-A01 for optimisation) was then diluted 1:750 in PBST, loaded into each 
well and the plates were incubated O/N at 4°C with shaking.  Following the O/N 
incubation, plates were washed four times with PBST.  The anti-goat (or anti-mouse 
for A01 antibody, AP326P) HRP-conjugated secondary antibody (P0449) was then 
diluted 1:7500 in PBST, loaded into each well, and plates were incubated for two 
hours at RT with shaking.  The plates were then washed again four times in PBST, 
and TMB was loaded to each well, protected from light.  The plates were then 
incubated in darkness for 15 – 25 minutes.  The reaction was stopped by applying 
1M H3PO4 to each well and the absorbance was measured at a wavelength of 450 
nm on a microplate reader to determine optical density. 
2.2.5.3.1  Preparation of human (HSA) and bovine (BSA) serum 
albumin 
Lyophilized preparations of purified BSA, Fraction V BSA, and HSA were diluted to 
60 and 30 mg/mL in PBST.  Solutions were then diluted 1:2 as per plasma dilutions 
and assayed using the IDE sandwich ELISA protocol as detailed previously in section 
2.2.5.3.  The diluted solutions of purified BSA and HSA were also diluted as detailed 
in Section 2.2.6.7 and assayed using the IDE fluorometric activity assay. 
2.2.5.4  Low-level data analysis 
Blank (background) optical density values were subtracted from the sample optical 
density values obtained, and were normalised to the internal standard sample value 
included on each plate to control for plate-to-plate variation.  Values less than the 
mean plus three times the standard deviation of the blanks were considered below 
the detection limit.  Duplicates with a coefficient of variation (CV) >15% were 
omitted from the analysis; if PCP (internal standard) values exceeded this CV the 
whole plate was omitted. 
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2.2.6  Catalytic activity of plasma IDE by immunocapture-based IDE-
specific fluorometric assay 
The fluorometric assay used was adapted from Miners, et al., 2008(b) and Wang, et 
al., 2010.  All well volumes are 100 μL per well unless otherwise specified.  All 
assays used PBST for dilutions and washing with the exception of the test between 
PBST and TBST where TBST was included as a sample buffer. 
2.2.6.1  Immunocapture-based IDE specific fluorometric assay 
96-well Nunc MaxiSorp™ Black Microplates (modules) were coated with an inactive 
domain IDE antibody ab28561 diluted at 2.5 μg/mL in 50 mM carbonate buffer (pH 
8.6), and incubated O/N at 4°C, with shaking.  Following the O/N incubation, the 
plate was washed 4 times in PBST using a plate washer, then blocked for 30 mins at 
RT (with shaking) with a 2% BSA/PBST solution (or 3% ECL Advance Blocking Agent 
in PBST for one optimisation step).  The blocking solution was not removed from 
the wells after incubation.  IDE protein standards were prepared from rrIDE diluted 
in PBST, at concentrations from 312.5 to 7500 ng/mL (for the AIBL samples, 
otherwise as specified) and 50 μL per well was added to the plates in duplicate.  
Plasma samples including an internal standard of PCP, were diluted in PBST to a 
concentration of approximately 19 μg/μL total protein (for the AIBL samples, 
otherwise as specified), and 50 μL per well was added to the plates in duplicate.  
The plates were then incubated O/N at 4°C with shaking.  After the O/N incubation, 
plates were washed 4 times with PBST, and the internally-quenched fluorogenic 
peptide substrate (Mca-R-P-P-G-F-S-A-F-K(Dnp)-OH) was diluted in 50 mM HEPES to 
a concentration of 2.5 μL/mL (10 μM) and applied to each well while protecting 
from direct light.  The fluorescence generated by the cleavage of the fluorogenic 
substrate was incubated and measured in a microplate reader (in darkness) with 
excitation at 320 nm and emission at 405 nm (at 31°C), immediately (baseline) and 
then hourly for 6 hours (for AIBL samples, otherwise as specified).  The cut off point 
of 6 hours was used as maximum activity was reached after 5 hours in the original 
study (Miners, et al., 2008(b)) and it was considered important to measure the 
highest reading possible within the linear range to maximise the chances of 
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detecting any differences between the groups.  The gain adjustment setting for 
early optimisation experiments using Ab 3 (Batch 1) was variable (as specified), 
however for Batch 2 the gain adjustment was set to 1487 for all assays.  The data 
values were interpolated from the standard curve of rrIDE as a measure of the 
equivalent amount of recombinant rat IDE (ng/mL). 
2.2.6.2  Inhibition of catalytic activity of IDE by IDE-specific 
antibodies and Aβ40 
To determine the specificity of the assay, four tubes containing PCP (1180 μg total 
protein each) were diluted in PBST to a volume of 125 μL, including no inhibitor 
(control), or either 20 μL of IDE antibodies AB9210 (A), LS-C55007 (B), or 20.5 μg of 
Aβ40 (C).  Antibody AB9210 binds to residues 200-250 of IDE which contains part of 
the catalytic site, while LS-C55007 binds close to the C-terminus of IDE in a domain 
which is distinct from the catalytic site.  Aβ40 was prepared as per Aβ42 as previously 
described in section 2.2.4.15.  The four tubes were then pre-incubated for 2 hours 
at RT on a rolling mixer, prior to adding these samples to the plates.  The assay was 
otherwise conducted as described above in section 2.2.6.1.  Specificity was 
determined by comparing the fluorescence generated by PCP in the presence or 
absence of each inhibitor. 
2.2.6.3  Inhibition of catalytic activity of IDE by Aβ42 
To assist with the determination of the assay specificity, 50 μL per well of 50 mM 
HEPES containing 0, 10 and 100 μM Aβ42 (prepared as detailed in Section 2.2.4.15) 
was added to the immunocaptured IDE (from PCP), and incubated for 2 hours at RT, 
with shaking, prior to the addition of 50 μL per well of 20 μM fluorogenic substrate.  
The assay was otherwise conducted as described in Section 2.2.6.1.  Specificity was 
determined by comparing the fluorescence generated by PCP in the presence or 
absence of each concentration of Aβ42. 
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2.2.6.4  Preparation of insulin 
Lyophilized insulin was dissolved in 0.01 M hydrochloric acid (HCl, pH 2.0) to a 
concentration of 10 mg/mL and then sterile-filtered through a 0.2 μm pore size 
filter.  The insulin solution was then diluted with HEPES (pH of approximately 8.0 to 
counteract low pH of HCl) to a concentration of 1 mM.  Serial dilutions of insulin 
were then made to 0.5 and 0.25 mM in HEPES (pH 7.5).   
2.2.6.5  Inhibition of catalytic activity of IDE by insulin 
50 μL per well of 50 mM HEPES containing 0, 0.25, 0.5 and 1.0 mM of insulin was 
added to the immunocaptured IDE (from PCP), and incubated for 2 hours at RT, 
with shaking.  50 μL per well of 10 μM fluorogenic substrate diluted in HEPES was 
then added to each well, and the assay was otherwise conducted as described in 
section 2.2.6.1.  Specificity was determined by comparing the fluorescence 
generated by PCP in the presence or absence of each concentration of insulin. 
2.2.6.6  Determination of fluorometric activity assay cross-
reactivity with human (HSA) and bovine (BSA) serum albumin 
HSA and BSA (Sigma) was prepared as described in section 2.2.5.3.1 to 
concentrations of 60 and 30 mg/mL each, diluted in PBST.  Each dilution was further 
diluted as per plasma samples (40 μl + 85 μL PBST), and then assayed in duplicate 
using the fluorometric activity assay protocol as detailed in Section 2.2.6.1.  Cross-
reactivity was determined to be fluorescence generated above the value of the 
(PBST only) blank.  Results are shown in the Appendix.  
2.2.6.7  Comparison of IDE activity from EDTA collected plasma 
and Lithium-Heparin (Li-Hep) collected plasma 
EDTA plasma and Li-Hep plasma were diluted in PBST to contain 960 ug total 
protein per well (50 μL) and IDE activity was measured with the activity assay as 
detailed in Section 2.2.6.1. 
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2.2.6.8  Low-level data analysis 
Duplicate values with a coefficient of variation (CV) of >15%, and assays where the 
standard curve values were > 2x standard deviation of the mean of each 
concentration were removed from the analysis.  Values were then interpolated 
from the standard curve included on each plate. 
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2.2.7  Statistical Analysis 
All data was analysed using IBM® Statistical Package for the Social Sciences (SPSS®) 
Version 19.0.0 (for Windows).  Normality of the frequency distribution was 
determined using z-scores for skewness and kurtosis, the Kolmogorov-Smirnoff and 
Shapiro-Wilk tests, histograms, boxplots and normal Q-Q plots.  Levene’s test was 
used to determine homogeneity of variance. 
Data was determined to have a non-normal distribution if z-scores for skewness 
and kurtosis were outside the range of ± 1.96, and Kolmogorov-Smirnoff/Shapiro-
Wilk tests produced a significance value of p ≤0.05.  Histograms, boxplots and 
normal Q-Q plots were also visualised for normal shape of the distribution and 
outliers.  A significance of p ≥0.05 for Levene’s test was used to determine 
homogeneity of variances.  Data found to be not normally distributed was 
subsequently transformed if possible. 
Data that satisfied the normality criteria following transformation was then 
analysed with the parametric Student’s T-test, one-way analysis of variance 
(ANOVA) or analysis of covariance (ANCOVA) using Tukey Post-Hoc analyses 
(independent samples, two-tailed analysis).  Correlations were determined using 
Spearman’s Rho, with Bonferroni-Holm correction applied to correct for multiple 
testing, which is a slightly less stringent correction method than the Bonferroni 
method (Holm, 1979). 
Data that still displayed non-normal distribution after transformation was analysed 
with the non-parametric Mann-Whitney and Kruskall-Wallis tests.  Mann-Whitney 
tests were used as Post-Hoc tests for the Kruskall-Wallis test with Bonferroni 
correction applied to correct for multiple testing.  The Monte Carlo method was 
used to determine the estimate of significance which is more accurate than the 
Asymptotic Method when data is poorly distributed.  Significance was considered to 
be p≤0.05.  Correlations were determined using Spearman’s Rho, with Bonferroni-
Holm correction applied to correct for multiple testing. 
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CHAPTER 3 – Full-length plasma IDE Levels are higher 
in MCI in comparison to healthy controls or AD, as 
measured by Western Immunoblotting. 
3.1  Introduction 
Beta-amyloid (Aβ) is believed to be a key peptide involved in the pathogenesis of 
Alzheimer’s disease (AD), and higher than normal levels of Aβ peptides in the brain 
lead to Aβ aggregation and neurotoxicity, and appear to instigate the development 
of extracellular senile plaques (SP) and subsequently the formation of intracellular 
neurofibrillary tangles (NFT) which are the primary lesions found in the brains of 
AD patients.  It has been demonstrated that Aβ is produced within brain cells as 
well as within the cerebrovasculature (Reviewed by Wilson, et al., 1999; Kalaria, et 
al., 1996), and can be transported out into the periphery. However free Aβ can 
also be transported into the brain, across the blood-brain barrier from the 
peripheral circulation (Deane, et al., 2003).  It has been shown that plasma levels 
of Aβ increase in AD patients prior to the formation of SP, but decrease 
considerably as levels of brain Aβ increase and begin forming insoluble fibrillar 
deposits of amyloid (Kawarabayashi, et al., 2001; Schupf, et al., 2008).  This 
suggests that peripheral Aβ may be a source for the Aβ that accumulates in the 
brain, and it is likely that regulation of Aβ levels in the periphery may be of 
importance in the pathogenesis of AD. 
Insulin-degrading enzyme (IDE) has been demonstrated to be a primary 
metalloprotease responsible for the regulation of monomeric Aβ levels in the brain, 
but not oligomeric or fibrillar forms (Leissring, et al., 2003; Farris, et al., 2003).  It 
has also been shown that overexpression of IDE not only reduces the soluble levels 
of brain Aβ, but also attenuates the formation of SP and prevents early death in 
transgenic mouse models.  These results suggest that the reduction of monomeric 
Aβ levels is sufficient to prevent SP formation.  In accordance with this, recent work 
has shown that the formation of Aβ fibrils is critically influenced by the oligomeric 
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state of soluble Aβ, as well as the balance of monomeric to aggregated forms of 
Aβ42, revealing more about the role of Aβ42 in the amyloidogenic pathway (Jeong, et 
al., 2013).  It has also been shown that amyloid formation is reversible (Lazerov, et 
al., 2002).  It is possible then that reducing monomeric Aβ in the periphery by way 
of IDE clearance may have some impact on preventing cerebral accumulation of the 
peptide, as well as its oligomerisation and fibrillisation,  and hence the 
development of AD.  Therefore, the levels of IDE in human plasma could be integral 
in regulating not only plasma Aβ, but also Aβ in the brain.  Furthermore, plasma IDE 
levels may also reflect cerebral levels of Aβ, and thus provide a useful biomarker for 
the assessment and monitoring of brain Aβ levels and/or early pathological 
processes that lead to neurodegeneration.  Plasma IDE levels could also potentially 
be utilised as a biomarker in clinical trials for determining the efficacy of drugs, 
preventative interventions and other relevant treatments for AD. 
It has been shown that truncated isoforms of IDE have little or no activity (Li, et al., 
2006), therefore the first aim of this project was to determine if full-length IDE was 
present in human plasma.  Western immunoblotting was employed for this 
purpose, and a number of IDE antibodies were screened for suitability.  Once the 
presence of full-length IDE was confirmed, the levels of plasma IDE in AD patients 
and MCI individuals were measured against the levels in healthy controls (HC), to 
see if they were altered in the prodromal period of AD (MCI) or in the disease state. 
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3.1.1  Aims 
 
1. To use Western immunoblotting techniques to characterise commercial IDE 
antibodies and to determine whether full-length IDE is present in human 
plasma. 
2. To measure levels of plasma IDE using a well-characterised Western 
immunoblotting technique to determine if plasma IDE levels can 
differentiate between classifications of AD, MCI and HC. 
3. To determine if the presence of the APOE4 allele has any impact on the levels of 
full-length plasma IDE. 
4. To identify any relationships between full-length plasma IDE and other 
biochemical data obtained from the AIBL study. 
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3.2  Experimental Summary 
3.2.1  Antibody characterisation: Pre-incubation of polyclonal IDE 
antibody Ab 1 with recombinant human IDE to check specificity for 
human plasma IDE. 
Experiments were carried out to test if IDE antibody AB9210 (Ab 1(a) (Batch 1) – 
refer to Table 2.1 for details) detects full-length IDE in human plasma, and to 
determine if the bands seen are specific. SDS-PAGE and Western immunoblotting 
were performed as previously outlined in Sections 2.2.4.1 and 2.2.4.3, including a 
pre-incubation blocking step prior to the primary antibody incubation as outlined in 
Section 2.2.4.10. 
 
3.2.2  Testing the batch-to-batch variability of IDE antibody Ab 1 on 
human plasma and rrIDE. 
Experiments were carried out to test if a second batch of IDE antibody AB9210 (Ab 
1(b)- refer to Table 2.1 for details) could detect full-length IDE in human plasma as 
efficiently as the previous batch (Ab 1(a)). Recombinant rat IDE (rrIDE) was used as 
a positive control, and SDS-PAGE and Western immunoblotting were performed as 
outlined in Sections 2.2.4.1 and 2.2.4.3. 
 
3.2.3  Test of alternate polyclonal IDE antibody Ab 2: comparison with 
IDE antibody Ab 1. 
SDS-PAGE and Western immunoblotting were performed as outlined in Sections 
2.2.4.1, 2.2.4.2 and 2.2.4.3, to determine if an alternate IDE antibody LS-C55007 (Ab 
2 – refer to table 2.1 for details) could detect full-length IDE in human plasma and 
rrIDE as efficiently as IDE antibody AB9210 (Ab 1(a) (Batch 1)). Subsequent 
experiments showed that an extended development time of one hour was required 
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to adequately visualise the band of interest in the region of 115-120 kDa, however 
background was also amplified.  Consequently ECL Advance/Prime detection agents  
were used along with additional washing steps in order to increase the sensitivity of 
the method for the detection of full-length IDE in human plasma while minimizing 
the background generated. 
 
3.2.4  Determination of the effect of EDTA in blood collection tubes on 
levels of human plasma IDE detected with IDE antibody Ab 2. 
As EDTA is a chelating agent and IDE is a metalloprotease, an experiment was 
conducted to analyse whether the EDTA in the blood collection tubes has an effect 
on the amounts of full-length plasma IDE that are detected using IDE antibody LS-
C55007 (Ab2).  SDS-PAGE and Western immunoblotting were performed as outlined 
in Sections 2.2.4.1, 2.2.4.2 and 2.2.4.7. 
 
3.2.5  Investigating potential cross-reactivity of IDE antibody Ab 2 with 
purified human and bovine albumin. 
Human plasma contains diverse components including many proteins, and the most 
abundant of these is albumin.  Cross-reactivity occurring between plasma albumin 
and a specific antibody of interest could therefore potentially mask the detection of 
other less abundant proteins by the antibody in question.  In addition, bovine 
serum albumin is often used as a blocking agent in various immune-based protein 
detection methods, and sometimes cross-reacts with antibodies raised in goats due 
to species similarity.  Therefore purified human (HSA) and bovine (BSA) serum 
albumin was analysed by SDS-PAGE and Western immunoblotting (as described in 
Sections 2.2.4.1, 2.2.4.2 and 2.2.4.8 with IDE antibody LS-C55007 (Ab 2) to 
determine if either of these albumins could be detected in the region of interest.  
The concentrations of albumin used reflected physiological levels found in plasma 
in normal human physiology.  In addition, HSA was spiked with recombinant human 
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IDE to determine if any interactions between IDE and HSA occur under denaturing 
and reducing conditions. 
 
3.2.6  Pre-incubation of IDE antibody Ab 2 with a synthesised 
immunogen peptide to assess specificity of antibody to IDE in human 
plasma. 
To determine if the bands detected by IDE antibody LS-C55007 (Ab 2) are specific 
for IDE in human plasma and specific for rrIDE, SDS-PAGE and Western 
immunoblotting were performed as outlined in Sections 2.2.4.1 and 2.2.4.2. The 
experiment included a pre-incubation blocking step using a custom-synthesised 
peptide identical to the Ab 2 immunogen. This step was carried out prior to the 
primary antibody incubation, as outlined in Section 2.2.4.11. 
 
3.2.7  Test of alternate polyclonal IDE antibody Ab 3: assessment of its 
detection of rrIDE as well as full-length IDE in human plasma. 
To determine if an alternative polyclonal IDE antibody ab28561 (Ab 3 - refer to 
Table 2.1 for details) can detect full-length IDE in human plasma, as well as purified 
rrIDE used as a positive control, SDS-PAGE and Western immunoblotting were 
performed as outlined in Sections 2.2.4.1 and 2.2.4.4.  Homogenised rat liver, 
human frontal cortex and purified recombinant human IDE were also included as 
further positive controls. 
 
3.2.8  Determination of the effect of EDTA in blood collection tubes on 
the detection of human plasma IDE using IDE antibody Ab 3. 
To determine the effect, if any, of EDTA’s presence in human blood samples on the 
detection of full-length IDE by IDE antibody ab28561 (Ab 3), membranes previously 
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analysed by IDE antibody LS-C55007 were stripped of antibodies and re-probed (as 
described in Sections 2.2.4.7 and 2.2.4.5). 
 
3.2.9  Testing  IDE antibody Ab 3 for cross-reactivity with BSA, HSA 
and a non-albumin containing blocking agent. 
As IDE antibody LS-C55007 was found to cross-react with albumin, an experiment 
was conducted to identify any cross-reactivity between polyclonal IDE antibody 
ab28561 (Ab 3) and purified BSA or an alternative, commonly used blocking agent 
which contains no albumin (ECL™ Advance Blocking Reagent).  SDS-PAGE and 
Western immunoblotting were performed as described in Sections 2.2.4.1 and 
2.2.4.4.  The concentrations of albumin (or non-albumin blocking agent) used 
reflected physiological levels of albumin found in plasma in normal human 
physiology. The same experiment was subsequently repeated to include HSA and 
BSA, as well as rrIDE/rhIDE-spiked HSA as outlined in Sections 2.2.4.8 and 3.2.5. 
 
3.2.10  Pre-clearing and albumin-removal from human plasma. 
As immunoglobulins and albumin may be interfering factors in antibody-based 
detection and immunoprecipitation methods, it was considered that it would be 
beneficial to reduce the immunoglobulin and albumin content of human plasma.  A 
pre-clearing step was performed as described in Section 2.2.4.13 to remove 
immunoglobulins that may non-specifically bind to the beads used in the 
immunoprecipitation protocols.  The pre-cleared plasma was then also depleted of 
albumin content using the immunoaffinity-based protocol described in Section 
2.2.4.14, using a monoclonal antibody to human albumin GTX27793 (AL-01). 
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3.2.11  Immunoprecipitation (IP) of IDE from human plasma with 
polyclonal IDE antibodies Ab 4 and Ab 5. 
IDE immunoprecipitation experiments were carried out on untreated human 
plasma, and to investigate whether there are any non-specific contaminating 
factors, immunoprecipitation was also carried out on human plasma which had 
been pre-cleared of immunoglobulins and depleted of albumin prior to IP.  RrIDE 
and rhIDE (AF2496 only) were immunoprecipitated to be included as positive 
controls. A sample of rhIDE pre-incubated with Aβ42 (Aβ42 preparation is detailed in 
Section 2.2.4.15) was also included in the IP experiment, to determine if IDE-Aβ 
interactions were resistant to the IP method as well as to the denaturing and 
reducing conditions of the subsequent Western immunoblotting step, leading to an 
increased molecular weight.  The IP experiment was performed as described in 
Section 2.2.4.16, using polyclonal IDE antibodies 250706 (Ab 4) or AF2496 (Ab 
5)(refer to Table 2.1 for details).  The immunoprecipitated samples were then 
resolved by SDS-PAGE and Western immunoblotting with IDE antibody ab28561 (Ab 
3) as described in Sections 2.2.4.1 and 2.2.4.4. 
 
3.2.12  Testing the specificity of IDE antibody Ab 3 for IDE in human 
plasma by pre-incubation with a commercial blocking peptide. 
To determine if the bands detected from human plasma samples by IDE antibody 
ab28561 (Ab 3) were specific, SDS-PAGE and Western immunoblotting were 
performed as outlined in Sections 2.2.4.1 and 2.2.4.4, including a pre-incubation 
blocking step with peptide, that was used as the immunogen, prior to the primary 
antibody incubation, as outlined in Section 2.2.4.12.  rrIDE, rat liver and zebrafish 
brain homogenates were included as positive controls. 
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3.2.13  Determination of full-length IDE levels in the plasma samples 
of the AIBL cohort by SDS-PAGE and Western immunoblotting, using 
IDE antibody Ab 3. 
Samples which had been collected using the methods described in Section 2.2.2 
from the AIBL cohort were tested to measure full-length IDE levels. These 
investigations used SDS-PAGE and Western immunoblotting, and IDE antibody 
ab28561 (Ab 3), as outlined in Sections 2.2.4.1 and 2.2.4.4.  An internal control 
sample of pooled control plasma (PCP) and a positive control of rrIDE were included 
on each gel.  Ponceau S staining of the antibody stripped membrane prior to 
immunoblotting, was performed as previously described in Section 2.2.4.6, to 
ensure complete transfer of proteins as well as providing a gel loading control.  
Alternatively, blots were re-stripped following immunoblotting and Coomassie 
stained.  Following ECL detection of bands, levels of full-length plasma IDE were 
quantified by scanning on a Bio-Rad densitometer GS-800 and images were 
analysed using Quantity-One software (V4.5.1). 
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3.3  Results 
3.3.1  Bands detected by IDE antibody Ab 1(a) (Batch 1) in human 
plasma are IDE. 
When using immunoaffinity methods such as Western immunoblotting, it is 
common to detect several bands, particularly when using polyclonal antibody sera 
which may detect multiple epitopes on the protein of interest, and which may also 
contain antibodies to other proteins.  Although the bands detected may be specific 
and represent multiple isoforms of the protein, it is also common to have non-
specific binding occur.  Therefore it is important to identify which of the detected 
bands (if any) is the target protein. 
One commonly used technique is to absorb antibody activity by pre-incubation with 
the immunising peptide, thus blocking the antibody binding sites (also called 
peptide competition assay); the blocked antibody is then used in immunoblotting.  
Briefly, the antibody is pre-incubated with an excess of the immunising peptide 
used to raise the antibody, or a peptide or protein that contains the matching 
epitope of interest, prior to adding to the membrane.  The peptide binds to the 
antibody, effectively blocking it from binding to the target epitope.  The resulting 
blot will show that the specific bands are significantly reduced in intensity or 
absent, while non-specific bands remain.  While this technique is generally more 
effective on monoclonal antibodies, which usually recognise just one epitope on the 
protein of interest, it can also be useful for determining the specificity of polyclonal 
antibodies. 
An immunising peptide blocking experiment was performed on Ab 1(a) (AB9210) to 
determine if the single band detected at 105 kDa in human plasma is IDE (Figure 
3.1).  This antibody was raised against a synthetic peptide of rat IDE spanning from 
amino acids 200 to 250.  As this sequence shows 96.1% homology with the human 
IDE peptide it would be expected to detect IDE in human plasma.  Results show that 
the band density was reduced by more than 50% after using full-length human IDE 
to neutralise the antibody.  This indicates that the band seen is likely to be IDE, 
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despite a slightly lower estimated molecular weight when compared to most 
published studies.  A limitation of this test was that it was only performed once and 
should have been repeated twice to ensure validity of the results.  In addition, it 
would have been useful to include increasing doses of IDE to observe a dose-curve 
effect.  However, as the subsequent batches of this antibody performed differently, 
it was decided not to continue with this antibody (discussed in Section 3.3.2) so 
further testing was considered unnecessary. 
 
 
Figure 3.1  Immunising peptide (protein) blocking experiment on IDE antibody 
AB9210 (Ab 1(a)).  Western immunoblot probed with polyclonal IDE antibody 
AB9210 (1:8000) after pre-incubating primary antibody solution without human IDE 
protein (membrane A.) or with 1.32 μg recombinant human IDE as detailed in 
Sections 2.2.4.1 and 2.2.4.3 and 2.2.4.10.  Sample is 1 μL pooled control plasma 
(PCP) per lane in duplicate. Results show signal is reduced by approximately 50% in 
B. as compared with the control.  Coomassie stain of membrane was included as a 
loading control.  Error bars indicate ±SD. 
 
3.3.2  Subsequent batches of polyclonal IDE antibody Ab 1 are unable 
to detect full-length IDE in human plasma. 
While monoclonal antibodies are known to be more specific than polyclonal 
antibodies, there are nevertheless certain advantages to using polyclonal 
antibodies.  These include reduced cost, and they can also be more sensitive than 
monoclonals in detecting the protein.  One drawback, however, is the possibility of 
batch-to-batch variation in polyclonal antibodies.  It is important to compare each 
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new batch of polyclonal antibody with the previous batch to ensure consistency, 
and it is essential to use the same batch when conducting studies on a cohort 
where samples need to be compared to each other. 
The initial batch of IDE antibody AB9210 (Ab 1(a) (Batch 1)) was compared with a 
subsequent batch (Ab 1(b) (Batch 2)) to determine if results were comparable 
(Figure 3.2).  The results show that Batch 2 was unable to detect IDE in human 
plasma, even at double the original concentration used for Batch 1.  It was 
concluded that Batch 2 was unsuitable for measuring IDE in human plasma.  As 
supplies of Batch 1 were no longer available, an alternative antibody needed to be 
screened. 
 
 
Figure 3.2  Comparison of original batch of IDE antibody AB9210 (Ab 1(a) (Batch 
1)) with a subsequent batch of AB9210 (Ab 1(b) (Batch 2)) on human plasma and 
rrIDE.  Western immunoblot of human plasma and rrIDE probed with IDE antibody 
Ab 1(a) (Batch 1) (membrane A.) compared with Ab 1(b) (Batch 2) (membranes B. 
and C.) as detailed in Sections 2.2.4.1 and 2.2.4.3.  Samples are 1 μL/lane of pooled 
control plasma (PCP) and 50 ng/lane rrIDE in duplicate.  Results show that Ab 1(b) 
(Batch 2) is unable to detect IDE in human plasma at concentrations of 1:8000 or 
1:4000.  Ab 1(b) (Batch 2) is capable of detecting purified rrIDE, however appears to 
be less sensitive than Ab 1(a) (Batch 1).  Once past the primary antibody step, the 3 
blots were processed together. 
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3.3.3  Comparison of IDE antibody Ab 1 (AB9210, Batch 1) and IDE 
antibody Ab 2 (LS-C55007).   
A comparison was made between Ab 1(a) (Batch 1) (AB9210 original batch) and 
another polyclonal IDE antibody Ab 2 (LS-C55007) (Figure 3.3(A) and (B)).  Ab 2 was 
raised against a synthetic peptide of human IDE, spanning amino acids 914-924, 
targeting the C-terminal end of the IDE protein.  The reported truncated isoform of 
IDE contains this region, therefore Ab 2 would be expected to detect both the 
truncated plus the full-length isoforms of IDE.  The initial results show that at a 
concentration of 1:8000 for Ab 1(a) (Batch 1), and 1:5000 for Ab 2, both are able to 
detect rrIDE at 200-400 ng/well, however Ab 2 appears to have less affinity for 
recombinant rat IDE.  This may be because Ab 2 was raised against a human IDE 
sequence, whereas Ab 1 was raised against a rat IDE sequence.  However these 
antibodies are difficult to compare in this test.  Firstly, Ab 1 is in the form of 
antiserum, therefore the exact concentration of IDE-specific immunoglobulins 
cannot be determined (total IgG is estimated to be between 1-2 mg/mL), whereas 
Ab 2 is purified and the concentration determined to be 0.5 mg/mL.  In addition, 
these antibodies require different secondary antibodies (anti-Rabbit versus anti-
Goat), and different concentrations were used [Ab 2 (1:7500), Ab 1 (1:5000)], these 
issues would also have contributed to the observed differences in signal.  In human 
plasma, no bands were seen under the conditions used with Ab 2 in the range of 
100-120 kDa, which is the expected molecular weight for full-length IDE.  However a 
signal was detected at approximately 45 kDa which may correspond to the 
truncated form that has been reported. 
  
96 
 
 
 
 
Figure 3.3 (A) and (B)  Comparison of polyclonal IDE antibody AB9210 (Ab 1(a) 
(Batch 1)) with LS-C55007 (Ab 2) on human plasma and rrIDE.  Western 
immunoblot of human plasma and rrIDE probed with IDE antibodies Ab 1(a) (Batch 
1) (membrane A) compared with Ab 2 (membrane B) as detailed in Sections 2.2.4.1, 
2.2.4.2 and 2.2.4.3.  Samples are 1 μL/lane of pooled control plasma (PCP) and 400 
and 200 ng/lane of rrIDE in duplicate.  Results show Ab 2 detects a band at 
approximately 45 kDa, but not within the range of full-length IDE (100-120 kDa) 
under these conditions. 
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The Western blotting methods were modified slightly to try to improve the 
detection of full-length IDE in human plasma by Ab 2.  Three individual plasma 
samples (including PCP) and rrIDE were resolved by SDS-PAGE and probed with Ab 
2, using an extended exposure time when developing the film (Figure 3.4).  Results 
show that after a one hour exposure, additional bands to the 45 kDa bands 
previously demonstrated appeared at approximately 160 (ghost bands), 115-120, 
80 and 60 kDa.  The band at 115-120 kDa corresponded to various previous reports 
of the molecular weight of IDE, however differed from the molecular weight of the 
band seen using Ab 1 (105 kDa).  Cross-reactivity with the molecular weight marker 
(MWM) proteins at 80 and 60 kDa demonstrates some non-specific binding.   
To reduce the exposure time required and to retain sufficient visualisation of the 
bands within the region of interest (specifically the 115-120 kDa band), ECL™ 
Advance Detection Reagent was tested in this application (Figure 3.5) with five 
individual plasma samples including PCP, and rrIDE (previously ECL™ Detection 
Reagent was used).  ECL™ Advance is reported to be a more sensitive 
chemiluminescent reagent than ECL™, increasing the sensitivity of detection by up 
to ten times compared to standard ECL™.  Results show that ECL™ Advance did 
improve the detection of bands at 115-120, 80, 70 and 45 kDa, although the 
background was also significantly enhanced.  The previously observed “ghost” 
bands at 160 kDa (Figure 3.4) were not apparent.    
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Figure 3.4  Investigating the effect of extended ECL development time on the 
detection of full-length human plasma IDE with Ab 2.  Pooled control plasma 
(PCP), and two individual plasma samples (S1 and S2) were run in triplicate (1 
µl/lane) as detailed in Sections 2.2.4.1 and 2.2.4.2.  The rrIDE sample contained 100 
ng.  After transfer, the immunoblot was probed with primary antibody Ab 2 (LS-
C55007) and developed for 1 hr.  Results show that multiple bands are detected in 
plasma after exposing for one hr, at approximate molecular weights of 160, 115-
120 (close to expected size), 80, and 70 kDa, and strong bands at approximately 45 
kDa. Cross-reactivity is apparent with the MWM at 80 and 60 kDa.  Differences in 
intensity of the plasma bands between individual samples at 115-120 kDa are 
apparent, although intra-sample variation is also apparent. 
 
 
Differences in intensity of the 115-120 kDa band were apparent between individual 
samples.  The development time was reduced from 60 min with standard ECL™ to 1 
min using ECL™ Advance.  It should be noted that the last lane was markedly lighter 
than its duplicate; this was unlikely to be due to imprecise pipetting, as this 
phenomenon was observed consistently.  As it was only a positive control loaded in 
this lane in all gels, and not used for quantification, it was not considered to be an 
issue in this instance.  
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Figure 3.5  Plasma samples probed with Ab 2 (LS-C55007), using rrIDE as positive 
control, and developed using ECL™ Advance.  Pooled plasma (PCP), and four 
individual plasma samples (S1, S2, S3 and S4) all at 1 μL plasma per lane, were run 
in duplicate as detailed in Sections 2.2.4.1 and 2.2.4.2. The rrIDE sample contains 
100 ng.  Results show that multiple bands are detected in the plasma samples after 
exposing for 1 min, at approximate molecular weights of 115-120 (close to 
expected), 80, and 70 kDa, and strong bands at approximately 45kDa.  Cross-
reactivity is apparent with the MWM at 80 and 60kDa. Differences in intensity of 
the plasma bands between individual samples at 115-120 kDa are apparent.  The 
background is considerably darker with this developer. 
 
 
3.3.4  EDTA has no effect on the intensity of the 115-120 kDa band 
detected with IDE Ab 2. 
EDTA is a common anticoagulant used in blood collection tubes to prevent the 
clotting cascade, when separating plasma out of whole blood.  Final concentrations 
of EDTA in blood after collection range from approximately 1.2 to 2.0 mg/mL, and 
as EDTA is water-soluble, it is most likely that a majority of this would remain in the 
plasma following red blood cell removal.   EDTA functions as a chelating agent, 
sequestering metal ions from proteins, and this may have an effect on the 
antibody-antigen interaction in immunoblotting techniques when detecting metal-
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dependent enzymes such as IDE.  To determine whether IDE detection is influenced 
by EDTA in the blood samples, plasma which was collected in non-EDTA collection 
tubes (using Lithium-heparin as anticoagulant) was spiked with EDTA to give final 
concentrations from 0 to 2.0 mg/mL.  SDS-PAGE and Western immunoblotting were 
then performed on these samples with IDE Ab 2 (Figure 3.6).  Results show there 
was no difference in the levels of IDE detected when comparing the control plasma 
(0 mg/mL of EDTA) with the plasma samples containing concentrations of EDTA up 
to 2.0 mg/mL. 
 
 
Figure 3.6: Investigating the effect of EDTA on IDE detection.  Western blot of an 
individual plasma sample collected in lithium-heparin collection tube subsequently 
spiked with EDTA to final concentrations of 1.0, 1.5 and 2.0 mg/mL as detailed in 
Sections 2.2.4.7, 2.2.4.1 and 2.2.4.2. The blot contained rrIDE as a positive control, 
and was probed with IDE Ab 2 (LS-C55007).  Duplicate aliquots of plasma sample S1 
(1 μL/lane) were loaded. The rrIDE lane contained 50 ng protein.  Results show no 
significant differences between IDE band intensities for EDTA concentrations from 0 
to 2.0 mg/mL.  
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3.3.5  IDE Ab 2 cross-reacts with HSA strongly, and BSA weakly, in 
Western immunoblotting. 
Albumin is the most abundant plasma protein and therefore cross-reactivity 
between albumin and a detecting antibody may potentially mask true levels of a 
less abundant protein.  The plasma levels of albumin in the AIBL cohort range from 
approximately 30 to 60 mg/mL (which would equate to 30-60 µg/lane in the 1 µl 
plasma aliquots/lane).  Therefore Western immunoblotting experiments were 
carried out to determine whether IDE Ab 2 (LS-C55007) cross-reacts with purified 
bovine (BSA) and/or human (HSA) serum albumin at concentrations within the 
physiological range in AIBL participants (Figure 3.7).  HSA was also spiked with 
purified recombinant human IDE (rhIDE) to determine if any interaction occurs 
between the proteins that would produce additional bands in Western 
immunoblotting.  The results show that Ab 2 cross-reacted with purified HSA 
strongly at both 30 and 60 µg/lane, with two close bands detected at approximately 
45 kDa.  Very slight cross-reactivity was also observed between Ab 2 and BSA at 
both concentrations.  The bands observed did not appear to be dose-responsive for 
either HSA or BSA, although a lower exposure time may have shown band intensity 
differences.  No other bands were observed when HSA was spiked with rhIDE.  It 
was concluded that the cross-reactivity between Ab 2 and albumin was of little 
significance in the Western immunoblotting method as no bands were seen in the 
region of interest (100-120 kDa).  Interestingly the molecular weight of human 
albumin is 66 kDa and no bands were observed in this region. 
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Figure 3.7  Test of cross-reactivity between Ab 2 (LS-C55007) and HSA or BSA.  
Purified human serum albumin (HSA), bovine serum albumin (BSA), and HSA spiked 
with recombinant human IDE (rhIDE) were probed with IDE Ab 2 as detailed in 
Sections 2.2.4.8, 2.2.4.1 and 2.2.4.2.  HSA and BSA lanes contain 60 and 30 μg 
protein per lane in duplicate.  HSA + rhIDE contains 30 μg HSA and 175.2 ng rhIDE in 
duplicate.  Results show that the antibody cross-reacts with HSA, with strong bands 
appearing at approximately 45-50 kDa.  Detection appears to be non-dose 
responsive.  BSA also appeared to be detected weakly at approximately 50kDa, also 
in a non-dose responsive fashion. 
 
3.3.6  Testing the specificity of IDE Ab 2 by pre-incubation blocking of 
the antibody with the immunising peptide. 
To determine which of the bands (if any) observed in human plasma by Western 
immunoblotting with Ab 2 are IDE, a pre-incubation step with the immunising 
peptide was performed on Ab 2 (refer to Section 3.3.1 for overview). Such a pre-
incubation should block the antibody binding sites. The peptide was custom-
synthesised to be identical to the immunogen used to raise Ab 2.  The test was 
carried out in 3 slightly different ways, to ensure accuracy of the results (Figures 
3.8(A)(B)(C)).  Results showed that the 118 kDa bands observed in rrIDE and rhIDE 
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lanes were absent after pre-incubating Ab 2 with the blocking peptide, however no 
differences were seen between any of the bands from human plasma in the 
molecular weight region of interest.  The results indicate that Ab 2 is specifically 
detecting the purified recombinant IDE, however also indicate that the bands seen 
in human plasma are most likely non-specific. 
 
  
Figure 3.8(A)  Pre-incubation  of IDE Ab 2(LS-C55007) with the immunising peptide 
to test antibody specificity (Test 1).  Pooled control plasma (PCP) and recombinant 
rat IDE (rrIDE - positive control) were probed with IDE Ab 2, some antibody aliquots 
of Ab 2 were blocked (prior to adding to immunoblots) with a custom-made peptide 
identical to the immunogen (20, 40, 80 and 180 μg peptide/blot) as detailed in 
Sections 2.2.4.11, 2.2.4.1 and 2.2.4.2.  PCP lanes contain 1 μL plasma per lane.  
rrIDE lanes contain 200 ng per lane.  Results show rrIDE bands (118 kDa) absent at 
all concentrations of blocking peptide, however no differences can be seen in PCP 
lanes in the region of interest. 
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Figure 3.8(B)  Pre-incubation  of IDE Ab 2(LS-C55007) with the immunising peptide 
to test antibody specificity (Test 2).  Pooled control plasma (PCP) and recombinant 
rat IDE (rrIDE - positive control) were probed with IDE Ab 2, which had been 
neutralised/blocked prior to incubation with the custom peptide identical to the 
immunogen (250 and 500 μg peptide/blot - higher amount/sample than in previous 
experiment) as detailed in Sections 2.2.4.11, 2.2.4.1 and 2.2.4.2.  PCP lanes contain 
1 μL plasma per lane in duplicate.  rrIDE lanes contain 200 ng per lane in duplicate.  
Results show that the rrIDE bands (118 kDa) are absent at all concentrations of 
blocking peptide, however no difference can be seen in PCP bands.  
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Figure 3.8(C)  Pre-incubation  of IDE Ab 2 (LS-C55007) with the immunising 
peptide to test antibody specificity (Test 3).  Pooled control plasma (PCP), 
recombinant rat IDE (rrIDE), recombinant human IDE (rhIDE) and human brain 
frontal cortex (FC) were probed with IDE Ab 2, with some antibody samples having 
been blocked prior to incubation with a custom peptide identical to the immunogen 
(50 and 500 μg peptide/blot) as detailed in Sections 2.2.4.11, 2.2.4.1 and 2.2.4.2.  
PCP lanes contain 1 μL plasma/lane, rrIDE lanes contain 200 ng/lane, rhIDE lanes 
contain 127 ng/lane and FC lanes contain 1µL brain homogenate/lane (15.2 µg total 
protein).  Results show rrIDE and rhIDE bands (118 kDa) are absent at all 
concentrations of blocking peptide, however no difference can be seen in the PCP 
or FC bands. The immunoblotting results had been transformed with Quantity One 
software to aid visualisation of bands. 
 
 
3.3.7  Test of IDE antibody ab28561 (Ab 3). 
An alternate IDE antibody (ab28561), which binds to an epitope encompassing an 
area that is not part of the active site of IDE, was tested for its ability to detect 
plasma IDE by Western immunoblotting (Figure 3.9).  The antibody (designated Ab 
3) was tested using both ECL™ (standard) and ECL™ Prime Detection Reagents.  
ECL™ Prime is a replacement product for ECL™ Advance (now discontinued), 
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therefore has greater sensitivity than standard ECL™.  Samples of rrIDE, rhIDE, rat 
liver homogenate and human frontal cortex (FC) were also included on the Western 
blots.  The results showed that Ab 3 can detect rrIDE and rhIDE as a single band at 
118 kDa, similar to Ab 1 and 2.  Using standard ECL™, several bands were detected 
at approximately 50, 70, 80 and 120-130 kDa in human plasma, as well as a single 
band at 110 kDa in rat liver and single bands for recombinant IDE (rat and human – 
rrIDE/rhIDE, respectively).  No bands were detected in the FC sample using standard 
ECL™ under these conditions.  When ECL™ Prime was used as the detection 
reagent, multiple other bands became visible in all samples, including the rrIDE, 
rhIDE and FC.  In plasma, an additional band at approximately 160 kDa was 
observed.  These results indicated that Ab 3 may be suitable for detecting IDE in 
human plasma, however specificity needed to be checked. 
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Figure 3.9  Test of Ab 3 (ab28561) on human plasma, rat liver, human frontal 
cortex and recombinant IDE (rat and human).  Pooled plasma (PCP), recombinant 
rat IDE (rrIDE), rat liver homogenate, human brain frontal cortex (FC and 
recombinant human IDE (rhIDE) were probed with IDE Ab 3 (ab28561), and 
developed with either ECL (membrane A) or ECL Prime (membrane B) as detailed in 
Sections 2.2.4.1 and 2.2.4.4.  PCP lanes contain 1 μL plasma per lane. The rrIDE 
samples contained 100 ng per lane, rat liver samples: 47.4 μg total protein per lane, 
human FC samples: 15.2 μg total protein per lane and rhIDE samples: 127 ng per 
lane.  Single bands were observed for rrIDE, rat liver and rhIDE at 110-118 kDa using 
ECL Normal.  For PCP, bands appear at approximately 120-130, 80, 70 and 50 kDa.  
No band was apparent for human FC (Membrane A).  With ECL Prime, an extra band 
was seen in the PCP at just over 160 kDa and several extra bands in rat liver (two at 
around 80 kDa, one at 55-60 kDa and one at 50 kDa).  For human FC, three bands 
were detected using ECL Prime in the region of interest (approximately 125, 115 
and 100 kDa) as well as two strong bands at approximately 55 and 50 kDa. 
Membrane B has been transformed with Quantity One software to aid visualisation 
of bands. 
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3.3.8  EDTA has no effect on the intensity of the 120-130 kDa band 
detected with IDE Ab 3 (ab28561). 
As previously described in Section 3.3.4, Ab 3 was tested to determine if the EDTA 
in the plasma samples influences the binding of Ab 3 to IDE.  The immunoblot which 
had been used for this purpose to test IDE Ab 2 was stripped of antibodies, and re-
probed using Ab 3 (Figure 3.10).  Results showed that there was no difference in 
protein band intensities between the control plasma sample and the samples 
containing EDTA up to 2.0 mg/mL. 
 
  
Figure 3.10  Investigating whether EDTA in blood samples interferes with Ab 3 
(Ab28561) detection of putative IDE protein bands. The Western blot run for the 
purpose of investigating Ab 2 in the same manner (see Fig. 3.6) was stripped and re-
probed with IDE antibody Ab 3 (ab28561) as detailed in Sections 2.2.4.5 and 2.2.4.4.  
Plasma sample (S1) contains 1μL plasma/lane in duplicate. The rrIDE lane contains 
50ng protein.  The plasma samples had been spiked with EDTA to 1.0, 1.5 and 
2.0mg/mL.  Results show no significant difference between band intensities of 
control plasma samples and samples spiked with EDTA, when detected with Ab 3. 
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3.3.9  Ab 3 (ab28561) cross-reacts with BSA, HSA and a non-albumin 
containing blocking agent. 
As both monoclonal and polyclonal IDE antibodies have previously been reported to 
cross-react with other proteins (Yfanti, et al., 2008), and results on Ab 2 (LS-C55007) 
from the current project show cross-reactivity with HSA and BSA (refer to Section 
3.3.5), Ab 3 (ab28561) was also tested (Figure 3.11(A)).  The amounts loaded onto 
the gel were 30 µg and 60 µg which reflected physiological albumin levels found in 
the plasma volumes normally loaded onto the gels (1 µL/lane).  The results showed 
that Ab 3 strongly cross-reacts with BSA in a dose-dependent manner, with bands 
visible at 40, 38 and 20 kDa in the 60 µg lane, and only the 40 and 20 kDa bands 
visible in the 30 µg BSA lane. With HSA, weak signals were detected at ~ 50 and 36 
kDa at 60 µg HSA, but not at 36 kDa in the 30 µg HSA lane.  In addition, no extra 
bands were observed when 60 µg HSA was spiked with either rrIDE or rhIDE.  It 
should be noted that the quantity of rhIDE used was approximately 20-fold the 
rrIDE quantity; as the rhIDE was past its expiry date, it was used in excess in case 
there had been significant protein degradation.  As this was not a test requiring 
quantification of the IDE, this excessive use of rhIDE was determined to be of no 
consequence. 
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Figure 3.11(A)  Test of cross-reactivity of IDE Ab 3 with HSA and BSA.  Purified HSA, 
BSA, and HSA spiked with recombinant rat (rrIDE) or human IDE (rhIDE) were 
resolved by SDS-PAGE and probed with primary antibody (Ab 3) ab28561 as 
detailed in Sections 2.2.4.8, 2.2.4.1 and 2.2.4.4.  HSA and BSA lanes contained 30 or 
60 μg protein, in duplicate.  HSA + rrIDE, or rhIDE, contained 60 μg HSA + 8 ng rrIDE, 
or 175.2ng rhIDE, respectively, in duplicate.  Results show that the antibody cross-
reacts with BSA at levels that would be found in plasma volumes frequently loaded 
onto gels, with strong bands appearing at ~ 40 and 20kDa and light bands at ~ 
38kDa only in 60μg lanes. Signals appear to be dose responsive.  HSA also appeared 
to be detected weakly at ~ 50 and 36kDa. 
 
To investigate further whether IDE Ab 3 may cross-react with other blocking agents 
which did not contain albumin, ECL™ Advance Blocking Reagent was tested.  Due to 
proprietary restrictions, it was not possible to determine the components present 
in the ECL™ blocking agent or their respective physiological concentrations; 
however it was stated by the manufacturer that the preparation should not contain 
albumin or globulin.  The preparation was primarily produced from bovine milk 
powder and therefore would be expected to contain milk proteins such as casein 
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and other whey proteins.  The ECL™ blocking agent was tested for Ab 3 cross-
reactivity at concentrations up to 60 mg/mL (Figure 3.11(B)).  The results show that 
Ab 3 can cross-react with ECL™ blocking agent at 30-60 mg/mL, with bands at 
approximately 55 kDa, however no bands were visible at 15 mg/mL.  The signal 
detected was dose-responsive. 
 
  
Figure 3.11(B)  Test of cross-reactivity of IDE antibody Ab 3 with BSA and ECL™ 
Advance Blocking Reagent.  BSA and ECL lanes contain 15, 30 and 60 μg protein 
each in duplicate.  The recombinant rat IDE (rrIDE) lane contains 7.5 ng.  Experiment 
was performed as detailed in Sections 2.2.4.9, 2.2.4.1 and 2.2.4.4.  Results show 
that the antibody cross-reacts with BSA at levels equivalent to albumin in the 
physiological range of human plasma, with bands at 40kDa (30-60 μg) and 20kDa 
(60 μg).  The signal appears to be dose-responsive.  Similarly, the ECL block is also 
cross-reactive with bands appearing at 55kDa (for 30-60 μg).  No signal was 
detected for either BSA or ECL at 15 μg at this exposure.  
 
As there was no signal present in the expected 100-130 kDa range for HSA, BSA or 
ECL™ Blocking Reagent, it was concluded that Ab 3 may still be suitable for the 
measurement of plasma IDE by Western immunoblotting.  However, the cross-
reactivity observed may have implications for the detection of IDE in other 
immunoaffinity-based applications. 
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3.3.10  Immunoprecipitation of IDE from human plasma. 
As IDE Ab 3 (ab28561) binds non-specifically with other proteins in human plasma, 
it is likely that one or more of the bands seen in Western immunoblotting are non-
specific.  To reduce the number of confounding factors in the sample, and to 
improve determination of the bands of interest, an immunoprecipitation (IP) 
method was trialled using Protein G-coupled magnetic sepharose beads, with yet 
another polyclonal IDE antibody (Figure 3.12(A)).  The IP antibody was raised in 
mouse against a synthetic peptide derived from the N-terminus of human IDE, and 
designated Ab 4 (250706).  As such, Ab 4 would not be expected to capture the 
truncated isoform of IDE as it does not contain the N-terminal half.  The 
immunoprecipitated samples were resolved by SDS-PAGE and detected on Western 
blots using Ab 3 (ab28561).  Results showed that the recovery of purified rrIDE was 
poor (under the conditions employed) with only approximately 14% of the protein 
recovered after immunoprecipitation with this protocol and antibody.  Numerous 
bands were still observed after both albumin depletion (including pre-clearing of 
immunoglobulins) and immunoprecipitation of plasma.  However, in the region of 
interest (approximately 100-130 kDa) only one band was clearly visible after either 
albumin depletion and/or immunoprecipitation, although this band was less intense 
than in the plasma control which had only 25% of the plasma content used in the 
IP.  This band was determined to be approximately 120-130 kDa.  In addition, the 
band at 160 kDa in plasma was not observed after IP, and the 70 kDa band was 
significantly reduced.  The 80 kDa band observed in plasma however, was still 
present after albumin depletion and/or IP.  It was concluded that the 160 and 70 
kDa bands were non-specific, whereas the 120-130 kDa band appears to be specific.  
Interestingly, the 80 kDa band also appears to be specific, however analysis of this 
band is outside the scope of this project. Nevertheless, it may be worth 
characterising this 80 kDa band in future studies.  
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Figure 3.12(A)  Immunoprecipitation of IDE from human plasma using IDE mouse 
polyclonal Ab 4 (250706).  IDE was immunoprecipitated from pooled plasma (PCP), 
albumin-depleted PCP (AD) and recombinant rat IDE (rrIDE) samples, using IDE Ab 4 
(250706) and probed with IDE Ab 3 (ab28561) as detailed in Sections 2.2.4.16, 
2.2.4.1 and 2.2.4.4.  PCP was pre-cleared of IgG, and albumin-depleted with 
antibody AL-01, prior to IP (see Sections 2.2.4.13 and 2.2.4.14).  PCP lanes contain 1 
μL/lane in duplicate.  IP from PCP used 4μL of plasma/sample (per lane), run in 
duplicate, and rrIDE lanes contain 50ng or equivalent/lane in duplicate.  AD lanes 
contain 1, 0.5, and 0.25 μL plasma/lane as indicated.  An extra band appears at just 
over 50kDa in the rrIDE IP, suggesting cross-reactivity of Ab 3 or the secondary 
antibody to the heavy chain of the eluted IP antibody.  Blot A. (lower image) has 
been transformed with Quantity One software to aid visualisation of upper band. 
 
A further IP experiment was performed using the same protocol, to test a second 
polyclonal IDE antibody designated Ab 5 (AF2496) (Figure 3.12(B)).  Ab 5 was raised 
in goat against full-length human recombinant IDE.  Using a full-length protein as an 
immunogen for generating an antibody is likely to result in conformational 
epitopes, thus the antibody is more likely to recognise the native protein, and may 
be more sensitive in an IP in which IDE has not been denatured or reduced.  One 
rhIDE sample was pre-incubated with Aβ42, and immunoprecipitated, to determine 
if binding between these proteins was resistant to the IP procedure (as well as the 
denaturing and reducing conditions) which would lead to an upward shift in 
molecular weight.  Immunoprecipitated samples were subsequently resolved by 
SDS-PAGE and immunoblotted using Ab 3 (ab28561).  Results showed that Ab 5 
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produced similar results to those obtained using Ab 4, with clear bands apparent at 
120-130 and 80 kDa.  No bands were observed at 160 kDa, and the 70 kDa band 
previously observed with Ab 4 was very faint and only seen in PCP, and not in the 
AD PCP.  Ab 5 detected very weak bands in the rrIDE lanes compared with rhIDE 
lanes.  No shift in molecular weight was observed in the Aβ42-spiked rhIDE 
compared with rhIDE alone, however the bands were fainter.  AD PCP IP bands at 
120-130 kDa were also fainter than PCP IP bands.  Overall it appears that the 120-
130 kDa and the 80 kDa bands in human plasma are specific, while it is unlikely that 
the 160 kDa or 70 kDa bands are IDE.  
 
 
 
Figure 3.12(B)  Immunoprecipitation of IDE from human plasma using IDE 
antibody Ab 5 (AF2496).  IDE immunoprecipitation was carried out from pooled 
plasma (PCP), albumin-depleted PCP (AD), recombinant rat IDE (rrIDE) and 
recombinant human IDE (rhIDE) using polyclonal IDE AF2496 as detailed in Sections 
2.2.4.16, 2.2.4.1 and 2.2.4.4.  Following SDS-PAGE and Western blotting, blots were 
probed with IDE ab28561 (Ab 3).  Image A(2) is a longer exposure of Blot A.  The 
two right lanes contain 50ng rhIDE + 9μg beta-amyloid 42 (Aβ42).  For AD, PCP 
samples were pre-cleared of IgG and albumin-depleted with antibody AL-01, prior 
to IP (see Sections 2.2.4.13 and 2.2.4.14).  IP PCP and AD samples originally used 
2μL of plasma per lane in duplicate, and rrIDE/rhIDE and rhIDE+Aβ42 lanes contain 
50ng or equivalent of IDE per lane in duplicate. Bands lower than 60kDa in all lanes 
are contaminated with the immunoprecipitating antibody fragments which were 
eluted with the sample.  At 3 min exposure, rhIDE is detected at 118kDa, no visible 
bands for rrIDE (Blot A).  At 10 min exposure, the rrIDE bands are faintly visible at 
118kDa (Blot A(2)). 
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3.3.11  Pre-incubation immunising peptide blocking test on IDE 
antibody Ab 3 (ab28561) for specificity. 
To determine the specificity of the bands detected by Western immunoblotting 
with Ab 3, a blocking test involving pre-incubation with the immunising peptide was 
performed (similar to the test performed with Ab 1 and 2, in Sections 3.3.1 and 
3.3.6) using a commercial peptide which was the Ab 3 immunogen (Figure 3.13).  
The results were difficult to interpret as the immunising peptide increased the 
background of the immunoblot and this caused difficulties in visualisation of the 
bands.  However, despite this issue, it was still possible to observe a reduction in 
band intensity for rrIDE, the major band in rat liver at 115 kDa and an 80 kDa band 
in zebrafish brain.  It also appeared that the upper two bands in plasma 
disappeared with the peptide pre-immunisation (120-30 and 160 kDa), as did the 95 
and 50 kDa bands in zebrafish brain.  Figure 3.13 was transformed by Quantity One 
software to maximise the signal to noise ratio and shows no bands visible in these 
regions.  Densitometric analysis of the 120-130 kDa band shows a reduction of 97% 
in the absorbed sample (antibody neutralised with 5 μg peptide).  The band in 
plasma at 115 kDa conversely, appears to be stronger after peptide pre-
immunisation.  These results support the results obtained by the IP experiments 
which suggest that the band observed at 120-130 kDa after immunoblotting with 
Ab 3 is IDE.  In addition, IDE has been demonstrated to be 110 kDa in rat liver in 
previous studies, and Ab 3 specifically detects a band at a similar molecular weight, 
lending further support to the likelihood that this antibody detects full-length IDE in 
human plasma.  Interestingly, Ab 3 also appeared to detect IDE at different 
molecular weights in zebrafish brain (50, 80 and 95 kDa) indicating different 
isoforms may be present in this species, however further characterisation of these 
bands is outside the scope of this project. 
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Figure 3.13  Testing IDE Ab 3 (ab28561) specificity by blocking with the 
immunising peptide prior to adding to Western blots.  Pooled plasma (PCP), 
recombinant rat IDE (rrIDE), rat liver and zebrafish brain (ZF) samples were run on 
SDS-PAGE and transferred to Western prior to being probed with IDE ab28561, 
some of which had been blocked prior to incubation with a commercial peptide 
identical to the immunogen (0, 5 and 40μg peptide/blot).  The test was performed 
as detailed in Sections 2.2.4.12, 2.2.4.1 and 2.2.4.4.  PCP: 1 μL plasma per lane.  
rrIDE: 25 ng per lane.  Rat liver: 31.6 μg total protein/lane and ZF brain: 25 μg total 
protein/lane.  Due to high background, the images were enhanced to optimize the 
signal to noise ratio, to assist in visualising bands. 
 
 
3.3.12  Measurement of the 120-130 kDa band in plasma samples 
obtained from the AIBL cohort at baseline 
The samples were resolved by SDS-PAGE (under reducing conditions), transferred 
to Western blots, and immunoblotting was performed using Ab 2 (LS-C55007).  
However, as this antibody subsequently failed the immunising peptide blocking 
test, it could not be determined if the bands seen with this IDE antibody were 
specific (Section 3.3.6).  Therefore, the immunoblots were stripped and re-probed 
using Ab 3 (ab28561) (example Figure 3.14).  The band observed at 120-130 kDa 
was determined to be IDE and quantified using Quantity One software.  Pooled 
control plasma (PCP) was used as an internal standard on each gel to control for 
gel-to-gel and blot-to-blot variation.  The blots were Ponceau S stained after re-
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stripping and prior to immunoblotting (or Coomassie stained following 
immunoblotting and subsequent re-stripping) to ensure equal loading. 
 
 
Figure 3.14  120-130 kDa band measured in human plasma samples obtained from 
the AIBL cohort (Ab 3).  Example Western blot of 5 individual AIBL samples, 
including pooled control plasma as an internal standard (PCP) and recombinant rat 
IDE (rrIDE) as a positive control (Figure A.).  SDS-PAGE and immunoblotting were 
performed as detailed in Sections 2.2.4.1 and 2.2.4.4.  Plasma samples including 
PCP (1 μL/lane) were loaded in duplicate, rrIDE (100 ng/lane) was also loaded in 
duplicate as a positive control.  Antibody used here was Ab 3, (ab 28561).  Results 
show differences in band intensities between individual samples.  Figure B. 
Coomassie stain of membrane as loading control.   
 
3.3.13  Low-level data analysis. 
Results were considered to be semi-quantitative.  Raw data were normalised for 
inter-gel variation by adjusting to the PCP internal control included on each gel.  
Coefficient of variation (CV) values of duplicates which were >15% were excluded 
from the analysis.  If the CV of the PCP duplicates was >15%, the entire gel was 
excluded from the analysis.  Data points determined to be outliers were removed 
from the analysis (n = 2). 
The overall data were observed to have a non-normal distribution (Figure 3.15(A), 
Table 3.1), therefore it was transformed by square root (Figure 3.15(B), Table 3.1).  
The transformation improved the normality issues, determined by inspecting the 
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frequency histogram, and with the z-score for skewness being <1.96.  There were 
still some normality issues after transformation determined by the z-score for 
kurtosis of 2.189 (absolute value), and significant p-values for the Kolmogorov-
Smirnoff (K-S) and Shapiro-Wilk (S-W) tests.  However the z-score was very close to 
the cut-off point of 1.96 indicating that the normality issues were minimal.  In 
addition, the K-S and S-W tests are very sensitive to sample size, and as it was 
reasonably large, it would be expected to show significance even with minimal 
normality issues.  Furthermore, when the data was stratified by classification, the 
healthy control group particularly, demonstrated non-normal distribution prior to 
transformation (Figures 3.16(A)(B)(C), Table 3.2), while after transformation the z-
scores for both skewness and kurtosis were below the cut-off point of 1.96 for all 
classifications, indicating normality (Figures 3.17(A)(B)(C), Table 3.3).  While there 
still seemed to be minor normality issues for healthy controls only, as evidenced by 
significant K-S and S-W tests, the frequency histogram was a normal shape after 
transformation.  Therefore the normality issues after transformation were 
determined to be within acceptable limits and parametric tests were used to 
analyse the data for differences between classification and APOE4 genotype status 
(ANOVA (with Tukey HSD post-hoc tests) and Student’s t-tests).  However, as 
existing biochemical data had non-normal distribution also, the non-parametric 
Spearman’s Rho test was used to analyse correlations. 
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Figure 3.15(A)  Frequency histogram of overall data (IDE levels measured by 
Western immunoblotting) before transformation.  Band intensity results for the 
IDE Western blot (WB) results (untransformed).  Histogram shows a positive skew of 
the data, indicating non-normal distribution (n = 157). 
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Figure 3.15(B)  Frequency histogram of overall data (IDE levels measured by 
Western immunoblotting) after square root transformation.  Band intensity 
results for the IDE Western blot (WB) results transformed to square root, outliers 
removed (n = 2).  Histogram shows the data is improved after transformation by 
square root and following the removal of two outliers (n = 155), indicating a more 
normal distribution. 
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Table 3.1  Values of skewness, kurtosis, Kolmogorov-Smirnoff (K-S) and Shapiro-
Wilk (S-W) tests of distribution normality in the overall data before and after 
square root transformation.  Values prior to transformation indicate non-normal 
distribution; after transformation skewness and kurtosis values are within 
acceptable limits regardless of significant p-values for the K-S and S-W tests (n = 
157/155). 
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Figures 3.16 (A)(B)(C)  Frequency histograms of data (IDE levels measured by Western immunoblotting (WB)) stratified by classification (HC, 
MCI, AD, respectively) before transformation.  Histograms show the data is positively skewed in all classifications, indicating a deviation from 
normal distribution. 
 
 
A. B. C. 
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Table 3.2  Values of skewness, kurtosis, Kolmogorov-Smirnoff (K-S) and Shapiro-
Wilk (S-W) tests of distribution normality in the data before transformation.  
Values prior to transformation indicate non-normal distribution in the HC and AD 
data, MCI data is within acceptable limits. 
 
 
 
Table 3.3  Values of skewness, kurtosis, Kolmogorov-Smirnoff (K-S) and Shapiro-
Wilk (S-W) tests of distribution normality in the data after transformation by 
square root.  Values after transformation by square root and removal of 2 outliers 
indicate normal distribution in the MCI and AD data.  Values for skewness and 
kurtosis for HC data indicate normality, however the K-S and S-W tests still indicate 
some deviation from normality. 
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Figures 3.17 (A)(B)(C)  Frequency histograms of data (IDE levels measured by Western immunoblotting) stratified by classification (HC, MCI, 
AD, respectively) after transformation by square root.  Histograms show the data is improved after transformation (and removal of 2 outliers) 
in all classifications, particularly in the HC data, indicating a more normal distribution. 
 
 
A. B. C. 
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3.3.14  Full-length plasma IDE levels are increased in MCI compared with 
HC in the total cohort. 
To determine IDE levels according to cognitive status, the cohort was divided into the 
clinically classified groups, healthy controls (HC - including subjective memory 
complainers), mild cognitive impairment (MCI) and probable AD (AD). As only a subset 
of the cohort was used, the HC and SMC groups were combined to form the healthy 
control group.  Mean age was significantly different between the groups.  It should be 
noted that the subset of samples used to measure IDE levels by Western 
immunoblotting was different from the subsets subsequently used to measure IDE 
levels by ELISA and IDE activity (detailed in Chapters 4 and 5, respectively).  This is 
because all samples in the cohort were initially going to be assayed, however due to 
the time-frame required for optimisation of the procedures, the whole cohort was not 
able to be completed. 
The demographics for this subset of the AIBL cohort are shown in Table 3.4.  AD and 
MCI patients were significantly older than the HC group.  As expected, AD patients had 
a significantly higher percentage of APOE ε4 carriers and brain Aβ load than the control 
or MCI groups.  Plasma Aβ1-42 was significantly decreased in the AD group compared 
with MCI and HC groups.  For Aβx-40, the MCI group had significantly higher levels 
compared with controls, with the AD group having levels in between MCI and HC 
groups.  Levels of ApoE4 were significantly decreased in the MCI group compared with 
HC and AD, and estradiol was significantly reduced in MCI and AD groups 
(HC>MCI>AD).  All other variables were not significantly different between 
classifications. 
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Table 3.4  Demographics of the AIBL cohort subset used for the Western 
immunoblotting IDE analysis.  Plasma samples (1.0 μL per well in duplicate) from the 
AIBL cohort were measured by Western immunoblotting as detailed in Sections 2.2.4.1 
and 2.2.4.4.  Other variables were measured as outlined in Section 2.2.2.1.  Full-length 
plasma IDE level data underwent square root transformation; the remainder of the 
variables are not transformed.  Continuous variables are expressed as mean (median) ± 
standard deviation.  P values determined by Kruskall-Wallis tests using the Monte 
Carlo method (untransformed) or one-way analysis of variance (transformed).  As only 
a subset of the cohort was tested, the HC and subjective memory (SMC) groups were 
combined to provide the healthy controls for this assay.  As ApoE4 is only expressed in 
individuals carrying the APOE ε4 allele, the n-values are reduced for this variable.  As 
only a subset of the cohort were measured with Pib-PET (for Neocortical SUVR – Brain 
Aβ load), n-values are reduced for this variable. 
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Full-length IDE levels as determined by Western immunoblotting (Figure 3.18) were 
found to be significantly higher in MCI individuals when compared with HC subjects (p 
= 0.037).  IDE levels in MCI individuals were also higher than in AD patients, however 
this did not reach significance (p = 0.054 – a significant difference for all results 
requires p ≤ 0.05).  There was no significant difference between the HC and AD groups. 
 
 
Figure 3.18  Levels of full-length plasma IDE are increased in MCI compared with HC 
and AD.  Plasma samples (60 μg/ lane total protein in duplicate) from the AIBL cohort 
were resolved by 10% SDS-PAGE, transferred to Western blots and probed for full-
length IDE as described in Sections 2.2.4.1 and 2.2.4.4, the antibody used was Ab 3 (Ab 
28561). The average optical density of the duplicate bands was obtained for each 
sample, and the mean of these values was compared by ANOVA with Tukey post-hoc 
analysis.  Data represents mean ± SEM ,n = 155 (90 HC/25 MCI/40 AD).  Results show 
IDE levels in MCI are significantly increased compared with HC (p = 0.037) and trended 
towards an increase in levels compared with AD (p = 0.054). 
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3.3.15  Full-length plasma IDE levels are increased in females with MCI 
compared with HC and AD 
Further analysis revealed a significant difference in IDE levels between males and 
females (p = 0.000), with females having higher levels of full-length IDE than males 
(Figure 3.19).  Therefore, the data was subsequently analysed by classification 
separately for males and females (Figure 3.20).  The results show that the significant 
difference seen in the MCI group compared with the HC group is only demonstrated in 
females (p = 0.014).  In addition, the difference between the female MCI and AD 
groups was also highly significant (p = 0.008).  When analysing the data for the male 
participants only, no significant difference between classifications was observed. 
 
 
Figure 3.19  Full-length plasma IDE is higher in females compared with males.  Plasma 
samples (60 μg/lane total protein in duplicate) were resolved by 10% SDS-PAGE, 
transferred to Western blots and probed for  IDE as described in Sections 2.2.4.1 and 
2.2.4.4,  the antibody used was Ab 3, (Ab 28561). The average optical density of 
duplicate bands was obtained for each sample, and the mean of these values was 
compared by Students T-test.  Data represents mean ± SEM, n = 155 (62 M/93 F).  
Results show that full-length plasma IDE is significantly higher in females compared 
with males (p = 0.000). 
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Figure 3.20  Full-length plasma IDE levels are increased in MCI compared with HC and 
AD in females only.  Plasma samples (60 μg/lane total protein in duplicate) were 
resolved by 10% SDS-PAGE, transferred to Western blots and probed for full-length IDE 
as described in Sections 2.2.4.1 and 2.2.4.4, using Ab 3.  The average optical density of 
the duplicate bands was obtained for each sample, and the mean of these values was 
compared by ANOVA with Tukey post-hoc analysis.  Data represents mean ± SEM, n = 
155 (HC-38 M/52 F, MCI-13 M/12 F, AD-11 M/29 F).  Results show that full-length 
plasma IDE is significantly increased in female MCI individuals compared with both 
female HC (p = 0.014) and female AD (p = 0.008) participants.  In addition, IDE is 
significantly higher in females compared with males in both the HC (p = 0.008) and the 
MCI (p = 0.001) groups but not in the AD group (p = 0.190). 
 
 
3.3.16  Levels of full-length plasma IDE do not differ in APOE ε4 carriers 
compared with non-carriers. 
As the APOE ε4 genotype is considered a risk factor for AD, and it has been reported 
that levels of IDE are reduced in neurons exposed to the ApoE4 protein in vitro (Du, et 
al., 2009), the data was analysed to see if there was any difference between full-length 
plasma IDE in individuals carrying the ε4 allele compared to non-carriers (Figure 3.21 
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(A)).  The results show that there was no significant difference in plasma full-length IDE 
levels between ε4 carriers and non-carriers, for the data overall (p = 0.183)  When 
stratified by ε4 status, a similar pattern was seen by classification as in the overall 
subset, however the increase in IDE levels in the MCI group was no longer significant 
for either ε4 carriers (p = 0.128) or non-carriers (p = 0.271)(Figure 3.21(B) and (C), 
respectively). 
 
 
 
Figure 3.21(A)  Full-length plasma IDE levels are no different in ε4 non-carriers 
compared with carriers.  Plasma samples (60 μg/lane total protein in duplicate) were 
resolved by 10% SDS-PAGE, transferred to Western blots and probed for full-length IDE 
as described in Sections 2.2.4.1 and 2.2.4.4, using Ab 3.  The average optical density of 
the duplicate bands was obtained for each sample, and the mean of these values was 
compared by Students T-test.  Data represents mean ± SEM ,n = 152 (54 ε4/98 non-
ε4).  Results show that there is no significant difference in full-length plasma IDE levels 
for ε4 non-carriers compared with carriers (p = 0.183). 
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Figure 3.21(B) and (C)  Full-length plasma IDE levels are not significantly different by 
clinical classification for ε4 non-carriers or carriers.  Plasma samples (60 μg/lane total 
protein in duplicate) were resolved by 10% SDS-PAGE, transferred to Western blots 
and probed for full-length IDE as described in Sections 2.2.4.1 and 2.2.4.4, using Ab 3.  
The average optical density of the duplicate bands was obtained for each sample, and 
the mean of these values was compared by Students T-test.  Data represents mean ± 
SEM, (ε4 carriers) n = 54 (25 HC/10 MCI/19AD), (non-carriers) n = 98 (64 HC/15 MCI/19 
AD).  Results show that there is no significant difference in full-length plasma IDE levels 
by clinical classification for either ε4 carriers (p = 0.128) or non-carriers (p = 0.271). 
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When the overall data is controlled for gender, similar results are observed between 
classifications, with the MCI group having significantly higher full-length IDE levels than 
controls (p = 0.026), but with levels in the MCI group being significantly higher than the 
AD group as well (p = 0.040).  As age has also been shown to be significantly different 
between the groups in this subset (p = 0.013), this was also controlled for along with 
gender, and results showed the same trend: MCI subjects have significantly higher IDE 
levels than both HC (p = 0.010) and AD (p = 0.014).  Even though there were no 
significant differences in IDE levels in ε4 carriers versus non-carriers, the ε4 status has 
the potential to affect the levels of IDE in plasma, and controlling for this as well as 
gender and age strengthened this trend with the MCI group again having significantly 
higher levels than both HC (p =0.004) and AD (p = 0.006) (Figure 3.22).  Conversely 
when analysing full-length IDE levels by ε4 status, no effect of covariates was observed 
demonstrating no significant differences between carriers and non-carriers (data not 
shown). 
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Figure 3.22  Full-length plasma IDE levels are significantly increased in MCI compared 
with HC and AD.  Plasma samples (60 μg/lane total protein in duplicate) were resolved 
by 10% SDS-PAGE, transferred to Western blots and probed for full-length IDE as 
described in Sections 2.2.4.1 and 2.2.4.4, using Ab 3.  The average optical density of 
the duplicate bands was obtained for each sample, and the mean of these values was 
compared by ANCOVA.  Data represents mean ± SEM, n = 152 (89 HC/25 MCI/38 AD).  
Data is controlled for gender, age and APOE ε4 status.  Results show that full-length 
plasma IDE levels are significantly higher in the MCI group compared with the HC (p = 
0.004) and AD (p = 0.006) groups. 
 
3.3.17  Relationships between total plasma IDE levels and other 
biochemical data collected in the AIBL study. 
To determine if there were any relationships between plasma levels of full-length IDE 
and other biochemical data collected as part of the AIBL study, correlation analyses 
were performed.  Details of the methods used to measure the variables other than IDE 
are outlined in Section 2.2.2.1.  As full-length IDE was shown to differ by gender in the 
current study, it was included in the correlation analyses.  Plasma IDE was also 
analysed for any correlation with age as it has been reported that expression of IDE 
shows an age-dependent reduction in the brain (Caccamo, et al., 2005).  Plasma 
insulin, Aβ40 and Aβ42 (and N-terminally truncated fragments), and total ApoE and 
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ApoE4 were analysed for correlations with IDE, as both insulin and Aβ are substrates of 
IDE and ApoE has been associated with reduced IDE expression (Cook, et al., 2003; Du, 
et al., 2009).  The levels of testosterone, estradiol and cholesterol (plus LDL/HDL 
subfractions) were also examined for correlation with full-length IDE levels, as these 
have also been associated with changes in IDE expression (Udrisar, et al., 2005; 
Sharma, et al., 2008).  Furthermore, full-length plasma IDE levels were also compared 
with brain Aβ load to see if any correlation exists between these two variables. 
Results showed that in the whole subset (Table 3.2), and in addition to a positive 
correlation with gender (rs = .282, p = 0.000), only total and free testosterone 
negatively correlated with full-length plasma IDE, however these associations were 
weak [(rs = -.235, p = 0.004) and (rs = -.255, p = 0.001), respectively].  Oestradiol, the 
predominant female sex hormone, almost reached significance (rs = -.173, p = 0.053), 
however the association was again weak.  No other variables correlated with plasma 
full-length IDE.  After Bonferroni-Holm correction for multiple testing (Holm, 1979), 
only gender (p = 0.000) and free testosterone (p = 0.017) were still significant although 
total testosterone also showed a trend towards significance (p = 0.064). 
As both testosterone and oestradiol both significantly correlate with gender and with 
each other, males and females were analysed separately to see if the relationship 
between full-length plasma IDE with these variables was due to the effect of gender 
(Tables 3.3(A) and (B)).  The results showed that these correlations were not significant 
when males and females were analysed separately.  No correlations between plasma 
IDE and the remaining biochemical variables were observed when the genders were 
analysed separately, however in males insulin approached significance for a negative 
association (rs = -.239, p = 0.064). 
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Table 3.2  Correlation matrix of full-length plasma IDE levels with other variables.  
Plasma levels of full-length IDE were analysed for relationships with sex, age, and 
plasma insulin, Aβ species, ApoE species, testosterone, oestradiol, lipids and brain Aβ 
load (two tailed) (methods of data collection are outlined in Section 2.2.2.1).  n values 
vary due to missing values for some data or in the case of brain Aβ load only a subset 
of the cohort underwent PiB-PET scans.  For ApoE4, n value is lower as only the APOE 
ε4 carriers express this isoform.  Results show a significant but weak correlation exists 
between IDE levels and both sex (rs = .282, p = .000), total testosterone (rs = -.235, p = 
.004) and free testosterone (rs = -.282, p = 0.001).  Oestradiol approached a weak 
correlation however did not reach significance (rs = -.173, p = 0.053).  Only sex (gender) 
and free testosterone remained significant following Bonferroni-Holm correction for 
multiple testing.  * indicates significance at the 0.05 level, ** indicates significance at 
the 0.01 level.  (“unadj.” = unadjusted, prior to Bonferroni-Holm correction, “adj.” = 
adjusted by Bonferroni-Holm correction).   
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Tables 3.3 (A)  Correlation matrix of full-length plasma IDE levels with other 
biochemical variables (males only).  Table 3.3 (A) shows correlation analysis of full-
length plasma IDE with age, and plasma insulin, Aβ species, ApoE species, 
testosterone, oestradiol, lipids and brain Aβ load (two tailed).  Methods of data 
collection are outlined in Section 2.2.2.1.  n values vary due to missing values for some 
data or in the case of brain Aβ load only a subset of the cohort underwent PiB-PET 
scans.  For ApoE4, n value is lower as only the APOE ε4 carriers express this isoform.  
Results show that insulin demonstrates a trend toward a negative correlation (rs = -
.239, p = 0.064), however there were no other significant correlations or trends in 
males.  
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Tables 3.3 (B)  Correlation matrix of full-length plasma IDE levels with other 
biochemical variables (females only).  Table 3.3 (B) shows correlation analysis of full-
length plasma IDE with age, and plasma insulin, Aβ species, ApoE species, 
testosterone, oestradiol, lipids and brain Aβ load (two tailed).  Methods of data 
collection are outlined in Section 2.2.2.1.  n values vary due to missing values for some 
data or in the case of brain Aβ load only a subset of the cohort underwent PiB-PET 
scans.  For ApoE4, n value is lower as only the APOE ε4 carriers express this isoform.  
Results show no significant correlations or trends in females.  
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When stratified by APOE ε4 status (Tables 3.4 (A) and (B)), for the non- ε4 carriers 
there were positive correlations observed between full-length IDE levels and sex (rs = 
.314, p = 0.002) and total ApoE (rs = .232, p = 0.021), and inverse correlations with Aβ1-
40 (rs = -.230, p = 0.023), total testosterone (rs = -.282, p = 0.006), free testosterone (rs = 
-.306, p = 0.002), oestradiol (rs = -.242, p = 0.034) and brain Aβ load (rs = -.401, p = 
0.019).  Following Bonferroni-Holm correction however, only gender (p = 0.036) and 
free testosterone (p = 0.034) remained significant.  For the ε4 carriers, no significant 
correlations were seen between full-length IDE and any of the variables tested. 
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Table 3.4 (A)  Correlation matrix of full-length plasma IDE levels with other variables 
for APOE ε4 non-carriers only.  Plasma levels of full-length IDE were analysed for 
relationships with sex, age, and plasma insulin, Aβ species, ApoE species, testosterone, 
oestradiol, lipids and brain Aβ load (two tailed) after stratifying data by APOE ε4 status 
(methods of data collection are outlined in Section 2.2.2.1).  n values vary due to 
missing values for some data or in the case of brain Aβ load only a subset of the cohort 
underwent PiB-PET scans.  For ApoE4, no values are shown as only the APOE ε4 
carriers express this isoform.  Results show significant positive correlations between 
IDE levels and sex (rs = .314, p = 0.002) and total ApoE (rs = .232, p = 0.021), and inverse 
correlations with Aβ1-40 (rs = -.230, p = 0.023), total testosterone (rs = -.282, p = 0.006), 
free testosterone (rs = -.306, p = 0.002), oestradiol (rs = -.242, p = 0.034) and brain Aβ 
load (rs = -.401, p = 0.019).  Only gender (p = 0.036) and free testosterone (0.034) 
remained significant following Bonferroni-Holm correction for multiple testing.  * 
indicates significance at the 0.05 level, ** indicates significance at the 0.01 level. 
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Table 3.4 (B)  Correlation matrix of full-length plasma IDE levels with other variables 
for APOE ε4 carriers only.  Plasma levels of full-length IDE were analysed for 
relationships with sex, age, and plasma insulin, Aβ species, ApoE species, testosterone, 
oestradiol, lipids and brain Aβ load (two tailed) after stratifying data by APOE ε4 status 
(methods of data collection are outlined in Section 2.2.2.1).  n values vary due to 
missing values for some data or in the case of brain Aβ load only a subset of the cohort 
underwent PiB-PET scans.  Results show no significant correlations between full-length 
plasma IDE and any other variables tested. 
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3.3.17.1  The ratio of full-length IDE to insulin is not significantly 
different between classifications. 
IDE has a high affinity for both insulin and Aβ and as a result they may compete for the 
enzyme in the circulation.  This does depend on a plethora of other factors such as 
binding affinities of these peptides (and other IDE substrates) for IDE, plasma levels of 
the free peptides (as opposed to those bound to other proteins), levels of other IDE 
substrates, levels of other enzymes that degrade one or both of these peptides (for 
example neprilysin, amongst others, can also degrade Aβ), binding/clearance by other 
tissues, and conformation of the peptides.  For many reasons, it is possible that the 
ratio of IDE to insulin in plasma may help to differentiate between HC and MCI and/or 
AD.  Therefore a ratio was calculated between the untransformed measurements of 
full-length plasma IDE and plasma insulin levels and compared between clinical 
classifications (Figure 3.23(A)).  The results showed no significant differences in the 
ratio of full-length IDE to insulin (p = 0.092), although the ratio tended to be a little 
higher in MCI compared with HC group.  It was concluded that there was no overall 
improvement when considering full-length IDE levels relative to insulin for 
differentiating between clinical classifications, compared with IDE alone. 
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Figure 3.23(A)  The ratio of full-length IDE to insulin is not significantly different 
between classifications.  Insulin levels were measured as outlined in Section 2.2.2.1.  
Plasma samples (60 μg/lane total protein in duplicate) were resolved by 10% SDS-
PAGE, transferred to Western blots and probed for full-length IDE as described in 
Sections 2.2.4.1 and 2.2.4.4, using Ab 3.  The average optical density of the duplicate 
bands was obtained for each sample, and a ratio was calculated of (untransformed) 
full-length plasma IDE to plasma insulin (IDE/Insulin ratio).  The median of these values 
were compared between classifications by a Kruskall-Wallis test.  Data represents 
medians with 95% confidence interval (CI), n = 153 (89 HC/25 MCI/39 AD).  Results 
show no significant differences in the IDE/insulin ratio between classifications (p = 
0.092).  
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3.3.17.2  The ratio of full-length IDE to total Aβ (42+40) tends to be 
higher in MCI compared with HC. 
Similarly to the IDE/insulin ratio, the levels of full-length IDE relative to the levels of 
Aβ1-42 and Aβ1-40 may be more informative with respect to differentiating between 
clinical classifications of AD and MCI with controls, than levels of IDE alone.  It has been 
demonstrated that plasma Aβ is generally elevated in early AD compared with controls 
and reduces as Aβ is deposited into SP in the brain (Kawarabayashi, et al., 2001; 
Schupf, et al., 2008), therefore the ratio of plasma IDE/Aβ levels may be pertinent in 
the prodromal stages of AD with respect to the regulation of plasma Aβ levels.  This 
may be reflected in the MCI group, which represents the pre-symptomatic period prior 
to full-blown AD symptoms becoming apparent.  Therefore, a ratio of plasma full-
length IDE with total levels of Aβ1-42 + Aβ1-40 were calculated and compared between 
clinical classifications (Figure 3.23(B)).  Results showed that the ratio of full-length 
IDE/Aβ42+40 demonstrated a trend toward an increase in MCI compared with HC, 
however did not quite reach significance (p = 0.052).  Similar to the IDE/insulin ratio, it 
was concluded that there were no benefits in considering IDE relative to Aβ42+40 
compared with IDE alone, for differentiating between clinical classifications. 
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Figure 3.23(B)  The ratio of full-length IDE to Aβ42+40 is not significantly different 
between classifications.  Aβ1-42 and Aβ1-40 levels were measured as outlined in Section 
2.2.2.1.  Plasma samples (60 μg/lane total protein in duplicate) were resolved by 10% 
SDS-PAGE, transferred to Western blots and probed for full-length IDE as described in 
Sections 2.2.4.1 and 2.2.4.4, using Ab 3.  The average optical density of the duplicate 
bands was obtained for each sample, and a ratio was calculated of (untransformed) 
full-length plasma IDE to plasma Aβ1-42 + Aβ1-40 (IDE/Aβ42+40 ratio).  The median of 
these values were compared between classifications by a Kruskall-Wallis test.  Data 
represents medians with 95% confidence interval (CI), n = 154 (90 HC/24 MCI/40 AD).  
Results show a trend towards MCI having higher full-length IDE/Aβ42+40 ratios than HC, 
however this did not reach significance (p = 0.052).  
149 
 
3.3.17.3  The ratio of full-length IDE to insulin + total Aβ42+40 is not 
different between clinical classifications. 
As both insulin and Aβ are competing substrates of IDE, it is possible that there is a 
combined effect of these which may affect their relationship with levels of full-length 
IDE.  The total levels of these substrates relative to IDE may therefore be able to 
differentiate between HC, MCI and AD better than the IDE/insulin or IDE/Aβ42+40 ratios 
alone.  Thus, to investigate this possibility, the values of plasma insulin (in mU/L) were 
converted to pg/mL and added to the values of Aβ1-42 + Aβ1-40, to give a total value of 
insulin+Aβ42+40 in pg/mL.  The ratio of full-length IDE to insulin+ Aβ42+40 was then 
analysed by clinical classification to determine if they could differentiate between MCI, 
AD and controls better than either IDE alone, the IDE/insulin ratio or the IDE/ Aβ42+40 
ratio (Figure 3.23(C)).  Results showed no significant differences in IDE/insulin+Aβ42+40 
ratio between clinical classifications (p = 0.171).  Hence, it was concluded that the ratio 
of full-length IDE with the combination of insulin and Aβ42+40 provided no additional 
benefits for differentiating between clinical classifications than levels of full-length IDE 
alone, the IDE/insulin ratio or the IDE/Aβ42+40 ratio.  
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Figure 3.23(C)  The ratio of full-length IDE to insulin + Aβ42+40 is not significantly 
different between classifications.  Aβ1-42 and Aβ1-40 levels were measured as outlined 
in Section 2.2.2.1.  Plasma samples (60 μg/lane total protein in duplicate) were 
resolved by 10% SDS-PAGE, transferred to Western blots and probed for full-length IDE 
as described in Sections 2.2.4.1 and 2.2.4.4, using Ab 3.  The average optical density of 
the duplicate bands was obtained for each sample, and a ratio was calculated of 
(untransformed) full-length plasma IDE to the combined values of plasma insulin + Aβ1-
42 + Aβ1-40 (IDE/insulin + Aβ42+40 ratio).  The median of these values were compared 
between classifications by a Kruskall-Wallis test.  Data represents medians with 95% 
confidence interval (CI), n = 154 (89 HC/24 MCI/39 AD).  Results show no difference 
between clinical classifications for the full-length IDE/insulin + Aβ42+40 ratio (p = 0.171).  
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3.4  Discussion 
The aim of this chapter was to optimise a Western immunoblotting protocol to be able 
to quantitate levels of full-length IDE in human plasma.  Using blood samples obtained 
from AIBL study participants, the test was used to determine if IDE levels differed in AD 
patients and MCI individuals compared with HC individuals, and to determine whether 
IDE levels were related to other AD-related genetic and biochemical factors. 
While most studies of IDE involve generating in-house antibodies for use, there are a 
number of commercially-available antibodies which have been used in the published 
literature.  At the commencement of this project, no other study had been undertaken 
on determining the levels of IDE in human plasma, therefore a number of 
commercially-available antibodies were screened for their suitability for this purpose.  
It was also important that the antibody used was able to measure levels of full-length 
IDE specifically, as truncated forms of IDE are not catalytically active. 
Human blood plasma is a complex mixture with many constituents, and as such can 
present difficulties when attempting to detect low-abundance proteins.  Non-specific 
cross-reactions may occur between the antibodies used and other proteins in the 
plasma, leading to false-positive results, or banding which is inconsistent with the 
published molecular weight of the protein of interest.  Non-specific binding of the 
antibody to other proteins may also reduce the availability of the antibody to bind to 
the target protein, therefore leading to reduced detection.  As such, it is necessary to 
determine specificity of the immune reaction when using methods such as Western 
immunoblotting to detect proteins in complex samples.  Data was collected in the 
current study on three polyclonal IDE antibodies (Ab 1, Ab 2 and Ab 3) to determine if 
bands observed in the region of interest are in fact IDE.  At the start of this study, there 
were no publications which had used these antibodies specifically for Western 
immunoblotting.  It was demonstrated that for the single band detected with Ab 1(a), 
approximately 50% of the immunoreactivity could be blocked by pre-incubation of the 
antibody with full-length recombinant IDE (not the immunizing peptide), suggesting 
that some of the signal observed was specific, and the single band observed at 105 kDa 
was of a molecular weight similar to that previously reported in numerous 
publications.  Therefore, it was likely that this band was indeed IDE.  However, only a 
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small quantity of full-length recombinant IDE was used as the blocking protein, rather 
than a peptide specific to the epitope to which the antibody binds, and this may be 
why the band was not completely absent.  In addition, 1.32 μg of full-length protein 
would have considerably fewer epitopes to block the binding sites of the IDE antibody 
than 1.32 μg of peptide specific to the paratope of the antibody.  It may be that 
prohibitively large quantities of full-length IDE are required to block all the paratopes 
to prevent binding to the band on the immunoblot. However, it cannot be ruled out 
that another protein can be detected non-specifically by Ab 1 at the same molecular 
weight. 
Subsequent batches of Ab 1 were unable to detect the same band in the plasma, and 
this may have been due to the antibody being sourced from a different bleed of the 
immunised animal, or even a different animal altogether.  Polyclonal antibodies are 
essentially a mixture of antibodies which bind to different epitopes within the region 
of the immunogen, and sometimes to other proteins altogether.  Batch to batch as 
well as bleed to bleed variation is not uncommon.  As the immunogen for Ab 1 was 
derived from rat, the antibody would be expected to detect the recombinant rat IDE.  
However, it is possible that Ab 1(b) (Batch 2) did not contain one or more of the 
antibodies that were present in Ab 1(a) (Batch 1) and part of the epitope in human IDE 
was altered enough to resist binding of the antibodies from Batch 2, either from an 
alteration in the sequence or some post-translational modification that may occur in 
the plasma (refer to Figure 3.20 - diagram of hypothetical mechanism).  Regardless, it 
was concluded that this antibody was unsuitable. 
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Figure 3.24  Hypothetical representation of potential mechanism of batch-to-batch variability in polyclonal antibodies.  Antibodies in 
different batches may recognise different epitopes within the same region of the antigenic protein.  Due to batch-to-batch variation in 
antibody generation, the presence of post-translational modifications can cause non-recognition of the protein leading to loss of binding by 
the antibody. 
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Ab 2 initially did not show immunoreactivity in the region of interest for IDE in 
plasma, but detected a large, band at approximately 45 kDa.  This band was excised 
and sent for mass-spectrometry analysis, however was not able to be identified due 
to albumin contamination (data not shown).  When testing purified rat IDE, the 
antibody detected a band at 118 kDa, which corresponds to the published 
molecular weight of full-length IDE in the UniProtKB database of 117.968 kDa.  This 
is slightly higher than most published studies which report IDE at 110 kDa.  After 
using extended development times or a more sensitive detection system, a band at 
115-120 kDa was observed as well as other bands at lower molecular weights of 
approximately 80, 70 and 45 kDa.  It was difficult to determine the exact molecular 
weight of the 115-120 kDa band as the difference between the 110 kDa and the 160 
kDa marker was only several millimetres wide.  Ideally, it would have been useful to 
run the gel for considerably longer to allow better resolution of the bands to 
improve the estimation of the molecular weight, or to use lower acrylamide 
content (8.5% gels, for example).  Alternatively, a different molecular weight 
marker could have been used which was more specific to the region of interest.  
Using the enhanced detection system (ECL™ Prime) with Ab 2 dramatically 
enhanced the background of the blots, although not enough to impair visualisation 
of the bands.  The background was subsequently minimised to an acceptable level 
by increasing the number of washing steps performed after the primary and 
secondary antibody incubations.  Although the 115-120 kDa band was slightly 
higher than the published molecular weight for IDE, it is possible that some post-
translational modifications may occur in plasma.  Another possibility considered 
was that IDE-Aβ binding was resistant to the denaturing and reducing conditions 
used in the SDS-PAGE (as suggested by Llovera, et al., 2008), increasing the 
molecular weight of the band by 4 kDa.  However, pre-incubation of purified Aβ and 
purified rat IDE did not produce an upward shift in molecular weight for Ab 3, 
suggesting that the denaturing and reducing conditions of SDS-PAGE was sufficient 
to dissociate any binding.  It should be noted that while this result was observed 
with purified protein, it cannot be ruled out that in a complex matrix such as 
plasma, other factors may affect the binding affinity of IDE to Aβ and the results 
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may not reflect what occurs in human plasma.  Plasma IDE may also bind to 
another, as yet unknown, peptide or protein.  
Strong cross-reactivity was noted with human serum albumin (HSA) and weakly 
with bovine serum albumin (BSA) using Ab 2, as well as with some of the molecular 
weight marker proteins.  However, none of these proteins were in the molecular 
weight region of interest, suggesting that Ab 2 may still be a valid antibody for the 
measurement of IDE in human plasma.  A blocking test using the immunising 
peptide was therefore performed to check specificity.  The results showed that Ab 2 
can detect purified IDE, as the purified IDE band disappeared from the Western blot 
when the primary antibody Ab 2 was blocked. However this was not the case with 
the bands seen in the plasma samples:  the non-specific binding of Ab 2 to other 
bands in the molecular weight region of interest indicated this antibody was not 
going to be suitable for the assay.  
A third IDE antibody was therefore screened for its suitability for measuring plasma 
IDE (Ab 3).  This purified rabbit polyclonal detected a band at approximately 110 
kDa in rat liver and human frontal cortex, as well as a band at 118 kDa for both 
purified rat and human IDE.  In human plasma, Ab 3 detected several bands of 
similar molecular weight to those detected by Ab 2; 120-130, 80 and 70 kDa, as well 
as the characteristic wide band at 50 kDa.  Using the enhanced detection system, 
other bands also became apparent in the plasma around the region of interest, at 
160 and 115 kDa, as well as several others in rat liver and human frontal cortex.  
While it is possible that these extra bands are simply due to non-specific binding, it 
is also possible that multiple isoforms of human IDE exist in plasma. 
Further analysis of Ab 3 showed strong cross-reactivity with BSA, and weak cross-
reactivity  with HSA, however the bands were not in the region of interest and not 
likely to impair visualisation of full-length IDE.  With BSA, the bands were visible at 
40 and 20 kDa, thus smaller than the reported molecular weight of BSA 
(approximately 66-67 kDa).  It is possible that these bands represent degraded 
fragments of BSA, as a BLAST (NCBI) protein search showed three regions of BSA 
which share sequence similarity with regions of the immunogen for Ab 3 
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(http://blast.ncbi.nlm.nih.gov/Blast.cgi, accessed 18th February, 2014).  
Interestingly, a study on BSA degradation demonstrated bands at 40 and 20 kDa (as 
well as some others) which correspond to the molecular weights observed in the 
current study (Estey, et al., 2006), however it should be noted that this degradation 
occurred as a result of acidic conditions and may not be relevant to our study.  Two 
regions in HSA also share sequence similarity with regions of the immunogen for Ab 
3, which may explain the cross-reactivity with HSA.  Alternatively, the bands seen 
may also represent contaminants of the BSA/HSA preparations.  Furthermore, 
when testing a commercial blocking agent composed primarily of bovine milk 
powder, Ab 3 again showed some cross-reactivity.  The company which produced 
this blocking agent stated that the blocking agent was unlikely to contain BSA or 
globulin, but instead contained milk proteins.  Interestingly, two other unrelated 
IDE antibodies have been reported to cross-react with fibrinogen, casein and 
thrombin, all of which are found in bovine milk (Yfanti, et al., 2008).  A BLAST 
comparison of sequences revealed one region of sequence similarity (to the 
immunogen used to produce Ab 3) with bovine fibrinogen (gamma chain), three 
regions in the alpha chain, and two in the beta chain 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi, accessed 18th February, 2014).  
Furthermore, three regions of bovine beta-casein, and one region of bovine 
prothrombin also showed sequence similarity.  However, human fibrinogen and 
beta-casein had no sequence similarity with the immunogen for Ab 3 but there 
were still two regions of similarity with human prothrombin.  Regardless, the bands 
observed were not in the region of interest and therefore would not interfere with 
the detection of full-length plasma IDE. 
As mentioned, co-incubation of purified recombinant Aβ with both purified 
recombinant rat and human IDE showed no shift in molecular weight of IDE 
detected with Ab 3 indicating that any binding between recombinant IDE and Aβ 
was dissociated by the denaturing and reducing conditions of the SDS-PAGE.  
However, it cannot be excluded that such binding observed with purified proteins 
and peptides may be quite different to that which occurs when the proteins are in 
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native form, and in their normal more complex environment, in this case – in 
plasma (Cavalcante Braga, et al., 2013).   
To remove some of the components of plasma which may be causing non-specific 
cross-reactivity with the antibody, and to clarify the band of interest, an 
immunoprecipitation (IP) procedure was performed with two separate IDE 
antibodies (Ab 4 and Ab 5).  The IP was performed with both unprocessed plasma 
and also plasma which had been pre-cleared of immunoglobulins and depleted of 
albumin.  The two antibodies produced a similar reaction pattern, with only one 
band remaining in the region of interest at 120-130 kDa.  Interestingly, the 80 kDa 
band persisted following IP, and it would be of value to investigate this band in the 
future.  However, within the scope of this project only the full-length isoform of IDE 
being the 120-130 kDa band was determined to be relevant. 
To investigate further the specificity of the 120-130 kDa band, an antibody blocking 
test using the immunising peptide was performed.  However, the blocking peptide 
significantly increased the background of the immunoblot; nevertheless, it could be 
seen that the band at 118 kDa from recombinant rat IDE was reduced dose-
dependently, as was the 115 kDa band in rat liver, and the 95 kDa band observed in 
zebrafish disappeared.  This indicated that the bands observed close to the region 
of interest in several different species and tissues were most likely IDE.  In plasma, 
the 160 and 120-30 kDa bands were not visible after peptide treatment, however 
the band at 115 kDa appeared to be stronger.  This would suggest that the band at 
120-130 was specifically IDE, in accordance with this band also persisting after IP 
with a different IDE antibody.  However, as the 115 kDa persisted after peptide 
blocking it could suggest that this band is not specific.  Interestingly, the 
observation that the 160 kDa band also was not visible after peptide blocking was 
not what was expected, as this band seemed to be absent following 
immunoprecipitation.  This would indicate that the band seen is specifically IDE.  As 
this band was considerably higher than the expected molecular weight of IDE, it 
may be part of a complex of proteins including IDE, which is resistant to denaturing 
and reducing conditions.  Unfortunately, investigating this band was outside of the 
scope of this project. 
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Our studies and other studies have found that different IDE antibodies detect 
different bands by Western blotting (Yfanti, et al., 2008).  There are a number of 
possible explanations for this.  Firstly, each of the three antibodies used were raised 
against a different size epitope of IDE, for example Ab 2 was raised to an 11 amino 
acid peptide, whereas Ab 3 was raised to an IDE sequence of over 150 amino acids, 
and secondly, the regions of the IDE sequence used were all different.  Thirdly, the 
immunogens were all synthetic, and it is not known how much of the immunogen 
sequences were in a secondary structure that would be similar to native or 
denatured IDE. Fourthly, synthetic proteins do not contain post-translational 
modifications which may be present on the native protein. 
Yet another factor which may have an effect on the reaction patterns seen in 
Western immunoblotting is the species from which the immunogen was sourced: 
the Ab 1 immunogen was a rat IDE sequence, whereas Ab 2 and 3 were raised 
against human IDE sequences.  The host in which the antibodies are raised can also 
be an issue; Ab 1 and 3 were raised in rabbits, whereas Ab 2 was raised in a goat.  
Regardless of this, however, even antibodies raised in the same type of host can 
vary from animal to animal and even from bleed to bleed, which is one major 
drawback of using polyclonal antibodies.  A recent study demonstrated that even 
the method of immunisation can produce highly variable results when it comes to 
antibody production (Brown, et al., 2011). 
Following preliminary testing, Ab 3 was chosen for the measurement of full-length 
IDE in human plasma: the antibody has a high affinity for recombinant human IDE, 
and it showed specificity on a number of different tissues from different species, 
including the 120-130 kDa band in human plasma.  Importantly, 
immunoprecipitation methods using two alternative IDE antibodies (Ab 4 and Ab 5) 
showed almost identical reaction patterns with the band at 120-130 kDa being the 
only remaining band to persist after IP in the region of interest.  Although results 
are not shown in this chapter, Ab 3 also showed specificity in an IDE activity assay 
using several inhibitors which will be discussed in Chapter 5.  Results from our 
group also previously demonstrated a reduction of the 110 and 80 kDa bands in an 
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IDE knock-down experiment in zebrafish, using Ab 3 for the immunoblotting (Chen, 
et al., 2012). 
IDE is widely reported as being 110 kDa in a number of tissues and species, 
therefore the band at 120-130 kDa seen with Ab 3 is larger than expected.  A 
number of factors could be responsible for this difference.  It is possible that IDE 
undergoes post-translational modifications in plasma such as phosphorylation, 
acetylation, ubiquitination and/or glycosylation.  Sequence analysis of IDE using 
prediction programs shows that the protein contains numerous motifs and sites 
that may be modified by such processes (Prasad, et al., 2009; Li, et al., 2006; Hastie, 
et al., 2001; Gupta & Brunak, 2002).  Therefore it is possible that the increased 
molecular weight may be due to post-translational modifications.  Another 
possibility is that a larger isoform may be found in human blood, however there 
have been no reports to date of a larger isoform existing in any other tissues, with 
the exception of the 115 kDa membrane-bound form of IDE and the mitochondrial 
isoform of IDE (Vekrellis, et al., 2000; Leissring, et al., 2004).  However, these 
isoforms are unlikely to be in the peripheral circulation.  It may be simply that our 
estimation of IDE molecular weight is different due to the lack of protein separation 
on the 10% acrylamide gels – the 110 kDa and 160 kDa weight markers were very 
close.  However, the band for recombinant rat IDE was consistently observed to be 
higher than the 110 kDa marker, and the plasma band (estimated to be 
approximately 120-130 kDa) was consistently observed to be higher than that.  In 
addition and as mentioned previously, the predicted molecular weight of the full-
length isoform as determined from the UniProtKB database is 117.968 kDa, and this 
is similar to the molecular weight observed in the current study.  In addition, this 
antibody detected a band in rat liver of 110 kDa which is consistent with previous 
reports, suggesting that it is unlikely that this is an estimation error. 
It has been reported in the literature that IDE levels in the brain tend to be lower in 
AD patients and MCI individuals (Zhao, et al., 2007; Qin & Jia, 2008; Cook, et al., 
2003; Perez,et al., 2000), and that this drop in IDE levels has been associated with 
higher levels of soluble cerebral Aβ.  A large body of evidence indicates that the 
levels of soluble Aβ in the brain are integral to the process of AD pathogenesis.  It is 
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also known that brain Aβ can originate from the periphery, such that levels of 
soluble Aβ in the blood may influence brain levels of the peptide.  Furthermore, it is 
highly likely that levels of Aβ-degrading enzymes in the blood play an important 
part in regulating the peripheral Aβ content.  As IDE has been found to be one of 
the primary Aβ-degrading enzymes, its blood concentration may be related to the 
accumulation of both peripheral, and subsequently brain Aβ.   
The levels of full-length IDE measured by Western immunoblotting in this project 
were found to be similar in healthy controls and AD patients.  However, a significant 
increase in full-length IDE was observed in the MCI group compared with both 
controls and AD patients.  Upon further analysis this observation was determined to 
be significant only in females, however a similar pattern existed in males.  This 
increase in IDE levels in the MCI group is contrary to what would be expected; 
genetic polymorphisms in IDE have been associated with increased levels of plasma 
Aβ in individuals at risk of LOAD (Ertekin-Taner, et al., 2004; Ertekin-Taner, et al., 
2008) and if IDE is primarily responsible for regulating the levels of plasma Aβ, as is 
seen in the CNS, then it might be expected that early deficits in the levels of plasma 
IDE could feasibly be a contributing factor to increased circulating Aβ.  Based on the 
results of the current study, it is possible then that any potential reductions in levels 
of plasma IDE occur well before the onset of cognitive deficits which are observable 
in the MCI participants.  Furthermore, it is therefore possible that the increase in 
IDE levels in MCI individuals may be indicative of a compensatory mechanism 
comprising the upregulation of full-length (active isoform) IDE, perhaps in response 
to increased levels of IDE substrates such as Aβ and insulin in plasma.  It may be 
that increased Aβ species and/or an increase in insulin may be a very early event in 
AD pathogenesis which saturates all available IDE in the plasma and thus triggers its 
upregulation.  However, in this subset of the AIBL cohort there was no significant 
increase observed in either Aβ or insulin for the MCI participants overall, and there 
was no correlation observed between any of the Aβ species or insulin and levels of 
full-length IDE overall.  In addition, there were no significant differences between 
clinical classifications for any of the calculated ratios of IDE with insulin or Aβ (or 
the combination), although a trend toward a higher IDE/Aβ42+40 ratio was observed 
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in MCI participants compared with controls (but not in AD), which would be 
primarily due to the increase seen in full-length IDE levels.  However, as pathogenic 
processes have already commenced by the MCI stage, an increase in IDE substrates 
may occur much earlier than this prodromal period which may return to more 
normal levels following the upregulation of IDE.   
Alternatively, any potential deficit in IDE function may not be necessarily related to 
a reduction in IDE levels but possibly a reduction in IDE catalytic activity.  A previous 
study reported increased levels of IDE concomitantly with reduced IDE activity in 
brain microvessels of AD/CAA patients compared with controls, and this may be 
related to the increase in full-length IDE levels found in the circulation in the 
current study (Morelli, et al., 2004).  The high variation evident in the MCI group 
also highlights heterogeneity in the group itself; not all MCI individuals will convert 
to AD and some will even revert to normal, therefore this is likely to be a 
confounding factor.  It is not clear why the increase in MCI seems to be more 
pronounced in females than in males, however may be reflective of hormonal 
differences. 
It is possible that levels of both Aβ and IDE in the plasma negatively reflect the 
levels in the brain.  Thus high levels of IDE in the plasma may indicate low levels of 
IDE in the brain, and concomitantly low levels of Aβ in the plasma may reflect high 
cerebral Aβ levels.  One group has shown this to be the case for Aβ42 after 
glucocorticoid treatment, with increasing levels of Aβ42 observed in the brain and a 
corresponding decrease observed in plasma Aβ42 (Kulstad, et al., 2005).  This was 
also accompanied by a reduction of IDE in the brain, and did not appear to affect 
Aβ40 levels.  This would be consistent with Aβ42 being the primary species 
implicated in AD.  Unfortunately plasma IDE was not measured in the same study so 
it is unknown if a corresponding increase occurs in the plasma.  Another study 
supporting the hypothesis that IDE is primarily responsible for regulating the levels 
of Aβ showed that increases in cerebral Aβ42 (both intracellular and extracellular) 
were consistently associated with a reduction in IDE levels (both membrane-bound 
and cytosolic) in patients with a PS1 mutation (Qin & Jia, 2008).  It must be noted 
though that early-onset familial AD may not have the same pathogenic processes as 
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sporadic AD.  However, as previously mentioned, genetic studies have 
demonstrated association between IDE variants and plasma Aβ42 levels in LOAD 
families (Ertekin-Taner, et al., 2004; Ertekin-Taner, et al., 2008). 
Accumulating evidence appears to support the notion that during the development 
of AD pathology, plasma Aβ42 levels decline as plaques develop in the brain 
(Kwarabayashi, et al., 2001; Kuo, et al., 2000; Schupf, et al., 2008).  One of these 
investigations was a large study examining both Aβ42 and Aβ40, and demonstrated 
that only Aβ42 levels in plasma were affected during the conversion to AD, with high 
initial levels followed by a decline during the onset of AD (Schupf, et al., 2008), 
reflecting the deposition of Aβ in the brain.  Another study showed that 
intraperitoneal inoculation of Aβ can also trigger amyloid formation in the brains of 
transgenic mice (Eisele, et al., 2010).  This is supportive of the theory that the 
elevated Aβ levels in the brain originate, at least in part, from the peripheral blood 
supply.  However, it should be noted that previous work by Eisele and colleagues 
(2009) showed no initiation of Aβ deposition when injected intravenously, although 
soluble levels of brain Aβ were not monitored in that study. 
A recent study using AD transgenic mice demonstrated that an increase in plasma 
Aβ levels occur concurrently with a reduction in intracellular Aβ in the brain, after 
treatment with a γ-secretase inhibitor which also acts on microglial activation 
(Sivilia, et al., 2013).  This study also reported cognitive improvement and reduced 
amyloid deposition in the mice. It is believed that a potential therapeutic pathway 
involves reducing levels of soluble Aβ in the brain by increasing its efflux across the 
BBB into the plasma, where it may be degraded by IDE and other Aβ-degrading 
pathways (Deane, et al., 2009).  Recent studies support this concept, as it has been 
demonstrated that a reduction in plasma Aβ leads to a reduction in cerebral Aβ in 
AD transgenic mice (Guan, et al., 2009; Liu, et al., 2010; Sutcliffe, et al., 2011), 
although another recent study refutes these findings (Walker, et al., 2013).  
However, as IDE is the primary enzyme responsible for insulin degradation in the 
periphery, the challenge would be to increase the degradation of Aβ selectively 
without disturbing the degradation of insulin by IDE (and other substrates).  As it 
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has been established that IDE may be regulated selectively in this fashion by small 
peptide activators, and other regulatory factors, this may prove possible. 
It is important to note that IDE is too large to cross the blood-brain barrier (BBB), 
therefore separate pools are likely to exist in the periphery and the brain.  It would 
be unlikely that IDE would move from the brain to the periphery.  Therefore it is 
more likely that IDE would be independently upregulated in the periphery, possibly 
in response to increased plasma Aβ or insulin.  Upregulation of IDE has been 
reported previously, in response to Aβ, insulin and also various cellular stressors 
(Vepsalainen, et al., 2008; Zhao, et al., 2004; Tundo, et al., 2013). 
Furthermore, it can be speculated that reduced brain IDE may initiate the increase 
of cerebral Aβ that many studies have documented, and this excess may increase 
transfer of Aβ across the BBB into the periphery. This could subsequently instigate 
the upregulation of plasma IDE also, however if the enzyme is unable to control the 
levels of peripheral Aβ sufficiently, the peptide may reach a critical level, 
disruptions to insulin metabolism may occur, both of which may then cause 
alterations to BBB permeability.  This would probably lead to increased Aβ influx 
back into the brain and a reduction in efflux to the periphery.  In support of this 
theory, it has been demonstrated that increased levels of brain Aβ are capable of 
upregulating IDE levels and therefore it is possible that this also occurs in the 
periphery (Vepsalainen, et al., 2008).  The increased transport of peripheral Aβ to 
the brain, as well as the reduction in efflux (partly due to greater aggregation and 
deposition of Aβ in Aβ fibrillar deposits and plaques), in conjunction with the 
increased plasma Aβ degradation via elevated levels of plasma IDE may then lead to 
the characteristic reduction in plasma Aβ during Aβ deposition which is seen later in 
AD patients.  The drop in Aβ may then lead to the subsequent down-regulation of 
plasma IDE as less would be required, and this is reflected in the results of the 
current study. 
When the cohort was split into carriers and non-carriers of APOE ε4 alleles, no 
significant difference in full-length plasma IDE levels was observed.  This is an 
interesting finding as it has been reported that carriers of the ε4 allele have lower 
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levels of brain IDE compared with non-carriers or controls (Cook, et al., 2003).  This 
does not support the hypothesis that plasma levels of IDE negatively reflect the 
levels in the brain, and instead supports the notion that brain and plasma IDE 
function independently.  However, it would be of value to examine the results more 
thoroughly by way of specific APOE genotypes rather than just ε4 carriers versus 
non-carriers, as it has been shown that the different genotypes confer different 
risks for developing AD (Farrer, et al., 1997).  To characterise properly the effect of 
APOE genotype on IDE levels, the results should ideally be analysed after dividing 
according to the 6 possible APOE genotypes.  Unfortunately the small sample size 
precluded this analysis due to a lack of power. 
One limitation of this study is that it was not possible to analyse potential effects of 
medications on plasma IDE levels, due to the size of the cohort, and the fact that 
only a small number of participants were not taking medication.  A number of 
compounds and medications have been implicated in the regulation of IDE (this will 
be discussed in more detail in Chapter 6).  Therefore, as a substantial proportion of 
the AIBL cohort were taking at least one, or a combination of these medications at 
the time blood samples were taken, it is likely that these will have influenced the 
measured levels of plasma IDE.  A significant correlation was observed between 
testosterone and IDE in the whole cohort, although this disappeared when 
analysing male and female participants separately.  Oestradiol showed a trend 
toward association with IDE however this also disappeared when data was split by 
gender.  This suggests that the potential relationship between IDE and these sex 
hormones is not necessarily gender specific.  Larger cohorts and additional analysis 
will be required to determine if such hormones and medications influence plasma 
IDE levels in humans.  
Another limitation which should be mentioned is the method of Western 
immunoblotting itself.  As there were a large number of samples, and only five 
samples could be run on each gel in duplicate, a large number of gels were needed.  
An internal standard of pooled control plasma was included in each gel, to which 
sample results were normalised to control for inter-gel variation.  However, the 
large number of gels would have increased the chance that errors were going to 
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occur when normalising to correct for inter-gel variation.  Another source of 
variation in the experiment was due to the step in which the blots were stripped of 
antibodies following the initial immunoblotting procedure, and re-probed with a 
different primary antibody; although this is generally considered an acceptable 
practice. 
Western immunoblotting is considered to be a semi-quantitative procedure, and 
subject to variation even through such things as the method of quantification 
(Gassmann, et al., 2009).  Therefore, even a small degree of imprecision may affect 
the means or medians, and as such it cannot be excluded that during normalisation 
procedures the trend of this data may have been affected by these factors. 
 
3.4.1  Summary 
The results in this chapter demonstrate that levels of plasma full-length IDE are 
elevated in MCI individuals in comparison to healthy controls as well as AD patients, 
and that no difference is observed between healthy controls and AD.  In addition, 
no difference in plasma IDE levels was seen in APOE ε4 carriers versus non-carriers.  
These results for full-length plasma IDE were contrary to what was expected, as it 
conflicts with the hypothesis that low plasma IDE levels are an initiating factor in 
the development of AD.  However, one could argue that AD pathogenesis starts 
well before MCI stages, as AD-related early memory loss often indicated by MCI 
indicates that synaptic and neuronal loss have already occurred to an extent.  
Based on these results and others from the AIBL study, an alternative chain of 
events may be occurring. Firstly, it is possible that a trigger such as high plasma Aβ 
and/or insulin initiate an upregulation of plasma IDE.  Although within this subset of 
the AIBL cohort there was no significant increase of either Aβ1-40, Aβ1-42 or insulin 
observed in MCI, potentially this may have occurred well prior to the MCI stage.  
However, recent results from the AIBL study have shown that individuals who 
convert from healthy to MCI have a reduction in plasma Aβ42, while an increase is 
seen with Aβ40 in MCI and AD participants after controlling for various factors such 
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as gender and APOE status, among others (Rembach, et al., 2014).  As Aβ40 
encompasses the majority of the Aβ species, this alone may be adequate for the 
saturation of IDE, which may potentially lead to its upregulation in the plasma.  
Furthermore, even though the full-length Aβ40 and Aβ42 peptides were not 
significantly increased, a significant increase in Aβx-40 (but not Aβx-42) was observed 
within this subset.  This also highlights the need to consider Aβ42, Aβ40 and Aβ 
fragments separately in addition to as a single species of peptide.  BBB damage may 
then contribute to increased influx and decreased efflux of excess Aβ to/from the 
brain, respectively, and lead to the characteristic accumulation of cerebral Aβ seen 
in AD.  The subsequent decrease in plasma Aβ that has been documented may then 
be a result of both Aβ trafficking to the brain and increased plasma degradation of 
Aβ due to elevated plasma IDE.  Reports from another recent study have shown 
that alterations of plasma insulin can occur at the MCI stage, but again appear to be 
influenced by gender and APOE status (Cholerton, et al., 2012).  Collectively, these 
results outline the complexity of the mechanisms surrounding AD pathology and 
highlight the need to take into account various factors such as gender, APOE 
genotype and differentiating between Aβ species when translating the data.  It 
would be useful in future studies to examine blood IDE at regular intervals in AD 
transgenic animals from a very early age to see if the decrease in plasma Aβ that 
has been documented occurs prior to or concurrently with an increase in plasma 
IDE, or alternatively if the decrease occurs following an increase in plasma IDE, as 
well as monitoring plasma insulin levels. 
The overall results though suggest that the differences observed in plasma full-
length IDE levels measured with Western immunoblotting could be reflective of 
biochemical changes in the prodromal period of AD, and that IDE may be a suitable 
biomarker candidate to include in a panel of biomarkers for early detection.  
Various limitations, however, such as the effects of medications, sex hormones, 
gender and APOE status among others, on plasma IDE must be acknowledged and 
need further investigation before any conclusions may be formed from these 
results.  In addition, studies that progressively monitor levels of IDE from a non-
pathological state through the conversion to AD would provide more information to 
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the comparison of MCI and AD with controls and would be of considerable value as 
a future direction. 
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CHAPTER 4 – Total plasma IDE Levels measured by 
enzyme-linked immunosorbent assay (ELISA) are 
decreased in MCI in comparison to healthy controls or 
AD. 
4.1  Introduction 
Western blotting techniques are widely used in research and have several 
advantages over other immunoaffinity applications for the detection of proteins; 
one being good sensitivity to detect low-abundance proteins in a complex sample 
such as plasma, and also the specificity to differentiate between proteins based on 
molecular weight.  However, there are some limitations to Western 
immunoblotting; firstly it is considered a semi-quantitative application, and 
secondly it is not ideal for use when measuring a large number of samples due to 
the inter-assay variation.  In addition, the proteins in Western blotting are usually in 
a denatured and reduced conformation compared to the native protein.  Hence 
some antibodies may not detect specific proteins as they bind to conformational 
epitopes and this generally occurs when using antibodies that are raised against the 
full-length protein.  There are other immunoaffinity applications which are more 
suited to protein quantification and also more suited to processing large numbers 
of samples, such as the enzyme-linked immunosorbent assay, or ELISA.  Using a 96-
well plate, this application permits the simultaneous measurement of up to 40 
samples in duplicate per assay, including an 8-point standard curve (in duplicate). 
One common limitation of ELISA-based detection of proteins is the inability to 
differentiate between different isoforms of a protein.  However, several 
publications have reported total levels of IDE (primarily in brain), and it would be 
useful to characterise IDE in human plasma by ELISA and compare with the results 
from these other studies.  The measurement of total plasma IDE using an ELISA may 
also uncover differences compared to measuring with Western immunoblotting: 
ELISAs may prove more suitable for measuring IDE as a clinical biomarker.  There is 
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one commercially available ELISA kit for the measurement of IDE, however it was 
found to be unsuitable for our purposes.  Therefore an in-house ELISA was 
developed for the purpose of measuring total IDE in human plasma from the AIBL 
cohort. 
 
4.1.1  Aims 
 
1. To develop an in-house ELISA for the purpose of measuring total IDE levels in 
human plasma. 
2. To determine if levels of total IDE differ between HC, MCI and AD participants. 
3. To determine if the presence of the APOE4 allele has any impact on levels of 
total plasma IDE. 
4. To identify any relationships between total plasma IDE, full-length IDE and other 
biochemical data obtained from the AIBL study. 
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4.2  Experimental Summary 
4.2.1  Test of commercial IDE ELISA kit for suitability in testing human 
plasma. 
To screen a commercial ELISA kit to determine its suitability for the measurement 
of IDE in human plasma, the assay was performed twice (Run 1 and Run 2) as per 
manufacturer instructions, as described in Section 2.2.5.1. 
 
4.2.2  Screening of eight commercial IDE antibodies to determine 
suitability for an in-house, indirect IDE ELISA for use on human plasma 
samples. 
Antibodies that were screened for their suitability to be used in an indirect ELISA for 
plasma IDE are listed in Section 2.1.1 and in Table 2.1.  An indirect ELISA was 
performed using each of the antibodies as described in Section 2.2.5.2 using 
purified rat IDE as a standard, and plasma, both neat and diluted. 
 
4.2.3  Test of the three most suitable IDE antibodies for an IDE 
sandwich ELISA. 
Using IDE antibody ab28561 (Ab 3) as the coating antibody, a sandwich ELISA was 
performed using either H00003416-A01 (Ab 6) or LS-C55007 (Ab 2) as detection 
antibody, as described in Section 2.2.5.3.  Purified rat IDE was used as a standard, 
and both neat and diluted plasma samples were tested. 
 
4.2.4  Assay control tests. 
Using IDE antibody ab28561 (Ab 3) as coating antibody, and LS-C55007 (Ab 2) as 
detection antibody, a sandwich ELISA was performed as described in Section 
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2.2.5.3, with minor changes.  The coating buffer was at a pH of 8.6 rather than 9.6; 
and no Tween detergent was present in the PBS used for the washing steps, with 
the exception of the wash following the secondary antibody incubation.  The 
blocking agent used in this protocol was Fraction V BSA.  Omission of the capture 
and detection antibodies, and the blocking agent was tested to ensure there was no 
interference by any of these components in the assay, and these controls used 
recombinant rat IDE at a concentration of 625 ng/mL as the control sample. 
 
4.2.5  Optimisation of coating conditions for the IDE sandwich ELISA. 
Using IDE antibody ab28561 (Ab 3) as coating antibody, and LS-C55007 (Ab 2) as 
detection antibody, a sandwich ELISA was performed as described in Section 
2.2.5.3.  The conditions of coating overnight at 4°C was compared with coating for 2 
hr at room temperature, as well as the effect of the buffer pH of 9.6 compared with 
8.6.  Purified rat IDE was used for the standard, and plasma was tested, both neat 
and diluted. 
 
4.2.6  Optimisation of sample and antibody diluents in the IDE ELISA. 
For this purpose, the assay was performed as described in Section 2.2.5.3, using 
PBST alone for diluting the samples, detection antibody and secondary antibody, 
compared with adding 1% bovine serum albumin (BSA) to the sample diluents, or 
adding 2% polyethylene glycol (6000) to the detection antibody diluent.  Purified rat 
IDE was used for the standard, and plasma was tested, diluted 1:1 and 1:2. 
 
4.2.7  Optimisation of detection antibody incubation in the IDE ELISA. 
To determine if overnight incubations of the detection antibody at 4°C can improve 
the signal obtained in the sandwich ELISA, the ELISA was performed as described in 
Section 2.2.5.3 (Ab 3 and 2), using a 2 hr incubation at room temperature for the 
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detection antibody, compared with an overnight incubation at 4°C.  Purified rat IDE 
was used for the standard, and five individual plasma samples were used diluted 
1:2. 
 
4.2.8  Investigation of the upper detection limit of the IDE sandwich 
ELISA. 
For this purpose, the experiment was performed as described in Section 2.2.5.3.  An 
11-point standard curve of recombinant rat IDE ranging from 50 to 64000 ng/mL 
and five individual plasma samples (1:2) were included in the assay. 
 
4.2.9  Optimisation of coating antibody concentration and extension 
of standard curve for upper detection limit analysis in the IDE 
sandwich ELISA. 
The ELISA was performed as previously described in Section 2.2.5.3.  Three 
concentrations of coating antibody (Ab 3) were used on a standard curve of 
recombinant rat IDE to determine the optimal concentration (5, 1 and 0.1 μg/mL).  
The IDE concentrations ranged from 50 to 160000 ng/mL. 
 
4.2.10  Test of non-albumin containing blocking agent to reduce 
background in the IDE sandwich ELISA. 
To try and decrease the elevated background absorbance, the ELISA was performed 
as described in Section 2.2.5.3, substituting 3% ECL™ Blocking agent in the blocking 
buffer.  Recombinant rat IDE was used for the standard curve ranging from 500 to 
16000 ng/mL, and PCP was diluted 1:2. 
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4.2.11  Measurement of total plasma IDE levels in a subset of the AIBL 
cohort. 
Total IDE levels of 177 samples from the AIBL cohort (57 HC/50 MCI/70 AD) were 
measured with the in-house sandwich ELISA as detailed in Section 2.2.5.3.  
Recombinant rat IDE was used for the standard curve ranging from 50 to 16000 
ng/mL and an internal standard of pooled control plasma (PCP) was included on 
each plate for normalisation of inter-assay variance (all in duplicate).  AIBL samples 
were all assayed in duplicate. 
 
4.2.12  Testing for potential cross-reactivity of BSA (standard and 
Fraction V) and HSA in the IDE sandwich ELISA. 
The IDE sandwich ELISA was performed as described in Section 2.2.5.3.  BSA 
(standard and Fraction V) and HSA were prepared as outlined in Section 2.2.5.3.1 at 
concentrations equivalent to the lowest and highest levels of albumin likely to be 
found in human serum, then diluted as per PCP.  PCP was diluted 1:2.  Fraction V 
BSA was used for the blocking step. 
 
4.2.13  Spike and recovery assessment of IDE sandwich ELISA. 
To assess the effect of plasma proteins and other plasma constituents on the 
detection of IDE, recombinant rat IDE was diluted 1) in PBST (control), and 2) in 
PBST-diluted plasma (1:2) to provide matching standard curves ranging from 1250 
to 10000 ng/mL IDE.  The IDE ELISA was performed as outlined in Section 2.2.5.3.  
Absorbance value of the diluted plasma blank (no spike) was subtracted from the 
plasma diluted standard curve to account for the signal from the plasma itself. 
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4.3  Results 
4.3.1  The commercial IDE ELISA kit is unsuitable for the testing of 
human plasma samples. 
When using commercial kits to measure proteins in a complex mixture, it is 
important to test the kit to determine if it produces expected results.  Therefore, 
the commercial IDE ELISA kit that was available at the time was trialled using two 
human plasma samples at various dilutions.  The test was carried out twice to 
ensure the results were accurate.  The results showed that goodness of fit of the 
standard curve was r2 = 0.8674 (Run 1) and r2 = 0.9858 (Run 2) (Figure 4.1(A)).  
There was considerable difference in the absorbance values of the standard curve 
for each Run; the maximum absorbance (50 ng/mL) for Run 1 was 1.77 compared 
with Run 2 which was only 1.04.  In addition, there was little or no correlation 
between plasma sample dilution levels and measured levels of IDE for either run, 
with high inconsistency between Run 1 and Run 2 (Figure 4.1(B)). 
To address the possibility that the poor standard curve in Run 1 may have affected 
the interpolated plasma values and therefore contributed to the variation 
observed, raw absorbance values of the plasma dilutions were normalised to the 
mean of the blanks and compared between Run 1 and Run 2 (Figure 4.1 (C)).  
Results demonstrated that the plasma dilutions showed considerable variation 
independently of the standard curve.  Inter-assay variation was up to 56%, while 
intra-assay variation was up to 30%.  It was considered to be particularly important 
to have consistency between assays due to the fact that the sample size was large, 
requiring more than one plate, and therefore plates needed to be compared.  
Although some assay-to-assay and within-assay variation is expected (preferably 
<15%), these results demonstrated that there was excessive inter- and intra-assay 
variation with this commercial ELISA kit. 
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Figure 4.1 (A)  Comparison of standard curves from Run 1 and Run 2, using the 
commercial IDE ELISA kit.  Assay was performed as detailed in Section 2.2.5.1.  
Standards were prepared in a range of 0.78 ng/mL to 50 ng/mL as per manufacturer 
instructions.  Results showed considerable differences in the standard curves for 
each Run; goodness of fit was r2 = 0.8674 with a maximum absorbance value of 1.77 
for Run 1 compared with r2 = 0.9858 and a maximum absorbance value of 1.04 for 
Run 2. 
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Figure 4.1 (B)  Test of commercial IDE ELISA kit with human plasma (Run 1 versus 
Run 2).  Assay was conducted as detailed in Section 2.2.5.1.  Individual human 
plasma samples (2) were prepared as per manufacturer instructions and diluted up 
to 1:10 (4 dilutions).  Results show that the interpolated concentrations from the 
plasma dilutions were not dose-responsive for the plasma in either run.  In addition, 
concentrations for the plasma samples were inconsistent between Run 1 and Run 2.  
The interpolated concentration of undiluted plasma for sample 1 in Run 1 was 
below the limit of detection compared with 5.06 ng/mL in Run 2.  The interpolated 
concentration for undiluted sample 2 was below the limit of detection in Run 1 and 
16.85 ng/mL in Run 2. The results indicate that this kit has high inter-assay variation 
and poor linearity of dilution. 
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Figure 4.1 (C)  Test of commercial IDE ELISA kit with human plasma – raw values 
(Run 1 versus Run 2).  Individual human plasma samples (2) were prepared as per 
manufacturer instructions and diluted up to 1:10 (4 dilutions).  The dashed (black) 
line indicates background absorbance (blank).  Results showed no linearity of 
dilution and poor concordance between runs. 
 
 
4.3.2  Indirect ELISA detection is effective for purified rat IDE, but not 
for IDE in human plasma. 
As the commercial IDE ELISA kit was determined to be unsuitable for measurement 
of plasma IDE in the AIBL study, development of an in-house ELISA assay was 
required.  As a result, there were a number of important factors to consider.  Two 
options were available – an indirect ELISA and a sandwich ELISA.  As an indirect 
ELISA is simpler, requiring only one detection antibody, this was trialled first.  With 
an indirect ELISA, the antigen or sample is directly adsorbed to a surface 
(microplate well) and the protein of interest is detected by the addition of a specific 
antibody to which a labelled secondary antibody is used to quantify the protein 
present.  An ideal antibody would have low background, produce a high dynamic 
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range of the standard curve, and demonstrate good linearity of dilution.  Not all 
antibodies are effective for use in ELISA, especially if the antibody has been raised 
against a small peptide.  This may produce antibodies which prefer a linear 
conformation of the antigen, which may be buried in the structure of the natively-
folded protein.  However, this is not always the case, as some linear epitopes are 
presented on the surface of the native enzyme.  In addition, it is important to 
determine if there is any cross-reactivity of the antibodies (primary and secondary) 
to non-specific components of the sample matrix.   
Eight commercially-available antibodies were selected for screening for the 
development of an in-house indirect IDE ELISA; A-MMS-282R (monoclonal), B-
GTX111664, C-AB9210, D-250706, E-5282-1 (monoclonal), F-H00003416-A01, G-LS-
C55007 and H-ab28561; designated Abs 1-4 and Abs 6-9 as summarised in Table 2.1 
(Figure 4.2, A-H).  The screening tests used purified rat IDE for the standard curve 
and pooled control plasma (PCP) both undiluted and using a range of dilutions.  
Results showed that all antibodies detected the purified IDE dose-dependently, 
although the dynamic range varied considerably.  The three antibodies with the 
highest dynamic range were MAb 9 (Graph set E), Ab 8 (Graph set B) and Ab 3 
(Graph set H), respectively.  However, the results for the plasma samples varied 
considerably, with a majority of the antibodies demonstrating a dose-dependent 
signal in the reverse direction.  For monoclonal MAb 7, the plasma signals fell below 
the background signal (Graph set A).  With antibodies Ab 8, Ab 1 (Graph set C) and 
Ab 4 (Graph set D) the plasma signals observed were not dose-dependent and were 
situated toward the lower end of the standard curve.  When testing MAb 9 (Graph 
set E), plasma samples showed very little difference in signal between the undiluted 
samples and those diluted 1:5, and OD readings were almost as low as the 
background signal.  Of the three remaining antibodies; Ab 6, Ab 2 and Ab 3 (Graph 
sets F-H, respectively), all showed good dynamic range of the standard curve with 
the highest being for Ab 3.  For the plasma (neat and diluted) samples, all three 
antibodies showed a similar reverse trend, however for Ab 6 and Ab 2, the dynamic 
range of the plasma dilutions was much lower than Ab 3. 
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Figures 4.2 A (A) and (B)  Screening of monoclonal IDE antibody MMS-282R (MAb 
7).  Test of indirect ELISA using mouse antibody MAb 7 (Clone 9B12) at a dilution of 
1:1000, with a recombinant rat IDE (rrIDE) standard curve (Graph A.) and pooled 
control plasma (PCP) dilutions (Graph B.).  Assay was performed as detailed in 
Section 2.2.5.2.  The dashed line indicates the OD of the blank.  The standard curve 
ranged from 78ng/mL to 5000ng/mL with each concentration in duplicate.  PCP was 
neat (PCP1), diluted 1:1 (PCP2), 1:2 (PCP3) and 1:3 (PCP4) in duplicate.  Results 
show that while the assay works for rrIDE with the highest OD reading of almost 
1.000, the background is very high (~0.250) and all PCP OD readings fell below the 
OD of the blank. 
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Figures 4.2 B (A) and (B)  Screening of polyclonal IDE antibody GTX111664 (Ab 8).  
Test of indirect ELISA using polyclonal rabbit Ab 8 at a dilution of 1:1000, with a 
recombinant rat IDE (rrIDE) standard curve (Graph A.) and pooled control plasma 
(PCP) dilutions (Graph B.).  Assay was performed as detailed in Section 2.2.5.2.  The 
dashed line indicates the OD of the blank.  The standard curve ranged from 
78ng/mL to 5000ng/mL with each concentration in duplicate.  PCP was neat (PCP1), 
and diluted 1:1 (PCP2), 1:2 (PCP3), 1:3 (PCP4) and 1:4 (PCP5) in duplicate.  Results 
show that the assay works for rrIDE with the highest reading of approximately 
3.000, and the background is very low (0.011).  However, while all PCP dilutions fall 
above the OD of the blank, values were very low (all ≤0.025), inconsistent, and did 
not demonstrate a dose-response. 
182 
 
 
 
Figure 4.2 C (A) and (B)  Screening of polyclonal IDE antibody AB9210 (Ab 1).  Test 
of indirect ELISA using polyclonal rabbit Ab 1 at a dilution of 1:1000, with a 
recombinant rat IDE (rrIDE) standard curve (Graph A.) and pooled control plasma 
(PCP) dilutions (Graph B.).  The dashed line indicates the OD of the blank.  Assay 
was performed as detailed in Section 2.2.5.2.  The standard curve ranged from 
78ng/mL to 5000ng/mL with each concentration in duplicate.  PCP was neat (PCP1), 
and diluted 1:1 (PCP2), 1:2 (PCP3), 1:3 (PCP4) and 1:4 (PCP5) in duplicate.  Results 
show that the assay works for rrIDE with the highest reading of approximately 
3.400, and the background is quite low (0.027).  However, while all PCP dilutions fall 
above the OD of the blank, values were very low (all ≤0.048) and not dose-
responsive. 
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Figure 4.2 D (A) and (B)  Screening of polyclonal IDE antibody 250706 (Ab 4).  Test 
of indirect ELISA using polyclonal mouse Ab 4 at a dilution of 1:1000, with a 
recombinant rat IDE (rrIDE) standard curve (Graph A.) and pooled control plasma 
(PCP) dilutions (Graph B.).  The dashed line indicates the OD of the blank.  Assay 
was performed as detailed in Section 2.2.5.2.  The standard curve ranged from 
78ng/mL to 5000ng/mL with each concentration in duplicate.  PCP was neat (PCP1), 
and diluted 1:1 (PCP2), 1:2 (PCP3), 1:3 (PCP4) and 1:4 (PCP5) in duplicate.  Results 
show that while the assay seems dose-responsive for rrIDE, the highest reading of 
0.195 is very low.  The background is reasonably low (0.034).  However, readings for 
the PCP dilutions were only just above the blank OD (all ≤0.064) and did not 
demonstrate a dose-response.  
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Figure 4.2 E (A) and (B)  Screening of monoclonal IDE antibody 5282-1 (MAb 9).  
Test of indirect ELISA using rabbit MAb 9 as detection antibody, at a dilution of 
1:1000, with a recombinant rat IDE (rrIDE) standard curve (Graph A.) and pooled 
control plasma (PCP) dilutions (Graph B.).  Dashed line shows OD of blank.  Assay 
was performed as detailed in Section 2.2.5.2.  The standard curve ranged from 
5ng/mL to 500ng/mL.  PCP was diluted 1:1 (PCP1), 1:5 (PCP2) and 1:20 (PCP3).  
Results show that the assay works for rrIDE with the highest reading of 
approximately 4.500, and the background is very low (0.014).  However, while all 
PCP dilutions fall above the OD of the blank, values are very low for 1:1 and 1:5 
(<0.04), while diluting to 1:20 yields the highest signal of almost 0.100. 
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Figure 4.2 F (A) and (B)  Screening of polyclonal IDE antibody H00003416-A01 (Ab 
6).  Test of indirect ELISA using polyclonal mouse Ab 6 at a dilution of 1:1000, with a 
recombinant rat IDE (rrIDE) standard curve (Graph A.) and pooled control plasma 
(PCP) dilutions (Graph B.).  The dashed line indicates the OD of the blank.  Assay 
was performed as detailed in Section 2.2.5.2.  The standard curve ranged from 
625ng/mL to 5000ng/mL.  PCP was diluted 1:1 (PCP1), 1:5 (PCP2) and 1:20 (PCP3).  
Results show that the assay works for rrIDE with the highest reading of 
approximately 4.200, the background is negligible (0.082) and all PCP dilutions fall 
well above the OD of the blank.  However, PCP dilutions appear to be dose-
responsive in the reverse direction. 
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Figure 4.2 G (A) and (B)  Screening of polyclonal IDE antibody LS-C55007 (Ab 2).  
Test of indirect ELISA using polyclonal goat Ab 2 at a dilution of 1:1000, with a 
recombinant rat IDE (rrIDE) standard curve (Graph A.) and pooled control plasma 
(PCP) diluted samples (Graph B.).  The dashed line indicates the OD of the blank.  
Assay was performed as detailed in Section 2.2.5.2. The standard curve ranged from 
117ng/mL to 7500ng/mL, with each concentration in duplicate.  PCP was diluted 1:1 
(PCP1), 1:2 (PCP2), 1:5 (PCP3) and 1:10 (PCP4) in duplicate.  Results show that the 
assay works for rrIDE, however the top three concentrations have exceeded the 
maximum absorbance of 4.500.  The background is reasonable (0.081) and all PCP 
dilutions fall well above the OD of the blank.  However, PCP dilutions have a very 
small dynamic range, with less than 0.054 OD units between the 1:2 dilution and 
1:10 dilution.  In addition, PCP appears to be dose-responsive in the reverse 
direction.  
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Figure 4.2 H (A) and (B)  Screening of polyclonal IDE antibody ab28561 (Ab 3).  
Test of indirect ELISA using polyclonal rabbit Ab 3 at a dilution of 1:1000, with a 
recombinant rat IDE (rrIDE) standard curve (Graph A.) and pooled control plasma 
(PCP) dilutions (Graph B.).  The dashed line indicates the OD of the blank.  Assay 
was performed as detailed in Section 2.2.5.2.  The standard curve ranged from 
78ng/mL to 5000ng/mL with each concentration in duplicate.  PCP was neat (PCP1), 
and diluted 1:1 (PCP2), 1:2 (PCP3) and 1:3 (PCP4) in duplicate.  Results show that 
the assay works for rrIDE, with the highest reading of almost 3.400, the background 
being negligible (0.036) and all PCP dilutions falling well above the OD of the blank.  
However, PCP dilutions again appear to be dose-responsive in the reverse direction. 
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4.3.3  Optimisation of a sandwich ELISA for measuring plasma IDE in 
the AIBL cohort. 
The trials above of the indirect ELISA method demonstrate that this does not 
appear to be an appropriate method to detect IDE from complex mixtures like 
plasma.  Due to the high content of other proteins, it may be that the levels of IDE 
binding to the plate were not reflective of the levels in plasma, due to non-specific 
binding of other proteins, both to the plate and to IDE itself, for example. 
Therefore, the use of an indirect ELISA was determined to be unsuitable for the 
measurement of plasma IDE.  
As there was a selection of IDE antibodies available, raised to a variety of regions of 
the IDE protein and from different sources (rabbit, goat, mouse), a sandwich ELISA 
was then trialled. The sandwich ELISA was developed using polyclonal antibody 
ab28561 (Ab 3) as the coating antibody and H00003416-A01 (Ab 6) as the detection 
antibody (Figures 4.3 (A) and (B)).  Ab 3 was used as a coating antibody for two 
reasons; firstly, it was determined to be the antibody with the highest affinity for 
plasma IDE.  Secondly, it was affinity purified, which is essential for a coating 
antibody, as impurities in the antibody will compete for binding sites on the ELISA 
plate.  Ab 6 is an unpurified antibody, it therefore was not appropriate as a coating 
antibody, but could function well as a detection antibody.  Ab 3 binds to a location 
of IDE that spans the interface between Domains 1 and 2, between residues 238-
416, while Ab 6 binds to an epitope in Domain 4 between residues 920-1019.  
Therefore these two antibodies bind to distinct sites and should not interfere with 
each other as a result of steric hindrance.  Results showed that the background was 
considerably higher in the sandwich ELISA than using the antibodies separately in 
an indirect ELISA.  In addition, the standard curve values were considerably reduced 
compared with the values seen in the indirect ELISA.  However, the PCP sample 
values were much higher than seen in the indirect ELISA and were appropriately 
dose-responsive up to a dilution of 1:10. 
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Figures 4.3 (A) and (B)  Optimisation of IDE sandwich ELISA using Ab 3 and Ab 6.  
Sandwich ELISA trial using ab28561 (Ab 3) as coating antibody (1:400) and 
H00003416-A01 (Ab 6) as detection antibody (1:750), using a recombinant rat IDE 
(rrIDE) standard curve (Graph A.) and pooled control plasma (PCP) dilutions (Graph 
B.)  The dashed line indicates the OD of the blank.  The assay was performed as 
detailed in Section 2.2.5.3.  The standard curve ranged from 78ng/mL to 5000ng/mL 
with each concentration in duplicate.  PCP was neat (PCP1), diluted 1:1 (PCP2) or 
1:10 (PCP3) in duplicate.  Results show that the assay has a low dynamic range for 
rrIDE and background is high (0.318).  PCP readings are above the blank OD, and 
appear dose-responsive up to a 1:10 dilution.  
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To determine if antibody LS-C55007 (Ab 2) would be a better detection antibody 
than Ab 6, the sandwich ELISA was performed again, trialling both Ab 2 and Ab 6 
(Figures 4.4 (A) and (B)).  As Ab 2 bound to a similar region to Ab 6 (close to the C-
terminus), it was expected that Ab 3 and Ab 2 would also not interfere with each 
other when bound to IDE.  As Ab 2 is affinity purified, it would also allow greater 
control over the assay, as it would be possible to determine exact concentrations of 
the antibody.  In addition, there would be no other contaminants which could 
potentially affect the function of the assay.  The results were similar for both 
antibodies, however Ab 2 demonstrated a slightly better dynamic range for both 
the standard curve and plasma dilutions.  In addition, the background was 
approximately 35% lower with Ab 2 than with Ab 6.  It was concluded that Ab 2 was 
the superior detection antibody. 
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Figures 4.4 (A) and (B)  Comparison of the potential detection antibodies Ab 6 and 
Ab 2.  Comparison of H00003416-A01 (Ab 6) and LS-C55007 (Ab 2) as detection 
antibodies using ab28561 (Ab 3) as coating antibody, a recombinant rat IDE (rrIDE) 
standard curve (Graph A.) and pooled control plasma (PCP) dilutions (Graph B.)  The 
assay was performed as detailed in Section 2.2.5.3.  Data is shown without blank-
adjustment.  Both primary antibodies were diluted to 1:1000.  The standard curve 
ranged from 78ng/mL to 5000ng/mL with each concentration in duplicate.  PCP was 
neat (0), and diluted 1:1, 1:2, 1:5, 1:8, 1:10 and 1:15 in duplicate.  Results show that 
Ab 2 demonstrated a slightly higher dynamic range for both the standard curve and 
PCP dilutions, and lower background compared with Ab 6 (Background of 0.222 and 
0.344, respectively).  PCP dilutions for both antibodies fall above the OD of the 
blanks and appear dose-responsive.  Ab 2 shows linearity of dilution for PCP up to 
approximately 1:5.  
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4.3.4  Tests for non-specific binding of IDE sandwich ELISA reagents. 
To determine if there was any signal being generated which was not specific to the 
antigen being measured, the ELISA was tested by separate omission of the capture 
antibody, detection antibody and blocking agent (Figure 4.5).  Results showed that 
omission of either the capture and detection antibody resulted in a low background 
signal, indicating negligible cross-reactivity of the antibodies, with either the 
secondary antibody or the blocking agent.  However, it should be noted that there 
were some differences in the protocol used to measure the AIBL samples from this 
protocol:  1) The coating pH was 8.6 in this protocol instead of 9.6; 2) Tween-20 was 
only present in the PBS wash following the secondary antibody, and 3) Fraction V 
BSA was used instead of cell-culture grade BSA.  There was negligible cross-
reactivity observed between assay reagents using this protocol. 
 
Figure 4.5  Testing for non-specific binding/cross-reactivity in the IDE sandwich 
ELISA using ab28561 as coating antibody (1:400) and LS-C55007 as detection 
antibody (1:750).  Pooled control plasma (PCP) was run diluted at 1:2 and all 
control wells contained 625 ng/mL of purified recombinant rat IDE (rrIDE).  Plates 
were coated at pH 8.6 O/N at 4°C.  Otherwise, the assay was performed as detailed 
in Section 2.2.5.3.  Data is not blank adjusted – dashed line indicates blank.  Results 
show there is negligible signal generated when either coating or detection antibody 
was omitted, whereas the signal was increased 2-fold when blocking agent was 
omitted.  
  
193 
 
4.3.5  Optimising the coating conditions for the IDE sandwich ELISA 
For this purpose, a comparison was made between coating overnight at 4°C and 
coating for 2 hr at room temperature (RT ~ 25°C).  The pH of the coating buffer was 
also compared (original conditions of pH 8.6 were compared to pH 9.6), as the 
recommended pH for the coating buffer was pH 9.6.  The results show that coating 
at a pH of 9.6 for 2hr at RT was superior to other conditions for the rrIDE standard 
curve (Figure 4.6 (A)), with a larger dynamic range, however background was similar 
for all conditions (difference of 0.049 between lowest and highest value). 
For the plasma dilutions (Figure 4.6 (B)), the coating condition of overnight at 4°C 
with the coating buffer at pH 8.6 was optimal.  Coating for 2 hr at room 
temperature (pH 9.6) provided the next best result, however for the 1:2 dilution 
there was negligible difference in signal compared with coating overnight at 4°C (pH 
8.6) (difference of 0.032 OD units for 1:1 dilution and 0.002 units for 1:2).  As the 
plasma would need to be diluted to fall within the range of the standard curve, it 
was concluded that overall the optimal coating condition was 2 hr at room 
temperature (pH 9.6).  
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Figures 4.6 (A) and (B)  Optimisation of coating conditions for the IDE sandwich 
ELISA.  The sandwich ELISA used ab28561 (Ab 3) as coating antibody (1:400) and LS-
C55007 (Ab 2) as detection antibody (1:750).  The assay was performed as detailed 
in Section 2.2.5.3.  Data is shown without blank-adjustment.  Recombinant rat IDE 
(rrIDE) used for the standard curve (Graph A.) at 50 to 5000ng/mL.  Pooled control 
plasma (PCP) was run neat (0) and diluted 1:1 and 1:2 (Graph B.).  Plates were 
coated at pH 8.6 or 9.6 O/N at 4°C, and pH 8.6 or 9.6 for 2hr at room temperature 
(RT - approximately 25°C).   
  
195 
 
4.3.6  Optimising the sample and detection antibody diluent in the IDE 
sandwich ELISA. 
The composition of the sample and antibody diluents in a sandwich ELISA can have 
a dramatic impact on the binding behaviour of the antibodies to the antigen.  
Phosphate-buffered saline at a pH of 7.4 is one of the most commonly used diluents 
in ELISAs due to its stability at physiological pH.  Often low concentrations of BSA 
are added to buffers to stabilise proteins in solution.  Therefore the addition of 1% 
BSA to PBST as the sample diluent was tested compared with PBST alone (Figures 
4.7 (A) and (B)).  In addition, it has been shown that the addition of polyethylene 
glycol (PEG) can increase the speed of an immune reaction and enhance the signal 
in an ELISA (Morissette, et al., 1991).  Consequently, PEG (6000) was also added to 
the detection antibody buffer (PBST) and compared with using PBST alone (Figures 
4.7 (A) and (B)).  The buffer conditions were tested on purified rat IDE as well as 
two plasma dilutions (1:1 and 1:2).  The results showed that the addition of 1% BSA 
to the sample diluents had virtually no effect on the standard curve (Graph A.), 
however caused a reduction of signal in the plasma (Graph B.).  The addition of PEG 
to the detection antibody buffer (PBST) increased the signal for the standard curve, 
however also increased the background in a similar fashion, resulting in no overall 
benefit (Graph A.).  Results for plasma were similar with or without the addition of 
PEG.  Overall, it was concluded that no benefit in signal amplification or dynamic 
range was seen with either the addition of BSA or PEG to the buffers.  PBST alone 
was therefore considered to be the optimal buffer for all dilution steps in the 
sandwich ELISA. 
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Figures 4.7 (A) and (B)  Optimising buffer constituents for the dilution of samples 
and detection antibody in sandwich ELISA.  Optimisation of sample and antibody 
diluents for sandwich ELISA using ab28561 (Ab 3) as coating antibody (1:400) and 
LS-C55007 (Ab 2) as detection antibody (1:750).  The assay was performed as 
detailed in Section 2.2.5.3.  Recombinant rat IDE (rrIDE) was used for the standard 
curve (Graph A.) at 50 to 5000ng/mL.  Pooled control plasma (PCP) was diluted at 
1:1 and 1:2 (Graph B.).  Data is shown without blank-adjustment.  Standard diluent 
(PBST alone for sample and antibody) was compared with adding 1% BSA to the 
sample diluent, and also compared to adding 2% PEG 6000 to the detection 
antibody diluent.  
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4.3.7  Improvements in detected signals in the IDE sandwich ELISA 
following changes to the detection antibody incubation time and 
temperature.  
Overnight incubations of antibodies at 4°C rather than 2 hr at room temperature 
have frequently been found to improve the signals obtained (Dako, Abcam, Cell-
signalling technology (CST)).  Therefore a 2 hr incubation (at room temperature) of 
the detection antibody was compared with incubating overnight at 4°C (Figures 4.8 
(A) and (B)).  The results demonstrated a considerably increased signal and 
improved dynamic range when incubating overnight at 4°C for both the standard 
curve and all of the individual plasma samples.  Although the background was also 
increased (background OD of 0.263 (2hr) compared with 0.377 (overnight)), this 
increase was negligible compared to the increase in signal.  Therefore, it was 
concluded that overnight incubation of the detection antibody at 4°C was superior 
to 2 hr at room temperature. 
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Figures 4.8 (A) and (B)  Optimisation of detection antibody incubation time and 
temperature.  Optimisation of detection antibody (Ab 2 diluted to 1:750) 
incubation conditions for sandwich ELISA using Ab 3 as coating antibody (1:400).  
The assay was performed as detailed in Section 2.2.5.3.  Recombinant rat IDE 
(rrIDE) was used for the standard curve (Graph A.) at 50 to 16000ng/mL.  Individual 
plasma samples were diluted at 1:2 (S1-S5 - Graph B.).  Detection antibody was 
applied and incubated for 2 hr (2hr or 2h) at room temperature (RT), compared 
with overnight (O/N) incubation at 4°C.  All other conditions were identical for both 
plates.  Data is shown without blank-adjustment.   
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4.3.8   A trial IDE sandwich ELISA was linear to approximately 4000 
ng/mL and upper detection limit was not reached at 64000 ng/mL. 
The standard curve in an ELISA is generally sigmoidal in shape, therefore 
discrimination between data points is reduced at the extreme ends of the curve.  As 
the concentration values of the samples are interpolated from the standard curve it 
is necessary for the absorbance readings of the samples fall within the linear range.  
The lower detection limit can be determined by calculating the mean of the optical 
density of the blanks and adding three standard deviations.  Values that fall below 
this detection limit should be (and were) considered to be too low to differentiate 
from background noise. 
An ELISA was run to determine the upper detection limit; this involved setting up an 
extended standard curve.  On the same ELISA plate, five individual plasma samples 
were diluted and measured to see if their readings fell within the linear portion of 
the standard curve (Figures 4.9 (A) and (B)).  The results showed that the assay was 
linear to 4000 ng/mL, the curve flattened out somewhat above this concentration, 
yet the signal continued to rise up to 64000 ng/mL.  This observation suggests an 
upper detection limit was not reached.  Considerable variation can be seen in the 
plasma samples; three of the five plasma samples assayed had values within the 
standard curve range, yet two of the samples fell above the highest standard curve 
value.  It was concluded that the standard curve would need to be extended further 
to establish the upper limit of detection. 
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Figure 4.9 (A) and (B)  Trial IDE sandwich ELISA to give an extended 11-point 
standard curve and measure five individual plasma samples.  Investigation of the 
upper detection limit in the sandwich ELISA using Ab 3 as coating antibody (1:400) 
and Ab 2 as detection antibody at 1:750.  The assay was performed as detailed in 
Section 2.2.5.3.  Recombinant rat IDE (rrIDE) was used for the 11-point standard 
curve (Graph A.) at 50 to 64000ng/mL.  Individual plasma samples were diluted at 
1:2 (S1-S5 - Graph B.) and shown on the graph, so can be compared with the lowest 
and highest data point of the standard curve (0 ng (blank) and 64000 ng).  Data is 
shown without blank-adjustment, dashed line indicates blank.   
  
201 
 
4.3.9  Coating concentration of Ab 3 in IDE sandwich ELISA produces 
the highest signal at 5 μg/mL and upper detection limit is not reached 
at 160000 ng/mL IDE. 
To optimise the coating concentration for the ELISA, and to investigate further the 
potential upper detection limit of the assay, three concentrations of Ab 3 were 
trialled with a standard curve range of rat IDE from 50 to 160000 ng/mL (Figure 
4.10).  The three concentrations of Ab 3 used were 5, 1 and 0.1 μg/mL.  It should be 
noted that only 50 μL/well of diluted coating antibody was used in this particular 
test therefore the concentration of 5 μg/mL would contain the same amount of 
antibody as 100 μL/well of 2.5 μg/mL, which was the coating concentration used in 
previous optimisation steps.  The results demonstrated that a reduction of the 
concentration of coating antibody caused a reduction in background, signal and 
dynamic range.  With all three concentrations the signal was linear to 10000 ng/mL 
but continued to rise and a plateau was not reached, even at 160000 ng/mL.  
However, the slope of the curve above 10000 ng/ml was flatter, and past the linear 
range. Based on these observations it was determined that the 5 μg/mL was the 
most suitable coating concentration, as regardless of the increased background, it 
produced the highest signal to noise ratio and largest dynamic range.   
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Figure 4.10  Optimisation of coating conditions with Ab 3 and extension of 
standard curve to 160000 ng/mL.  Comparison of coating antibody (Ab 3) 
concentration for sandwich ELISA using Ab 2 as detection antibody (1:750).  The 
assay was performed as detailed in Section 2.2.5.3.  Recombinant rat IDE (rrIDE) 
was used for the standard curve at concentrations of 50 to 160000 ng/mL. Coating 
antibody is diluted to 5µg/mL, 1.0µg/mL and 0.1µg/mL (50µl volume).  Data is 
shown without blank-adjustment.  Results show that standard curve is linear to 
approximately 10000 ng/mL for all three coating concentrations, however 
continues to increase with increasing concentration of rrIDE.   Increasing coating 
antibody concentration also increases background, yet the signal to noise ratio is 
optimal at 5 μg/mL. 
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4.3.10  Testing a non-albumin containing blocking agent in the IDE 
sandwich ELISA. 
Due to the high background absorbance of the ELISA, and the observation that both 
Ab 2 and Ab 3 cross-reacted with albumin in Western immunoblotting, the blocking 
agent (BSA) was replaced by a 3% solution of a non-albumin containing blocking 
agent (ECL™ Advance Blocking agent) to see if the background would decrease.  
Results showed that the non-albumin blocking agent increased the background 
compared with previous assays which used BSA (Figure 4.11).  It should be noted 
that the assays were not performed simultaneously and therefore a direct 
comparison could not be made.  However, when previously using BSA as the 
blocking agent, the background absorbance was consistently approximately 0.35; 
with the non-albumin block it was over 0.40.  As BSA produced a lower background, 
it was used as the blocking agent in subsequent experiments. 
 
Figure 4.11  Test of non-albumin containing blocking agent in the IDE sandwich 
ELISA.  Test of ECL™ Advance Blocking Agent to improve background absorbance 
for IDE sandwich ELISA using Ab 3 as coating antibody (1:400) and Ab 2 as detection 
antibody (1:750).  The assay was performed as detailed in Section 2.2.5.3.  
Recombinant rat IDE (rrIDE) was used for the standard curve at 500 to 16000ng/mL.  
Pooled control plasma (PCP) diluted to 1:2.  Data is shown without blank-
adjustment.  Blocking step was using 3% ECL Advance Blocking Agent in PBS.  
Results show that using the non-albumin containing blocking reagent produces a 
high background absorbance of >0.4 in the sandwich ELISA. 
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4.3.11  Low-level data analysis. 
Raw data was normalised for inter-plate variation by adjusting to a PCP internal 
control which was included on each plate.  Intra-assay variation (n = 215, based on 
the 6 plates used in the analysis) was determined to be ~11% (including samples 
with a CV of >15% that were subsequently removed from the analysis).  Following 
the removal of these samples, average CV was 5%.  Inter-assay variation was 
determined to be ~16% (n = 6).  Coefficient of variation (CV) values of duplicates 
which were >15% were excluded from the analysis.  If the CV of the PCP duplicates 
was >15%, the entire plate was excluded from the analysis.  Values < mean + 3x 
standard deviation of the blanks were considered as below the detection limit.  
Sample values for each plate were normalised to the PCP sample.  As some of the 
sample values fell outside the range of the standard curve, the concentrations could 
not be interpolated and therefore only relative differences in absorbance (minus 
blank absorbance) were compared for all samples. 
The data was noted to have a non-normal distribution as determined by visually 
inspecting histograms, box-plots and normal Q-Q plots, as well as calculating z-
scores of skewness and kurtosis.  In addition, normality tests such as the 
Kolmogorov-Smirnoff and Shapiro-Wilks tests were highly significant.  A variety of 
transformations were used to correct the normality issues (square root, natural log, 
natural log +1, reciprocal), however these were not effective.  Therefore non-
parametric tests were used to analyse the data (Kruskall-Wallis, Mann-Whitney and 
Spearman’s Rho). 
 
4.3.12  Total plasma IDE levels are reduced in MCI and AD compared 
with HC. 
A sample standard curve and set of 10 AIBL samples is shown in Figures 4.12(A) and 
(B).  To determine IDE levels according to cognitive status, the cohort was divided 
into the clinically classified groups, healthy controls (HC - including subjective 
memory complainers), mild cognitive impairment (MCI) and probable AD (AD). As 
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only a subset of the cohort was used, the HC and SMC groups were combined to 
form the healthy control group.  Mean age was significantly different between the 
groups.  It should be noted that the subset used to measure IDE levels by ELISA was 
different from the subsets used to measure IDE levels by Western immunoblotting 
and IDE activity (detailed in Chapters 3 and 5, respectively). 
The demographics for this subset of the AIBL cohort are shown in Table 4.1.  AD 
patients were significantly older, and as expected had a significantly higher 
percentage of APOE ε4 carriers than the control or MCI groups.  The plasma Aβ1-42/1-
40 ratio was significantly decreased in the MCI and AD groups, while Aβx-40 was 
significantly increased in both MCI and AD groups as compared with HC.  Plasma 
ApoE was significantly lower in AD patients, while ApoE4 levels were higher in the 
MCI group compared with HC and AD groups.  P values were not shown for brain Aβ 
load as in this subset there was only one individual in the HC group who underwent 
the PiB-PET scan.  All other variables were not significantly different between 
groups. 
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Figure 4.12 (A) and (B)  Sample standard curve and 10 sets of samples.  The assay 
was conducted as detailed in Section 2.2.5.3.  Recombinant rat IDE (rrIDE) was 
diluted to concentrations of 50 to 16000 ng/mL (Graph A.) and plasma samples 
(Graph B) including PCP were loaded at a dilution of 1:2 (33.3 μL plasma per well) in 
duplicate.  Error bars indicate ±SD.  Data is not blank-adjusted, dashed line indicates 
blank (Graph B).  Some samples had absorbances outside of the range of the 
standard curve; as a result only relative differences could be compared. 
 
  
207 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK)  
208 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1  Basic demographics of the AIBL cohort subset of participants for whom 
plasma IDE levels were measured by ELISA.  Plasma samples (33.3 μL per well in 
duplicate) from the AIBL cohort were assayed with an in-house sandwich ELISA as 
detailed in Section 2.2.5.3.  Other variables were measured as outlined in Section 
2.2.2.1.  Continuous variables are expressed as mean (median) ± standard 
deviation.  P values were determined by Kruskall-Wallis tests using the Monte Carlo 
method.  As only a subset of the cohort was tested, the HC and subjective memory 
(SMC) groups were combined to provide the healthy controls for this assay.  n 
values vary due to missing values for some data or in the case of brain Aβ load, only 
a subset of the cohort underwent Pib-PET scans.  P value was not given for brain Aβ 
load as there was only one healthy control in this subgroup.  As ApoE4 is only 
expressed in individuals carrying the APOE ε4 allele, the n-values are reduced for 
this variable. 
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Total IDE levels as determined by the developed sandwich ELISA (Figure 4.13(A)) 
were found to be significantly lower in the MCI (p = 0.000) group compared with 
the HC group.  IDE levels were also lower in the AD group compared with the 
controls, however failed to reach significance (p = 0.062, after Bonferroni correction 
for multiple testing p = 0.186).  There was no significant difference between IDE 
levels in the MCI and AD groups (p = 0.260, after Bonferroni correction p = 0.780).  
No differences were observed in total IDE levels between males and females (Figure 
4.13(B), p = 0.136). 
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Figure 4.13(A) and (B)  Levels of total plasma IDE are decreased in MCI and AD 
compared with HC, and no different in males versus females.  Plasma samples 
(diluted 1:2 - 33.3 μL per well in duplicate) from the AIBL cohort were assayed with 
an in-house sandwich ELISA to measure total IDE as detailed in Section 2.2.5.3.  The 
average absorbance of the duplicates was obtained for each sample, and the 
median of these values by classification were compared by a Kruskall-Wallis test, 
using Mann-Whitney tests for post-hoc analysis with Bonferroni correction applied 
to adjust for multiple testing for significant comparisons only.  Data represents 
medians with 95% confidence interval (CI), n = 177 (57 HC/50 MCI/70 AD).  Values 
were blank adjusted and normalised to the internal standard sample value included 
on each plate to control for plate-to-plate variation.  Results showed a significant 
reduction in total IDE for MCI compared with HC (p = 0.000), however the reduction 
seen in AD compared with HC lost significance after Bonferroni correction (Graph 
A., p = 0.186).  No differences in total IDE levels were seen between males and 
females (Graph B., p = 0.136). 
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4.3.13  Total plasma IDE levels reduce (not significantly) with age. 
As IDE levels in the hippocampus have previously been reported to decline with 
ageing (Caccamo, et al., 2005), total levels measured with ELISA were analysed by 
age quartiles to determine if this phenomenon occurs in the periphery (Figure 
4.14).  Results showed that similar to the hippocampus, IDE levels in the blood also 
tend to decrease with age, particularly in age groups over 78 years, however the 
reduction was not statistically significant. 
 
Figure 4.14  Total plasma IDE levels reduce (not significantly) with age.  Plasma 
samples (diluted 1:2 - 33.3 μL per well in duplicate) from the AIBL cohort were 
assayed with an in-house sandwich ELISA to measure total IDE as detailed in Section 
2.2.5.3.  The average absorbance of the duplicates was obtained for each sample, 
and the median of the groups were compared by a Kruskall-Wallis test.  Data 
represents medians with 95% confidence interval (CI).  n = 177 (Quartile 1 (60-68) n 
= 52/Quartile 2 (69-77) n = 59/Quartile 3 (78-86) n = 50/Quartile 4 (87-96) n = 15).  
Results show that IDE levels tend to reduce with age, albeit not significantly (p = 
0.119). 
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4.3.14  APOE ε4 carriers do not have significantly different total 
plasma IDE levels compared with non-carriers. 
Several studies have demonstrated a difference in cerebral IDE expression between 
APOE ε4 carriers and non-carriers, with ε4 carriers shown to have reduced 
expression of IDE.  To ascertain if this effect also occurs in the plasma, total IDE 
levels were compared between carriers and non-carriers (Figure 4.15(A)).  Results 
showed that ε4 carriers tended to have lower total IDE levels than non-carriers, 
however this was not statistically significant (p = 0.109).  When stratified by ε4 
status and analysed by classification (Figures 4.15(B) and (C)), there was a non-
significant trend toward lower IDE levels in MCI and AD compared with controls still 
in ε4 carriers (p = 0.068), but not in non-carriers (p = 0.114). 
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Figure 4.15(A)  Total IDE levels are not significantly reduced, in APOE ε4 carriers 
compared with non-carriers.  Plasma samples (diluted 1:2 - 33.3 μL per well in 
duplicate) from the AIBL cohort were assayed with an in-house sandwich ELISA to 
measure total IDE as detailed in Section 2.2.5.3.  The average absorbance of the 
duplicates was obtained for each sample, and the median of these values by APOE 
ε4 genotype status were compared by a Kruskall-Wallis test.  Data represents 
medians with 95% confidence interval (CI), n = 174 (89 ε4/85 non-ε4).  Results show 
no significant reduction in IDE levels between ε4 carriers and non-carriers (p = 
0.109). 
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Figure 4.15(B) and (C)  Total IDE levels are reduced in MCI and AD (but not 
significantly), in APOE ε4 carriers but not in non-carriers.  Plasma samples (diluted 
1:2 - 33.3 μL per well in duplicate) from the AIBL cohort were assayed with an in-
house sandwich ELISA to measure total IDE as detailed in Section 2.2.5.3.  The 
average absorbance of the duplicates was obtained for each sample, and the 
median of these values (after stratification by APOE ε4 genotype status) by clinical 
classification were compared by a Kruskall-Wallis test.  Data represents medians 
with 95% confidence interval (CI), (ε4 carriers) n = 88 (19 HC/23 MCI/46 AD), (non-
carriers) n = 86 (38 HC/26 MCI/22 AD).  Results show a trend toward lower IDE in 
MCI and AD for ε4 carriers (Graph B., p = 0.068) but not for non-carriers (Graph C., 
p = 0.114).  
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4.3.15  Relationships between total plasma IDE levels and other 
biochemical data collected in the AIBL study 
4.3.15.1 Total IDE levels correlate with age, Aβ, testosterone, 
and HDL cholesterol. 
To determine if there were any relationships between total plasma IDE levels and 
other biochemical data collected in AIBL study, correlation analyses were 
performed (Table 4.2).  Details of the methods used to measure the variables other 
than IDE are outlined in Section 2.2.2.1.  Plasma IDE was analysed for any 
correlation with age as it has been reported that IDE expression shows an age-
dependent reduction in the brain.  Plasma insulin, Aβ40 and Aβ42 (and fragments), 
and total ApoE and ApoE4 were analysed for correlations with IDE, as both insulin 
and Aβ are substrates of IDE, and ApoE has been associated with reduced IDE 
expression.  Testosterone (total and calculated free), estradiol and cholesterol were 
also examined for correlation with total IDE levels, as these have been associated 
with changes in IDE expression.  Total plasma IDE was also analysed against brain 
Aβ load to see if any correlation existed.  Results demonstrated a significant inverse 
correlation between levels of total plasma IDE and both plasma Aβ1-42 (rs = -.236, p 
= 0.002) and Aβ1-40 (rs = -.225, p = 0.003).  IDE also tended towards an inverse 
correlation with Aβx-42 (rs = -.144, p = 0.060), however this did not reach 
significance.  Total IDE in plasma also showed an inverse correlation with age (rs = -
.182, p = 0.015) and HDL cholesterol ( rs = -.158, p = 0.036), and a positive 
correlation with total testosterone (rs = .173, p = 0.022) and free testosterone (rs = 
.172, p = 0.022).  No other variables correlated with plasma total IDE.  Because 
using Bonferroni correction to adjust the rejection criteria for multiple testing 
would be too stringent in this instance (because of 18 tests in total), Bonferroni-
Holm correction was instead used to reduce the chances of Type II errors (Holm, 
1979).  After the correction was made, only Aβ1-42 (p = 0.036) was still significant, 
however Aβ1-40 almost reached significance (p = 0.051).  
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Table 4.2  Correlation matrix of total plasma IDE levels with other variables.  
Plasma levels of total IDE were analysed for relationships with sex (gender), age, 
and plasma insulin, Aβ species, ApoE species, testosterone, oestradiol, lipids and 
brain Aβ load (two tailed) (methods of data collection are outlined in Section 
2.2.2.1).  n values vary due to missing values for some data or in the case of brain 
Aβ load only a subset of the cohort underwent PiB-PET scans.  For ApoE4, n value is 
lower as only the APOE ε4 carriers express this isoform.  Results show a significant 
but weak negative correlation exists between IDE levels and age (rs = -.182, p = 
.015), Aβ1-42 (rs = -.236, p = .002), Aβ1-40 (rs = -.225, p = .003), and HDL cholesterol (rs 
= -.158, p = .036).  Significant positive correlations were observed with total 
testosterone (rs = .173, p = .022) and free testosterone (rs = .172, p = .022).  Aβx-42 
approached a weak correlation however did not reach significance (rs = -.144, p = 
.060).  Following Bonferroni-Holm correction for multiple testing, only Aβ1-42 (p = 
0.036) was still significant, although Aβ1-40 almost reached significance (p = 0.051).  
* indicates significance at the 0.05 level, ** indicates significance at the 0.01 level.  
(“unadj.” = unadjusted, prior to Bonferroni-Holm correction, “adj.” = adjusted by 
Bonferroni-Holm correction). 
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To exclude the possibility of an effect of gender on the results, particularly 
regarding testosterone and oestradiol which differ greatly between males and 
females, the overall subset was stratified by gender and correlation analyses 
performed again (Tables 4.3(A) and (B)).  Results showed that the unadjusted 
correlation between IDE and Aβ1-42 was still significant in both males (rs = -.265, p = 
0.031) and females (rs = -.225, p = 0.019).  In males the correlation with Aβ1-40 was 
also still significant (rs = -.287, p = 0.019), but in females was reduced to a non-
significant trend (rs = -.180, p = 0.061).  Similarly, the correlation with age was 
reduced to a non-significant trend for both males (rs = -.224, p = 0.070) and females 
(rs = -.160, p = 0.095).  Associations between IDE and HDL cholesterol disappeared 
when stratified by gender.  The positive correlations of IDE with total and free 
testosterone, however, were strengthened in males when stratified [(rs = .314, p = 
0.010) and (rs = .334, p = 0.006), respectively] but in females this correlation 
disappeared (rs = .039, p = 0.689).  When adjusted for multiple testing by 
Bonferroni-Holm correction, all associations became non-significant. 
When stratified by APOE ε4 status (Tables 4.4 (A) and (B)), for the non- ε4 carriers 
significant inverse correlations were observed between total plasma IDE and Aβ1-40 
(rs = -.255, p = 0.015), Aβ1-42 (rs = -.226, p = 0.038), and HDL cholesterol (rs = -.247, p 
= 0.022).  For ε4 carriers, an inverse correlation was seen with Aβ1-42 (rs = -.245, p = 
0.022) and a positive correlation with total testosterone (rs = .213, p = 0.048) and 
free testosterone (rs = .221, p = 0.038).  Following Bonferroni-Holm correction 
however, associations for both ε4 carriers and non-carriers were no longer 
significant. 
After stratification by clinical classification, the correlations seen between total IDE 
and Aβ1-42 and Aβ1-40 were found to be restricted to AD patients only (rs = -.361, p = 
0.002, n = 70) and (rs = -.268, p = 0.025, n = 70), respectively (not shown in tables).  
Stratifying further by ε4 status showed that the association in AD was only in non- 
ε4 carriers for Aβ1-42 (rs = -.634, p = 0.002, n = 22), and Aβ1-40 (rs = -.527, p = 0.012, n 
= 22).  This stratification strengthened the correlations by approximately two-fold. 
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Tables 4.3 (A)  Correlation matrix of total plasma IDE levels with other 
biochemical variables separately by gender (males only).  Table 4.3 (A) shows 
correlation analysis of total plasma IDE with age, and plasma insulin, Aβ species, 
ApoE species, testosterone, oestradiol, lipids and brain Aβ load (two tailed).  
Methods of data collection are outlined in Section 2.2.2.1.  n values vary due to 
missing values for some data or in the case of brain Aβ load only a subset of the 
cohort underwent PiB-PET scans.  For ApoE4, n value is lower as only the APOE ε4 
carriers express this isoform.  Results show that significant negative correlations are 
retained in males between IDE and Aβ1-42 (rs = -.265, p = 0.031), Aβ1-40 (rs = -.287, p = 
.019), and the positive correlation in males was stronger with total testosterone (rs 
= .314, p = .010) and free testosterone (rs = .334, p = .006).  However, following 
Bonferroni-Holm correction, all associations were no longer significant.  ** 
indicates significance at the 0.01 level, * indicates significance at the 0.05 level. 
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Tables 4.3 (B)  Correlation matrix of total plasma IDE levels with other 
biochemical variables separately by gender (females only).  Table 4.3 (B) shows 
correlation analysis of total plasma IDE with age, and plasma insulin, Aβ species, 
ApoE species, testosterone, oestradiol, lipids and brain Aβ load (two tailed).  
Methods of data collection are outlined in Section 2.2.2.1.  n values vary due to 
missing values for some data or in the case of brain Aβ load only a subset of the 
cohort underwent PiB-PET scans.  For ApoE4, n value is lower as only the APOE ε4 
carriers express this isoform.  Results show that significant negative correlations are 
retained in females only between total IDE and Aβ1-42 (rs = -.225, p = 0.019),.  
However, following Bonferroni-Holm correction, the association was no longer 
significant.  * indicates significance at the 0.05 level. 
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Table 4.4 (A) Correlation matrix of total plasma IDE levels with other variables for 
APOE ε4 non-carriers only.  Plasma levels of full-length IDE were analysed for 
relationships with sex, age, and plasma insulin, Aβ species, ApoE species, 
testosterone, oestradiol, lipids and brain Aβ load (two tailed) after stratifying data 
by APOE ε4 status (methods of data collection are outlined in Section 2.2.2.1).  n 
values vary due to missing values for some data or in the case of brain Aβ load only 
a subset of the cohort underwent PiB-PET scans.  For ApoE4, no values are shown 
as only the APOE ε4 carriers express this isoform.  Results show significant inverse 
correlations between IDE levels and Aβ1-40 (rs = -.262, p = 0.015), Aβ1-42 (rs = -.226, p 
= 0.038) and HDL cholesterol (rs = -.247, p = 0.022).  Following Bonferroni-Holm 
correction for multiple testing, no associations remained significant.  * indicates 
significance at the 0.05 level. 
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Table 4.4 (B) Correlation matrix of total plasma IDE levels with other variables for 
APOE ε4 carriers only.  Plasma levels of full-length IDE were analysed for 
relationships with sex, age, and plasma insulin, Aβ species, ApoE species, 
testosterone, oestradiol, lipids and brain Aβ load (two tailed) after stratifying data 
by APOE ε4 status (methods of data collection are outlined in Section 2.2.2.1).  n 
values vary due to missing values for some data or in the case of brain Aβ load only 
a subset of the cohort underwent PiB-PET scans.  Results show significant inverse 
correlations between IDE levels Aβ1-42 (rs = -.245, p = 0.022) and a positive 
correlation with total testosterone (rs = .213, p = 0.048) and free testosterone (rs = 
.221, p = 0.038).  Following Bonferroni-Holm correction for multiple testing, no 
associations remained significant.  * indicates significance at the 0.05 level. 
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4.3.15.2  The ratio of total IDE to insulin is lower in MCI and AD 
individuals. 
As previously mentioned, IDE has a high affinity for both insulin and Aβ, and as a 
result the levels of these substrates in relation to IDE may provide better 
discrimination between clinical classifications than the levels of IDE alone.  
Therefore the ratio of total IDE to insulin was calculated and compared between 
classifications (Figure 4.16(A)).  An increase in insulin relative to total IDE levels or a 
decrease in IDE relative to insulin levels would lead to a reduction of the IDE/Insulin 
ratio.  Either of these changes could influence the degradation of Aβ (both directly 
and indirectly via other effects of insulin, for example), and may lead to an increase 
in plasma Aβ due to decreased degradation.  The results showed that the 
IDE/insulin ratio was significantly lower in MCI subjects compared with HC subjects 
(p = 0.009).  After applying Bonferroni correction for multiple testing the difference 
was still significant (p = 0.027).  The IDE/insulin ratio was also lower in the AD group 
compared with controls (p = 0.032) however after Bonferroni correction for 
multiple testing was no longer significant (p = 0.096). 
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Figure 4.16(A)  AD and MCI individuals have a lower IDE/Insulin ratio than 
controls (overall).  Insulin levels were measured as outlined in Section 2.2.2.1.  
Plasma samples (diluted 1:2 - 33.3 μL per well in duplicate) from the AIBL cohort 
were assayed with an in-house sandwich ELISA to measure total IDE as detailed in 
Section 2.2.5.3.  The average absorbance of the duplicates was obtained for each 
sample, and a ratio was calculated of total plasma IDE to plasma insulin (IDE/Insulin 
ratio).  The median of these values were compared between classifications by a 
Kruskall-Wallis test with Mann-Whitney post-hoc tests (Bonferroni correction 
applied for multiple testing).  Data represents medians with 95% confidence 
interval (CI), n = 176 (57 HC/50 MCI/69 AD).  Results show the MCI group has a 
lower IDE/insulin ratio than HC (p = 0.027 after Bonferroni correction). 
 
When the groups were stratified for APOE ε4 status, only the non-ε4 carriers had 
significantly different IDE/Insulin ratios by classification (Figure 4.16(B) and (C)).  
Results for this group showed a significant reduction of the IDE/Insulin ratio in the 
MCI group compared with HC group (p = 0.012, after Bonferroni correction p = 
0.036).  There was no significant differences observed between the AD group and 
either MCI (p = 0.247), or HC group (p = 0.235).  For the ε4 carriers there were no 
significant differences between classifications (p = 0.386). 
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Figure 4.16(B) and (C)  MCI individuals that do not carry an APOE ε4 allele have a 
lower IDE/Insulin ratio than non-ε4 controls.  Insulin levels were measured as 
outlined in Section 2.2.2.1.  Plasma samples (diluted 1:2 - 33.3 μL per well in 
duplicate) from the AIBL cohort were assayed with an in-house sandwich ELISA to 
measure total IDE as detailed in Section 2.2.5.3.  The average absorbance of the 
duplicates was obtained for each sample, and a ratio was calculated of total plasma 
IDE to plasma insulin (IDE/Insulin ratio).  Data was stratified by APOE ε4 status and 
the median of these values were compared between HC/MCI/AD classifications by a 
Kruskall-Wallis test with Mann-Whitney post-hoc tests, and found to be significantly 
different in the non-ε4 carriers only (p = 0.036 after Bonferroni correction applied 
for multiple testing) but no differences were observed between classifications for 
ε4 carriers (p = 0.386).  Data represents medians with 95% confidence interval (CI), 
(non-ε4) n = 85 (38 HC/26 MCI/21 AD), (ε4 carriers) n = 88 (19 HC/23 MCI/46 AD). 
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4.3.15.3  The ratio of total IDE to Aβ42+40 is significantly lower in 
MCI and AD compared with HC. 
Similar to the IDE/insulin ratio, the ratio of IDE to total levels of both Aβ42 and Aβ40 
may offer some information about AD, and in fact may be more relevant to 
Alzheimer’s pathology than IDE/Insulin ratios.  It has been observed that plasma Aβ 
is generally elevated in early AD compared with controls and reduces as Aβ is 
deposited into SP in the brain (Kawarabayashi, et al., 2001; Schupf, et al., 2008), 
therefore the ratio of plasma IDE/Aβ levels may be pertinent in the prodromal 
stages of AD with respect to the regulation of plasma Aβ levels.  This may be 
reflected in the MCI group, which represents the pre-symptomatic period prior to 
full-blown AD symptoms becoming apparent.  Hence, the IDE/Aβ42+40 ratios were 
calculated (using Aβ1-42 and Aβ1-42) and analysed by classification (Figure 4.17(A)). 
The results show a significant reduction in the IDE/Aβ42+40 ratio in MCI (p = 0.000) 
and AD (p = 0.024) compared with HC after Bonferroni correction for multiple 
testing (MCI<AD<HC). When stratified for APOE status (Figures 4.17(B) and (C)), no 
significant differences were observed between clinical classifications for the 
IDE/Aβ42+40 ratio, however a trend toward lower ratios were seen in the MCI group 
compared with controls and AD (p = 0.071) but only in the non-ε4 carriers. 
The decrease in IDE levels (as shown in the current study) relative to Aβ, together 
with an increase in Aβ accounts for the reduction in IDE/Aβ42+40 ratios observed.  
Only a slight increase was observed in Aβ40 species indicating that the reduction of 
IDE was the major factor contributing to the differences observed.  It was 
concluded that the IDE/Aβ42+40 ratio may be of benefit for differentiating between 
healthy controls and pre-symptomatic or symptomatic AD patients. 
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Figure 4.17(A)  The plasma IDE/Aβ42+40 ratio is significantly reduced in MCI and AD 
in comparison to HC.  Aβ1-42 and Aβ1-40 were measured as outlined in Section 
2.2.2.1.  Plasma samples (diluted 1:2 - 33.3 μL per well in duplicate) from the AIBL 
cohort were assayed with an in-house sandwich ELISA to measure total IDE as 
detailed in Section 2.2.5.3.  The average absorbance of the duplicates was obtained 
for each sample, and a ratio of total plasma IDE to plasma Aβ42+40 (IDE/Aβ42+40 ratio) 
was calculated.  The median of these values were compared between classifications 
by a Kruskall-Wallis test with Mann-Whitney post-hoc tests (with Bonferroni 
correction applied for multiple testing).  Data represents medians with 95% 
confidence interval (CI), n = 175 (57 HC/48 MCI/70 AD).  Results show that after 
Bonferroni correction the IDE/Aβ42+40 ratio is significantly lower in MCI (p = 0.000) 
and AD (p = 0.024) compared with HC. 
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Figure 4.17(B) and (C)  The plasma IDE/Aβ42+40 ratio is not significantly reduced in 
MCI and AD in comparison to HC when stratified by APOE status.  Aβ1-42 and Aβ1-40 
were measured as outlined in Section 2.2.2.1.  Plasma samples (diluted 1:2 - 33.3 μL 
per well in duplicate) from the AIBL cohort were assayed with an in-house sandwich 
ELISA to measure total IDE as detailed in Section 2.2.5.3.  The average absorbance 
of the duplicates was obtained for each sample, and a ratio of total plasma IDE to 
plasma Aβ42+40 (IDE/Aβ42+40 ratio) was calculated.  The median of these values were 
compared between classifications by a Kruskall-Wallis test with Mann-Whitney 
post-hoc tests (with Bonferroni correction applied for multiple testing).  Data 
represents medians with 95% confidence interval (CI).  (Non-ε4 carriers) n = 85 (38 
HC/25 MCI/22 AD), (ε4 carriers) n = 87 (19 HC/22 MCI/46 AD).  Results show no 
significant differences between classifications for ε4 carriers (p = 0.092), however a 
trend toward lower IDE/Aβ42+40 ratio was seen in MCI for the ε4 non-carriers only (p 
= 0.071). 
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4.3.15.4  The ratio of total IDE to Insulin + Aβ42+40 is significantly 
lower in MCI and AD compared with HC. 
Because significant differences were observed between the classifications for both 
the IDE/Insulin ratio and also the IDE/Aβ42+40 ratio, there may be a combined effect 
of increased insulin and increased Aβ with reduced IDE in plasma, thus the ratio of 
IDE to combined levels of insulin and Aβ could potentially differentiate MCI and AD 
compared to control subjects better than the IDE/insulin or IDE/Aβ42+40 ratios.  To 
address this possibility, insulin values (in mU/L) were converted into pg/mL and 
added to the Aβ42+40 values to give a total value of Insulin + Aβ42+40 in pg/mL.  The 
ratio of IDE to insulin + Aβ42+40 was then analysed by classification to see if it could 
differentiate between MCI and/or AD with controls more effectively than insulin or 
Aβ42+40 alone (Figure 4.18(A)). 
The results show that the IDE/Insulin + Aβ42+40 ratio was similar to the IDE/Aβ42+40 
ratio in that there was a highly significant decrease in MCI compared with controls 
(p = 0.000) and a significant reduction in AD compared with controls (p = 0.024) 
after Bonferroni correction for multiple testing (MCI<AD<HC).  Using the 
combination of insulin and Aβ levels in the ratio rather than just Aβ alone did not 
produce any additional benefits to using Aβ levels alone in this subgroup.  However, 
when stratified by APOE status (Figures 4.18(B) and (C)), the non-ε4 carriers showed 
a similar result to the overall results with a significantly lower ratio in MCI 
compared with HC (p = 0.048 after Bonferroni correction), while the ε4 carriers 
were not significantly different between classifications (p = 0.172).  It was 
concluded that similar to the IDE/Aβ42+40 ratio, the IDE/Insulin + Aβ42+40 ratio may 
be useful for differentiating between healthy controls and pre-symptomatic or 
symptomatic AD patients. 
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Figure 4.18(A)  The plasma IDE/Insulin+Aβ42+40 ratio is significantly reduced in MCI 
and AD in comparison to HC.  Insulin, Aβ1-42 and Aβ1-40 were measured as outlined 
in Section 2.2.2.1.  Plasma samples (diluted 1:2 - 33.3 μL per well in duplicate) from 
the AIBL cohort were assayed with an in-house sandwich ELISA to measure total IDE 
as detailed in Section 2.2.5.3.  The average absorbance of the duplicates was 
obtained for each sample, and a ratio of total plasma IDE to plasma Insulin + Aβ42+40 
(IDE/Insulin+Aβ42+40 ratio) was calculated.  The median of these values were 
compared between classifications by a Kruskall-Wallis test with Mann-Whitney 
post-hoc tests (with Bonferroni correction applied for multiple testing for significant 
results only).  Data represents medians with 95% confidence interval (CI), n = 174 
(57 HC/48 MCI/69 AD).  Results show that after Bonferroni correction MCI (p = 
0.000) and AD (p = 0.024) were significantly lower than HC. 
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Figure 4.18(B) and (C)  The plasma IDE/Insulin+Aβ42+40 ratio is significantly 
reduced in MCI in comparison to HC in APOE ε4 non-carriers only.  Insulin, Aβ1-42 
and Aβ1-40 were measured as outlined in Section 2.2.2.1.  Plasma samples (diluted 
1:2 - 33.3 μL per well in duplicate) from the AIBL cohort were assayed with an in-
house sandwich ELISA to measure total IDE as detailed in Section 2.2.5.3.  The 
average absorbance of the duplicates was obtained for each sample, and a ratio of 
total plasma IDE to plasma Insulin + Aβ42+40 (IDE/Insulin+Aβ42+40 ratio) was 
calculated.  The median of these values were compared between classifications by a 
Kruskall-Wallis test with Mann-Whitney post-hoc tests (with Bonferroni correction 
applied for multiple testing for significant results only).  Data represents medians 
with 95% confidence interval (CI), (non-ε4 carriers) n = 84 (38 HC/25 MCI/21 AD), 
(ε4 carriers) n = 87 (19 HC/22 MCI/46 AD).  Results show that after Bonferroni 
correction MCI (p = 0.000) and AD (p = 0.024) were significantly lower than HC. 
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4.3.16  Follow-up optimisation (1): Cell-culture grade BSA produces a 
dose-dependent signal in IDE sandwich ELISA but Fraction V BSA and 
HSA do not. 
After the AIBL samples were assayed in the IDE sandwich ELISA assays mentioned 
above (using cell-culture grade BSA), some experiments were performed to find out 
if a purer form of BSA could reduce the high background observed in the ELISA.  
Cross-reactivity had been seen with both Ab 2 and Ab 3 with cell-culture grade BSA 
and HSA at an equivalent range of concentrations of albumin found in human 
serum with Western immunoblotting, therefore it was deemed worthwhile to 
determine if there was still cross-reactivity under non-denaturing and reducing 
conditions.  Fraction V derived BSA is a purer formulation of BSA than cell-culture 
grade, and hence may result in less background in the sandwich ELISA due to 
reduced levels of contaminants.  Therefore, cell-culture grade BSA was compared 
with Fraction V BSA and human serum albumin (HSA) to determine if these latter 
two could contribute to any part of the signal observed in the ELISA (Figure 4.19).  
Fraction V BSA was used as the blocking agent.  The results demonstrate that there 
is no signal derived above the absorbance of the blank, from the Fraction V BSA or 
from HSA at any of the concentrations tested.  However, a dose-dependent signal 
was observed with the cell-culture grade BSA.  Furthermore, the background 
absorbance was considerably reduced by using the Fraction V BSA as a blocking 
agent instead of the cell-culture grade BSA, compared with previous experiments.  
Nevertheless, the cell-culture grade BSA was used in the experiments in this 
chapter, and the background absorbance was removed prior to analysing the 
values, therefore it was concluded that it was not a confounding issue in the assay.  
In addition, since the readings of HSA in this assay were negligible, it is likely that 
the human albumin in the plasma samples was not interfering with the detection of 
IDE in the sandwich ELISA.  Finally, Fraction V BSA was determined to be the 
superior grade of BSA as a blocking agent in this assay as compared with cell-culture 
grade BSA.  This highlights the importance of choosing the correct blocking agent 
for the assay. 
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Figure 4.19  Determination and comparison of potential cross-reactivity of 
different albumins in the IDE sandwich ELISA.  A sandwich ELISA was carried out 
using HSA and two types of BSA at different dilutions in place of plasma samples. 
HSA was diluted to physiological concentrations (60, 45, 30 and 15mg/mL) and then 
diluted as per plasma samples (1:2).  The two types of BSA were also diluted to 
concentrations equivalent to the highest and lowest physiological plasma levels of 
HSA (60 and 30 mg/mL, respectively) and then diluted as per plasma samples (1:2).  
The two types of BSA tested were Cell Culture Grade BSA (BSAS) and Fraction V BSA 
(BSAV).  Fraction V BSA was also used for the blocking step.  The OD readings 
obtained for the blank and a pooled plasma control sample are included in graph 
(PCP diluted to 1:2).  Data is shown without blank-adjustment, the blank reading is 
indicated by the dashed line.  The results show that the background absorbance can 
be reduced considerably using Fraction V BSA or HSA as blocking agents, compared 
with previous experiments which used cell-culture grade BSA. 
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4.3.17  Follow-up optimisation (2): Spike and recovery assessment of 
IDE sandwich ELISA. 
As plasma contains a plethora of constituents which potentially may interfere with 
the detection of IDE in the ELISA, a spike and recovery assessment was performed 
using recombinant rat IDE (Figure 4.20).  The assay was performed as detailed in 
Section 2.2.5.3 with the following exceptions.  Rat IDE was used to prepare two 
identical standard curves; one diluted in PBST alone (control) and the other diluted 
in a 1:2 solution of PCP.  Ideally, the two standard curves should be the same; 
however values that fall within 80-120% of the control curve are considered to be 
an acceptable recovery.  Results demonstrated significant interference by the 
plasma matrix with 100% of the standard curve signal suppressed, even at the 
highest concentrations of IDE. 
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Figure 4.20  Assessment of the potential interference of plasma components in 
the IDE sandwich ELISA.  Spike and recovery assessment ELISA was carried out on 
plasma using Ab 3 as coating antibody (1:400) and Ab 2 as detection antibody 
(1:750) as detailed in Section 2.2.5.3.  Recombinant rat IDE (rrIDE) used for the 
standard curve at concentrations of 1250 to 10000ng/mL in PBST (PBST - Control).  
Data is shown without blank-adjustment.  Pooled control plasma (PCP) was diluted 
1:2 in PBST, and used as the diluent for an identical standard curve to the control 
(PCP/PBST).  Values for the PCP/PBST samples were obtained by subtracting control 
blank from the PCP/PBST blank to obtain the signal generated from the plasma-
containing diluent, then removing this value from the spiked values (without blank 
adjustment). 
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4.4  Discussion 
The aim of this chapter was to determine IDE levels in human plasma, in samples 
which had been obtained from AIBL study participants, using an ELISA method for 
the enzyme measurement.  The test was developed to ascertain if there were any 
differences in total plasma IDE levels in AD or MCI patients, when compared with 
healthy controls.  Correlations between the IDE levels and levels of other AD-
related genetic or biochemical parameters which had been analysed in the AIBL 
study were also investigated, to determine if there were any significant 
relationships. 
At the time of starting this project, there was only one available commercial IDE 
ELISA kit recommended for the detection of IDE in human plasma.  This kit was 
screened for its suitability for measuring plasma IDE and reproducibility between 
runs.  From two runs, the kit showed a high coefficient of variation (CV) within 
duplicates (intra-assay variation) and between runs (inter-assay variation); ideally 
the variation should not exceed 15%.  The reasons for the high coefficients of 
variation were not clear; however one possibility may be related to the storage of 
the plasma samples.  The company states that plasma samples should be stored for 
less than 2 months at -80°C. Although stored correctly, the samples used to test the 
kit were in excess of 6 months old, as were the AIBL samples which were to be 
assayed.  Another possible reason for the variation may be related to the assay 
procedure: during the first 37°C incubation on Run 1, the plate sealer provided with 
the kit had warped and partially peeled off the plate.  This may have introduced 
some variation due to uneven evaporation of the wells and temperature 
differences.  An alternate brand of plate sealers were therefore used for 
subsequent incubations.  However, this would not have accounted for the high CV 
observed in the second test.  While it would have been of value to screen the kit 
further, this was not viable due to the high cost of the kit and therefore this kit was 
deemed unsuitable for this project. 
As a result, the development of an in-house ELISA was necessary.  The indirect 
(antigen coating) method was chosen initially due to its simpler design; only one 
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primary antibody was required, negating the need to screen for matching pairs of 
antibodies.  There were considerable differences in assay results, dependent on the 
primary antibody used.  Eight commercially-available IDE-specific primary 
antibodies were screened for this purpose, and these were rated according to a 
number of criteria.  These included the amount of background signal produced, the 
strength of the signal above the blank, dynamic range of the standard curve, and 
linearity of dilution.  MAb 7, one of two monoclonal antibodies that were screened, 
was also the only antibody that produced a high background, with plasma signal 
values being less than the background signal.  This antibody had been reported 
(Yfanti, et al., 2008) to cross-react with several proteins which are present in human 
plasma; it is possible that it also cross-reacted with the BSA used as the blocking 
agent, although this was not tested.  Cross-reactivity with BSA may also have 
accounted for the plasma signal being lower than the background as the HSA in 
plasma would have bound to the plate, acting as a blocking agent itself and 
preventing the BSA from binding.  This would be feasible if the antibody cross-
reacted with BSA and reacted weakly or not at all with HSA.  However, again this 
was not tested.  The other monoclonal MAb 9 produced an adequate standard 
curve dynamic range, however the values for the plasma dilutions did not 
demonstrate a dose-response.  These antibodies were therefore considered 
unsuitable for the indirect ELISA. 
The polyclonal antibodies screened showed considerable variation. While Ab 8 and 
Ab 1 had good dynamic range on the standard curve, plasma values were very low 
and there was no linearity of dilution.  Similarly Ab 4 had low plasma values but also 
a poor range on the standard curve.  In addition there was no linearity of dilution 
apparent for all three of these antibodies.  Therefore Ab 8, 1 and 4 were excluded 
as candidates for the indirect assay.  The three remaining antibodies (Ab 6, Ab 2 and 
Ab 3) showed an acceptable dynamic range on the standard curve, but plasma 
dilutions demonstrated signal in the reverse direction: showing increasing 
absorbance as the dilution increased.  One reason for this observation that is likely 
is that plasma proteins may have acted like a blocking agent, occupying binding 
sites on the plate and essentially competing for space with IDE, therefore more 
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dilution would result in less non-specific protein present, leading to less of a 
blocking effect and a more specific signal.  Therefore, it was concluded that the 
indirect method would not be appropriate for the measurement of IDE in a complex 
matrix such as plasma, and that a sandwich ELISA would be more suitable for this 
purpose. 
Three antibodies (Ab 6, 2 and 3) from the indirect ELISA tests were selected to 
develop a sandwich ELISA based on a good dynamic range on the standard curve, 
and positive signal above the blank in the plasma.  Of these, Ab 6 was in an 
unpurified form therefore was unsuitable to use as a coating antibody, as 
contaminants in the antibody preparation would compete for binding sites on the 
plate.  In addition, as Ab 2 demonstrated a strong cross-reaction with HSA, which is 
present in human plasma, it was also considered not to be suitable for a coating 
antibody as it would be capturing the HSA from the plasma as well as the IDE.  
Hence Ab 3 was tested as a coating antibody with both Ab 6 and Ab 2 tested as 
potential detection antibodies.  As both bind to similar regions which are distinct 
from the Ab 3 IDE epitope, this reduced the likelihood of steric hindrance between 
the capture and detection antibodies.  Both Ab 6 and Ab 2 worked well as detection 
antibodies, producing similar results and plasma dilutions being correctly reflected 
dose-dependently in absorbances observed.  Ab 2, however, had a marginally 
higher dynamic range for both standard curve and plasma dilutions, a lower 
background, and as Ab 2 was affinity purified it would not contain contaminants 
which could potentially interfere with the assay.  Therefore Ab 2 was chosen as 
detection antibody. 
The reagents for the sandwich ELISA were tested for cross-reactivity and generation 
of any non-specific signal by omitting each from the assay separately.  Omission of 
the capture or detection antibodies resulted in low background signals, indicating 
negligible cross-reactivity.  When the blocking agent was omitted, signal was 
increased approximately two-fold.  This would be expected as unbound sites on the 
plate surface would therefore be available for the sample or detection antibody to 
bind to, leading to a higher overall signal.  However, there were two limitations of 
this experiment; firstly the controls were performed using purified IDE and may not 
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be reflective of potential cross-reactivity which may occur with the assay reagents 
and other components of plasma.  Secondly, there were three differences in 
protocol for this experiment compared with the protocol used to measure IDE in 
the AIBL samples; the coating step was at pH 8.6 instead of 9.6, there was no 
Tween-20 in the PBS buffer washes until the final wash step after the secondary 
antibody, and Fraction V BSA was used instead of cell-culture grade BSA.  The 
change in pH would only be likely to affect the strength of binding of the antibody 
to the microplate minimally, and potentially lead to a slightly lower overall signal.  
However, it was demonstrated that coating at a pH of 8.6 produced a slightly higher 
signal in rrIDE compared with pH 9.6.  Similarly, the presence of Tween-20 in the 
wash steps would probably only slightly reduce the likelihood of non-specific 
binding, and its absence might lead to a higher overall signal.  As there was only a 
very low background observed by omission of both the coating and detection 
antibodies, it is unlikely that these two factors would significantly alter the results 
observed in a negative direction (ie. increase the background).  At the time of this 
particular experiment, the concept that assay results could be influenced by 
different formulations of BSA had not been considered, and the results obtained 
using Fraction V BSA possibly did not reflect potential cross-reactivity with cell-
culture grade BSA which was used in the protocol when testing the AIBL samples.  
Therefore in hindsight, the control tests should have been done using the cell-
culture grade BSA, and this would need to be investigated in future.  In addition, it 
would have been of value to test the assay using plasma from an animal which had 
the expression of IDE knocked out to ensure that other contaminants of the plasma 
sample were not cross-reacting with the assay components.  Unfortunately, no IDE-
knockout plasma samples were available at that time.  The cross-reactivity of BSA 
will be discussed in subsequent paragraphs.  Nonetheless, while there were some 
limitations, these control tests confirmed that negligible cross-reactivity exists 
between the secondary antibody and both the capture and detection antibodies. 
A number of conditions for the sandwich ELISA were subsequently optimised.  For 
the coating step; the antibody concentration, the buffer type and pH, and the time 
and temperature of the coating incubation were tested.  A shorter incubation time 
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of two hours at room temperature in carbonate/bicarbonate buffer (pH 9.6) was 
demonstrated to be superior for results.  Regarding blocking agents, BSA (cell-
culture grade) versus a non-albumin blocking agent were also compared (discussed 
below).  PBST was chosen as sample diluent due to its superiority in maintaining its 
pH at different temperatures (discussed further in Chapter 5).  Additionally, as the 
plasma sample dilutions were observed to be linear to 1:5, a dilution of 1:2 was 
chosen as the dilution for the AIBL samples as a midpoint between undiluted 
plasma and 1:5.  Furthermore, the addition of BSA to the sample and detection 
antibody diluents (common in ELISA assays) led to the slight reduction in signal.  
However, this test used cell-culture grade BSA which was observed to be cross-
reactive with the antibodies, and this may have caused inhibition of the signal 
through interfering with the antibody-antigen binding.  The addition of 
polyethylene glycol (PEG) to incubation buffers has been reported to increase the 
speed of the antigen-antibody reaction (Ka̧tnik, et al., 1987), however in the 
present study there was no overall benefit observed by its addition to the detection 
antibody diluent. 
The IDE sandwich ELISA, although not completely optimised due to time limitations, 
was subsequently used to measure the total IDE in the plasma of a subset of AIBL 
participants (n = 177, 57 HC/50 MCI/70 AD).  The results showed that there was a 
reduction of IDE levels for both MCI and AD groups, with only the MCI group being 
statistically significant.  The trend was observed in both male and female 
participants.  The effect of the APOE ε4 allele was seen to reduce the level of IDE 
but was not statistically significant.  Similarly, the levels of plasma IDE were 
observed to reduce with age, similar to previous reports of cerebral IDE (Caccamo, 
et al., 2005) but results were again not statistically significant; however there was a 
significant inverse correlation between IDE levels and age, albeit very weak.  The 
high variation in IDE levels was evident, and may be related to diet, exercise or 
medications which alter the expression of IDE.  It would be of value to investigate 
the potential effect of these factors on IDE expression. 
Total plasma IDE levels also correlated inversely with levels of plasma Aβ40 and Aβ42, 
and this result is supported by genetic evidence of a link between IDE 
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polymorphisms and levels of plasma Aβ (Carrasquillo, et al., 2010; Ertekin-Taner, et 
al., 2000).  This may highlight the importance of IDE in the regulation of circulating 
Aβ.  This result would support the hypothesis that a reduction in plasma IDE may 
contribute to an accumulation of Aβ species in the periphery.  Statistically this 
association was highly significant, yet the correlation was weak, which suggests that 
there are other Aβ-degrading enzymes which contribute to the regulation of plasma 
Aβ.  However when stratified by classification and APOE ε4 status, the correlation 
strengthened by two-fold only in AD non-carriers, while the association 
disappeared in MCI, HC, and ε4 carriers.  This suggests a major contribution of IDE 
toward Aβ regulation in AD patients who do not carry an ε4 allele. 
A positive correlation was also observed between plasma IDE levels and both total 
and free testosterone levels, but when split by APOE ε4 status only the ε4 carriers 
showed significant correlation.  This is not entirely unexpected due to reports in the 
literature which show that testosterone upregulates IDE expression (Udrisar, et al., 
2005; César Vieira, et al., 2011) but this has not been investigated by APOE 
genotype.  Statins have been found to lower levels of testosterone, and as there 
was a high level of statin use amongst AIBL participants, this may have confounded 
the results (Schooling, et al., 2013).  While the literature reports that oestrogen and 
progesterone also upregulate IDE (Udrisar, et al., 2005; Jayaraman, et al., 2012; 
Zhao, et al., 2010), no association was found between ELISA-measured levels of 
plasma IDE and oestrogen in the current study, and progesterone levels were not 
measured.  It would be useful to investigate the potential interaction between 
progesterone and IDE, and perhaps the cumulative effect of sex hormones on the 
regulation of IDE in future studies. 
The negative correlation between total IDE levels and plasma levels of HDL 
cholesterol is also puzzling.  When split by APOE ε4 status, only the ε4 non-carriers 
showed significance.  This result appears counter-intuitive as HDL cholesterol is 
considered to be beneficial, and as lower levels of IDE were found in the MCI and 
AD groups compared with controls it would suggest that higher levels of HDL should 
be found in the pathological state, which is contrary to what the literature has 
reported.  In fact, high levels of plasma HDL have been associated with a reduced 
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risk of AD while low levels have been found in AD patients (Reitz, et al., 2010; Kuo, 
et al., 1998) although the levels of HDL may be different prior to the MCI stage of 
pathogenesis.  No other studies have reported a potential interaction between IDE 
and HDL cholesterol, however it has been shown that both IDE and HDL can be 
regulated by dietary factors (Du, et al., 2010; Mensink, et al., 2003) and exercise 
(Kim, et al., 2011; Kodama, et al., 2007).  In particular, saturated fatty acids have 
been shown to decrease expression of IDE while other studies have demonstrated 
that they increase levels of HDL.  This perhaps could be a chance association, 
however while outside the scope of this project it would be of interest to 
investigate this potential association further. 
As the levels of insulin and Aβ were likely to be influenced by IDE levels, ratios of 
IDE to these peptides were calculated (both individually and in combination).  The 
ratios of IDE/Aβ40+42, and IDE/insulin+Aβ40+42 showed better sensitivity for 
differentiating between the HC/MCI/AD classifications than IDE levels alone.  
Conversely, no improvement of sensitivity was seen with the ratio of IDE/insulin 
compared to IDE alone.  All ratios of IDE:peptides were consistently lower in MCI 
than HC, and the IDE/Aβ40+42, and IDE/insulin+Aβ40+42 ratios were significantly lower 
in both MCI and AD, when compared with HC.  When stratified by APOE ε4 status, 
all IDE:peptide ratios were considerably lower in MCI when compared to HC, yet for 
non-ε4 carriers the ratios were higher in AD patients, almost to the same level as 
the controls.  Only in case of the IDE/Aβ40+42, and IDE/insulin+Aβ40+42 ratios did the 
ε4 carriers remain significantly lower in the AD group.  In the case of the non-ε4 
carriers, only the IDE/insulin ratio and the IDE/insulin+Aβ40+42 ratio reached 
statistical significance between MCI and HC.  The differences observed in ratios 
between ε4 carriers and non-carriers in the AD group may be related to insulin 
resistance that has been previously observed to be characteristic of non-carriers 
(Craft, et al., 2000).  However, no significant differences in insulin levels were found 
between classifications in the AIBL cohort either overall, or stratified by APOE ε4 
status. 
When Aβ1-42 and Aβ1-40 levels were analysed separately, there was no difference in 
plasma Aβ42 between classifications in this AIBL subgroup.  However, there was an 
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increase in plasma Aβ1-40 for MCI and AD groups compared with HC, albeit not 
significant, as well as a significant increase in Aβx-40.  Although the results for Aβ1-40 
were not significantly different between classifications in this subgroup, it was 
shown that after controlling for a number of covariates the differences became 
significant (Rembach, et al., 2014).  It is possible that the combination of reduced 
IDE and increased Aβ1-40 with Aβx-40 could lead to the saturation of, or at least a 
major reduction in available IDE in the plasma.  Impairment of Aβ or insulin 
degradation would then lead to an accumulation of these substrates in the 
peripheral circulation, contributing to the characteristic hyperinsulinemia and 
elevated plasma Aβ which has been linked with AD pathogenesis and pathology 
(Ertekin-Taner, et al., 2008; Kuusisto, et al., 1997; Muller, et al., 2007). 
 
Analysing ELISA background problems 
One noteworthy observation was the considerably higher background of the 
sandwich ELISA compared with the background of the indirect assays.  This 
background was shown not to be related to the secondary antibody cross-reacting 
with either the detection or coating antibodies.  Therefore, following the 
measurement of the AIBL samples above, further optimisation tests were 
performed.  The use of Fraction V BSA as the blocking agent reduced the 
background OD reading to about 1/3 of that observed with cell-culture grade BSA 
(used as a blocking agent in the AIBL sample assays).  However, the background 
signal observed with Fraction V BSA was still considerably higher than the 
background observed when either the coating or detection antibody was omitted.  
This result suggests that there may be some small degree of cross-reactivity 
between the capture and detection antibody.  This is not an unusual phenomenon 
in sandwich ELISA assays, and as the concentrations and volumes were constant for 
both antibodies the background generated was consistent across wells, and 
therefore easily removed from the analysis.  However, the potential interaction 
between the antibodies may have reduced the overall specific signal due to this 
non-specific binding which may have rendered a portion of the antibodies 
inaccessible for binding to IDE.  It is unfortunate that the cell-culture grade BSA was 
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used in the protocol for the AIBL samples, however, a constant concentration and 
amount was added to all the wells in the blocking step and the background OD 
reading was subtracted from all samples, thus this may not be an issue. Similarly 
though, the use of cell-culture grade BSA might lead to a reduced amount of Ab 3 
available for specific binding to IDE.  These factors may account for the decreased 
values seen in the standard curve in the sandwich assay as compared with each of 
the antibodies separately in the indirect assay.  However, the low background 
observed in the indirect assays for both of the antibodies suggests there was 
negligible cross-reaction with BSA, as the antibody was applied subsequent to the 
blocking agent.  Regardless, the sandwich assay could not be accurately 
quantitative because of this interference and only relative differences could be 
compared.  Future assays should use BSA preparations such as Fraction V to 
minimise the background. 
The use of antibodies raised in goat can be problematic, for example, BSA may 
contain contaminating bovine IgG which may cross react with the anti-goat 
secondary antibody, causing problems with detection.  In addition, human samples 
may contain anti-bovine IgG as well, which may cross-react with one or more of the 
three antibodies used in the assay (Kragstrup, et al., 2013; Henning & Nielsen, 
1992).  As a goat raised antibody is used for detection in this assay, it was important 
to make sure this was not occurring to ensure that there were not false positives.  
However, a mouse raised antibody was initially used for detection, and was 
compared against the goat antibody.  Although the mouse antibody produced 
slightly overall lower signal in the plasma, it demonstrated a very similar dilution 
curve to the goat antibody.  This suggests that there was unlikely to be interference 
by anti-bovine IgG in the assay.   
Although Ab 2 was shown to cross react with HSA in the Western immunoblotting 
method, plasma-derived human albumin would have been washed away prior to 
the detection antibody being applied so therefore it was determined not to be an 
issue.  Even though Ab 3 demonstrated a weak cross-reactivity with HSA on 
Western immunoblotting tests, activity experiments on degradation of a 
fluorescent peptide substrate in plasma following immunocapture with Ab 3 show 
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that 100% of activity can be inhibited with two known IDE inhibitors (to be 
discussed further in Chapter 5), providing further evidence that IDE Ab 3 shows 
negligible binding to anything else in the plate-based assays.  In addition, when 
testing purified HSA at levels found physiologically in plasma, the OD signal 
produced in the sandwich ELISA was not above background, therefore it was 
thought that HSA was unlikely to be a confounding factor in the plasma samples 
tested in the assay.  A major reason HSA was detected by Ab 3 in the Western Blot 
but not in the sandwich ELISA may be related to the denatured conformation of the 
protein under the denaturing and reducing conditions in the former method, while 
the proteins in ELISA are in native conformation. 
One limitation of this assay was related to the particularly high background 
observed when using a non-albumin containing blocking agent (that is derived 
mainly from bovine milk).  One previous study reported that two IDE antibodies 
(one monoclonal, one polyclonal) used in their project were observed to cross-react 
with fibrinogen, casein and thrombin; clotting elements of plasma which are found 
in bovine milk (Yfanti, et al., 2008).  Even though the antibodies used in the current 
study were not the same ones, it is possible therefore that the higher background 
seen with the use of the non-albumin blocking agent was due to the IDE antibodies 
similarly cross-reacting with these or other proteins in this preparation.  If this is the 
case, these elements being present in human plasma as well may be cross-reacting 
with the assay.  However, contrary to this there was little or no background 
observed when using this antibody in Western immunoblotting experiments, which 
used milk powder as a block.  This may have been due to the fact that the milk 
powder was in a less purified form, therefore having lower levels of potential cross-
reactants.  Although not addressed within the time-frame of this project, it would 
be of benefit to further investigate these potentially confounding factors.  It may be 
of value to assess circulating IDE levels in serum rather than plasma if this if the 
case. 
Perhaps the most concerning limitation of this IDE ELISA assay is the poor spike and 
recovery results.  Generally, recovery should be approximately 80-120% of the 
control value (Shah, et al., 1992).  In the current study 100% of the signal was 
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suppressed by the plasma matrix, indicating major interference.  The reason for this 
result is unclear; however there are a number of possibilities to consider.  It is 
possible that the recombinant IDE is sequestered by plasma proteins and therefore 
its detection is masked in the ELISA.  This would not have been an issue in the 
denaturing and reducing conditions of the Western blot as the conditions cause 
most proteins to disassociate.  It would be of value in the future to perform a spike 
and recovery experiment using Western immunoblotting as the method of 
measurement.  Co-immunoprecipitation experiments in plasma would also help 
determine if this is the case.  As mentioned earlier, IDE has been shown to bind to 
numerous other proteins that are present in human plasma (Bennett, et al., 
2000(a); Kurochkin & Goto, 1994; Roth, et al., 1984).  It is also known that IDE can 
be complexed with the proteasome, and that the proteasome is present in human 
plasma (Bennett, et al., 2000(b); Ichihara, 1993; Egerer, et al., 2002). 
Furthermore, heterophilic antibodies, human anti-animal antibodies and 
rheumatoid factors, which are present in human plasma, can also be responsible for 
analyte masking (Urbonaviciute, et al., 2007; reviewed in Tate & Ward, 2004).  
Cross-reactants (including BSA) can weakly link the antigen to the antibodies which 
are then removed by the washing steps along with the analyte or antibodies of 
interest, leading to falsely negative results (Valdes & Jortani, 2002).  Recent studies 
have sought to address such issues by outlining some validation steps designed to 
identify these confounding variables (Kragstrup, et al., 2013). 
Another possibility for apparently low plasma readings of IDE is that IDE itself is 
degraded by other proteases present in the plasma.  It would be of value to repeat 
the experiment with a protease inhibitor cocktail present in the plasma diluent. 
An increase in IDE concentration may cause what is known as the “hook effect” 
(reviewed in Tate & Ward, 2004) leading to a false negative result.  This occurs due 
to competition for the capture antibody.  However, the likelihood of this is low 
considering the observation that the highest concentration of standard tested in 
this assay was 160000 ng/mL and did not show a reduction of signal at the higher 
end of the curve.  The lowest concentration used in the spike and recovery test was 
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1250 ng/mL.  Unless the concentration of IDE in the plasma was higher than 160000 
ng/mL, it would be unlikely that this phenomenon would be the cause of the lack of 
signal.  Alternatively, the increase in IDE concentration in the plasma in association 
with components of the plasma matrix may cause IDE to self-aggregate.  This would 
lead to the epitopes being masked and inaccessible for antibody binding. 
Another potential factor may be that rat IDE and human IDE behave differently in 
plasma.  Although rat IDE has 95% sequence similarity to human IDE, the 
differences may still lead to structural or functional differences as observed with 
other enzymes (Pearce, et al., 1992; Glatt and Oesch, 1987).  It is also possible that 
the recombinant protein behaves differently in plasma to the native protein, for 
example altering conformation to an extent that would reduce or prevent 
antibodies from binding to the rrIDE (Cavalcante Braga, et al., 2013).   
However, failure of the spike and recovery test does not necessarily mean that the 
signal observed from human plasma samples in the AIBL cohort is not IDE.  It may 
be that the recombinant rat IDE changes conformation in human plasma, and/or 
binds to plasma proteins that do not influence human IDE.  Alternatively, it may be 
that only a portion of IDE present in the plasma is free protein, with a proportion of 
it bound to other proteins, or present in the form of dimers and tetramers which 
may not be detected by ELISA.  As mentioned previously, increasing the 
concentration of IDE may also change the binding properties toward other plasma 
constituents and/or may also induce self-aggregation. Regardless, in this project 
there is good evidence that the capture antibody Ab 3 specifically and exclusively 
binds to IDE (to be discussed further in Chapter 5) and therefore it is likely that this 
in-house IDE sandwich ELISA is specifically measuring only IDE.  However, if 
aggregation does occur, it is likely that the true level of IDE in plasma samples is 
much higher than the values measured with this assay.   
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4.4.1  Summary 
The aim of this chapter was to develop and optimise an in-house ELISA which could 
accurately and specifically measure IDE in human plasma from the AIBL cohort.  The 
development of the assay was complicated by a number of cross-reactivity issues 
associated with the antibodies and blocking buffer chosen, and the finding that 
factors in plasma appeared to interfere significantly with the detection of IDE.  As 
such, a fully-quantitative assay could not be developed, and only relative 
differences could be compared. Promising results were observed, with altered 
levels of plasma IDE in the prodromal and symptomatic stages of AD, particularly 
when considered together with circulating insulin and Aβ levels.  However, more 
work needs to be done to ascertain the source/s of the confounders and to 
determine if this has affected the accuracy of the IDE levels measured.  The ELISA 
protocol needs to be improved, and followed by validation studies and tests of 
other cohorts before the results can be confirmed, and therefore, caution should be 
exercised when considering the current results.  Indeed, the IDE levels measured by 
ELISA contradict the results obtained via Western immunoblotting.  If the results 
reflected by the sandwich ELISA are subsequently confirmed to be accurate, then 
plasma IDE may be useful as part of a biomarker panel for very early stages of AD.  
Studies of a much larger cohort would allow for the testing of a larger number of 
classifications, for example HC under 65, HC over 65, memory complainers, MCI and 
AD.  This would then reveal how IDE changes in early AD pathogenesis, and also 
help to determine IDE’s role in the development of AD. 
 
  
259 
 
CHAPTER 5 –IDE enzyme activity in plasma is higher in 
MCI compared with HC and AD. 
5.1  Introduction 
Changes in enzyme protein levels are often indicative of biochemical changes which 
may cause or reflect pathological changes in human physiology.  Often however, 
these measurements are not truly representative of the functional abilities of the 
protein in question.  In the case of an enzyme, its catalytic activity may differ due to 
a number of factors which are unrelated to enzyme protein levels themselves.  
Some of these factors include different concentrations of enzyme substrates or co-
factors such as metals, inhibitors or activators of the enzyme, or post translational 
modifications such as phosphorylation, alkylation, oxidation, s-nitrosylation, s-
glutathionylation and ubiquitination.  While there are many other types of post-
translational modifications that can occur, the types mentioned here have been 
associated specifically with the inhibition of IDE.  Other factors such as medications, 
or even alternate isoforms or the aggregation status of IDE can also have an effect 
on the function of the protein. 
A number of studies suggest that the catalytic activity of IDE does not correlate with 
IDE expression levels (Kim, et al., 2007; Miners, et al., 2009; Behl, et al., 2009).  
Therefore, assessing IDE catalytic activity is an important consideration when 
assessing IDE’s influence on Aβ and insulin levels. An immunocapture-based 
fluorometric activity assay has been previously developed to assess the catalytic 
activity of IDE in brain homogenates (Miners, et al., 2008(b); Wang, et al., 2010).  
The assay uses a specific IDE antibody to capture IDE from the sample onto a solid-
phase (96-well microplate).  A fluorogenic substrate of IDE (derived from the 
sequence of bradykinin), fluoresces when cleaved and directly represents activity 
levels.  In this chapter, the suitability of this assay for measuring IDE activity in 
plasma is investigated, prior to assessing activity in samples from the AIBL cohort. 
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5.1.1 Aims 
1. To use a fluorometric activity assay to measure the catalytic activity of IDE in 
human plasma, and determine whether the catalytic activity can 
differentiate between HC, MCI and AD. 
2. To determine if the presence of the APOE4 allele has any impact on the catalytic 
activity of plasma IDE. 
3. To identify any relationships between plasma IDE catalytic activity, expression 
levels of plasma IDE and other biochemical data obtained from the AIBL 
study. 
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5.2  Experimental summary 
The catalytic activity assay was adapted from the original assay developed by 
Miners and colleagues (2008(b), using amendements to the protocol as published 
(Wang, et al., 2009).  All of the catalytic activity assays performed were based on 
this method.  Gain adjustment was set at 1487 for all assays unless otherwise 
specified.  Assays were incubated with the fluorogenic peptide for 6 hours unless 
otherwise specified. 
 
5.2.1  Test of immunocapture-based fluorometric assay for the 
measurement of the catalytic activity of plasma IDE. 
The catalytic activity of plasma IDE was tested as detailed in Section 2.2.6.1 using 
pooled control plasma (PCP), following a previously published method (Miners, et 
al., 2008(b); Wang, et al., 2009). 
 
5.2.2  Test of fluorometric IDE activity assay specificity 
To test the specificity of the IDE catalytic activity assay further, the IDE 
substrates/inhibitors insulin and Aβ were trialled as IDE enzyme inhibitors in the 
assay, as detailed in Sections 2.2.6.2, 2.2.6.3, 2.2.6.4 and 2.2.6.5. 
 
5.2.3  Comparison of EDTA-collected blood and lithium-heparin-
(LiHep) collected blood: determining which is better in the IDE activity 
assay. 
To ascertain if the presence of EDTA as an anticoagulant in the plasma samples was 
inhibitory in the IDE activity assay, plasma isolated from EDTA-collected blood was 
compared with plasma isolated from LiHep-collected blood in an assay performed 
as described in Section 2.2.6.1. 
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5.2.4  Determination of plasma IDE catalytic activity in the AIBL cohort 
using the IDE immunocapture-based fluorometric activity assay. 
IDE catalytic activity was measured in the sub-set of samples obtained from the 
AIBL cohort as detailed in Section 2.2.6.1.  An internal control of PCP was included 
on each plate as a reference sample.  IDE activity was interpolated from the 
standard curve and expressed as the Equivalent Concentration of rrIDE (ng/mL). 
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5.3  Results 
5.3.1  PCP and rrIDE generate a time and dose-dependent signal in the 
fluorometric activity assay. 
The immunocapture-based fluorometric activity assay developed by Miners and 
colleagues (2008(b)) was originally used to measure IDE activity in brain tissue 
homogenates.  The assay has not previously been used to assess IDE activity in 
plasma, therefore it was important to carefully characterise the assay prior to 
adapting it to be used for plasma.  The capture antibody used for development of 
the assay in plasma was Ab 3 (see Section 2.1.1 for details), since it was the most 
suitable antibody to detect IDE protein in plasma by Western immunoblotting and 
to capture IDE in ELISAs (see Sections 3.3.7 and 4.3.3, respectively).  Miners, et al., 
(2008(b)) also found that, of the four IDE-specific antibodies tested, Ab 3 showed a 
consistent dose-response in activity with purified human and rat IDE and produced 
the highest signal in brain homogenates. 
To initially assess the efficacy for Ab 3 to capture IDE, the activity of diluted rrIDE or 
pooled control plasma (PCP) was measured.  Purified recombinant rat IDE (rrIDE) 
was chosen as it has similar activity to recombinant human IDE (rhIDE) (Miners, et 
al., 2008(b)).  A concentration range of rrIDE and or PCP was assessed, however 
1250 to 12500 ng/mL rrIDE and 480-1680 µg total protein PCP were found to show 
a signal above that observed for the blank.  It is noted that the blank generated a 
signal of an average of ~ 8000 fluorescence units, which may have impacted on the 
sensitivity of the assay particularly detecting lower concentrations of the rrIDE or 
PCP.  Nevertheless, the results [Figure 5.1(A) and (B)] showed a strong linear 
relationship between the amount of fluorescence and increasing concentrations of 
rrIDE (A) or PCP (B).  This association was more prominent with increasing 
incubation periods (up to the 6 hours), consistent with that shown for brain 
homogenates by Miners and colleagues where a maximum signal level was 
observed at 5 hours.  There was little difference between the 1440 μg TP/well 
samples and 1680 μg TP/well samples; the reason for this was not pursued, but it 
was decided that the loading of plasma TP/well for the measurement of IDE 
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catalytic activity needed to be restricted to between 480 and 1440 μg TP.  Overall 
these results indicate that a standard curve could be generated with Ab 3, and a 
dose and time dependent fluorescence signal was observed for plasma. The 
specificity of the observed activity in plasma was subsequently further investigated. 
The assay was performed with PCP (480μg TP) under several conditions, including: 
without the use of blocking agent, no substrate and no sample.  The results are 
shown in Figure 5.1(C).  As before, the PCP sample generated a signal that increased 
with time.  Omission of the blocking agent (BSA) led to a negligible reduction in 
signal, therefore it was concluded that there was no significant effect of the 
blocking agent in the activity assay.  Omission of the sample (vehicle buffer only) 
did result in a moderate fluorogenic signal however this did not increase with time, 
indicating that cleavage of the peptide was not occurring.  This was considered to 
be the background signal of the assay.  The majority of the background 
fluorescence appeared to be related to the fluorogenic peptide itself, with omission 
of the peptide reducing the fluorescence by ~85%.  In addition, it was observed that 
the gain adjustment setting was related to the background reading (as well as the 
samples); for a single test plate the background signal changed from 8736 RFU with 
a gain of 1712, 7435 RFU with a gain of 1679 and 3147 RFU with a gain of 1487.  At 
the higher gain settings the signal exceeded the maximum RFU of the plate reader, 
thus it was decided that subsequent assays would be gain adjusted to 1487.  
The specificity for the Ab 3 antibody to detect IDE in plasma samples was assessed 
through incubating PCP (480μg TP) with IDE antibodies Ab 1 (final amount was 8 µL 
anti-serum/well), Ab 2 (4 µg/well, purified), or with Aβ40 (8.2 µg/well).  Ab 1 binds 
to an epitope which is located within the catalytic domain of IDE (Domain 1), 
whereas Ab 2 binds to an epitope distal to the catalytic domain in Domain 4 (see 
section 2.1.1 for antibody details).  As the Aβ40 peptide is a substrate for IDE it was 
used as a competitive inhibitor thought to occupy the catalytic site of IDE, resulting 
in reduced cleavage of the fluorogenic peptide and thus a reduced signal. 
Results (Figure 5.1(D)) showed that pre-incubating the PCP sample with either Ab 1 
or Aβ40 resulted in an approximately 50% reduction in cleavage of the fluorogenic 
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peptide.  Pre-incubating PCP with Ab 2 had no effect in reducing IDE activity.  It is 
possible that this reflects that Ab 2 binds too distal to the catalytic domain to have 
an inhibitory effect on enzyme activity.  The inhibition seen by Ab 1 and Aβ40 
suggests however, that at least 50% of the fluorescence observed in the assay is 
specifically due to the cleavage of the fluorogenic peptide by IDE.   
The stocks of Ab 3 were exhausted at this stage and a new batch was obtained.  As 
batch to batch variations do occur amongst antibodies, the new batch required 
similar validation as the old antibody, prior to any further analysis and assaying the 
AIBL samples. 
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Figures 5.1(A) and (B)  Test of fluorometric IDE enzyme activity assay, using 
ab28561 (Ab 3) as coating antibody.  The activity assay was performed as detailed 
in Section 2.2.6.1 for 6 hours.  The recombinant rat IDE (rrIDE) standard curve is 
represented in Graph A, and the assay results of the pooled control plasma (PCP) 
dilutions are shown in Graph B.  The standard curve ranged from 1250ng/mL to 
12500ng/mL (50 μl/well) with each concentration in duplicate.  PCP was diluted to 
provide from 480 to 1680 μg of total protein per well in duplicate.  Fluorescence 
was generated by incubation with the fluorogenic substrate (Mca-RPPGFSAFK(Dnp)-
OH) and fluorescence measurements reflect the amount of cleavage of the 
substrate at pH 7.5 by the immunocaptured IDE.  Gain adjustment was set to 1712.  
Data is not blank-adjusted. 
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Figure 5.1(C).  Test of immunocapture-based IDE fluorometric activity assay (with 
Ab 3) to analyse components of the assay.  The activity assay was performed as 
detailed in Section 2.2.6.1 and 2.2.6.2.  Controls include the addition of PCP at 480 
μg TP for all wells with the exception of the “no sample” wells, and all samples were 
run in duplicate.  “No substrate” indicates all assay components as usual without 
the addition of the fluorogenic peptide (HEPES only).  Results show a low reading 
without the addition of fluorogenic peptide.  With all components added except the 
sample (PBST only) there is a high level of background fluorescence with this gain 
adjustment setting (1712).  Negligible difference occurs with or without the 
blocking step. 
  
268 
 
 
Figure 5.1(D).  Further validation test of fluorometric activity assay using specific 
IDE antibodies and Aβ40 as inhibitors of IDE-based cleavage of the fluorogenic 
peptide.  Prior to being added to the microplate, PCP dilutions (480 μg TP/well) 
were pre-incubated with 20 μL each of IDE antibodies Ab 1 or Ab 2, or with 20.5 μg 
of Aβ40.  IDE antibody Ab 1 was raised against an epitope of IDE which is within the 
catalytic domain, while Ab 2 was raised against an epitope close to the C-terminus 
of IDE distinct from the catalytic site.  The assay was carried out as described in 
section 2.2.6.1 and 2.2.6.2 over 6 hours, and all samples were run in duplicate.  
Blank (background) is indicated by the dashed line.  Gain adjustment was set to 
1712.  Results show that pre-incubation of PCP with Ab 2 had no effect on the 
catalytic activity of plasma IDE, however Ab 1 and Aβ40 partially reduced the activity 
of IDE by approximately 50% for the course of the experiment.  
 
 
5.3.2  Validating the new batch of coating antibody Ab 3 (ab28561). 
Polyclonal antibodies may vary considerably between batches due to a number of 
factors.  Therefore, it is essential to thoroughly screen each batch prior to use, and 
if comparisons need to be made between runs of an assay, it is important to use the 
same batch of antibody throughout.  Hence, as stocks of the original batch of Ab 3 
were exhausted, a new batch needed to be validated under the same conditions as 
the previous batch. 
Results (Figure 5.2(A) and (B)) showed the new batch of Ab 3 generated a similar 
standard curve correlation to that of the original batch (see Figure 5.1(A)), with R2 
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values of 0.9882 for Batch 1 and 0.9618 for Batch 2 at the 6 hour timepoint. 
However the maximum signal achieved was ~4-fold lower than that observed for 
the original batch.  Compared with the previous batch (using the same gain 
adjustment setting) the background was similar, with values of 3090.5 for Batch 1 
and 3114 for Batch 2.  Signal was also reduced in the PCP for the new batch, 
although not to the same extent.  The lower fluorescence signals most likely 
indicate lower IDE levels captured, possibly due to a lower affinity of IDE-specific 
antibodies in the newest batch of Ab 3, however the original and new batches were 
not tested on the same plate so could not be directly compared.   
Similarly to the previous batch of Ab 3 (Figures 5.1(A) and (B)), using the new batch 
in the fluorogenic assay resulted in standard curves that increased linearly in slope 
with increasing IDE concentration, with apparently proportional increases in signal 
up to at least 7500 ng/ml (375 ng/well IDE).  For the PCP dilutions, the assay 
demonstrated a good linear time- and protein loading-dependent response for all 
dilutions tested up to 6 hr, and up to the concentration of 1200 μg TP/well.  Similar 
to the results from the previous batch of Ab 3, little difference between the 1200 μg 
TP/well and the 1440 μg TP/well was observed.  With this batch of antibody the 
optimal protein loading of PCP appeared to be 960 μg TP/well, as this was the 
highest concentration where the signal could be differentiated from the higher 
concentrations of PCP.  It was concluded that although the overall signal was 
reduced with the new batch of Ab 3 compared to the old batch, it was still suitable 
to use in the assay. 
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Figures 5.2(A) and (B)  Test of fluorometric IDE activity assay using new batch of 
IDE Ab 3 as capture antibody.  Recombinant rat IDE (rrIDE) was used to produce a 
standard curve (Graph A) with wells containing concentrations from 625 to 12500 
ng/mL. Pooled control plasma (PCP) was diluted to aliquot 480 to 1440 μg total 
protein/well (Graph B).  All samples were run in duplicate.  The fluorogenic catalytic 
assay was run according to the method described in section 2.2.6.1.  Data is not 
blank-adjusted.  Results show that the new lot of Ab 3 produced fluorescence that 
was, overall, considerably lower than the previous lot of antibody.  However, the 
fluorescent signal was consistently reflective of the amount of protein present up to 
7500 ng/mL for the standard curve and 1200 μg total protein/well for PCP, as well 
as the time incubated. 
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Similar to the old batch, control tests were subsequently performed using the new 
batch of Ab 3 to ascertain specificity.  The first assessment was whether the 
background observed was related to the capture antibody or its components, or 
BSA which was used as the blocking agent (Figure 5.3).  The plate was coated with 
Ab 3 diluted to 2.5, 1.25 and 0.625 μg/mL, washed, and then assayed with the 
fluorogenic peptide (diluted in HEPES as previously detailed in Section 2.2.6.1).  As 
50% glycerol was a component of Ab 3, glycerol alone was also tested (1.25 μL/mL) 
with the peptide, with and without the blocking agent.  Finally, the blocking agent 
was tested alone with the peptide.  These control tests were run alongside two 
samples, containing all components of the assay with and without PCP.  Results 
showed that the signal was at the same intensity as the blank for all wells not 
containing PCP, while the wells containing PCP increased in signal for the duration 
of the assay (2 hours).  The assay was incubated for 2 hours as increases in 
fluorescent signal (above the blank) occurred within the first hour and reflected the 
pattern of results at 6 hours.  As samples wells that did not contain PCP did not 
change over time, a true signal was observed at this time point.  In addition, (on 
separate plates) the peptide alone diluted in HEPES (no other assay components) 
was tested as well as a no peptide control.  The results showed that the diluted 
peptide alone generated a similar signal to the background, with an average 
reading of 3544.25 RFU (±83.7551 SD, n=4) for the diluted peptide, while omission 
of the peptide reduced the signal by ~ 64%.  This indicates that the background 
observed is a product of the fluorogenic peptide itself, and not related to either the 
capture antibody, glycerol contained in the antibody, or blocking agent reacting 
with the fluorogenic peptide, in agreement with previous optimisation experiments 
(see Graph 5.1 (C)).  However, even though the extent of the reduction in signal 
after omission of the peptide was not as pronounced in this experiment, this may 
be related to the different gain adjustment settings.  The assay was also tested to 
see if different buffers may have any effect on the background or signal generated; 
and results showed that there was little difference between using PBST or TBST as 
the sample diluent and for washes (see Appendix).  It was also demonstrated that 
the highest physiological levels of HSA or BSA produced no signal above the blank, 
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confirming no cross-reactivity was occurring with albumin in the plasma or in the 
blocking agent (See Appendix).  
Together, these results suggest that the background was a product of the peptide 
alone, and not because of any cross-reactivity between components of the assay.  
Therefore the background was not likely to be an interfering factor in the 
measurement of IDE activity with this assay.  Therefore, for subsequent 
experiments, data was subtracted from the background signal (from Section 5.3.3 
onward). 
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Figure 5.3  Test of immunocapture-based IDE fluorometric activity assay (with 
new batch of Ab 3) to analyse components of the assay.  The activity assay was 
performed as detailed in Section 2.2.6.1 for 2 hours.  The test includes blank wells 
(all components except sample), and PCP at 480 μg TP/well (including all other 
assay components), as well as Ab 3 coated at 2.5, 1.25 and 0.625 μg/mL with the 
fluorogenic peptide (diluted in HEPES) only.  Glycerol (1.25uL/mL) was also tested 
with the peptide with and without the blocking agent (BSA – “Blk”), and BSA was 
also tested alone with the peptide.  All tests were done in duplicate.  Negligible 
difference occurs for the background signal obtained for all control wells including 
the blank, while the PCP showed an increasing signal over the three readings.  Error 
bars indicate ±SD. 
 
5.3.3  EDTA collected plasma produces a higher signal than Lithium-
heparin collected plasma in the IDE fluorometric activity assay. 
IDE is a metalloprotease which is dependent on the presence of a zinc atom for its 
catalytic activity (Ansorge, et al., 1984; Ebrahim, et al., 1991), and therefore, 
chelating agents such as EDTA or phenanthroline are likely to affect the measurable 
activity of IDE.  The collection protocol of plasma from blood requires the inclusion 
of an anticoagulant such as EDTA or Lithium-Heparin (LiHep) so that the cellular 
components of blood may be removed while retaining the other factors and 
proteins, without activating the clotting cascade.  Much of the anticoagulant is also 
retained in the plasma, which may interfere with certain down-stream applications.  
Plasma collected from the AIBL cohort is collected in the presence of either EDTA or 
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Heparin, dependent on the assay that is performed.  Thus, to determine which 
collection method is suitable for the fluorescent assay, IDE activity was assayed in 
either EDTA-collected plasma or LiHep-collected plasma. 
The results showed that whilst LiHep-collected plasma generated a similar signal to 
the blank (ie background fluorescence), EDTA collected plasma generated a signal 
above the blank (Figure 5.4). The enzymatic activity measured in the LiHep plasma 
was only approximately 15% of the signal generated from EDTA plasma.  Although 
the assay was incubated for 4 hours rather than the full 6 hours, it is not likely that 
the signal would increase to a level comparable to that seen for EDTA plasma.  
While the reasons for this difference in signal was not pursued, the findings indicate 
that EDTA collected plasma was more suitable for measurements of IDE activity 
than plasma collected in LiHep tubes. 
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Figure 5.4  Comparison of IDE activity in PCP originating from blood collected in 
EDTA tubes versus LiHep tubes.  Pooled control plasma (PCP) isolated from blood 
collection tubes originally containing EDTA or Lithium-Heparin (LiHep), were loaded 
at a concentration of 960 μg total protein per well with 8 replicates of each.  The 
IDE activity assay was conducted over 4 hr, otherwise was carried out as described 
in section 2.2.6.1 and 2.2.6.9.  Data has been blank-adjusted.  The results show that 
PCP obtained from LiHep-collected blood had very little fluorescence compared 
with PCP obtained from EDTA-collected blood, implying less active enzyme in the 
LiHep-collected blood.  Error bars indicate ±SD. 
 
5.3.4  Investigating the specificity of the IDE catalytic activity assay 
using the IDE inhibitors Aβ42 and insulin. 
According to the company product datasheet, the fluorogenic peptide Mca-R-P-P-
G-F-S-A-F-K(Dnp)-OH (Substrate V) is able to be cleaved by a number of different 
enzymes such as neprilysin (NEP), endothelin converting enzyme-1 (ECE-1), 
angiotensin-converting enzyme (ACE), cathepsin A and cathepsin X (also called 
cathepsin Z or P).  The peptide may also theoretically be cleaved by any protease 
capable of cleaving the amide bond between the amide group and quencher group.  
While the signal derived in the assay is likely to be from IDE due to the initial 
immunocapture step by a specific IDE antibody, specificity can also be assessed 
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with competing substrates.  For IDE the major substrates are Aβ and insulin which 
binds to the catalytic site, rendering it unavailable for the fluorogenic peptide.  
Plasma samples were therefore incubated with either Aβ42 or insulin prior to 
assaying.  
The results (Figures 5.5(A) and (B)) show that the signal generated from the 
fluorogenic activity assay in plasma was reduced dose-dependently, by either Aβ42 
or insulin.  At concentrations of 100 μM Aβ42 and 1mM insulin, IDE activity was 
inhibited completely.  These results indicate that the activity observed in plasma is 
most likely attributed to IDE. 
 
 
Figure 5.5(A).  Test of fluorometric activity assay specificity by inhibition with 
beta-amyloid isoform 42 (Aβ42).  The assay was conducted as detailed in Sections 
2.2.4.15, 2.2.6.3 and 2.2.6.1 over 6 hours.  Pooled control plasma (PCP) was loaded 
at a dilution of 960 μg total protein per well in duplicate and subsequently 
incubated with concentrations of 0, 25, 50 and 100 μM Aβ42.  Data has been blank-
adjusted.  Results show that Aβ42 inhibited the activity of immunocaptured IDE in a 
dose-responsive fashion, and total inhibition was seen at a concentration of 100 
μM.  Error bars indicate ±SD. 
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Figure 5.5(B).  Test of fluorometric activity assay specificity by inhibition with 
insulin.  The assay was conducted as detailed in Sections 2.2.6.4, 2.2.6.5 and 2.2.6.1 
over 5 hours.  Pooled control plasma (PCP) was loaded at a dilution of 960 μg total 
protein per well in duplicate and subsequently incubated with 0, 0.25, 0.5, and 1 
mM concentrations of insulin.  Data has been blank-adjusted.  The results show that 
insulin inhibited the activity of immunocaptured IDE in a dose-responsive fashion, 
and total inhibition was seen at a concentration of 1.0 mM insulin.  Error bars 
indicate ±SD. 
 
5.3.5  Optimisation Summary 
The IDE fluorometric activity assay that had previously been used for assaying IDE 
activity in brain homogenates was adapted for use in human plasma.  It was 
demonstrated that the fluorescent signal obtained for the standard curve and 
plasma sample increased in a time- and concentration-dependent manner, and no 
cross-reactivity occurred between the fluorogenic peptide and the capture 
antibody, glycerol, BSA or HSA.  Although a moderate background signal was 
observed, it was similar to that observed for the diluted peptide alone and did not 
increase over time, indicating no cleavage of the peptide was occurring.  Omission 
of the fluorogenic peptide significantly reduced the signal by at least two-thirds, 
indicating that the background was primarily due to the peptide alone. 
Fluorescence signal obtained for the sample was above the blank and could be 
completely inhibited by two known IDE substrates (insulin and Aβ).  This is 
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consistent with the original study (Miners, et al., 2008(b)) demonstrating minimal 
cross-reactivity with other related Aβ-degrading enzymes which cleave the 
fluorogenic peptide.  In addition, it was demonstrated that plasma collected with 
Lithium-Heparin collection tubes had very little activity compared with samples 
collected in EDTA-containing tubes, presumably due to differences in enzyme 
stability.  Therefore the assay was subsequently used to measure IDE catalytic 
activity in EDTA-collected plasma samples from a subset of the AIBL cohort. 
 
5.3.6  Low-level data analysis. 
A total of 384 plasma samples from a subset of the AIBL cohort were assayed for 
plasma IDE activity.  Coefficient of variation (CV) values of duplicates which were 
>15% were excluded from the analysis.  Plates with standard curves that did not fall 
within 2 times the standard deviation ± the mean of each concentration of rrIDE 
were also excluded (n = 2).  Values that fell below the mean of the blank 
(background) + 2 times the standard deviation were considered to be below the 
lowest level of detection.  Values were interpolated from the standard curve (rrIDE) 
of each microplate, multiplied by the dilution factor (3.125) and expressed as 
Equivalent amount of rrIDE (ng/mL).  Intra-assay variation (n = 351, based on the 9 
plates used in the analysis) was determined to be ~17% (including samples with a 
CV of >15% that were subsequently removed from the analysis).  Following the 
removal of these samples, average CV was 6%.  Inter-assay variation was 
determined to be ~15% based on low, medium and high concentrations of the 
standard curve (n = 9). 
The data was noted to have a non-normal distribution as determined by visually 
inspecting histograms, box-plots and normal Q-Q plots, as well as calculating z-
scores of skewness and kurtosis.  In addition, normality tests such as the 
Kolmogorov-Smirnoff and Shapiro-Wilks tests were highly significant.  A variety of 
transformations were used to correct the normality issues (square root, natural log, 
natural log +1, reciprocal), however were not effective.  Therefore non-parametric 
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tests were used to analyse the data (Kruskall-Wallis, Mann-Whitney and 
Spearman’s Rho). 
 
5.3.7  Plasma IDE catalytic activity is higher in MCI compared with HC 
and AD. 
To determine IDE activity according to cognitive status, the cohort was divided into 
the clinically classified groups, healthy controls (HC - including subjective memory 
complainers), mild cognitive impairment (MCI) and probable AD (AD). As only a 
subset of the cohort was used, the HC and SMC groups were combined to form the 
healthy control group.  It should be noted that the subset used to measure IDE 
activity was different from the subsets used to measure IDE levels by Western 
immunoblotting and ELISA (detailed in Chapters 3 and 4, respectively). 
 
The demographics for this subset of the AIBL cohort are shown in Table 5.1.  As 
expected, AD patients were significantly older, and had a significantly higher 
percentage of APOE ε4 carriers and brain Aβ load than the control or MCI groups.  
Plasma Aβ1-42 was significantly decreased in the MCI and AD groups compared with 
controls (HC>MCI>AD) while Aβx-42 was significantly reduced in both MCI and AD 
groups as compared with HC.  For Aβ1-40, AD patients also had a trend toward lower 
plasma levels, however this did not quite reach significance.  The Aβx-42/x-40 ratio 
also showed significant alterations with AD and MCI being lower than controls 
(HC>MCI>AD), along with levels of ApoE and ApoE4.  All other variables were not 
significantly different between groups. 
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Figure 5.6(A) and (B)  Sample standard curve and 10 sets of samples.  The assay 
was conducted as detailed in Sections 2.2.6.1 over 6 hours.  Recombinant rat IDE 
(rrIDE) was diluted to concentrations of 312.5 to 7500 ng/mL (Graph A.) and plasma 
samples (Graph B) including PCP were loaded at a dilution of 960 μg total protein 
per well (16 μL plasma per well) in duplicate.  Error bars indicate ±SD.  Graphs show 
raw values of final readings at 6 hours.  Data is blank-adjusted. 
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Table 5.1  Basic demographics of the AIBL cohort subset of participants for whom 
plasma IDE catalytic activity was measured by fluorometric assay.  Plasma samples 
(16 μL per well in duplicate) from the AIBL cohort were assayed in the IDE 
fluorometric activity assay for 6 hours as detailed in Section 2.2.6.1.  Other variables 
were measured as outlined in Section 2.2.2.1.  Continuous variables are expressed 
as mean (median) ± standard deviation.  P values were determined by Kruskall-
Wallis tests using the Monte Carlo method.  As only a subset of the cohort was 
tested, the HC and subjective memory (SMC) groups were combined to provide the 
healthy controls for this assay.  As ApoE4 is only expressed in individuals carrying 
the APOE ε4 allele, the n-values are reduced for this variable.  As only a subset of 
the cohort were measured with Pib-PET (for Neocortical SUVR – Brain Aβ load), n-
values are reduced for this variable. 
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The catalytic activity of plasma IDE determined by the fluorometric activity assay 
(Figure 5.7) was found to be significantly higher in the MCI group (p = 0.007) 
compared with the HC group.  There was a trend towards higher IDE activity in the 
AD group compared with the controls (p = 0.082).  No significant difference was 
observed in the catalytic activity of MCI compared with AD groups (p = 0.642).  
After Bonferroni correction for multiple testing, the difference between HC and MCI 
groups remained significant (p = 0.021).  No differences were observed in total IDE 
activity between males and females overall [(p = 0.726)(Figure 5.8(A)], however 
when stratified by gender [Figures 5.8(B) and (C)] there was a trend toward higher 
IDE activity in MCI compared with controls for males only.  No difference was 
observed between AD and HC in males, or between classifications in females.  Large 
standard deviation was observed within the each classification, particularly for the 
MCI and AD groups. 
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Figure 5.7  Catalytic activity of plasma IDE is increased in MCI compared with HC 
and AD.  Plasma samples (16 μL per well in duplicate) from the AIBL cohort were 
assayed in the IDE fluorometric activity assay as detailed in Section 2.2.6.1. The 
average value of the duplicates was obtained for each sample, and the median of 
these values by classification were compared by a Kruskall-Wallis test, using Mann-
Whitney tests for post-hoc analysis with Bonferroni correction applied to adjust for 
multiple testing only with significant comparisons.  The data represent medians 
with 95% confidence interval (CI), n = 190 (84 HC/56 MCI/50 AD).  The results show 
a significantly higher level of plasma IDE catalytic activity in the MCI group when 
compared with the HC group (p = 0.007, after Bonferroni correction p = 0.021).  No 
significant difference was observed in IDE activity in the MCI group compared with 
the AD group (p = 0.642), however there was a trend toward the AD group being 
higher than HC group (p = 0.082). 
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Figure 5.8(A)  Gender has no effect on the catalytic activity of plasma IDE overall.  
Plasma samples (16 μL per well in duplicate) from the AIBL cohort were assayed in 
the IDE fluorometric activity assay as detailed in Section 2.2.6.1. The average value 
of the duplicates was obtained for each sample, and the median of these values by 
classification were compared by a Kruskall-Wallis test.  The data represent medians 
with 95% confidence interval (CI), n = 190 (71 Males/119 Females).  The results 
show no difference in IDE activity between males and females (p = 0.726). 
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Figure 5.8(B) and (C)  Plasma IDE activity is increased (not significantly) in male 
MCI compared with HC.  Plasma samples (16 μL per well in duplicate) from the AIBL 
cohort were assayed in the IDE fluorometric activity assay as detailed in Section 
2.2.6.1. The average value of the duplicates was obtained for each sample, and the 
median of these values by classification were compared by a Kruskall-Wallis test.  
The data represent medians with 95% confidence interval (CI), (Males) n = 71 (32 
HC/20 MCI/19 AD), (Females) n = 119 (52 HC/36 MCI/31 AD).  The results show a 
trend toward higher IDE activity in male MCI compared with HC  and AD (p = 0.085), 
while no differences were seen between classifications in females (p = 0.336).  
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5.3.8  Plasma IDE catalytic activity does not increase with age. 
As levels of IDE have been reported to reduce with age (Caccamo, et al., 2005), the 
activity of plasma IDE was analysed according to age quartiles (Figure 5.9).  No 
significant effect of age was seen on IDE activity (p = 0.395).  There was 
considerable variation in IDE activity in the oldest group, however it should be 
noted that this group had a small sample size (n = 13).   
 
 
Figure 5.9  Plasma IDE activity does not increase with age.  Plasma samples (16 μL 
per well in duplicate) from the AIBL cohort were assayed with a fluorometric 
activity assay to measure the catalytic activity of IDE as detailed in Section 2.2.6.1.  
The average value of the duplicates was obtained for each sample, and the median 
of these values by age quartiles were compared by a Kruskall-Wallis test (Q160-
68/Q2=69-77/Q3=78-86/Q4=87-96).  The data represent medians with 95% 
confidence interval (CI), n = 189 (61=Q1/63=Q2/52=Q3/13=Q4).  The results show 
that there was no significant effect of age on IDE activity (p = 0.395). . 
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5.3.9  APOE ε4 genotype does not impact on plasma IDE catalytic 
activity. 
Some studies have reported a reduction in levels of IDE in APOE ε4 carriers 
compared with non-carriers in AD brains (Cook, et al., 2003) and other studies have 
observed an increase in soluble and insoluble Aβ accumulation associated with the 
ε4 allele and/or ApoE4 isoform in both transgenic mice and humans (Youmans, et 
al., 2012; Reiman, et al., 2009; Bales, et al., 2009; Castellano, et al., 2011).  
Furthermore, this observation has been associated with Aβ clearance, and it has 
been shown that clearance of Aβ by IDE is facilitated by ApoE in an isoform-specific 
manner (E4<E3<E2) (Jiang, et al, 2008).  Hence there is a possibility that the 
impairment of Aβ degradation in ε4 carriers may be associated with a reduction in 
the catalytic activity of IDE.  It should be noted that no APOE ε4 –related differences 
in IDE levels were observed in the current study using either Western 
immunoblotting or ELISA methods (see Sections 3.3.16 and 4.3.14).  It is possible, 
however, that catalytic activity may be altered without a change in protein levels.  
To assess if this may be reflected in the IDE activity data in this project, the catalytic 
activity of ε4 carriers was compared with non-carriers (Figure 5.10(A)). 
The results indicate that there is no difference in the catalytic activity of plasma IDE 
between ε4 carriers and non-carriers (p = 0.529).  When the data was assessed in 
relation to classification when stratified by ε4 status, the MCI and AD ε4 carriers 
were observed to have a trend towards slightly higher IDE catalytic activity than the 
HC (HC<AD<MCI) (p = 0.091), while the ε4 non-carriers had similar activity between 
classifications (p = 0.277) (Figure 5.10(B) and (C)). 
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Figure 5.10(A)  Plasma IDE catalytic activity is not significantly different in APOE 
ε4 carriers compared with non-carriers.  Plasma samples (16 μL per well in 
duplicate) from the AIBL cohort were assayed with a fluorometric activity assay to 
measure the catalytic activity of IDE as detailed in Section 2.2.6.1.  The average 
value of the duplicates was obtained for each sample, and the median of these 
values by APOE ε4 status was compared by a Kruskall-Wallis test.  Data represents 
medians with 95% confidence interval (CI), n = 189 (88 ε4/101 non-ε4).  Results 
show no difference in the catalytic activity of plasma IDE in the ε4 carriers as 
compared with the non-carriers (p = 0.529). 
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Figure 5.10(B) and (C)  Plasma IDE catalytic activity is not significantly different 
between HC/MCI/AD classifications after dividing results into APOE ε4 carriers 
and non-carriers.  Plasma samples (16 μL per well in duplicate) from the AIBL 
cohort were assayed with a fluorometric activity assay to measure the catalytic 
activity of IDE as detailed in Section 2.2.6.1.  The average value of the duplicates 
was obtained for each sample, and the median of these values by classification 
separately by APOE ε4 status were compared by a Kruskall-Wallis test.  Data 
represents medians with 95% confidence interval (CI).  (ε4 carriers) n = 88 (27 
HC/26 MCI/35 AD), (non-carriers) n = 101 (57 HC/30 MCI/14 AD).  The results show 
no significant difference in the catalytic activity of plasma IDE between HC/MCI/AD 
classifications for either ε4 carriers (p = 0.091, Graph B.) or non-carriers (p = 0.277, 
Graph C.). 
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5.3.10  The ratio of IDE activity to insulin levels in plasma is not 
significantly different between classifications. 
The ELISA results from this study demonstrated that there is a significant reduction 
in the IDE levels/insulin levels ratio for MCI individuals who do not carry the APOE 
ε4 allele compared with controls (see Section 4.3.14.1).  Similar to the IDE/insulin 
ratio (for levels), an increase in insulin level or a decrease in IDE activity would lead 
to a reduction of the IDE activity/insulin level ratio.  To characterise further this 
potential relationship and to determine if the relationship of IDE activity to insulin 
levels may be able to differentiate between classifications in this subgroup, the 
ratio of plasma IDE catalytic activity and insulin levels was analysed both overall, as 
well as after stratification by APOE ε4 genotype. 
The results indicate no significant difference between classifications overall (p = 
0.294, Figure 5.11(A)) or between males and females (p = 0.596, Figure 5.11(B)).  
When stratified by APOE ε4 genotype (Figures 5.11(C) and (D), no significant 
differences in IDE activity/insulin level ratio were seen between classifications for 
the ε4 carriers (p = 0.141) or the non-carriers (p = 0.577), although in ε4 carriers the 
MCI group was slightly higher when compared with the HC group. 
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Figure 5.11(A)  The IDE activity/insulin level ratio is not significantly different 
between classifications in the overall subgroup.  Plasma samples (16 μL per well in 
duplicate) from the AIBL cohort were assayed with a fluorometric activity assay to 
measure the catalytic activity of IDE as detailed in Section 2.2.6.1.  The average 
value of the duplicates was obtained for each sample, and the ratios of these values 
to the level of plasma insulin were compared by classification using a Kruskall-Wallis 
test.  Data represents medians with 95% confidence interval (CI), n = 183 (79 HC/55 
MCI/ 49 AD).  Results show that the IDE activity/insulin ratio is not significantly 
different between classifications (p = 0.294). 
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Figure 5.11(B)  The IDE activity/insulin level ratio is not significantly different 
between males and females in the overall subgroup.  Plasma samples (16 μL per 
well in duplicate) from the AIBL cohort were assayed with a fluorometric activity 
assay to measure the catalytic activity of IDE as detailed in Section 2.2.6.1.  The 
average value of the duplicates was obtained for each sample, and the ratios of 
these values to the level of plasma insulin were compared by classification using a 
Kruskall-Wallis test.  Data represents medians with 95% confidence interval (CI), n = 
183 (67 males/116 females).  Results show that the IDE activity/insulin ratio is not 
significantly different between males and females (p = 0.596). 
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Figure 5.11(C) and (D)  The IDE activity/insulin level ratio is not significantly 
different between classification when stratified by APOE ε4 status.  Plasma 
samples (16 μL per well in duplicate) from the AIBL cohort were assayed with a 
fluorometric activity assay to measure the catalytic activity of IDE as detailed in 
Section 2.2.6.1.  The average value of the duplicates was obtained for each sample, 
and the ratios of these values to the level of plasma insulin were compared by 
classification using a Kruskall-Wallis test.  Data represents medians with 95% 
confidence interval (CI), (ε4 carriers – Graph A.) n = 85 (25 HC/25 MCI/35 AD), (non-
carriers – Graph B.) n = 97 (54 HC/30 MCI/13 AD).  Results show that the IDE 
activity/insulin ratio is not significantly different between classifications for ε4 
carriers (p = 0.141) or non-carriers (p = 0.577). 
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5.3.11  The ratio of IDE Activity:Aβ42 + Aβ40 levels increases in MCI and 
AD compared with HC. 
In the current study, it was shown that the ratio of plasma IDE levels to Aβ42 + Aβ40 
was significantly lower in the MCI group when compared with the HC group, and 
there was also a significant reduction in the ratio in AD compared with HC.  To 
determine if the ratio of plasma IDE activity to Aβ42 + Aβ40 was also significantly 
different between classifications, the ratio was calculated and compared between 
MCI, AD and controls (Figure 5.12(A)).  The data was also stratified for APOE ε4 
genotype and then compared by classification (Figure 5.12(B) and (C)). 
Results showed that the IDE Activity/Aβ42+40 ratio was increased in MCI and AD 
groups compared with HC, with HC having the lowest ratio values and AD having 
the highest ratio values (HC<MCI<AD).  Although these differences showed 
significance between HC vs MCI (p = 0.022) and HC vs AD (p = 0.008), only the AD 
group compared with the HC group remained significant following Bonferroni 
correction for multiple testing (p = 0.024).  When stratified for APOE ε4 genotype, 
no significant differences or trends were observed between classifications in the ε4 
non-carriers (p = 0.182), however, similar to the overall results an increasing trend 
was observed for the ε4 carriers (HC<MCI<AD, p = 0.058), however this did not 
reach significance. 
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Figure 5.12 (A)  The IDE Activity/Aβ42+40 ratio is increased in MCI (not significantly) 
and AD (significantly) when compared with HC.  Plasma samples (16 μL per well in 
duplicate) from the AIBL cohort were assayed with a fluorometric activity assay to 
measure the catalytic activity of IDE as detailed in Section 2.2.6.1.  The average 
value of the duplicates was obtained for each sample, and the ratios of these values 
to the combined levels of plasma Aβ42 and Aβ40 were compared by classification 
using a Kruskall-Wallis test, using Mann-Whitney tests for post-hoc analysis with 
Bonferroni correction applied to adjust for multiple testing only with significant 
comparisons.  Data represents medians with 95% confidence interval (CI), n = 186 
(82 HC/54 MCI/50 AD).  Results show that the IDE activity/Aβ42+40 ratio is 
significantly different in the AD group compared with HC following Bonferroni 
correction (p = 0.024), while the difference between MCI and HC is no longer 
significant, however a trend towards an increase is observed (p = 0.066).  No 
significant difference was seen between the MCI and AD groups (p = 0.981). 
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Figure 5.12 (B) and (C)  The IDE Activity/Aβ42+40 ratio is increased in MCI and AD 
(not significantly) when compared with HC in APOE ε4 carriers only.  Plasma 
samples (16 μL per well in duplicate) from the AIBL cohort were assayed with a 
fluorometric activity assay to measure the catalytic activity of IDE as detailed in 
Section 2.2.6.1.  The average value of the duplicates was obtained for each sample, 
and the ratios of these values to the combined levels of plasma Aβ42 and Aβ40 were 
compared by classification after dividing by APOE ε4 status, using a Kruskall-Wallis 
test.  Data represents medians with 95% confidence interval (CI), n = 86 (26 HC/35 
MCI/25 AD) for ε4 carriers and n = 99 (56 HC/29 MCI/14 AD) for ε4 non-carriers.  
Results show that an increasing trend is observed in the IDE activity/Aβ42+40 ratio for 
ε4 carriers (Graph B) however does not quite reach significance (p = 0.058), and no 
significant differences were seen in non ε4 carriers (Graph C, p = 0.182). 
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5.3.12  IDE Activity/Insulin + Aβ42+40 ratio increases in MCI compared 
with HC and AD. 
To determine if there was any additive effect of Aβ42+40 combined with insulin in 
relation to the catalytic activity of IDE, a ratio of IDE Activity and insulin + Aβ42+40 
was calculated and compared between classifications in the subset of the AIBL 
cohort (Figure 5.13(A)).  The results indicated that the MCI group was significantly 
higher than the HC group (p = 0.045 after Bonferroni correction) for the IDE 
Activity/insulin + Aβ42+40 ratio, while the increase in the AD group compared with 
the HC was no longer significant after Bonferroni correction, but demonstrated a 
trend (p = 0.072).  When the data was stratified by APOE ε4 status, no significant 
difference between classifications for ε4 carriers (p = 0.108, Figure 5.13(B)), or non-
carriers (p = 0.168, Figure 5.13(C)) was observed. 
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Figure 5.13(A)  IDE Activity/Insulin + Aβ42+40 ratios are increased in MCI 
(significantly) and AD (not significantly) compared with HC.  Plasma samples (16 μL 
per well in duplicate) from the AIBL cohort were assayed with a fluorometric 
activity assay to measure the catalytic activity of IDE as detailed in Section 2.2.6.1.  
The average value of the duplicates was obtained for each sample, and the ratios of 
these values to the combined levels of plasma insulin, Aβ42 and Aβ40 were 
calculated.  The ratios were compared by classification using a Kruskall-Wallis test, 
using Mann-Whitney tests for post-hoc analysis with Bonferroni correction applied 
to adjust for multiple testing only with significant comparisons.  Data represents 
medians with 95% confidence interval (CI), n = 179 (77 HC/53 MCI/49 AD).  Results 
show that the IDE activity/Insulin + Aβ42+40 ratio is significantly increased in MCI 
compared with HC (p = 0.045 after Bonferroni correction), while AD demonstrates a 
trend towards an increase compared with HC (p = 0.072, after Bonferroni 
correction).  No significant difference was seen between MCI and AD groups (p = 
0.951). 
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Figure 5.13(B) and (C)  IDE Activity/Insulin + Aβ42+40 ratios are no different by 
classification when stratified by APOE ε4 status.  Plasma samples (16 μL per well in 
duplicate) from the AIBL cohort were assayed with a fluorometric activity assay to 
measure the catalytic activity of IDE as detailed in Section 2.2.6.1.  The average 
value of the duplicates was obtained for each sample, and the ratios of these values 
to the combined levels of plasma insulin, Aβ42 and Aβ40 were calculated.  The ratios 
were compared by classification using a Kruskall-Wallis test.  Data was stratified by 
APOE ε4 status.  Data represents medians with 95% confidence interval (CI), (ε4 
carriers) n = 83 (24 HC/24 MCI/35 AD), (non-carriers) n = 95 (53 HC/29 MCI/13 AD).  
Results show no significant differences in IDE Activity/Insulin + Aβ42+40 ratio 
between classifications for ε4 carriers (p = 0.108, Graph B.) or non-carriers (p = 
0.168, Graph C.). 
 
  
309 
 
 
  
310 
 
5.3.13  Correlation analyses of plasma IDE catalytic activity with 
multiple biochemical measures in the AIBL cohort. 
To determine if there were any significant correlations between IDE activity and 
other parameters for which biochemical data was collected as part of the AIBL 
study, correlation analyses were performed.  As with the IDE levels measured in the 
ELISA, IDE activity was analysed for any correlations with sex, age, plasma insulin 
levels, Aβ species/ratios, total ApoE/ApoE4 levels, levels of testosterone/estradiol, 
plasma lipids (total cholesterol, LDL/HDL subfractions) and brain Aβ load.  IDE 
activity was also stratified by APOE ε4 status and analysed again for any 
correlations.  The biochemical variables and their data collection details are 
outlined in Section 2.2.2.1. 
Results overall (Table 5.2) showed a weak positive correlation with oestradiol (rs = 
.155, p = 0.047).  A weak inverse correlation was also seen between IDE activity and 
the Aβx42/x40 ratio (rs = -.156, p = .035).  Following Bonferroni-Holm correction for 
multiple testing, these correlations were no longer significant.  No other significant 
correlations or trends were observed with the remaining variables. 
When stratified by gender (Tables 5.3(A) and (B)), IDE activity positively correlated 
with age in males only (rs = .320, p = 0.065), however after correction was no longer 
significant.  In addition, the Aβx-42/x-40 ratio was observed to have a trend toward 
significance, while no other variables showed any significant relationships or trends 
with IDE activity.  For females, only estradiol was observed to be positively 
associated with IDE activity, but again, after correction was no longer significant. 
When stratified by ε4 status (Tables 5.4 (A) and (B)), IDE activity showed no 
significant correlations in the ε4 non-carriers, however a trend toward an inverse 
correlation with testosterone was observed (rs = -.176, p = 0.082).  For the ε4 
carriers, a significant positive correlation was shown between IDE activity and total 
testosterone (rs = .250, p = 0.022), but not for calculated levels of free testosterone 
which are considered a better measure of bioavailable testosterone (rs = .175, p = 
0.102).  Inverse correlations were observed between IDE activity and Aβ ratios 
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(Aβ42/40 - rs = -.235, p = 0.030, Aβx-42/x-40 - rs = -.305, p = 0.004), and total cholesterol 
(rs = -.214, p = 0.047).  No other significant correlations were observed with the 
remaining variables for ε4 carriers, however there were trends toward a negative 
correlation with HDL cholesterol (rs = -.196, p = 0.070) and a positive correlation 
with brain Aβ load (rs = .320, p = 0.065).  Following Bonferroni-Holm correction, 
however, none of the observed correlations were still significant, although there 
was a trend toward significance for the Aβx-42/x-40 ratio (p = 0.072). 
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Table 5.2  Correlation matrix of plasma IDE catalytic activity with other 
biochemical variables measured as part of the AIBL study.  The catalytic activity of 
plasma IDE was analysed for relationships with sex, age, and plasma insulin, Aβ 
species, ApoE species, testosterone, oestradiol, lipids and brain Aβ load (two 
tailed).  n values vary due to missing values for some data or in the case of brain Aβ 
load only a subset of the cohort underwent PiB-PET scans.  For ApoE4, n value is 
lower as only the APOE ε4 carriers express this isoform.  Results show a weak 
positive correlation with oestradiol (rs = .155, p = .047) and a weak inverse 
correlation between IDE activity and the Aβx42/x40 ratio (rs = -.156, p = .035)(“unadj.” 
= unadjusted, prior to Bonferroni-Holm correction).  No other variables showed 
correlations with IDE activity.  After Bonferroni-Holm correction these correlations 
were no longer significant (“adj.” = Bonferroni-Holm adjusted). 
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Table 5.3(A) Correlation matrix of plasma IDE catalytic activity with other 
biochemical variables measured as part of the AIBL study after stratification for 
gender – males only.  The catalytic activity of plasma IDE was split by APOE ε4 
status and analysed for relationships with sex, age, and plasma insulin, Aβ species, 
ApoE species, testosterone, oestradiol, lipids and brain Aβ load (two tailed).  n 
values vary due to missing values for some data or in the case of brain Aβ load only 
a subset of the cohort underwent PiB-PET scans.  For ApoE4, only the APOE ε4 
carriers express this isoform therefore is not included for the ε4 non-carriers.  
Results show no correlations of IDE activity with these variables. 
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Table 5.3(B) Correlation matrix of plasma IDE catalytic activity with other 
biochemical variables measured as part of the AIBL study after stratification for 
gender – females only.  The catalytic activity of plasma IDE was split by APOE ε4 
status and analysed for relationships with sex, age, and plasma insulin, Aβ species, 
ApoE species, testosterone, oestradiol, lipids and brain Aβ load (two tailed).  n 
values vary due to missing values for some data or in the case of brain Aβ load only 
a subset of the cohort underwent PiB-PET scans.  For ApoE4, only the APOE ε4 
carriers express this isoform therefore is not included for the ε4 non-carriers.  
Results show no correlations of IDE activity with these variables. 
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Table 5.4(A) Correlation matrix of plasma IDE catalytic activity with other 
biochemical variables measured as part of the AIBL study after stratification for 
APOE ε4 status - ε4 non-carriers only (unadjusted).  The catalytic activity of plasma 
IDE was split by APOE ε4 status and analysed for relationships with sex, age, and 
plasma insulin, Aβ species, ApoE species, testosterone, oestradiol, lipids and brain 
Aβ load (two tailed).  n values vary due to missing values for some data or in the 
case of brain Aβ load only a subset of the cohort underwent PiB-PET scans.  For 
ApoE4, only the APOE ε4 carriers express this isoform therefore is not included for 
the ε4 non-carriers.  Results show no correlations of IDE activity with these 
variables. 
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Table 5.4(B) Correlation matrix of plasma IDE catalytic activity with other 
biochemical variables measured as part of the AIBL study after stratification for 
APOE ε4 status - ε4 carriers only (unadjusted).  The catalytic activity of plasma IDE 
was split by APOE ε4 status and analysed for relationships with sex, age, and plasma 
insulin, Aβ species, ApoE species, testosterone, oestradiol, lipids and brain Aβ load 
(two tailed).  n values vary due to missing values for some data or in the case of 
brain Aβ load only a subset of the cohort underwent PiB-PET scans.  Results show a 
significant but weak positive correlation with testosterone (rs = -.250, p = .022) but 
not calculated free testosterone, and IDE activity was also significantly correlated 
inversely with cholesterol (rs = -.214, p = .047), Aβ42/40 ratio (rs = -.235, p = .030) and 
Aβx42/x40 ratio (rs = -.305, p = .004)(“unadj.” = unadjusted, prior to Bonferroni-Holm 
correction).  Following Bonferroni-Holm correction for multiple testing (“adj.” = 
Bonferroni-Holm adjusted), these correlations were no longer significant, however 
a trend toward significance was seen for the Aβx42/x40 ratio (p = 0.072).  * indicates 
significance at the < 0.05 level.  ** indicates significance at the < 0.01 level. 
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5.4  Discussion 
The aim of this chapter was to optimise a previously developed immunocapture-
based IDE-specific fluorometric activity assay (Miners, et al., 2008(b)) in order to 
measure the catalytic activity of IDE in plasma from individuals from the AIBL 
cohort.  The assay was used to determine if there were any differences in IDE 
catalytic activity in AD and MCI individuals compared with healthy controls, or if any 
differences in IDE catalytic activity were related to various AD-related genetic and 
biochemical factors. 
The assay was shown to reflect the concentration of protein over time both for 
purified recombinant rat IDE (rrIDE) and human plasma using two different batches 
of Ab 3.  Using the new batch of antibody, no significant difference was observed 
when using phosphate-based buffers for the blocking step, sample incubation and 
washes as compared with using tris-based buffers.  The signal had good linearity up 
to a concentration of 7500 ng/mL purified rrIDE and also for plasma (up to 
approximately 1200 μg total protein per well).  Over the 6 hour incubation time 
period the signal for rrIDE was linear for the first few hours but then appeared to 
plateau slowly at all concentrations assayed, while the signal in plasma remained 
linear for the duration of the assay.  It is possible that the plasma IDE is more stable 
than the purified enzyme due to the presence of endogenous proteins, while the 
rrIDE began degrading early in the incubation period.  Although the non-bound 
components of the plasma were washed away prior to the fluorogenic peptide 
being added, it is possible that the immunocaptured IDE is bound to other proteins 
which do not interfere with the catalytic site. 
It should be noted that Miners also found that the signal was maximal after 5 hours 
for brain homogenates, however the current study demonstrated that the signal in 
plasma continued to increase in a linear fashion up to at least 6 hours incubation.  
The signal may have increased further after extending the incubation beyond 6 
hours but this was not pursued; however it may be of value to investigate this in 
the future.  It may be that IDE levels are higher in the brain than in the plasma 
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which may have saturated the fluorogenic peptide earlier, leading to the plateau in 
signal observed in the Miners study. 
The finding that the assay was linear for rrIDE up to 7500 ng/mL is contrary to the 
results of Miners who found that the assay was linear only between 156 – 2500 
ng/mL for rrIDE.  Furthermore, the fluorescent values were more than double in the 
Miners results compared to the values observed in this study.  There were a 
number of differences in the Miners protocol by comparison which may account for 
these differences.  Firstly, the coating antibody was diluted in PBS (pH 7.4) in 
Miners study, while our study used a carbonate/bicarbonate coating buffer (pH 
8.6).  The microplate manufacturer advised that a coating buffer pH of 9.6 was 
optimal for antibody adsorption.  The lower pH though, would be more likely to 
result in weaker binding of the capture antibody to the microplate, which may have 
been displaced by the subsequent washes and led to a reduced signal, which is 
opposite to what was observed.  However, as well as the pH, the different 
components of the buffers may also have had an effect on the binding capabilities 
of the antibody.  Another difference was the use of BSA as a blocking agent in the 
current study.  This step was not included in the Miners assay and could potentially 
have led to exposed binding sites on the plate which may have allowed additional 
IDE or other enzymes to bind to the plate, leading to a higher signal.  Although 
omission of the blocking step did not alter the signal observed in plasma, it may be 
that the presence of BSA in the incubation step provided some extra stability to the 
purified IDE during the overnight incubation.  The Miners protocol also included an 
additional two washes in each washing step, although it is unclear how this would 
have contributed to an increased signal; it is possible though that the extra washes 
may have decreased the background leading to an improved signal to noise ratio.  
Similarly, the samples in our study were incubated overnight at 4°C rather than 1.5 
hours at RT; again it is not clear why this may contribute to a lower overall signal or 
to the differences observed in the range of linearity of the rrIDE.  Other differences 
include the presence of Tween-20 in the wash buffers and sample buffer (PBS) in 
the current study, which may have reduced the background reading and led to a 
better signal to noise ratio.  Perhaps though, most notable differences may be the 
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dilution buffer composition and incubation temperature of the fluorogenic 
substrate, which in the current study was 31°C compared with 37°C in the Miners 
protocol.  This was likely to have led to a reduction of enzyme activity and account 
for the lower signal observed.  In addition to this, the dilution buffer used for the 
fluorogenic peptide in the current study was HEPES, while Miners used a Tris-based 
buffer containing zinc.  The addition of zinc in the incubation buffer may have 
stimulated the activity of IDE, and this effect has been demonstrated in a recent 
study (Grasso, et al., 2012).  The combination of the activation of IDE by zinc, as 
well as the increased incubation temperature in the Miners study would have 
resulted in an increase in IDE activity by comparison with the current study, and 
would have saturated the peptide earlier, perhaps providing an explanation for why 
the linear range was lower in the Miners study.  One other factor which was not 
mentioned in the Miners study is the gain adjustment setting, which in our study 
was found to have a large impact on the values obtained.  This alone may have 
accounted for the higher values observed in the Miners study. 
The activity assay was seen to have a high level of background signal, and while the 
source of this background noise has not been confirmed, there are a few possible 
reasons.  It was determined that the background was not attributable to an 
interaction of the fluorogenic peptide with BSA (or contaminating proteases within 
the BSA preparation) used as the blocking agent, as no difference was seen when it 
was omitted from the assay.  Similarly, no interaction was seen between the 
fluorogenic peptide and the capture antibody or its component glycerol.  It was 
shown that a similar background signal occurred with just the diluted peptide 
alone, and omission of the peptide with all other assay components led to a 
significantly reduced signal, suggesting that the background was primarily due to 
the fluorescent peptide itself.  Regardless, the background fluorescence for both 
batches of antibody were similar, and also did not increase over time and this 
indicated that ongoing cleavage of the peptide was not occurring.  Although the 
increased background may have reduced the sensitivity of the assay at the lower 
limit of detection, the background was therefore not considered to be a significant 
factor and was subtracted from the values observed.  Furthermore, the reduced 
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signal observed with the second batch of Ab 3 compared with the original batch is 
likely due to a reduced affinity of the new batch of antibody to IDE, leading to 
reduced amounts of the enzyme captured.  This is not unusual for polyclonal 
antibodies, and highlights the importance of using a single batch of antibody for 
immunoassays which require comparisons between different experiments. 
The activity assay was also tested using samples collected in tubes containing 
different anticoagulants; namely EDTA and Lithium-Heparin (LiHep).  It was 
expected that the samples containing EDTA might have a lower activity by 
comparison due to the chelating effect of the EDTA on the essential zinc ion bound 
to the catalytic site of IDE.  Surprisingly, the opposite result was observed with 
LiHep samples having only approximately 15% of the activity of EDTA samples.  It is 
not clear exactly why this difference would occur, however may be potentially 
related to the tendency of EDTA collected samples to be vulnerable to haemolysis 
during blood processing, releasing intracellular IDE into the plasma and leading to 
an increased signal.  Alternatively, the differences may be related to the reduced 
stability of plasma proteins in LiHep collected blood, resulting in more degradation 
of IDE over time in LiHep tubes.  Other studies have shown that levels of certain 
analytes measured in EDTA-collected plasma are higher than samples collected in 
LiHep tubes or sodium-heparin tubes (Kragstrup, et al., 2013; de Jager, et al., 2009), 
and while the levels of IDE were not compared for differences between the two 
different anticoagulants in the current study, it would be of value to investigate in 
future whether the activity differences were related to IDE protein level, and/or 
due to haemolysis. 
The internally-quenched fluorogenic peptide which was used for this assay is not 
specific to IDE, and other enzymes such as neprilysin (NEP), endothelin converting 
enzyme (ECE-1), angiotensin converting enzyme (ACE), cathepsin A and cathepsin X 
(also called cathepsin Z or P) are also able to cleave this substrate according to the 
company datasheet.  Therefore it was essential to ensure that the capture antibody 
(Ab 3) was able to specifically bind to IDE but not bind to any other enzyme capable 
of degrading the peptide.  When testing activity assays for specificity, a common 
approach is to use specific inhibitors to block the activity generated by the assay.  
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Unfortunately most inhibitors are not specific for just one enzyme; for example Aβ 
is a substrate of IDE which inhibits its catalytic activity toward the fluorogenic 
substrate by competitive inhibition.  As some other proteases also cleave Aβ, it is 
likely that it would also inhibit other Aβ-degrading enzymes.  Therefore more than 
one inhibitor may need to be used to confirm the specificity of an assay in 
measuring a particular enzyme.  In the current study, two commonly used IDE 
inhibitors were employed; insulin and Aβ (both Aβ40 and Aβ42).  Aβ and insulin are 
both competitive inhibitors of IDE, by binding to the active site and preventing 
binding or cleavage of the fluorogenic peptide.  However, Aβ is also a substrate for 
NEP, ECE-1 and ACE as well as IDE and therefore not specific.  Insulin though, is 
primarily degraded by, and has a high affinity for insulin-degrading enzyme and has 
been previously used in IDE activity assays to determine specificity (Liu, et al., 
2012(a); Alper & Schmidt, 2009).  However, it should be noted that there are other 
enzymes present in the plasma that bind to insulin, and have been reported to be 
inhibited by insulin, although it is unknown if these enzymes are capable of cleaving 
the fluorogenic substrate (Lokhov, et al., 2004; Kashyap, et al., 2008).  Miners and 
colleagues (2008(b)) had previously showed that there was negligible signal from 
recombinant NEP, ACE and ECE-1 using the same IDE-specific capture antibody as 
the one in the current study (Ab 3), indicating that the signal observed is unlikely to 
be contributed to substantially by these particular proteases.  The signal observed 
in this activity assay derived from human plasma could be completely inhibited by 
both insulin and Aβ42, in a dose-dependent fashion.  Although the reduction in 
signal was only around 50% for Aβ40, this initial experiment used a lower 
concentration of Aβ and was the reason that larger amounts of Aβ42 were 
subsequently used.  These results indicate that it is likely that the signal is 
attributable to cleavage of the substrate by IDE, although it would be of interest to 
test other IDE-specific inhibitors in this assay.  Recently this has been addressed 
with the development of promising novel and specific IDE inhibitors (Abdul-Hay, et 
al., 2013; Leissring, et al., 2010). 
In addition, IDE-specific antibodies were also used in an attempt to neutralize the 
activity of IDE in plasma by interference of the fluorogenic substrate cleavage.  One 
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antibody (Ab 1) was targeted to a region within Domain 1 of IDE which is in close 
proximity to the catalytic site, while the other (Ab 2) targets a region near the C-
terminus of IDE which is far away from the catalytic site.  There was around 50% 
reduction of signal when the sample was pre-incubated with Ab 1, while no such 
decrease was observed with Ab 2.  This may suggest that Ab 1, by binding close to 
the catalytic site, is somehow interfering with the cleavage of the fluorogenic 
substrate, possibly by physically blocking binding to the catalytic site, or by steric 
hindrance.  It is also possible that binding of the antibody to IDE causes a 
conformational change that negatively affects binding or cleavage of the substrate.  
However, it should be noted that Ab 1 was in the form of anti-serum (as opposed to 
Ab 2 which was purified), which would contain other components which may have 
inhibited the signal also, and therefore this may not necessarily confirm specificity.  
Nevertheless, in Western immunoblotting experiments (see Section 3.3.1), Ab 1 
only detected a single band at the expected molecular weight, which could be 
considerably reduced by pre-incubation of the antibody with purified IDE, 
suggesting that the antibody is specific.  The observation that Ab 2 does not 
interfere with substrate cleavage indicates that the epitope location may be too 
distal from the catalytic region to interfere with binding or cleavage.  While it 
cannot be completely ruled out that other components of the antiserum (Ab 1) may 
have contributed to the reduction in signal in the activity assay, these results 
support that the signal observed is derived from IDE. 
The specificity of the assay was demonstrated by the complete reduction of signal 
by IDE substrates, Aβ and insulin, and no cross-reactivity was observed between 
assay reagents or with plasma albumin.  Therefore the assay was used to measure 
IDE activity in plasma samples obtained from the well-characterised AIBL cohort.  
The results for the AIBL samples showed that IDE activity in plasma was significantly 
higher in MCI individuals compared with healthy controls.  AD patients also had 
elevated IDE activity however this did not reach significance.  These results for IDE 
activity were contrary to what was expected; it was expected that MCI and AD 
might have decreased activity compared with HC.  A recent study by Liu, et al., 
2012(a) showed that MCI and AD individuals had lower serum IDE activity than 
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healthy controls, and the subjects with the lowest serum IDE catalytic activity also 
had correspondingly lower IDE levels compared with subjects with the highest 
catalytic activity (who had higher IDE levels) as determined by Western 
immunoblotting.  In the current study, plasma IDE activity was increased in MCI 
(and a trend toward an increase in AD) compared with HC, which was reflected by 
an increase in IDE levels for MCI (but not AD) in Western immunoblotting results.  
However, this was opposite to what was observed with IDE levels measured by 
ELISA, where MCI levels were significantly reduced compared with HC.  This will be 
discussed further in Chapter 6.  It should be noted that the study by Liu and 
colleagues used serum samples as opposed to plasma; one consideration related to 
this is that unlike serum samples, the plasma samples contained EDTA.  As 
mentioned above, EDTA has been shown to increase the likelihood of haemolysis, 
and as red blood cells contain IDE, this may have affected the results in this assay.  
It was demonstrated that EDTA containing plasma had significantly higher IDE 
activity than plasma sourced from Lithium-Heparin (LiHep) tubes and it is possible 
this may be due to haemolysis.  Conversely, it may be that IDE in the LiHep plasma 
samples was less stable than IDE in the EDTA plasma, and this may be the case for 
serum IDE also.  Until the implications of these differences are investigated, caution 
should be exercised when translating the results of this study.  In addition, the 
study by Liu and colleagues used a different capture antibody than the one used in 
the current study.  Although they demonstrated a reduction in activity with several 
substances which are known to inhibit IDE activity (insulin, Aβ, amylin and EDTA), 
the inhibition seen in their study was not complete (unlike in the current study 
where complete inhibition was seen with Aβ and insulin) and therefore it cannot be 
ruled out that proteases other than IDE were implicated in generating the 
measurable activity observed in the Liu study. 
As the Western immunoblotting data indicated that IDE levels differed between 
males and females, the IDE catalytic activity was also analysed by gender.  Although 
no significant differences were seen in IDE activity overall between males and 
females, when stratified by gender the males demonstrated a trend toward 
increased activity in MCI compared with HC, while no differences in IDE activity was 
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seen between classifications for females.  While it was noted that the increase did 
not reach significance, this may be due to reduced numbers as a result of stratifying 
the subset.  This indicates that the observed increase in IDE activity in MCI is 
primarily due to the effects in males.  The reason for the increase in the activity in 
male MCI participants is not clear; there was no increase in IDE substrates or 
hormones in the plasma that have been shown to upregulate IDE such as insulin, 
Aβ, testosterone (free or total) or oestrogen levels in this subset of the AIBL cohort, 
indicating other as yet unknown or non-assessed factors are involved.  It would be 
of value to investigate this finding in future studies. 
Based on the results of the current study, it is possible that the activity of IDE is 
upregulated in early AD (MCI) in an attempt to compensate for a reduction in total 
IDE levels, as reflected in the IDE ELISA data (although the Western immunoblotting 
results did not concur with the ELISA results; the different assays may be measuring 
distinct forms of IDE and this will be discussed more in Chapter 6).  This finding is 
consistent with previous reports on IDE activity in the brain using the same 
fluorometric activity assay; Miners and colleagues (2009) found an increase in brain 
IDE activity in AD patients compared with controls, which was not influenced by 
APOE ε4 genotype and independent of IDE levels.  Although not significant, 
differences in activity patterns between classifications in the current study 
observed between genders may be related to other factors such as intrinsic 
hormonal differences, effects of sex hormone-based or other medications, or 
lifestyle factors such as diet and exercise.  Indeed the high variation seen in the MCI 
and AD groups may indicate the influence of other variables.  Due to time-restraints 
it was not possible to investigate these possibilities within the time-frame of this 
project; however it would be of value to explore these theories in the future. 
The plasma catalytic activity of IDE was shown to be similar for APOE ε4 carriers and 
non-carriers overall.  When stratifying the classifications by ε4 status, although not 
statistically significant MCI and AD ε4 carriers tended to have increased IDE activity 
compared with control group, while no differences were seen in the non-carriers.  
The difference in IDE activity between classifications in carriers versus non-carriers 
may potentially reflect the pathological changes that may be occurring faster in ε4 
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carriers; as mentioned in Chapter 1 it has been shown that the onset of AD tends to 
be earlier, and the progression of degeneration faster for individuals carrying the ε4 
allele (Corder, et al., 2003; Chen, et al., 2007). 
To ascertain if there were any associations between IDE activity and other 
biochemical data collected as part of the AIBL study, correlation analyses were 
performed.  The variables were chosen based on two criteria; variables which have 
been associated with AD pathology such as age, plasma levels of Aβ (and N-
terminally truncated species), ApoE/ApoE4, cholesterol (and LDL/HDL subtypes), 
and brain Aβ load, and those which have been associated with alterations in IDE 
levels (sex, insulin, testosterone, and estradiol).  The correlations that were 
observed between IDE activity and other variables (only overall and in APOE ε4 
carriers) were not significant following Bonferroni-Holm correction, however this 
type of correction for multiple testing is very conservative and increases the 
chances of Type II errors occurring, albeit not quite as stringent as the original 
Bonferroni method.  However, as a large number of correlates were analysed, 
Bonferroni/Bonferroni-Holm is the best correction method to avoid the occurrence 
of Type I errors.  For the APOE ε4 carriers in the current study, four variables out of 
seventeen tested were significantly correlated with IDE activity prior to correction, 
which is more than would be expected by chance alone if none of these variables 
had a true relationship with IDE activity.  Therefore, one or more of these 
correlations may actually be true associations despite the corrected results.  In 
particular, the observation that both the Aβ42/40 ratio and Aβx-42/x-40 ratio showed a 
negative correlation with IDE activity prior to Bonferroni correction, and the 
correlation with Aβx-42/x-40 ratio was still close to significance following Bonferroni 
correction, is probably worth investigating further in the future. 
In the case of testosterone data, total levels were used in the correlation analyses 
as well as calculated levels of free testosterone, which is regarded as a better 
measure of bioavailable testosterone.  Analysing males and females together may 
be a limitation, as males have considerably higher levels of testosterone than 
females, although there were no associations overall or after stratification by 
gender in males or females between total or free testosterone and IDE activity.  
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However, in females a positive correlation was observed between estradiol and IDE 
activity; therefore the overall correlation seen with estradiol was due primarily to 
the association in females.  Although not significant after correction, this 
relationship is consistent with the published literature which suggests that estradiol 
positively regulates IDE activity (Udrisar, et al., 2005). 
As the subset of AIBL samples used in the IDE activity assay was different to the 
subsets used to measure IDE levels by Western immunoblotting and ELISA, it was 
not possible to assess any correlations between activity and levels due to the small 
number of samples in common.  However, a small sample set which were in 
common with the activity and levels (by Western immunoblotting) subsets showed 
a borderline correlation (data not shown). 
 
5.4.1  Summary 
In this project, a previously described fluorometric assay that had been developed 
for the purpose of measuring the catalytic activity of IDE in brain homogenates was 
adapted for measuring IDE activity in human plasma.  Although factors such as 
background signal may have impacted on the sensitivity of the assay at the lower 
limit of detection, specificity of the assay was shown by demonstrating no cross-
reactivity between assay reagents, as well as a complete reduction of signal by the 
use of IDE substrates that competitively and dose-dependently inhibited the activity 
generated from plasma.  Further development of the assay such as identifying ways 
to reduce the background signal, as well as investigating the reason for the 
differences in plasma collected with different anticoagulants would be of value.  
The use of additional IDE inhibition studies as well as genetic knock-down or knock-
out studies to further characterise and validate this assay for use in plasma should 
also be considered. 
This initial pilot study on the catalytic activity of plasma IDE was promising, and 
showed alterations in the plasma IDE activity which differed by clinical 
classification.  While gender did not have an effect on IDE activity overall, when 
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stratified by gender the differences seen between classifications were only found in 
the male subgroup.  IDE activity overall did not differ by APOE status, however a 
non-significant increasing trend was seen in IDE activity for MCI and AD compared 
with controls in ε4 carriers only, as well as an association of IDE activity with the Aβ 
ratios in ε4 carriers which requires further investigation.  It is possible that with a 
larger cohort these trends may become significant.  Notably, the ratio of IDE activity 
to Aβ levels was higher in MCI and AD participants compared with controls, as was 
the ratio of IDE activity to the collective levels of insulin and Aβ.  While only full-
length Aβ40 and Aβ42 was included in these ratios, it would be of interest to 
investigate if the N-terminally truncated species of Aβ were also implicated.  
However, there was high variation within each classification group, and this may be 
related to hormone levels, lipid composition and/or other factors which may inhibit 
or enhance the activity of IDE.   
The results suggest that IDE activity in plasma is upregulated in both the prodromal 
(represented by the MCI group) and symptomatic periods of AD, however whether 
IDE activity might be clinically useful as an early diagnostic biomarker is not clear at 
this stage.  It may be that other factors which regulate IDE may prove to be more 
relevant than IDE itself.  Indeed the observed associations with sex hormones 
requires further investigation.  Further work towards understanding the complex 
regulatory mechanisms of IDE catalytic activity in the peripheral circulation, and 
specifically in relation to its role in Aβ degradation or other potential roles in AD 
would therefore be of importance in future studies.  It is notable that the results 
are contrary to the only other published study on blood IDE activity who found 
lower IDE activity in MCI and AD individuals (Liu, et al., 2012(a)), however in their 
study they used serum rather than plasma, and a number of covariates were 
controlled for.  As non-parametric analyses were used in the current study this was 
not possible.  While the results from the current study show potential, and 
particularly in respect to plasma Aβ and insulin levels, they would require validation 
following further assay characterisation in a larger cohort before any conclusions 
could be made regarding the suitability of IDE activity as a plasma biomarker for the 
early detection of Alzheimer’s disease.   
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Chapter 6 – Final Discussion 
6.1  Introduction 
The number of AD sufferers is predicted to increase significantly in the coming 
years, therefore the development of a blood-based diagnostic test is crucial.  There 
are no effective treatments for AD, therefore prevention and/or delaying the onset 
of disease symptoms is the next best goal for anti-AD therapy.  AD has a long pre-
symptomatic phase, and thus diagnosis at the earliest stage possible will maximise 
the effect of disease-delaying treatments.  Therefore, the ideal panel of blood 
biomarkers will identify AD patients in early pre-symptomatic stages with high 
specificity and sensitivity.  To this end, potential blood biomarkers need to be 
characterised extensively, and reliable biomarker assays need to be developed.  The 
aim of the current study was to investigate insulin-degrading enzyme (IDE) in the 
plasma of MCI individuals, AD patients and healthy controls to ascertain if it is a 
suitable biomarker to include in such a biomarker panel. 
The specific aims of this project were: 
• To characterise commercial IDE antibodies for the measurement of plasma 
IDE levels using two distinct methods, 
• To measure the catalytic activity of plasma IDE using a previously developed 
activity assay to determine if the levels are altered in the prodromal period 
of AD (MCI) or in symptomatic AD,  
• To investigate any association between IDE (levels or activity) and other AD-
related biomarkers and genetic influences. 
The potential implications of these results will be discussed in the context of the 
current literature, and the limitations of the study will be addressed.  Prospective 
future directions will also be discussed. 
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6.2  Assay development and validation 
The only available commercial IDE ELISA kit on the market at the commencement of 
the project did not perform within the acceptable limits of inter-assay and intra-
assay variation, therefore it was not used for the measurement of plasma IDE levels 
in this project.  Although only two tests were performed using this kit, the 
prohibitively high cost prevented further characterisation.  Similarly, an in-house 
indirect ELISA was not suitable for measuring levels of IDE in plasma, as other 
proteins present in the matrix competed with IDE for binding to the ELISA plate.  
Therefore, an in-house sandwich ELISA assay was developed for the measurement 
of IDE levels. 
An ELISA is an antibody-based assay, and this project has demonstrated some of the 
numerous factors that should be considered when characterising antibodies for use 
in such an assay, as the choice of antibody is central to the integrity of the results.  
These are discussed in detail in Chapters 3 and 4, but highlighted below are some of 
the factors that were found to have the greatest impact.  Variable results were 
obtained in this project when using different antibodies in all the applications 
tested. The likely reasons for these variations or inconsistencies include differences 
in IDE epitopes to which the antibodies bind, differences in the immunogens used 
to initiate the immune response to generate the antibodies, or differences in host 
species in which the antibodies were generated.  Another important consideration 
when trying to set up a reliable immunoassay is the batch-to-batch variability of the 
antibodies.  It was demonstrated in this project that there can be substantial 
differences in assay results caused by differences in batches of polyclonal 
antibodies (both from commercial as well as private sources), highlighting one of 
the advantages of monoclonal antibodies, or if using polyclonals, the importance of 
sourcing antibodies from a single batch.  This is necessary to ensure consistency 
when measuring an analyte which will be compared between subjects in a cohort. 
In addition, at least two of the commercially-available IDE antibodies that were 
tested cross-reacted significantly with components of blocking solutions such as 
BSA, as well as plasma components such as HSA, under the denaturing and reducing 
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conditions of Western immunoblotting (WB), while not cross-reacting under the 
native conditions of the ELISA or fluorometric activity assay.  This outlines the 
importance of testing the specificity and potential cross-reactivity of the antibody 
within each application for which it is intended.  It was also demonstrated that 
some common reagents such as BSA that are used routinely in these applications 
can vary in purity, and this can also have a major impact on the outcome of the 
assay (Chapter 4, Section 4.3.16).  The finding that Fraction V grade BSA did not 
generate a signal in the ELISA while cell-culture grade BSA produced a dose-
dependent signal may have possibly been due to contaminants in the latter 
preparation.  Therefore it is critical that antibodies are tested thoroughly for cross-
reactivity with blocking reagents and with non-specific components of the sample 
matrix.  Although the ELISA assay cross-reacted with cell-culture grade BSA, no 
cross-reactivity issues were demonstrated with the fluorometric activity assay, 
which suggests that the cross-reactivity issues were related to the detection 
antibody in the ELISA.  While it is probably not feasible to test for cross-reactivity 
with every component in a complex fluid such as plasma, at least the major proteins 
or proteins known to be highly antigenic should be assessed, and ideally plasma 
from an IDE knock-out animal model could be used to validate the assay. 
The elimination of signal observed with the spike and recovery assessment in the 
sandwich ELISA (Chapter 4, Section 4.3.17) indicates a significant matrix effect of 
the plasma components on the assay.  It is important to identify the reason for this 
signal reduction, and the effect minimised, as part of assay validation.  Regardless, 
peptide blocking and immunoprecipitation experiments indicated that the 120-130 
kDa protein band detected by Ab 3 in plasma samples was IDE (discussed further in 
Chapter 3, Section 3.4). 
As Ab 3 detected multiple other bands which appeared to be non-specific in the 
Western immunoblotting results, it was also important to determine this antibody’s 
specificity in the ELISA and the fluorometric activity assay.  It was shown for the 
sandwich ELISA that there was negligible cross-reactivity between the secondary 
antibody and either the detection or capture antibodies.  The slightly elevated 
signal for the blank may indicate some cross-reactivity between the capture and 
332 
 
detection antibodies; however, the concentrations of these were consistent 
between wells and the background reading subtracted from results to account for 
this.  Nevertheless this high blank signal may have impacted on the sensitivity of the 
assay, leading to a reduced overall signal.  In addition, cell-culture grade BSA was 
used in the ELISA for the AIBL samples and was responsible for some cross-
reactivity, which may also have blocked some of the available antibody, leading to a 
reduced signal. 
Recent research is beginning to address potential interfering factors and cross-
reactivity issues in immunoassays.  Emerging studies on assay validation and cross-
reactivity show that interference can occur from other endogenous factors such as 
heterophilic, anti-animal or auto-antibodies and rheumatoid factors (reviewed in 
Tate & Ward, 2004).  Some exogenous potentially interfering factors have also been 
identified such as some plasticisers and organosilicone surfactants in plastic tubes 
(Bowen, et al., 2005 and reviewed in Bowen, et al., 2010).  While these factors were 
not addressed in the current study, variables such as these need to be considered 
carefully when developing and optimising an immunoassay, and therefore would be 
important for further refinement of the ELISA. 
The most robust specificity tests for Ab 3 were performed using the IDE activity 
assay; firstly at least half of the signal generated could be removed by pre-
incubation with Aβ40 and an IDE-specific antibody (Ab 1) which binds within the 
catalytic domain of IDE.  However, it should be noted that Ab 1 was in the form of 
antiserum which potentially could contain other inhibitory components as well as 
the specific IDE antibody.  Conversely, another IDE-specific antibody (Ab 2) had no 
effect on the catalytic activity observed, probably as it binds to an epitope of IDE 
too distal from the catalytic site to block the activity.  However it cannot be ruled 
out that because Ab 2 binds IDE within the C-terminal region it may also be binding 
to the inactive truncated isoform which is comprised of the C-terminal half of IDE.  
This may have bound a large amount of available antibody leading to insufficient 
antibody amounts left to neutralise active IDE.  However, such an effect would 
depend on the concentration of IDE fragments and the concentration of IDE-specific 
antibody in the sample, neither of which were determined.  Secondly, it was 
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demonstrated that the catalytic activity obtained from plasma after 
immunocapture with Ab 3 could be completely eliminated when the 
immunocaptured sample was pre-incubated with either of the known IDE 
substrates, Aβ42 or insulin.  These results indicate strongly that the signal derived 
from the immunocapture of protein using Ab 3 is specifically due to IDE.  However, 
it cannot be completely ruled out that part or all of the activity observed may be 
due to an unknown peptidase with similar properties to IDE.  Despite this 
possibility, Miners, et al., 2008(b) reported negligible cross-reactivity of the activity 
assay with other known Aβ-degrading enzymes such as neprilysin (NEP), 
angiotensin-converting enzyme (ACE) and endothelin-converting enzyme-1 (ECE-1), 
further supporting the theory that IDE cleavage of the peptide was responsible for 
the signal observed.  Overall, these results strongly suggest that the antibody is 
specifically binding IDE in the activity assay, and as the ELISA works on similar 
immunocapture principles, it is likely that the ELISA is also specific, regardless of any 
potential cross-reactivity of the detection antibody.  Conversely, this does not 
necessarily mean that Ab 3 is exclusively detecting IDE following the denaturing and 
reducing conditions of WB.  In fact, the observation of many additional bands in this 
application may be a result of these denaturing and reducing conditions, exposing 
different epitopes which were then detected by the primary antibody.  However, it 
cannot be ruled out that Ab 3 is detecting other fragments or forms of IDE. 
 
6.3  Potential significance of plasma IDE in AD pathology 
According to the “peripheral sink” hypothesis, the levels of brain Aβ may be 
controlled by peripheral clearance mechanisms (reviewed by Kurz & Perneczky, 
2011), and several studies have shown that this is possible.  For example, recent 
studies have demonstrated that peripherally-applied therapeutic compounds such 
as γ-secretase inhibitors which reduce plasma Aβ, can also deplete levels of brain 
Aβ (Sutcliffe, et al., 2011; Sivilia, et al., 2013).  Immunotherapy studies (despite 
autoimmune reactions) and studies of other compounds such as an extract of 
Withania somnifera suggest strongly that peripheral clearance of Aβ will reduce 
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brain Aβ levels (Sehgal, et al., 2012; Liu, et al., 2012(b)).  Similarly, reducing levels of 
peripheral Aβ by the upregulation of circulating proteases may also have some 
therapeutic benefits.  In accordance with this concept, it has been demonstrated 
that the peripheral expression of the metalloproteinase neprilysin (NEP) in 
transgenic mice reduces the levels of blood Aβ, and subsequently reduces levels of 
soluble brain Aβ as well as oligomeric and insoluble Aβ (Liu, et al., 2009; Liu, et al., 
2010; Guan, et al., 2009).  Importantly, other studies have shown that an increase 
in NEP in the brain is associated with a reduction in cognitive deficits (Poirier, et al., 
2006; Spencer, et al., 2008).  However, two recent studies have contradicted the 
hypothesis (Walker, et al., 2013; Henderson, et al., 2013).  These studies showed 
that while NEP peripheral administration did in fact reduce the levels of soluble Aβ 
in the plasma, it had no effect on cerebral Aβ accumulation in both wild-type and 
AD mouse models, or in monkeys.  However, these studies had a number of 
limitations including small sample sizes.  In both studies the degraded fragments of 
Aβ in the periphery were not measured and it is possible that the presence of these 
fragments may have had an effect on the Aβ efflux and/or influx across the BBB.  In 
the Walker study, they were also not able to measure circulating levels of Aβ42, and 
this may be more relevant to AD pathology.  Conversely, in the Henderson study, 
the soluble levels of Aβ40 in the primate brain were not measured.  It is likely that 
both isoforms of Aβ need to be considered in conjunction, to conduct a more 
thorough investigation between reduction of plasma Aβ and its potential effects on 
brain Aβ.  Furthermore, the transgenic mouse models used in the studies were 
different, making comparisons difficult, and some (or all) of these transgenic 
models may not be truly representative of the mechanisms of AD which occur in 
humans.  For example, a recent study has shown that some commonly used 
transgenic mouse models do not display the classic reduction in IDE levels and 
corresponding reduction in Aβ degradation that is seen in very early AD pathology 
in humans (Stargardt, et al., 2013).  These transgenic mice have mutations in the 
PS1 and/or APP genes which would be more relevant for EOFAD rather than LOAD.  
In addition, while NEP and IDE are considered to be two of the major Aβ-degrading 
enzymes, the two enzymes may function differently and perhaps have effects on 
AD pathology which are independent of their catalytic function.  Although the 
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results from some of these studies might suggest that the efflux of brain Aβ may 
not be able to be stimulated simply by reducing peripheral Aβ via increasing or 
upregulating plasma metalloproteinases, there is evidence that the pools of 
peripheral and cerebral Aβ exist in some kind of equilibrium and that the regulation 
of plasma Aβ-degrading enzymes offers a promising treatment option for AD.  
Further work which addresses these issues would need to be undertaken in order 
to confirm or negate this hypothesis. 
 
6.3.1  Findings of IDE levels/activity measurements by classification 
The results from the current study are difficult to interpret.  However, with all 
methods used in this study, alterations were detected in IDE levels and activity in 
the prodromal period of AD, represented by the MCI group.  The Western blot (WB) 
results show increased levels of full-length IDE in the MCI group, while for total IDE 
levels as measured by ELISA the opposite was observed, with decreased levels of 
IDE in MCI and also in the AD group compared with controls.  This discrepancy is 
likely to be related to the methods used for these measurements, but may also 
offer some further information in respect to this.  While there were some 
limitations in these applications, it is possible that these methods are reflecting 
particular characteristics or mechanisms of IDE.  It is probable that the denaturing 
and reducing conditions of the WB dissociated IDE which may have been bound to 
other proteins in the ELISA, and increased the overall detectable levels of IDE, 
whereas the ELISA may not have detected a portion of the total IDE due to the 
enzyme binding to other proteins.  Alternatively, the ELISA may have detected both 
full-length IDE as well as forms of IDE which were not full-length, which may have 
been missed on the WB, or may have been present at a different molecular weight.  
Supporting this idea, it cannot be discounted that some of the other bands seen in 
the WB experiments might also be IDE, particularly the 80kDa band, which was 
shown to be reduced in the peptide blocking experiments, and also was retained 
following immunoprecipitation.  These factors may at least partially account for the 
discrepancies seen between the WB and ELISA data. 
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Full-length IDE may not necessarily be catalytically active, as a portion of the 
measured IDE may represent the inactive 15b isoform, although the increase in 
protein levels in MCI individuals is reflected in the fluorometric activity assay, with a 
corresponding increase in activity in the MCI group compared with controls.  
However, it was observed that this trend of increased protein levels in MCI was 
seen only in females, while for the activity data only the males showed a trend 
toward increased activity in the MCI group.  However, the loss of significance may 
be because of smaller numbers due to stratification.  Thus, MCI levels of full-length 
IDE were higher than healthy control levels, yet interestingly, IDE levels in the AD 
group were similar to the healthy controls, and differences between MCI and AD 
almost reached significance.  This may suggest a compensatory upregulation of full-
length IDE as the disease progresses from HC to MCI which is then reduced during 
the progression from MCI to AD, possibly due to increasing severity of AD 
pathology.  However, when looking at the total IDE levels and activity data, the AD 
group is not statistically different from the MCI group, indicating no significant 
changes in IDE expression or activity occur during the progression from MCI to AD.  
Changes in IDE levels and activity may occur at early stages in the disease process, 
which would have been missed here as some of the healthy controls who will 
eventually develop AD may have already experienced these undetected changes as 
part of very early AD pathogenesis.  Longitudinal studies of larger healthy control 
cohorts may reveal earlier and greater changes in IDE expression and activity; 
therefore this enzyme warrants further investigation. 
In this project, the increase in full-length IDE as well as catalytic activity that was 
detected in the MCI group compared with controls was somewhat unexpected, as it 
was hypothesised that a reduction of IDE levels or activity might be seen in the MCI 
and AD groups.  However this may be a reflection of some compensatory 
mechanism in response to an earlier pathological event; since by the time MCI is 
apparent, AD pathogenesis has already started.  Studies have reported an 
upregulation in IDE levels and/or activity in the liver in response to a diet high in 
sugar, salt and fat (Castell-Auvi, et al., 2012) and as a response to a number of 
cellular stressors (Tundo, et al., 2013), both of which are related to AD pathology.  
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This may be regulated by the induction of heat-shock proteins (HSP), particularly 
HSP70 which has been demonstrated to induce expression of IDE (Hoshino, et al., 
2011).  More importantly, several studies in transgenic mice have reported an 
upregulation in IDE expression that may be a compensatory response to Aβ 
deposition in the brain (Leal, et al., 2006; Vepsäläinen, et al., 2008; Zhao, et al., 
2011).  One of these studies found that 17β-estradiol could upregulate IDE 
expression, correlating with an attenuation of Aβ deposition in the brains of 
ovariectomised AD-transgenic mice, also suggesting such a mechanism for the 
oestrogen-mediated preventative effect against AD, when hormone treatment is 
started at the onset of menopause (Zhao, et al., 2011).  While it would appear that 
the increase in IDE levels and/or activity in these studies may be in response to the 
formation of insoluble Aβ plaques rather than soluble Aβ, many other metabolic 
changes are likely to be occurring concurrently, and the changes that may be 
occurring in the plasma were not measured in these studies.  In another brain study 
carried out by Miners and colleagues (2010), an increase in IDE activity was 
reported with age which was not due to an increase in expression.  This study 
measured 4 enzymes involved in Aβ production and clearance in normal control 
brains (beta-secretase (BACE-1), NEP, IDE and angiotensin-converting enzyme 
(ACE)), and found that both Aβ-synthesising and -degrading enzyme activities 
increase with age, coinciding with declining soluble Aβ and increasing insoluble Aβ 
levels.  Furthermore, IDE activity correlated directly with insoluble Aβ levels, NEP 
activity was inversely related to soluble Aβ levels, whereas ACE level correlated 
directly with insoluble and inversely with soluble Aβ, in controls but not AD (Miners, 
et al., 2010).  These enzymes may have quite different profiles in plasma, and all 
should be characterised further to understand their involvement in AD. 
One factor to consider was the observation of the plasma IDE band being higher 
than the previously reported molecular weight of 110 kDa.  Although it is possible 
that the difference in molecular weight in this instance is due to incorrect 
estimation because of the lack of resolution of the protein bands, it was shown that 
the band was consistently higher than the 110 kDa molecular weight marker.  In 
addition, the single band observed for rrIDE was estimated to be approximately 118 
338 
 
kDa, which is consistent with the UniProtKB database estimation of 117.968 kDa, 
and the plasma band in question was consistently higher than that.  Furthermore, 
Ab 3 detected a band at 110 kDa for rat liver which is consistent with published 
studies (Kurochkin, et al., 1994; Authier, et al., 1996(b)).  Hence, it is perhaps more 
likely that the higher estimated molecular weight was due to some post-
translational modification of IDE that may occur in the plasma.  Sequence analysis 
of IDE shows multiple sites that could be subject to processes such as 
phosphorylation, acetylation, ubiquitination, and glycosylation, all of which would 
increase molecular weight to some extent.  In addition, IDE has been shown to be 
modified by glutathionylation (Cordes, et al., 2011), nitrosylation (Cordes, et al., 
2009) and alkylation (Shinall, et al., 2005).  Alternatively, there may be other 
isoforms of IDE in the plasma which have yet to be identified.  Thus, there may be 
structural and functional differences associated with such potential modifications of 
IDE that may also be relevant to Aβ clearance or to other AD-related pathological 
processes, and as a future direction, these would be of interest to explore. 
It is possible that total IDE levels (which potentially include truncated and inactive 
forms as measured by ELISA) are low in the early stages of AD pathology, and the 
full-length isoform is upregulated as a response to some event such as Aβ or insulin 
accumulation in the plasma.  The low IDE levels detected by ELISA may also have 
more relevance in AD in respect to other reported functions of IDE that are 
independent of its catalytic function.  These roles could include as a chaperone 
molecule to inhibit the fibrillisation of and toxicity of Aβ (de Tullio, et al., 2013), to 
regulate the efflux of Aβ through the blood-brain barrier (Ito, et al., 2014), or 
through regulation of IGF-1 signalling which may affect AD pathology via GSK-3α-
related effects on APP processing and GSK-3β-related effects on tau (Sharma, et al., 
2008; Hong & Lee, 1997).  Another non-catalytic IDE-mediated mechanism may 
involve the regulation of proteasomal degradation of AD-related proteins (Bennett, 
et al., 2003).  As the roles of IDE are diverse and probably relevant to many 
different aspects of AD pathology, it would be of value to investigate these 
potential functions further. 
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6.3.2  Impact of APOE ε4 genotype on IDE levels and activity 
There were no significant differences in full-length IDE protein levels or activity 
levels when comparing APOE ε4 carriers with non-carriers in these studies. This was 
unexpected, although total IDE levels did tend to be lower in the ε4 carriers than 
the non-carriers (non-significantly).  This result is consistent with a study by Miners, 
et al. (2009), that showed no overall effect of the ε4 genotype on IDE levels or 
activity in the frontal cortex.  The only study of IDE levels in blood did not 
investigate the effects of ε4 genotype (Liu, et al., 2012(a)).  When stratified by ε4 
status, there were still no significant differences in IDE levels (full-length or total) 
between classifications, although for total IDE only the ε4 carriers (but not non-
carriers) showed a trend toward reduced IDE levels in MCI and AD compared with 
controls.  This indicates that the overall results were primarily due to the 
differences in the proportions of ε4 carriers in the 3 groups, with the healthy 
control, MCI and AD groups consisting of approximately 33%, 47% and 68% ε4 
carriers, respectively.  After stratification of the IDE activity data by ε4 status, the 
differences seen between classifications overall were once again only reflected in 
the ε4 carriers, with a trend toward higher IDE in the MCI and AD groups.  In fact, 
correlation analyses showed differences between ε4 carriers and non-carriers for 
both IDE levels (full-length and total) and enzyme activity.  This indicates that the 
presence of the ε4 allele may indeed have some effect on the levels and activity of 
IDE.  It is possible that these potential effects of the APOE ε4 allele on IDE are 
indirect, as several factors reported to affect IDE expression and activity have been 
observed to be affected by ε4 status; these include levels of glucocorticoids, plasma 
lipids, insulin levels and even the ApoE4 protein as well as the lipidation status of 
the ApoE protein (Peskind, et al., 2001; Knouff, et al., 1999; Dallongeville, et al., 
1992; Craft, et al., 1999; Jiang, et al., 2008; Du, et al., 2009).  Hence the potential 
effects of ε4 status on levels and activity of IDE may be mediated by any 
combination of these factors, and this list is not exhaustive.  In the current study, no 
significant correlations were observed between IDE and plasma levels of the ApoE 
or ApoE4 protein.  It has been previously reported that ApoE protein regulates the 
expression of IDE in brain (Cook, et al., 2003; Du, et al., 2009); however, this 
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association may not be reflected in the blood.  In addition, it may not simply be the 
presence or absence of the ε4 allele that has an effect on IDE expression or activity, 
but perhaps there are differential effects resulting from specific APOE genotypes.  It 
was not possible to stratify the subsets by genotype due to loss of power in our 
study, but it would be of value to investigate this further with a larger cohort. 
 
6.3.3  Associations between IDE levels and activity with biochemical 
variables measured in the AIBL cohort 
6.3.3.1  Testosterone 
After Bonferroni-Holm correction, the results for full-length IDE levels in the overall 
AIBL subset correlated negatively with free testosterone levels, and trended toward 
a negative correlation with total testosterone levels.  This appears counter-intuitive, 
as testosterone has been reported to increase IDE levels (César Vieira, et al., 2011; 
Udrisar, et al., 2005).  The associations with testosterone were absent after 
stratifying the subset by gender, indicating that the association was not restricted 
to males or females.  This is interesting considering the much higher levels of 
testosterone found in males.  The association was again seen after stratification for 
APOE status, but only in non-ε4 carriers.  However, after Bonferroni-Holm 
adjustment it was no longer significant for total testosterone, though was still 
significant for free testosterone.  This may be due to the fact that free testosterone 
is a better measure of bioactive testosterone than total testosterone.  Conversely, 
when looking only at total IDE levels, positive correlations (unadjusted) were seen 
between IDE levels and total as well as free testosterone, which after stratification 
appeared to be only in males and in ε4 carriers.  It may be that females do not have 
a high enough level of testosterone to be able to regulate IDE levels in this way.  
Although not significant following correction for multiple testing, this would be 
consistent with previously published reports.  No overall association was seen in IDE 
activity with testosterone (total or free), but a positive correlation was observed 
with total testosterone only in ε4 carriers, although again this was not significant 
341 
 
following correction.  Changes in testosterone have been implicated in the 
pathogenesis of AD and differences related to APOE genotype have been reported 
(Verdile, et al., 2012; Moffat, et al., 2004; Hogervorst, et al., 2004).  Although the 
association observed between testosterone and IDE levels by WB was negative 
rather than positive which is a puzzling result, the results for the ELISA and activity 
data are consistent with the published literature and hence the association of IDE 
with testosterone in all three datasets is worth investigating further. 
6.3.3.2  IDE levels and plasma Aβ 
Numerous associations were observed between measurements of plasma Aβ and 
IDE levels/activity in the current study.  Negative correlations were observed 
between plasma Aβ1-40  and IDE levels (full-length and total), but not with the 
activity data; for the full-length levels the association was only seen in non-APOE ε4 
carriers, while with total IDE the association was seen in the overall subset and in 
non-APOE ε4 carriers (but not in ε4 carriers).  When stratified by gender, the 
association with total IDE was only observed for males.  Following correction for 
multiple testing, these associations were no longer significant although the 
correlation with total levels was close to significance.  The observation that the 
associations with Aβ1-40 and IDE levels were seen mainly in non-ε4 carriers is 
interesting, as this was not seen with Aβ1-42, and may indicate that regulation of the 
individual Aβ species by IDE is differentially affected by ε4 status; this raises the 
possibility that the presence of the ε4 allele disrupts the normal interaction 
between IDE and Aβ1-40.  In the AIBL study, Aβ1-40 was shown to increase in MCI and 
AD individuals compared to controls (Rembach, et al., 2014) and this would be 
consistent with the reduction of total IDE in MCI and AD that is seen in the current 
study.  Furthermore, the observation that the reduction of total IDE was primarily 
seen in the ε4 carriers supports the hypothesis that the presence of the ε4 allele 
may reduce the normal expression of total IDE, hence disturbing the balance of 
total IDE to Aβ1-40.  Indeed in the brain and in vitro, the presence of the ε4 allele has 
been reported to decrease the expression of IDE (Cook, et al., 2003; Du, et al., 
2009).  Additionally, in non-ε4 carriers, an inverse relationship was seen between 
levels of full-length IDE and brain Aβ load, although this lost significance after 
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correction, while in ε4 carriers a trend toward a positive correlation was seen 
between IDE activity and brain Aβ load.  Although the levels of full-length IDE were 
seen to increase in MCI compared to controls, this may be part of a compensatory 
mechanism to try and control the rising levels of Aβ1-40 during early AD pathology 
by upregulating the active form of IDE.  However, as a decrease was seen in the 
ELISA data, this may indicate that the levels of active (full-length) IDE contribute to 
only a small proportion of total IDE protein. 
Negative correlations were also seen between Aβ1-42 and total IDE levels (not with 
full-length IDE or activity) and unlike Aβ1-40, the association was not affected by ε4 
status or gender.  After correction for multiple testing these associations were still 
significant in the overall subset, but not after stratification for gender and ε4 status, 
probably due to reduced numbers.  Further analysis after stratifying by clinical 
classification showed that the relationship between total IDE and Aβ1-42 was 
restricted to AD patients only and this correlation was stronger than in the overall 
subset.  In accordance with these results, the relationship between total IDE and 
Aβ1-40 also was only seen in AD patients.   
It is probably not surprising that no relationship was seen between total IDE and Aβ 
in the MCI group.  Although the majority of MCI individuals will convert to AD at 
some stage, some will remain stable and others revert to healthy status.  In 
addition, the progression and stage of pathology may differ between MCI 
participants, therefore the heterogeneity in the MCI group may confound the 
results. 
Further investigation revealed that the correlation between total IDE and Aβ in AD 
patients was only seen in non-ε4 carriers.  This supports the idea that the presence 
of the ε4 allele contributes to a dysregulation of the IDE/Aβ interaction, possibly by 
reducing the efficiency of IDE to degrade Aβ (Jiang, et al., 2008).  Alternatively, it 
may also be related to differences in insulin sensitivity between ε4 carriers and non-
carriers (Kuusisto, et al., 1997; Craft, et al., 2003). 
Regarding IDE activity, no correlations were seen with levels of Aβ1-40 or Aβ1-42 
species, however inverse relationships between activity and Aβ ratios were 
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observed but only in ε4 carriers; following multiple testing correction these were no 
longer significant, although a trend remained for the Aβx-42/x-40 ratio.  The 
significance of this is uncertain, although as higher IDE activity was seen in MCI and 
AD compared with controls, this would suggest that Aβ ratios were lower with AD 
pathology, which is consistent with results from a meta-analysis of the published 
literature (reviewed by Koyama, et al., 2012).  The potential mechanisms behind 
this association are not clear, however as a trend still remained with the Aβx-42/x-40 
ratio following correction, it would be interesting to explore this further, in a larger 
cohort. 
As IDE was associated with levels of Aβ in plasma, the levels (both full-length and 
total) and activity of plasma IDE relative to levels of Aβ (42+40) were analysed as an 
IDE/Aβ42+40 ratio.  As insulin is also a substrate for IDE, similar to Aβ, its plasma 
concentration relative to IDE concentration may be more capable of differentiating 
between clinical classifications than IDE alone.  Therefore an IDE/insulin ratio as 
well as an IDE/insulin+Aβ42+40 ratio were calculated.  For full-length IDE, the results 
showed no significant differences between classifications for all three ratios, 
however, the IDE/Aβ42+40 ratio almost reached significance, with MCI having a 
higher ratio than controls.  When looking at total IDE on the other hand, the 
IDE/insulin ratio for the MCI group was significantly lower than for the control 
group, while for the IDE/Aβ42+40 and IDE/insulin+Aβ42+40 ratio, both MCI and AD 
groups were significantly lower than the controls.  Therefore, there may be some 
value in using total levels of IDE as a ratio with insulin and Aβ in a biomarker panel.  
Regarding IDE activity, the IDE activity/Aβ42+40 ratio was significantly higher in AD 
compared with controls, and MCI individuals showed a trend toward being 
significantly higher than controls after Bonferroni correction for multiple testing.  In 
addition, the IDE activity/insulin+Aβ42+40 ratio was significantly higher in MCI than 
controls, while the AD group showed a trend toward being higher than controls 
following correction.  While the consideration of insulin and Aβ levels in 
conjunction with IDE activity may show differences between clinical classifications 
which may be useful as a diagnostic biomarker, similar to full-length IDE there was 
no additional benefit of including them in a ratio.   
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As IDE is an Aβ-degrading enzyme, these observations support the notion that IDE 
may have a role in regulating the plasma levels of Aβ, and in particular in AD 
patients who do not carry an ε4 allele.  However as the correlations were only 
moderate/strong it indicates that other proteases are implicated.  Plasma contains 
other known Aβ-degrading enzymes such as neprilysin (NEP) and angiotensin-
converting enzyme (ACE) which would contribute to the clearance of Aβ.  
Nevertheless, these results do support the concept that IDE has a major role in the 
regulation of plasma Aβ. 
6.3.3.3  Associations with gender. 
IDE protein and activity levels were also seen to have relationships with other 
biochemical measures in the current study.  For example, it was shown that females 
have a higher level of full-length IDE than males.  This association was not affected 
by ε4 status, and was still significant after correction for multiple testing.  Females 
are considered to be at greater risk of AD than males generally (Bachman, et al., 
1992), and it was shown in the current study that full-length IDE levels are higher in 
MCI, which may be indicative of upregulation of the active form of IDE due to 
pathological mechanisms such as hyperinsulinemia or increased plasma Aβ levels.  
As a greater proportion of women develop AD than men, it may be argued that the 
higher IDE levels in women measured here reflect the greater level of AD pathology 
that is developing in the MCI females of the cohort.  However this gender 
difference was not seen with total (ELISA-measured) levels of IDE or activity.  
There are several potential reasons for this gender difference, with differences in 
sex hormones being the most likely.  Although the hormones oestrogen (estradiol), 
progesterone, testosterone, and luteinising hormone are best known for their roles 
in reproduction, many studies show these hormones have other roles, including 
neuroprotection.  Changes in the levels of these hormones that occur in 
reproductive senescence are hypothesised to increase risk of AD, as a result of 
reduced protection against oxidative insults (Barron, et al., 2006).  Both oestrogen 
and testosterone levels were lower in the females of this subset compared to the 
males (progesterone was not measured), and both of these hormones have been 
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shown to influence Aβ production and levels (Amtul, et al., 2010; Barron & Pike, 
2012).  Oestrogen has also been shown to influence lipid raft signalling complexes, 
which may modulate susceptibility to Aβ toxicity (Marin, et al., 2011).  Oestrogen 
effects on IDE expression and protein levels may play an important role in the 
oestrogen-mediated protection, as studies have shown that IDE expression is 
significantly increased by both oestrogen and progesterone in cultured neurons as 
well as in vivo, and is inversely associated with the soluble Aβ levels in vivo 
(Jayaraman, et al., 2012).  Others have shown in AD-model transgenic mice that 
17β-estradiol increases IDE expression in a brain region-specific manner; for 
example, in the hippocampus (but not the cerebellum) 17β-estradiol increased IDE 
expression and attenuated Aβ accumulation/plaque formation.  Furthermore, this 
IDE regulation was shown to be mediated by an ERβ/PI3-K pathway (Zhao, et al., 
2011).  It is interesting to note that in many AD-transgenic mouse models, the 
females show earlier and more prominent Aβ accumulation and deposition, as well 
as poorer behavioural performance, than the corresponding age-matched males 
(Vest & Pike, 2013), supporting the concept that the differences in AD risk seen in 
humans may be hormone-related, as diet and environmental factors are identical in 
the studies of male and female mice.  
In our studies, estradiol was observed to correlate negatively with levels of full-
length IDE (although only in non-ε4 carriers), and to correlate positively with IDE 
activity levels, a finding which appeared to be primarily due to the females in the 
cohort.  These associations were not significant after correction, and are contrary to 
the published reports which demonstrate that IDE expression is upregulated by 
estradiol. However, other studies investigated effects of oestrogen in the brain or in 
vitro (Jayaraman, et al., 2012; Zhao, et al., 2011).  It is possible that estradiol may 
have a different effect on plasma IDE, and future studies of oestrogen effects on 
IDE and Aβ levels in animal models should expand to investigate Aβ levels and IDE 
enzyme protein and activity level measurements in both brain and plasma. 
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6.4  Limitations 
Western immunoblotting is a commonly used method for the measurement of 
proteins, however it has a number of limitations.  Firstly, the technique is 
considered to be semi-quantitative; meaning only relative differences between 
samples can be obtained without a standard curve; even then it is generally only 
quantitative over a very narrow range.  In addition, the molecular weight can only 
be estimated rather than confirmed exactly.  In the current study, the molecular 
weight of full-length IDE was higher than reported previously, and while this may be 
due to inaccurate estimation, it may also be indicative of post-translational 
modifications.  As there were a large number of samples, many gels needed to be 
run, as only five samples could be measured in duplicate on any one gel.  Therefore 
errors may have been introduced when normalising for gel-to-gel variation, 
although a single (pooled control plasma) sample was run on each gel to adjust for 
this.  Furthermore, the membranes were stripped of the original primary antibody 
and re-probed with another antibody which may also have introduced variation.  
Even the method of quantification can produce variable results (Gassmann, et al., 
2009).  Therefore Western immunoblotting is not ideal for measuring and 
comparing analytes in large cohorts, and it cannot be excluded that potential 
variations related to this method may have rendered the results less accurate. 
A limitation of the sandwich ELISA assay is the poor spike and recovery results, with 
the signal being completely suppressed in plasma.  This indicates significant matrix 
effects, which may be affecting the accuracy of the IDE measurements.  However it 
has been shown that NEP, a similar peptidase to IDE, is unstable when added to 
plasma and quickly loses its catalytic activity, potentially by its rapid clearance (Liu, 
et al., 2007).  It is possible that the addition of recombinant IDE has the same effect; 
it may be degraded by endogenous proteases.  This could be overcome by the use 
of a protease inhibitor cocktail, and/or by further dilution of the plasma sample; 
these possibilities require further investigation. 
It should be noted that because some of the samples had values which fell above 
the standard curve range in the ELISA, and as cross-reactivity with the blocking 
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agent was possibly reducing sensitivity, only relative differences could be obtained 
and analysed.  However, as the standard curve began to plateau at higher 
concentrations, it is possible that this occurs in plasma also, and hence the overall 
results could have been affected because of reduced sensitivity at higher 
concentrations.  Ideally, a standard curve should only be used in the linear range, 
with plasma samples diluted to fall within this linear region, from which plasma 
concentrations of the protein in question are interpolated.  It would be of value to 
refine this assay to ensure this, possibly by screening alternative antibodies or 
recombinant IDE. 
Furthermore, cell-culture grade BSA was used to measure the AIBL samples, which 
was later found to cross-react with the ELISA assay; this was more than likely the 
reason for the high background.  Ideally the samples should be re-assayed using 
Fraction V BSA.  In addition, there may have been some small degree of cross-
reactivity between the capture and detection antibody which may have also 
contributed to the background.  Although the background reading was deducted 
from sample readings to account for this, both factors may have affected the 
sensitivity of the assay.  Moreover, cross-reactivity tests in the work-up of the assay 
were performed using Fraction V BSA instead of cell-culture grade BSA, which was 
used for the AIBL samples.  This is a limitation which requires further investigation; 
the control tests should be repeated using the cell-culture grade BSA. 
Similar to the sandwich ELISA assay, the background readings in the IDE activity 
assay were rather high.  Although it was confirmed that this was not due to cross-
reactivity between reagents, and that most likely it was a product of the fluorogenic 
peptide alone, the high background may have affected the sensitivity of the assay, 
particularly at the lower limit of detection.  In future studies it would be of interest 
to investigate ways to reduce the level of background noise seen, to improve assay 
sensitivity. 
Enzyme catalytic activity appeared to be significantly influenced by the type of 
anticoagulant used (EDTA or LiHep) in the plasma collection tubes, and clearly this 
needs to be taken into consideration.  It was shown that EDTA did not affect the 
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measurement of IDE protein levels.  However, in the activity assay, EDTA-collected 
plasma samples produced a significantly higher signal than the very low signal 
observed in the Lithium-heparin (LiHep)-collected plasma.  This was contrary to the 
expected result, despite the fact that there are some studies which have reported 
similar findings; IDE is a thiolmetalloendopeptidase that requires zinc for activity, 
thus EDTA would be expected to inhibit activity (depending on EDTA, enzyme and 
metal ion concentrations, as well as a host of other factors).  It is possible that the 
increased activity in EDTA plasma may be related to haemolysis of erythrocytes; it 
has been shown that in ostrich plasma, EDTA increases the likelihood of erythrocyte 
haemolysis when compared with the LiHep anticoagulant (Mafuvadze & Erlwanger, 
2007).  As erythrocytes are a rich source of IDE, haemolysis may release IDE into the 
plasma, thus increasing the levels measured.  However, great care was taken during 
plasma processing, and samples which had obvious haemolysis were not used.  
Despite this, there may have been some level of haemolysis in the EDTA samples, 
and the blood collection and processing methods would need to be investigated 
and possibly improved to minimise this problem in the future.  Another possibility is 
that the stability of plasma proteins is affected differently by the two anti-clotting 
agents, as it has been shown that plasma proteins in EDTA are less likely to be 
subject to degradation than proteins in LiHep plasma (Evans, et al., 2001; Käkönen, 
et al., 2000).  Therefore it may be that active IDE was degraded during storage at a 
faster rate in LiHep plasma compared with EDTA plasma.  Until the reasons for the 
differences have been identified, caution should be exercised when interpreting the 
data.  It would be of value to carry out further assay optimisation experiments, 
comparing serum with plasma samples, and comparing anticoagulants in the 
activity assay. 
Another limitation of this study worth noting is that the samples used in each of the 
experimental methods were from separate subsets, and very few individual 
samples were run on all three assays.  Therefore, it is difficult to compare the 
results from all three methods, as analysing only the common samples would lead 
to a loss of power to detect any differences due to small numbers.  Ideally, it would 
be of value to complete the analysis of all samples in the AIBL cohort as was the 
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intention at the commencement of the study.  However, due to the extended time-
period required for optimisation of the assays, it was not possible to complete 
these within the time-frame of the project. 
Another general limitation for all assays is that the AIBL samples should have been 
run at least twice to ensure accuracy of the results, however time and sample 
availability were factors.  Regardless, the samples were run in duplicate, and 
duplicates with a coefficient of variation greater than 15% were removed from the 
analysis.  In addition, assays were omitted from the analysis if any of the standard 
curve values were more than 2 standard deviations from the mean of each 
concentration. 
A potentially confounding factor of this study is that it was not possible to analyse 
potential effects of medications on plasma IDE levels due to the size of the cohort, 
and the fact that only a small number of participants were not taking medication.  
The AIBL cohort is comprised of elderly participants, the majority of whom take at 
least one type of medication: at baseline for example, 79% of HC, 87% of MCI and 
97% of AD participants were taking at least one medication (Ellis, et al., 2009).  A 
number of medications have been reported to increase levels of IDE; statins, for 
example, have recently been shown to increase levels of IDE in the plasma of mice 
via increased secretion (Tamboli, et al., 2010).  Similarly, another recent study has 
shown that propranolol (an antihypertensive drug) increases the blood (and 
hippocampal) levels of IDE in rats (Solas, et al., 2009).  Other medications such as 
oestrogen, progesterone, testosterone, N-methyl-D-aspartate receptor (NMDAR) 
antagonists and glucocorticoids have also all recently been reported to increase 
expression of IDE in vitro or in vivo (Zhao, et al., 2010; Jayaraman, et al., 2012; 
Vieira, et al., 2011; Du, et al., 2009).  Therefore, as a substantial proportion of the 
AIBL cohort were taking at least one, or a combination of these medications at the 
time blood samples were taken, it is likely that these will have influenced the 
results of this project.  
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6.5  Future Directions 
Greater assay characterisation is needed, as has been detailed in the sections 
above, before any conclusions may be made about the results.  For example, 
additional cross-reactivity tests should be performed to identify potentially 
confounding plasma components.  In the Western immunoblotting assay, it would 
be useful to increase the resolution to improve estimation of the molecular weight 
of the bands, perhaps by performing SDS-PAGE on a lower percentage gel and 
running the gels more slowly.  It would also be of interest to characterise the 80 
kDa band which was observed in plasma that appeared to be specific.  It is possible 
that this band is indeed IDE and has some function in plasma that might be relevant 
to AD.  Testing other IDE antibodies, for example using immunoprecipitation 
followed by Western blotting with a different antibody, may help determine 
whether the 80 kDa band is IDE and whether it is relevant when determining 
enzyme activity.  
Further refinement of the IDE sandwich ELISA is also required to develop a 
quantitative assay, by ensuring firstly that the standard curve provides a reasonable 
linear range, and secondly that the plasma samples are diluted to fall within that 
range.  It would be of interest to screen additional antibodies to determine if there 
are others more suitable (less cross-reactive), perhaps by the use of monoclonal 
antibodies rather than polyclonal.  While there are few commercially-available 
monoclonal IDE antibodies currently, it may be of value to develop in-house 
antibodies for this purpose.  In addition, investigation of the potential effects of 
interfering substances in blood such as heterophilic and anti-animal antibodies 
should be carried out to ensure they are not affecting the assay. 
Similarly, although the results from the current study indicate that the activity assay 
is specifically detecting IDE, it requires further validation, perhaps by the use of 
other known IDE inhibitors such as bacitracin, phenanthroline and N-
ethylmaleimide.  It would also be of interest to try other non-IDE protease 
inhibitors to eliminate the possibility that other proteases are contributing to the 
signal observed.  The screening of alternate IDE antibodies may also be of value to 
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compare the results obtained, particularly with monoclonal antibodies which are 
generally considered to be more specific. 
As the IDE was immunocaptured prior to adding the fluorogenic substrate, and the 
remaining plasma washed away, it would not have been subject to regulatory 
elements which may alter the activity when in the plasma matrix.  It is quite 
possible that that the regulatory elements governing IDE activity may be more 
relevant to its function than expression levels.  Alternatively, the assay may have 
caused IDE to bind to other plasma constituents that it would normally not bind to, 
which were captured as a complex, and this may have led to a loss of detectable 
catalytic activity due to interference with the catalytic site.  If possible, an activity 
assay which could specifically measure IDE activity within the plasma, while in the 
presence of normal regulatory factors, would give a better representation of its 
true physiological activity. 
The fluorogenic peptide substrate that was used in the activity assay was derived 
from a bradykinin sequence, and this may not necessarily reflect the contribution of 
IDE toward the cleavage of Aβ or insulin.  It would be of interest to use a 
fluorescently-labelled peptide substrate derived from the sequence of Aβ to 
analyse IDE more accurately toward Aβ cleavage activity.  In fact, an Aβ-derived 
fluorescent substrate has recently been generated by Stargardt and colleagues 
(2013) which would be more relevant in future Aβ-degrading protease activity 
studies. 
The many bands observed by Western immunoblotting in plasma suggest that some 
post-translational modifications occur to IDE in human plasma.  In particular, the 
finding in this study that the molecular weight of IDE was higher than expected 
supports this possibility.  Therefore, it would be of interest to investigate potential 
modifications, and identify how they affect the catalytic or non-catalytic functions 
of IDE.  For example, initial experiments could include cell culture IDE transfection 
experiments followed by treatment with N- and O-glycosylation inhibitors, then 
Western immunoblotting to investigate changes in IDE molecular weight.  In 
addition, co-purification experiments might assist with determining which other 
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plasma proteins interact with IDE, and this could help not only with assay 
development, but also may uncover functions of IDE which may directly or 
indirectly impact on aspects of AD pathology.  As a band of 160 kDa was retained in 
some of the immunoprecipitation experiments, it may indicate that IDE is found as 
part of a complex of proteins which are resistant to the denaturing and reducing 
conditions of Western immunoblotting.  Specifically, it would be of value to identify 
and characterise any regulatory components in the blood which affect the ability of 
IDE to degrade Aβ.  Such components may also alter in some way in the earliest 
stages of AD, and may be useful to identify, for the purposes of developing 
therapeutic treatments. 
Given the heterogeneity of the MCI group, it would also be of use to investigate 
potential differences in IDE expression and activity in separate subsets of MCI, 
including amnestic versus non-amnestic and MCI individuals who convert to AD 
compared with those who remain stable, or revert back to healthy.  Such 
longitudinal studies would reveal differences in those who are AD converters 
compared with those who are not, and would be of great benefit for the 
development of future diagnostic tests.  The same argument may apply to the 
control group, as AD pathology may already have started in some members of this 
group. 
Other factors may also affect the levels and activity of IDE, such as the presence or 
absence of hyperinsulinemia, the levels of plasma glucose, the interaction of IDE 
with the proteasome and effects of specific APOE genotypes.  It is also not known if 
IDE is subject to circadian fluctuations, although in the current study the samples 
tested were all from overnight fasted participants.  It would be of interest to 
investigate these factors in relation to circulating levels and activity of IDE. 
It is not currently known how IDE is cleared from the peripheral circulation (or the 
brain for that matter), therefore alterations in levels or activity could be related to 
the balance between production and clearance, similar to Aβ.  Therefore it would 
be interesting to explore this in a future study; it is probable that IDE could be 
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regulated through such clearance mechanisms rather than the upregulation of IDE 
expression, and this may have value in a therapeutic capacity. 
Nutritional status and neutraceutical intake are likely to influence the regulation of 
IDE, particularly sugar and carbohydrate intake, and the presence of, and/or 
treatments for diabetes and insulin resistance.  There are a number of dietary 
supplements and neutraceutical treatments which have recently been shown to 
offer some potential benefits in regulating IDE, such as docosahexaenoic acid (Du, 
et al., 2010), withanolide A (Patil, et al., 2010), Geranylgeranylacetone (Hoshino, et 
al., 2013), asiaticoside (Lin, et al., 2013), ginseng (Quan, et al., 2013), Tong Luo Jiu 
Nao (Liu, et al., 2011) and curcumin (Wang, et al., 2014).  A number of these have 
been investigated for their effects on AD pathology, for example, Withanolide A has 
been shown in primary neuronal cultures to upregulate IDE and downregulate 
BACE-1, one of the enzymes necessary for Aβ production from APP, and to 
upregulate ADAM10 which is necessary for non-amyloidogenic processing of APP 
(Patil, et al., 2010).  Even spirulina may have some benefits; there is no evidence as 
yet that it regulates IDE but it has been shown to improve insulin sensitivity more 
effectively than Pioglitazone and therefore may have indirect effects either by 
suppressing insulin secretion which would reduce the competition for IDE, or by 
increasing insulin signalling due to a reduction in insulin resistance (Ou, et al., 
2013).  It may have further benefits in preventing or improving AD pathology 
through its antioxidant properties and also its positive effects on dyslipidemia and 
inflammation (Romay, et al, 2003; Devesh, et al., 2012; Fujimoto, et al., 2012; 
reviewed by Deng & Chow, 2010).  
 
6.6  Conclusions 
Despite the potential limitations with the assays developed in this project, the main 
findings of the present study have demonstrated that plasma IDE levels and activity 
were significantly different in MCI compared with controls.  This may be of value 
eventually as part of an AD biomarker panel, and is an interesting finding 
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considering the heterogeneity of the MCI group.  The strength of these differences 
were improved by considering levels of plasma Aβ in conjunction with IDE (for total 
levels), which then demonstrated a similar significant finding in AD as seen in MCI.  
The significance of plasma Aβ in AD is still under investigation, however may prove 
to be a contributing factor in the initiation or progression of AD pathology.  There 
was still some overlap between groups, and as such this may limit the usefulness of 
IDE as a clinically relevant biomarker.  However, identifying the effects of 
potentially confounding variables may help address these issues.  It appears from 
these results and others that the regulation and functions of IDE are particularly 
complex, and require ongoing work to unravel the potential significance these may 
have in the pathology of AD.  Overall, however, based on the results from the 
current study it does appear that there are changes in both the levels and activity of 
plasma IDE in the early stages of AD, and while this pilot study suggests that IDE 
may have potential as an AD biomarker, further investigation is needed to confirm 
or negate the putative benefits of using IDE in a biomarker panel. 
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APPENDIX – Further optimisation tests for 
Fluorometric Activity Assay 
A1  Determination of fluorometric activity assay cross-
reactivity with human (HSA) and bovine (BSA) serum albumin 
It was demonstrated in the IDE ELISA assay that cell-culture grade BSA was cross-
reactive and produced a dose-responsive signal.  As the capture antibody Ab 3 was 
used for both the IDE ELISA and also the IDE fluorometric activity assay, it was 
important to test for any interference of both BSA (cell-culture grade) and HSA in 
the activity assay.  PCP as a control was also included to compare the extent of any 
HSA/BSA signal generated. 
HSA and BSA were prepared as described in section 2.2.5.3.1 to a concentration of 
60 mg/mL each (representing the highest concentration of human albumin in 
plasma) diluted in PBST (Figure A1).  Each dilution was further diluted as per plasma 
samples (40 μl + 85 μL PBST), and then assayed in duplicate along with PCP using 
the fluorometric activity assay protocol as detailed in Section 2.2.6.1.  The test was 
terminated after 2 hours incubation.  Cross-reactivity was determined to be 
fluorescence generated above the value of the (PBST only) blank. 
Results showed that neither BSA nor HSA generated a signal above the level of the 
blank, while the PCP control did generate a signal as expected.  It can be concluded 
by these results that neither HSA nor BSA was an interfering factor in this assay. 
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Figure A1  Investigating potential interference in the IDE fluorometric activity 
assay by purified human (HSA) or bovine serum albumin (BSA).  All tests were 
done in duplicate.  Solutions of BSA and HSA were prepared to a concentration of 
60mg/mL and diluted as per PCP in PBST.  PCP was determined to contain 960 μg 
total protein per well.  The assay was carried out as described in section 2.2.6.1, 
although conducted for only 2 hr.  The results show that purified HSA and BSA 
generate no detectable signal above the blank in the IDE fluorometric activity assay 
at the equivalent of the highest physiological level of albumin found in human 
plasma.  Error bars indicate ±SD. 
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A2  Testing phosphate-based buffers against tris-based 
buffers as sample diluents in the IDE fluorometric activity 
assay. 
Phosphate-based buffers have been known to have a chelating effect on some 
enzymes, and particularly when using long incubation times.  Similar to some other 
enzymes, IDE catalytic activity has previously been shown to be dependent on 
metal ions such as zinc.  As the samples in the IDE activity assay are diluted in PBST, 
and incubated overnight, it was important to determine if the chelating effect of 
the phosphates in PBST were having an effect on the amount of IDE activity 
measured.  Therefore the assay was tested with purified rrIDE and PCP using either 
PBST or TBST for blocking agents, sample dilutions and washes (Figure A2(A) and 
(B)). 
Results showed minimal differences between TBST and PBST in the fluorometric 
assay for both the standard curve (Graph A.), and for the plasma (Graph B.).  It was 
concluded that due to the pH instability of tris-based buffers with temperature 
changes, and the overnight incubation of the samples at 4°C in the protocol, PBST 
would be used for the IDE fluorometric assay. 
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Figure A2(A) and (B).  Test of PBST versus TBST as dilution buffers in the 
fluorescent activity assay for IDE.  Assay was performed as detailed in Section 
2.2.6.1 over 4 hours.  Recombinant rat IDE (rrIDE) was diluted to concentrations of 
312.5 to 7500 ng/mL (Graph A.) and pooled control plasma (PCP) was loaded at a 
dilution of 960 μg total protein per well (Graph B) in duplicate, using either PBST or 
TBST as assay diluents.  Data is shown at the 4 hour timepoint.  Results show that 
there is negligible difference in the rrIDE standard curve or plasma values when 
using either PBST or TBST diluents.  Error bars in Graph B indicate ±SD. 
 
